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ABSTRACT 
 
ISOLATION AND CHARACTERIZATION OF MEMBRANE VESICLES SECRETED BY 
HUMAN RENAL CELLS 
Mayank Saraswat 
 
Most cells release membrane vesicles for various purposes including, but not limited to, 
intercellular communication and disposal of membrane and soluble proteins. These vesicles 
are secreted into urine coming from the cells lining the urinary tract and bladder epithelium. 
These vesicles are a promising source of biomarkers for various cardiovascular and renal 
diseases. This thesis pursues twofold objectives, one being the development and 
improvement of an isolation method for urinary membrane vesicles and the second being 
proteomic characterization of the content of these vesicles. These objectives are important to 
realise the clinical potential of these vesicles. An alternative method for removal of 
contaminant high-abundant proteins was developed which preserves the activity of vesicular 
proteins. Moreover, lipid-affinity and lectin-affinity-based novel methods to enrich 
membrane vesicles from minimally processed urine were evaluated and developed. More 
than 600 proteins were identified in urinary membrane vesicles using shotgun proteomic 
analysis. Post-translational modification (PTM) proteomics was carried out to identify the 
PTM status of vesicular proteins. Many different PTMs like glycosylation, ubiquitination and 
palmitoylation were assessed. Surface glycan profiles of these vesicles were elucidated using 
fluorophore-linked lectin assay (FLLA) employing 18 different lectins. Lectin blotting, 
lectin-affinity chromatography using multiple lectins and hydrazide chemistry based 
enrichment of glycoproteins were carried out. As a result, 108 glycoproteins were identified. 
Immuno-affinity chromatography was used to enrich and identify ubiquitin-conjugated 
proteins present in urinary membrane vesicles. A number of potential palmitoylated proteins 
were identified as well. Computational prediction and validation methods were applied to 
these protein lists. In conclusion, novel methods to isolate urinary membrane vesicles were 
developed. In addition, a thorough proteomic characterisation of contents of urinary 
membrane vesicles was achieved. This work will serve as platform for further 
characterization of urinary membrane vesicles. 
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1.1 Introduction 
 
Urine is a combination of plasma filtrate and the secretion profile of cells lining the urino-
genital tract. In healthy individuals, the origin of approximately 70% of the urinary proteome 
is kidney and the rest represents the plasma filtered by the glomerulus (Thongboonkerd & 
Malasit, 2005). Proteins present in urine are a collection of proteins secreted by a number of 
cell types and/or tissues so it is not possible to correlate the mRNA abundance of any 
particular tissue with the urine proteome, as is the case of other body fluids like plasma 
(Kawamoto et al., 1996). This leaves proteomic analysis as the only option to reflect the 
disease state of an organism. Therefore, the urinary proteome might serve as a rich source of 
biomarkers for uro-genital and systemic diseases which have been reviewed previously 
(Pisitkun, Johnstone & Knepper, 2006). Moreover, urine collection is a non-invasive 
procedure which makes it an ideal source for biomarker discovery. Kidneys are located on 
each side of the vertebral column in the posterior part of the abdomen (Brenner, 1996). These 
organs maintain the water, electrolyte and pH balance of the human body (Knepper & Burg, 
1983). Each kidney is enveloped by a fibrous capsule and contains a renal artery and a renal 
vein (Brenner, 1996).  
 
Figure 1.1: Schematic diagram of bisected kidney (Brenner, 1996) 
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Kidney can be divided into cortex and medulla as can be seen in Figure 1.1, showing the 
bisected kidney. Nephrons are the functional unit of kidney and each kidney consists of 
approximately 1 million nephrons. Figure 1.2 displays the schematic diagram of the nephron 
elements. 
 
Figure 1.2: Schematic diagram of a nephron with its major segments (Nielsen et al., 2002). 
Glomeruli are found exclusively in the kidney cortex while tubular segements are found in 
the cortex, outer medulla and inner medulla, as can be seen in the Figure 1.2. The proximal 
tubule consists of segments of the convoluted and straight tubules and the loops of Henle, 
which is made up of a thin descending as well as an ascending limb and a thick ascending 
limb. This is followed by collecting ducts which consist of inner and outer medullar 
collecting ducts (Brenner, 1996). Kidney diseases are mostly due to genetic, inflammatory, 
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infectious or metabolic causes. Urinary proteins, interestingly, are derived from all segments 
of nephrons as well as the bladder epithelium and, thus, are expected to reflect respective 
changes in the characteristic urinary protein signature. Approximately 3% of urinary proteins 
are secreted encapsulated within membrane vesicles (Hoorn et al., 2005).  
1.2 Membrane vesicles  
Extracellular spaces of multicellular organisms contain a special set of cell secretion products 
including ions, metabolites, proteins and complex carbohydrates. It has recently been 
established that they also contain membrane vesicles secreted by various cells. Current 
research endeavours mainly focus on two types of membrane vesicles: microvesicles and 
exosomes whose primary characteristics are listed in Table 1.1. There are two main research 
themes in the membrane vesicle field. One establishes the role of membrane vesicles in 
cellular processes like growth, proliferation, differentiation and immune responses. The other 
focuses on biomarker discovery and validation of the vesicular secretory pattern. These 
biomarkers are further used for various disease diagnoses, for monitoring and for therapeutic 
efficacy, using membrane vesicles as the source for biomarkers. 
Acquisition of host major histocompatibility complex (MHC) antigens by donor T-
lymphocytes in tissue transplantations was observed thirty years ago (Sharrow, Mathieson & 
Singer, 1981). Since then many studies have reconfirmed that membrane proteins can be 
acquired by either cell to cell contact or through secretion of membrane vesicles. Similar 
membrane-coated vesicles had been seen in cultured malignant cells and red cells while little 
was understood of the significance of this phenomenon. A popular view was that they are the 
result of a less important mechanism of membrane shedding or membrane blebbing (Lutz, 
Liu & Palek, 1977; Dumaswala & Greenwalt, 1984; Taylor et al., 1988). They were even 
thought to be the result of cell lysis caused by small changes in the osmolarity of the medium. 
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Shortly thereafter, shedding of a major red cell protein, the transferrin receptor, by maturing 
reticulocytes was reported simultaneously in two publications (Harding, Heuser & Stahl, 
1984; Pan et al., 1985) which established them as being definitely physiological and not an 
artefact. Hence the name exosome was given to them owing to their obvious exocytic nature 
or derivation (Johnstone et al., 1987). Since then these membrane-coated vesicles have been 
known to be secreted by a multitude of cells.  The membrane vesicles appear spherical in 
shape and limited by a lipid bilayer. These vesicles contain soluble contents which are mainly 
derived from the cytosol of the respective secreting cell. Their membrane is in the same 
orientation (and not inside out) as that of the secreting cell. These membrane vesicles, 
depending on their intracellular site of origin may have different biochemical properties and 
composition. This suggests that they serve different functions in an organism’s physiology. 
The nomenclature of such vesicles is a source of confusion for the scientific community 
because of the different names used by different groups and also because these vesicles share 
many common physico-chemical properties like size and density. In addition, they have been 
called microparticles, vesicles, microvesicles, nano vesicles, membrane particles, exosomes, 
dexosomes, argosomes and ectosomes among other names (Johnstone, 2006; Thery, 
Ostrowski & Segura, 2009).  
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Figure 1.3: A schematic diagram showing the site and the process of secretion of various 
types of membrane vesicles. The figure was taken from (Thery, Ostrowski & Segura, 2009). 
A schematic diagram of secretion of different types of membrane vesicles is shown in Figure 
1.3. Major physicochemical characteristics of different types of defined vesicles known are 
summarised in Table 1.1.  
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Table 1.1 was taken from (Thery, Ostrowski & Segura, 2009). It summarises different type 
of membrane vesicles and their biophysical and other characteristics. ND: Not determined. 
 
*The listed features of vesicles secreted by live cells are based on observation of preparations of 100% pure vesicles. However, in practice, 
all vesicle preparations are heterogeneous, with different protocols allowing the enrichment of one type over another, and they can be 
classified according to the presence of several (but not necessarily all) of the listed features. ‡Appearance by electron microscopy is only an 
indication of vesicle type and should not be used to define vesicles, as their microscopic appearance can be influenced by the fixation and 
phase contrast techniques used. CR1, complement component receptor 1; ND, not determined; TNFRI, tumour necrosis factor receptor I; 
TSG101, tumour susceptibility gene 101. 
 
This process of secretion of membrane vesicles may be evolutionarily conserved as suggested 
by release of such vesicles by certain types of bacteria (Mashburn & Whiteley, 2005). Only 
the eukaryotic vesicles are discussed here.  
1.2.1 Ectosomes/Shed vesicles: 
Large membrane vesicles or microvesicles (100-1000nm) are secreted by budding or 
shedding from the plasma membranes of many types of cells (Figure 1.4) including, but not 
limited to, platelets, neutrophils, dendritic cells and tumour cells (Poutsiaka et al., 1985; 
Heijnen et al., 1999; Hess et al., 1999; Obregon et al., 2006; Al-Nedawi et al., 2008a). 
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Figure 1.4: Release of shedding vesicles/microvesicles from the cell surface upon 
exogenous/endogenous stimulus. The Figure was taken from (Cocucci, Racchetti & 
Meldolesi, 2009). 
However, some studies have reported their size is not 100-1000nm as is widely believed. 
These studies claim, that, if stringent criteria are used to distinguish the interference of cell 
debris and organelles from disrupted/apoptotic/necrotic cells, then these vesicles are no more 
than 200 nm in diameter (Scholz et al., 2002; Cocucci et al., 2007; Eken et al., 2008). The 
term, microvesicle is taken from the study for vesicles proven to be distinct from exosome 
(Heijnen et al., 1999) and it is not to be confused with context where the term microvesicles 
was applied to refer to a mixture of heterogenous vesicles including ectosomes and 
exosomes. These membrane shedded or budded vesicles are also called ectosome and the 
process is called ectocytosis. We use the term microvesicles for membrane-shed vesicles and 
it does not include exosomes. Apart from the specific sorting of proteins to these vesicles, 
specific enrichment of cholesterol and diacylglycerol suggest specific lipid sorting (Stein & 
Luzio, 1991). Membrane asymmetry at the cell surface upon activation was observed (Frasch 
et al., 2004) but it has not been conclusively proven that only these sites support ectocytosis 
and shedding of ectosomes. However, the exposure of phosphatidylserine (PS) on their 
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surface is a characteristic of microvesicles while one study disputes that PS exposure is 
always the case with these vesicles (Connor et al., 2010). Another study has characterised 
platelet-derived microvesicles after separating them into four fractions using chromatography  
(Dean et al., 2009). These four fractions differ in their average size of vesicles and also have 
different functions as well as different protein and lipid compositions as judged by different 
localisation of these proteins among the respective fractions (Figure 1.5).  
 
Figure 1.5: The subcellular localization of proteins identified in microvesicles fractionated 
according to size. The data for generating this figure was taken from (Dean et al., 2009). nm 
is short form for  nanometer and size given is the diameter of vesicles.  
Together, these data highlight that there is a great heterogeneity among the vesicles, which 
may not only be cell-specific, but may also be stimulation and secretion pathway-specific 
when derived from the same type of cells. Although secretion of such vesicles is stimulus-
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regulated, a constitutive level of their secretion is thought to occur and this is supported by 
the finding of such vesicles in normal plasma (Freyssinet 2003a) and urine (Pascual et al., 
1994; Lescuyer et al., 2008).  
1.2.1.1 Ectosome biogenesis 
Small cytoplasmic protrusions bud out from the cell at specific locations and then detach 
from the cell by fission of their stalk (Dolo et al., 2000; Cocucci et al., 2007). Complement 
attack was known to induce secretion of ectosomes by endothelial and circulating blood cells 
(Pilzer et al., 2005) while bacterial cell wall components such as lipopolysaccharide (LPS) 
induce their release from monocytes  (Satta et al., 1994). Platelets have been shown to release 
ectosomes upon activation by thrombin (Freyssinet, 2003b) while many cancerous cells have 
an activated phenotype with high levels of ectocytosis without any stimuli (Dolo et al., 1998; 
Johnstone, 2006; Al-Nedawi et al., 2008b). Specific protein sorting was observed in the buds 
with inclusion of some membrane proteins while exclusion of others (Cocucci et al., 2007; 
Moskovich & Fishelson 2007). The mechanism behind the specific sorting of cargo to these 
vesicles remains less well defined but many types of stimuli known to induce the secretion 
were reported. Use of inducers and inhibitors of specific pathways has shed light on the 
critical factors involved in release of such vesicles. The use of inhibitors of cholesterol 
synthesis has implicated the involvement of lipid rafts (Del Conde et al., 2005) but these 
special membrane domains are also implicated in exosome biogenesis (Lakkaraju & 
Rodriguez-Boulan 2008). Stimulation of cells, like dendritic cells and microglia, by calcium 
results in induction of ectosome release which can be recorded by confocal time-lapse 
microscopy (Bianco et al., 2005; Pizzirani et al., 2007). Induction by calcium is cell-type 
specific as induction of PC-12 cells by Ca
++
-ionophore fails to release shed vesicles while 
induction by phorbol ester involving activation of protein kinase C (PKC), is effective in 
these cells (Cocucci et al., 2007). Increase in intracellular calcium occurs before release of 
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vesicles upon activation of cell surface receptor or apoptosis (Baroni et al., 2007; Kahner, 
Dorsam & Kunapuli 2008). Activation of the purinergic receptor-channel P2X7 increases the 
release of shed vesicles in dendritic cells, macrophages and microglia while activation of P2Y 
coupled with Gq protein is important in other cells like platelets and PC12 (MacKenzie et al., 
2001; Wilson et al., 2004; Bianco et al., 2005; Pizzirani et al., 2007). Regardless of the type 
of stimulation the generation of shed vesicles is delayed by tens of seconds to 2 minutes 
depending on stimuli and type of cell (Lee et al., 1993; MacKenzie et al., 2001; Pilzer & 
Fishelson, 2005; Cocucci et al., 2007; Moskovich & Fishelson 2007; Pilzer et al., 2005; 
Pizzirani et al., 2007;). This implies that a specific sorting of proteins lipids and metabolites 
occurs upon stimulation, and consequently, the shed vesicles are released. The mechanism of 
cargo sorting and biogenesis of these vesicles remains to be understood in detail. 
1.2.1.2 Ectosome/Shed vesicle functions 
One of the first discovered physiological roles mediated by shed vesicles or microvesicles 
was that they supply the membrane surface necessary for assembling of procoagulant enzyme 
complexes (Sims et al., 1988). This is mediated by a tissue factor displayed by these vesicles 
on their surface (Spek, 2004). These vesicles bind to macrophages, neutrophils and other 
platelets activating them in the process (Polgar, Matuskova & Wagner, 2005; Pluskota et al., 
2008). Vesicles released by neutrophils are typically enriched in the adhesion molecule, Mac-
1, which also activate platelets (Andrews & Berndt 2004). Shed vesicles can also regulate the 
blood flow as shown in a study where, in a vesicular preparation from the T cell line, CEM, 
mediated the modulation of dilation and relaxation of mouse aortic rings and mesenteric 
arteries by decreasing the expression of nitric oxide synthase and consequently increasing the 
expression of caveolin-1 (Martin et al., 2004). Moreover, platelet-derived microvesicles can 
induce the expression of cyclooxygenase 2 (COX-2) in endothelial cells thereby inducing the 
vasodilation by prostagandin production (Barry et al., 1997; Barry et al., 1998). Complement 
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attack can also trigger the release of ectosomes, containing the membrane attack complex, by 
neutrophils, oligodendrocytes, platelets, glomerular epithelial cells, and the tumor cell lines 
Ehrlich, U937, and K562 thereby protecting them from cell death (Carney, Hammer & Shin, 
1986; Morgan et al., 1986; Morgan, 1989; Scolding et al., 1989). Human monocyte-derived 
macrophages demonstrate inflammatory responses to Zymosan A (inducer of experimental 
sterile inflammation) and LPS (inducer of immune response) which can be blocked by 
ectosomes derived from polymorphonuclear leukocytes (PMN) by inhibiting the release of 
tumour necrosis factor-α (TNF-α) and reducing the release of interleukin (IL)-8 and IL-10 
(Gasser & Schifferli 2004). PMN-derived ectosomes also interfere with maturation of 
monocyte-derived dendritic cells (Eken et al., 2008). However, in a later stage of 
inflammation these vesicles can become pro-inflammatory as suggested by the complement 
component C1q binding to microvesicles released from apoptotic Jurkat cells, and subsequent 
deposition of complement components C3 and C4 (Nauta et al., 2002). Classical complement 
pathway activation could thus trigger the proinflammatory effect of complement. 
Interestingly, platelet-derived microvesicles can deliver arachidonic acid directly to target 
cells. Arachidonic acid from microvesicles can also increase adhesion of monocytes to 
endothelial cells (Barry et al., 1998). Furthermore, arachidonic acid derived from 
microvesicles also increases expression of COX-2 in endothelial and monocyte cells 
stimulating production of prostaglandins (Barry et al., 1997; Barry et al., 1999), which may 
be involved in regulation of inflammation. Extracellular ATP-based induction of P2X7 
receptor in THP-1 monocytic cells stimulates shedding of microvesicles containing IL-1β 
(MacKenzie et al., 2001) which is a mediator of the inflammatory response and is distinctly 
involved in cell proliferation, differentiation and apoptosis. These contrasting anti- and pro-
inflammatory effects of microvesicles might be cell type and physiological state-dependent 
and probably the type of stimulation might determine their function post secretion.  
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1.2.2 Exosomes 
Although any membrane vesicles released by cells in extracellular space contain cell type-
specific proteins and lipids, distinct features of a sub-population of vesicles define them and 
they can be referred to as exosomes according to the following characteristics. Exosomes are 
40-100nm in diameter, and appear as “cup-shaped” or round in morphology in transmission 
electron microscopy or cryo-electron microscopy (Conde-Vancells et al., 2008). They 
typically float on a sucrose density gradient to a density that ranges from 1.13 to 1.19 g/ml 
(Simons & Raposo, 2009). Elements of cellular compartments, named multivesicular bodies 
(MVBs), containing intraluminal vesicles, can fuse with plasma membranes to release these 
vesicles, termed exosomes, to the extracellular space  (Lakkaraju & Rodriguez-Boulan, 
2008). Nearly all exosomes, regardless of the cell of origin, contain specific proteins because 
of their endosomal origin. These include proteins involved in membrane fusion and transport 
(Rab GTPases, Annexins, flotillin), MVB biogenesis (Alix, TSG101), heat shock proteins 
(hsp70 and 90), integrins and tetraspanins (CD63, CD9, CD81 and CD82). Some of these 
proteins merely reflect the cellular abundance of these proteins in secreting cells while others 
can be termed exosomal markers (Alix, TSG101, Flotillin and CD63). Similarly, some lipids 
are enriched in exosomes such as lipids localised to rafts e.g. cholesterol, sphingomyelin, 
ceramide and glycerophospholipids with long and saturated fatty-acyl chains (Wubbolts et 
al., 2003; Subra et al., 2007; Trajkovic et al., 2008). Although some vesicles shed directly 
from membranes can also be in the exosomal size range (50-100nm) (Booth et al., 2006), 
endosomal origin and specific enrichment of exosomal marker proteins and lipid as well as 
morphology of vesicles are used to define exosomes and differentiate them from such 
vesicles. 
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1.2.2.1 Exosome biogenesis 
Exosomes are intraluminal vesicles (ILVs) of MVBs and their biogenesis is thought to occur 
in MVB compartments (Figure 1.6).  
 
Figure 1.6: Formation of multivesicular body (MVB) and subsequent release of exosomes 
upon its fusion with plasma membrane. This figure was taken from  (Simons & Raposo 2009) 
Strong evidence that ILVs are indeed released as exosomes comes from a study in which a 
specific label was allowed to be internalised by cells and was found to be released with 
exosomes coming from endosomal-like domains (Raposo et al., 1996). The generation of 
ILVs involves lateral segregation of cargo within the limiting membrane of endosomes 
followed by inward budding of ILV and subsequent release of ILV into the lumen of 
endosome. Although Endosomal Sorting Complex Required for Transport (ESCRT) 
machinery is thought to function in cargo sorting, its role is not clear. Exosomes derived from 
various cell types contain enriched ESCRT components and ubiquitinated protein (Buschow 
et al., 2005; Liu et al., 2009) lending support to this theory. Figure 1.7 shows a schematic 
diagram of ESCRT components mediating sorting of cargo into multivesicular body lumen.  
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Figure 1.7: Ubiquitination of membrane proteins and their subsequent ESCRT-mediated 
incorporation into intralumenal vesicles of multivesicular bodies. This figure is taken from 
(Welchman, Gordon & Mayer, 2005) 
More support comes from other observations that Nedd4 family interacting protein-1 
expression is associated with increased ubiquitination in exosomes (Putz et al., 2008) and 
Alix, which associates with ESCRT machinery, is required for sorting of transferrin receptor 
into exosomes (Geminard et al., 2004). Moreover, treatment of TS/A tumour cell 
(metastasizing mouse cell line, originated from a mammary adenocarcinoma) with curcumin 
(an active component of spice turmeric) enhances ubiquitination of exosomal protein and 
their accumulation in tumour cell-derived exosomes (Zhang et al., 2007). Exosomes contain a 
number of ubiquitinated proteins (Buschow et al., 2005) leading to the conclusion that 
ubiquitination of proteins is involved in sorting of the cargo to exosomes and affects exosome 
functions. 
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However, the situation is more complex than it seems and some proteins are known to be 
sorted to exosomes independent of ESCRT involvement (Fang et al., 2007; Trajkovic et al., 
2008). Ceramide was shown to be involved in one of these ESCRT-independent pathways 
(Trajkovic et al., 2008; Bianco et al., 2009; Zhang et al., 2009). This is not surprising as 
ceramide is known to induce phase-separation and domain formation in model membranes 
(Goni & Alonso 2006). Protein such as tetraspanins may then partition into these domains. 
Tetraspanins are being suggested because they form tetraspanin webs by forming oligomers 
by interacting among themselves and also with other transmembrane and cytosolic proteins 
(Zoeller, 2009). This is further supported by observations that antibody-induced clustering of 
proteins, such as transferrin receptor, MHC-II and CD43, increases their secretion with 
exosomes in diverse cell types (Vidal, Mangeat & Hoekstra, 1997; Fang et al., 2007; 
Muntasell, Berger & Roche 2007). Addition of multiple homo-oligomerization domains to an 
acylated reporter protein enhances its exosomal secretion (Fang et al., 2007). Taken together, 
these data suggest that oligomerization and clustering of exosomal cargo alone, may lead to 
recruitment of these proteins into, and stabilisation of, exosomal membrane. Exosomal 
enrichment of lipid-rafts may lead to spontaneous budding of vesicles, driven by tension 
between liquid-ordered and disordered boundaries. This kind of mechanism would not need 
involvement of ESCRT machinery. Another example of oligomerization-mediated sorting of 
proteins into intralumenal vesicles is glycoprotein Pmel17. Pmel17 forms fibers with its 
luminal domains which induce its sorting into intralumenal vesicles of multivesiclular 
endosome in an ESCRT-independent manner (Theos et al., 2006). However, exosomes, in 
addition to proteins and lipids, also contain mRNA and miRNA and only a subset of cells’ 
mRNA and miRNA are found in exosomes suggesting involvement of an active sorting 
process. No studies have tried to uncover sorting of these RNA species to exosomes. In 
addition to MVBs, vesicles with exosomal characteristics have also been found to accumulate 
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into specific domains at plasma membranes and these domains have been termed, 
‘endosome-like’ domains (Booth et al., 2006). These domains are enriched in exosomal and 
endosomal proteins like CD63 and CD81. Moreover, a lipid probe, N-Rh-PE (1,2-
dipalmitoyl-sn-glycero-3-phophoethanolamine-N-[lissamine rhodamine B sulfonyl]) which 
normally internalises, and releases with exosomes, accumulates in these domains. Electron 
microscopy detected the budding profile of these domains proving that these domains serve 
as the sites for exosomal biogenesis. Moreover, addition of acyl chains to a reporter protein 
targeted it to these ‘endosome-like’ domains and increased its secretion with exosomes. 
Higher order oligomerization can target plasma membrane proteins to exosomes (Fang et al., 
2007). Various plasma membrane anchors, like the myristoylation tag and PIP2 binding 
domain, can target oligomeric proteins to these vesicles (Shen et al., 2011). This suggests that 
oliogmerization and plasma membrane association is one of the several signals which affect 
protein sorting to exosomes. Another important factor in specifying exosome secretion may 
be the interaction with a protein with known association to exosomes. Accordingly, CD43 
fusion protein is secreted in association with exosomes although to a lesser extent than other 
plasma membrane anchors (Shen et al., 2011). Tumour suppressor activated pathway 6 
(TSAP6), a p53-inducible 5-6 transmembrane protein, is associated with exosomes and it 
promotes the exosomal secretion of translationally controlled tumour protein (TCTP) 
(Amzallag et al., 2004).  More studies are needed to clarify the role of these different 
pathways in exosome biogenesis which might be cell type-specific.  
1.2.2.2 Exosomes function 
One of the earliest functions attributed to exosomes was elimination of proteins from cells 
needed for their maturation (Harding, Heuser & Stahl 1984; Pan et al., 1985). Transferrin 
receptor is lost from RBCs in all known species but sheep cells retain glucose transporter 
while losing nucleoside transporters and the reverse is true of pig cells (Jarvis et al., 1980; 
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Jarvis & Young 1982; Zeidler & Kim 1982; Johnstone et al., 1987) In addition to 
transmembrane proteins, GPI-anchored proteins like acetylcholine esterase and prions are 
secreted out from the cells using exosomes (Johnstone, Bianchini & Teng 1989; Fevrier et 
al., 2004; Porto-Carreiro et al., 2005). Some of the p53-regulated extracellular proteins are 
secreted via exosomes and this is accomplished by upregulation in the expression of the 
protein TSAP6 by p53 (Yu, Harris & Levine, 2006). Some cytokine receptors like Tumour 
Necrosis Factor (TNF) receptor 1 are released through exosomes (Zhang et al., 2006). These 
exosomes may compete for ligand binding and the local concentrations of such exosomes 
may regulate the effect of cytokines on target cells. Also, transfer of active cytokine receptors 
to target cells may increase the target cell response to such cytokines. In another example of 
their function, exosomes released by the epididymis, called epididysomes, are known to 
transfer proteins to sperm cells which are necessary for their maturation and for egg binding 
(Sullivan et al., 2005). Exosomes also have a well-recognised role in activation of the 
immune system. Thus, exosomes from mature dendritic cells (DC) are two orders of 
magnitude more effective in antigen-specific T cell activation compared to those from 
immature DC (Segura, Amigorena & Thery, 2005). This also suggests that exosome 
functions can also be regulated by differentiation/maturation status of the cell secreting them. 
Exosome secreted from tumour-antigen-pulsed DCs induce anti-tumour immunity (Quah & 
O'Neill, 2005) although this immunity is not specific to tumour type suggesting that 
mechanisms deeper than only antigen presentation are at work. However, this immunity is T 
cell dependent so caution has to be exercised while making inferences. Exosomes also 
function in antigen cross-presentation as they can transfer the antigens from tumour cells to 
DCs (Wolfers et al., 2001). Apart from antigen presentation, exosomes also function as 
immunosuppressive agents. Injection of donor-haplotype exosomes from bone marrow DCs 
before transplantation leads to prolonged heart allograft survival in congenic MHC-
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mismatched rats (Peche et al., 2003). The same study also shows significant decrease in 
CD4+ T cells upon exosome treatment suggesting a role played by them in immuno-
tolerance. Exosomes from IL-4 and IL-10-treated immature DCs reduce the severity of 
collagen-induced arthritis (Kim et al., 2005; Kim et al., 2007). Exosomes from T cells, 
melanoma cells and ovarian cancer cells are known to carry the Fas ligand (FasL) on their 
surface which can induce T cell apoptosis (Karlsson et al., 2001; Van Niel et al., 2003; 
Mallegol et al., 2007). Moreover, exosomes released from DCs, virally transduced to produce 
FasL, exhibit anti-inflammatory activity (Kim et al., 2006). Based on all the qualities outlined 
above, exosomes have huge potential clinical applications, particularly in treatment of 
autoimmune diseases like rheumatoid arthritis and inflammatory diseases. Among their roles 
in immune functions, it has been discovered that exosomes released from basolateral 
enterocytes appear to function to induce tolerance for food antigens possibly by transferring 
antigens from the intestine to local dendritic cells (Lin, Almqvist & Telemo, 2005; Mallegol, 
van Niel & Heyman, 2005). Therefore, intestinal exosomes may help to maintain 
tolerogenicity and immuno-suppressive environment of the intestine. Exosome-mediated 
transfer of mRNA and miRNA has been proposed to confer completely new functions to the 
target cells (Valadi et al., 2007).  
1.2.3 Analysis methods for exosomes and shed vesicles and associated challenges 
As the clinical interest in exosomes and shed vesicles increases, new detection and analysis 
methods are urgently needed. All methods have their own advantages and drawbacks which 
are discussed below. The following are the commonly used and novel methods used for this 
purpose. 
1.2.3.1 Electron microscopy 
Transmission electron microscopy (TEM) uses electrons to generate an image and the 
wavelength of electrons is three orders of magnitude shorter than visible light. Therefore 
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resolution down to 1nm can be achieved. TEM is currently among the best method to 
determine the morphology and size of both exosomes and shed vesicles (Pisitkun, Shen & 
Knepper, 2004). A known source of artefacts is the fixation and dehydration steps which may 
affect size and morphology of vesicles. Purified vesicles are used for TEM analysis. 
Therefore, pre-analytical factors, such as enrichment and aggregation of vesicles, can bias the 
counting making the determination of concentration inaccurate. The measurement time 
required for TEM is several hours and, additionally, fixation and negative staining have to be 
performed, further increasing the time required. Use of immunogold TEM can also provide 
information on biochemical composition (Pisitkun, Shen & Knepper, 2004) of the vesicles by 
detecting specific proteins although quantitation is not very accurate  (Griffiths & Hoppeler, 
1986) and sensitivity depends on retention of antigen conformation and antibody binding 
during fixation and staining. Field emission scanning electron microscopy (FESEM) has also 
been applied to image exosomes (Sharma et al., 2010) and the resulting images are three-
dimensional which seem better than TEM in determining morphology and size (Figure 1.8). 
 
Figure 1.8: TEM (a) is compared with FESEM (b) for determination of morphology, shape 
and size of exosomes. Both parts of image are for exosomes derived from saliva. The TEM 
image in part a) is taken from (Berckmans et al., 2011) and the FESEM image in part b) is 
taken from (Sharma et al., 2010) 
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A distinct advantage of FESEM is minimal sample preparation and elimination of the need 
for negative counterstaining of the exosome vesicles. Moreover, FESEM images are obtained 
at much lower beam energy compared to TEM which is expected to reduce the direct damage 
to vesicles during multiple imaging. 
1.2.3.2 Atomic force microscopy 
An atomic force microscope (AFM) consists of a cantilever with a tip at the end which scans 
the surface (Mica) without physical contact (tapping mode) and through recording the 
accurate movements of the tip, a three-dimensional image is created. AFM can be used to 
obtain information about size, morphology, shape and density of a vesicle population 
(Palanisamy et al., 2010). Figure 9 compares the images of exosomes obtained using tapping 
mode and amplitude modulation-AFM (AM-AFM)  (Sharma et al., 2010).  
 
Figure 1.9:  Salivary exosomal image obtained using the tapping mode (a) and the image 
obtained using amplitude modulation mode (b). In part (b), aggregation of vesicles can be 
more easily observed and tube like connections between individual vesicles are marked by 
arrows. This figure is taken from  (Sharma et al., 2010) 
However, AFM analysis entails immobilization of vesicles on a mica surface which can be 
physical adsorption or antibody-mediated immobilisation. Due to the variable efficiency of 
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these processes, the concentration of vesicles cannot be determined. Moreover, shape can be 
altered upon physical immobilization and the force applied by the AFM tip (Sharma et al., 
2010) may lead to generation of artefacts. A rise in concentration of the vesicles during 
isolation and purification can also produce artefacts like aggregation of exosomes. Density of 
protein receptors on the surface of individual vesicles can be obtained using antibody-
functionalised AFM tips or applying gold-conjugated antibody before AFM imaging (Sharma 
et al., 2010). The measurement time involved is in the order of many hours. 
1.2.3.3 Nanoparticle tracking analysis 
Nanoparticle tracking analysis (NTA) measures the absolute size distribution of particle in a 
fluid ranging from 50 nm to 1 µm. Particles in a fluid are illuminated by a laser light and 
scattered light is collected by an optical microscope. The movement of individual particles is 
followed by a video sequence and velocity is calculated which gives information about 
absolute size distribution of the particles after calibrating with beads of known size and 
concentration (Filipe, Hawe & Jiskoot, 2010). However, owing to the detection limit of the 
microscope, particles smaller than 50 nm cannot be detected. Fluorescence-based NTA 
methods are developing at a fast pace and they are ideally suited for exosomes (Sokolova et 
al., 2011) as the limit of detection is in range of the size of exosomes. Bigger vesicles 
(>50nm) can be readily analysed using NTA although the only information obtained is size 
distribution and biochemical composition and cellular origin remain undetermined. 
1.2.3.4 Flow cytometry 
In a flow cytometer (FC) particles are guided in a hydro-dynamically focused fluid stream 
using a laser beam. There are two detectors one measuring the forward light scattering (FSC) 
which is in line with laser and the other being perpendicular to the beam measuring side 
scattering (SSC). The lower detection limit of commercial flow cytometers for polystyrene 
beads is 300-500nm (Steen, 2004; Perez-Pujol, Marker & Key, 2007; Robert et al., 2009). 
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Only the particles differing in size by at least 280nm can be resolved by FC (Perez-Pujol, 
Marker & Key, 2007; Robert et al., 2009). Both these limitations mean that only certain sub-
populations can be detected by scattering FC and exosomes are not detected at all. 
Quantitative information about size is obtained by comparing the light scattering intensity of 
vesicles with beads of known size. However, scattering intensity is dependent not only on 
size but also on shape, refractive index and light absorption making inferences about size 
difficult. The concentration can be determined if the flow rate is known, provided that all the 
vesicles are detected and intensity of scattered light is above the detection limit. No 
information on morphology of vesicles from scattering FC is obtained. Information about 
rough biochemical composition and cellular origin can be obtained by correlating FSC with 
SSC. For example, FSC correlates with the volume of the particle and SSC correlates with 
inner structures such as shape of the nucleus. However, light scattered from surface of large 
vesicles masks the light scattered from structures inside the vesicles making it difficult to 
distinguish the vesicles with different cellular origins having different inner structures. 
However this analysis can be improved by analysing the polarization of light scattered 
sideward (Degrooth et al., 1987). Fluorescence based FC (FFC) is more sensitive than 
scattering-based FC as the intensity of the fluorescence is higher than scattered light. Modern 
FFC can detect a single fluorophore by minimizing interfering background fluorescence. 
However, enumeration of the vesicles depends on signal-to-background noise ratio which 
sometimes can give false results. Also the efficient labelling of all the vesicles and low 
background depends on efficiency of antibodies used and the density of the respective 
antigens on individual vesicle’s surface. Lipid-based probes have been proposed but when 
working on a whole fluid or non-purified samples then staining of cells and particularly, 
interference by membrane debris may pose problems. Calcein-AM has also been tested and 
brings advantages as only the intact vesicles are stained and not the debris (Kendall & 
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Macdonald, 1982). FC remains an active area of research for developing size evaluation and 
counting methods for exosomes and other defined shed vesicles. However, exosomes pose 
significant challenge owing to their small size. 
1.2.4 Urinary Exosomes and microvesicles 
Urine contains exosomes secreted by epithelial cells along all nephron segments (Pisitkun, 
Shen & Knepper, 2004) as well as other type of vesicles like podocyte microvilli-derived 
vesicles (Hara et al., 2010). Exosomes are released into urine by fusion of MVB membrane 
with the apical plasma membrane while podocyte-derived vesicles are generated by a process 
called tip vesiculation (Hara et al., 2010). Other type of vesicles, like ectosomes have not 
been studied from the urine although there is no reason to believe they are not present. 
Vesicles have been harvested from urine using the same methodology in multiple studies. 
However, different authors have given them different names leading to a high degree of 
confusion. For example Pistikun et al., describe these vesicles as exosomes (Pisitkun, Shen & 
Knepper, 2004) while Smalley et al., call them microparticles (Slrnalley et al., 2008). 
Exosomes from the urine contain the typical exosomal markers including CD63 and Tsg101 
while podocyte-derived vesicles contain podocalyxin and complement receptor 1 (CR1 or 
CD35) although there is an overlap of some of the marker proteins. Biogenesis of exosomes 
and the pathways and signals involved in protein sorting to exoxomes have already been 
discussed in previous sections (section 1.2.2.1). Urinary exosomes typically contain 
cytoplasmic protein entrapped at the time of inward budding into endosomal membrane. It 
also contains a snapshot of endocytotic proteome of the apical plasma membrane. Moreover, 
exosomes isolated from urine are in fact a mixture of exosomes secreted by all types of renal 
epithelial cells. Therefore, they contain proteins from glomerular podocytes, epithelial cells 
of proximal tubules, thick and thin ascending limbs of Henle, the distal convoluted tubule, the 
collecting duct, the renal papilla, the renal pelvis, the ureter as well as the transitional 
40 
 
epithelia of urinary bladder and urethra (see Figure 1.2). These characteristics make urinary 
exosomes an ideal source and starting material for biomarker discovery for diagnosis and 
monitoring of diseases affecting different parts of the nephron. Also, the isolation of urinary 
exosomes enriches for low abundant proteins by removing the higher abundant proteins 
normally present in urine and reduces the complexity of the urinary proteome. Together these 
facts make exosomes ideally suited for biomarker discovery. In a large-scale urinary exosome 
proteomics study, 177 proteins, that are associated with distinct diseases, were identified and 
34 of them were involved in specific kidney pathologies (Gonzales et al., 2009). Some of the 
proteins found in exosomes and those associated with specific renal pathologies or blood 
pressure regulation are shown in Table 1.2. 
 
Table 1.2: Selected proteins identified in urinary vesicles that are associated with kidney 
diseases or hypertension. The table has been taken from  (Pisitkun, Shen & Knepper, 2004) 
 
Kidney diseases or hypertension 
 
Identified proteins 
 
Autosomal dominant and autosomal recessive nephrogenic diabetes 
Insipidus 
Aquaporin-2 
 
Antenatal Bartter syndrome type 1 
 
Sodium potassium chloride 
cotransporter-2 
 
Gitelman’s syndrome 
 
Thiazide-sensitive Na-Cl 
cotransporter 
 
Autosomal recessive pseudohypoaldosteronism type 1 
 
Epithelial sodium channel α, 
β, γ 
 
Liddle syndrome 
 
Epithelial sodium channel β, 
γ 
 
Familial renal hypomagnesemia 
 
FXYD domain-containing 
ion transport regulator-2 
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Autosomal recessive syndrome of osteopetrosis with renal tubular 
acidosis 
Carbonic anhydrase II 
 
Proximal renal tubular acidosis Carbonic anhydrase IV 
Autosomal dominant polycystic kidney disease type 1 Polycystin-1 
Medullary cystic kidney disease 2 and familial juvenile 
hyperuricemicnephropathy 
 
Uromodulin 
 
 
Autosomal recessive steroid–resistant nephrotic syndrome Podocin 
Fechtner syndrome and Epstein syndrome 
 
Nonmuscle myosin heavy 
chain IIA 
 
2,8-Dihydroxyadenine urolithiasis Adenine 
phosphoribosyltransferase 
Hypertension 
 
 
 
 
 
 
Angiotensin I converting 
enzyme isoform-1 
Aminopeptidase A 
Aminopeptidase N 
Aminopeptidase P 
Neprilysin 
Hydroxyprostaglandin 
dehydrogenase 15- (NAD) 
Dimethylarginine 
dimethylaminohydrolase-1 
 
1.2.4.1 Exosomes as biomarkers 
An early example of clinical utility of urinary exosomes was demonstrated by 
immunoblotting analysis of urinary exosomes from two patients with Bartter syndrome type 
I. The patient with this syndrome present with mutations in SLC12A1 gene which codes for 
sodium-potassium-chloride co-transporter protein (NKCC2) and accordingly NKCC2 bands 
were absent in the urine of patients compared with appropriate controls (Gonzales et al., 
2009). Aquaporin-2, an important channel protein in water homeostasis, is delivered into 
urine via exosome secretion and is a well established biomarker of several water-balance 
disorders, such as diabetes insipidus (Kanno et al., 1995; Elliot et al., 1996; Valenti et al., 
2000; Ishikawa & Schrier, 2003). The Na+/H+ exchanger protein isoform 3 is a candidate 
biomarker of kidney tubular damage and could be useful in differential diagnosis between 
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acute tubular necrosis and other causes of acute kidney injury (AKI) (Du Cheyron et al., 
2003). Another study has reported urinary exosomal fetuin-A to be a potential biomarker of 
AKI in a rat model of the disease further verified in immunoblot analysis of human patient 
urine samples (Zhou et al., 2006a). A number of transcription factors were identified in 
urinary exosomes which could reflect a new class of biomarkers of AKI and chronic kidney 
diseases (Hogan et al., 2009) more related to activation of specific genetic pathways. 
Moreover, analysis of urinary exosomes in patients with malignancies of urinary drainage 
tract would be very helpful in diagnosis of the disease and monitoring of therapy. 
Accordingly the proteomic study of urinary microvesicles from individuals with bladder 
cancer revealed eight over-expressed proteins and one downregulated protein compared to 
healthy individuals (Slrnalley et al., 2008). Urinary exosomes also contain mRNA (Valadi et 
al., 2007) and identification of genetic mutations in these would be a lucrative non-invasive 
diagnostic test for genetic diseases.  
1.2.4.2 Isolation methods for urinary exosomes  
The traditional method for urinary exosome isolation has been differential centrifugation 
where a low speed centrifugation (17,000g) is adopted to remove whole cells, tubular casts 
and membrane fragments. This step is followed by ultracentrifugation (200,000g) to pellet 
down urinary exosomes and other similar sized vesicles (Pisitkun, Shen & Knepper, 2004). 
However, it has to be appreciated that direct 17,000g centrifugation pellets down not only 
cells but also larger groups of vesicles like shed vesicles. Furthermore, the 200,000g pellet 
often consists of vesicles other than exosomes such as similar size membrane particles and 
ectosomes. The stepwise centrifugation method yields a heterogenous mixture of vesicles and 
cannot be considered to contain pure exosomes. One additional problem associated with this 
method is contamination of 200,000g pellet with soluble or aggregated high-abundant 
proteins like Tamm-Horsfall glycoprotein (THP) and albumin. Thus, this pellet at best can be 
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considered a crude pellet of exosomes. Furthermore, it was found that entrapped in THP 
polymers, exosomes were also pelleting down at low speed (P18,000g) (Fernandez-Llama et 
al., 2010). To remove contamination of aggregated proteins one solution has been proposed 
which includes treatment of low speed and high speed pellets with dithiothreitol (DTT) 
followed by a second centrifugation at low and high speed.  
 
Figure 1.10: Effect of DTT treatment on THP behaviour of low (17,000g) and high speed 
(200,000g) pellets of urine. The figure has been taken from (Fernandez-Llama et al., 2010) 
DTT treatment largely removes the THP and exosomal markers from low speed pellet which 
now precipitate with the high speed pellet. This procedure increases the exosomal yield 
without any doubt but it creates a new problem as THP is now present in very high amounts 
in the high speed pellet (Figure 1.10). This fact often leads to interference in further analysis 
of the exosomal pellet by masking low abundance proteins. Another method which has been 
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employed is sucrose density gradient centrifugation. This was used to isolate exosomes from 
immune cells and cell culture and also on urinary exosome-like vesicles (Hogan et al., 2009). 
This method is presently the most sensitive one available and yields the purest forms of 
exosomes with minimal contamination with high abundant proteins. It has to be empahsized 
that both these ultracentrifugation methods are very labour intensive and require extensive 
instrumentation and long processing times making them unsuitable for clinical diagnostics. 
Moreover, this would make them impractical where a large number of samples have to be 
handled. Alternatives have been proposed like nanomembrane concentration (pore size 13nm 
and Molecular Weight ‘cut-off’ of 100kDa) to enrich the exosomal fraction from urine 
(Cheruvanky et al., 2007). It was possible in this study to recover membrane vesicles with 
exosomal markers as tested with western blotting (WB) and the yield was found to be similar 
to ultracentrifugation. There was minor loss of vesicles on the filter membrane surface which 
were recovered by 2X pre-heated Laemmli buffer which solubilised those vesicles. 
Advantages of the method include the short ‘processing time’ and the use of inexpensive 
instrumentation, e.g. the table top centrifuge. However, recovery of vesicles from filter 
surface with Laemmli buffer would yield solubilised exosomal proteins which can only be 
analysed by SDS-PAGE or WB and FC or TEM analysis would be rendered impossible. 
Other types of analysis like MS analysis would require additional purification steps. The ‘cut-
off’ at 100 kDa means that high molecular weight proteins and protein complexes not part of 
exosomes will be enriched as well and will interfere with further analysis by masking low 
abundance proteins in exosomes. As many proteins, like THP and albumin, remain in 
polymeric forms they will be enriched with exosomes as well. It has already been shown that 
nanomembrane ultrafiltration enriches soluble proteins like albumin and α-1-antitrypsin along 
with exosomes when applied to nephrotic urine (Rood et al., 2010) and limits the detection of 
microvesicular proteins.  Another alternative method showed that loading the crude 
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ultracentrifugation pellet onto a size exclusion chromatography column yielded three 
fractions (HMW, LMW and >10kDa). The high molecular weight fraction (HMW) showed 
the presence of exosomal markers while the low molecular weight (LMW) fraction had only 
high abundant proteins. The LMW fraction was present only in nephritic urine and absent in 
normal urine suggesting that large amounts of high abundance proteins interfere with the 
isolation and subsequent analysis of exosomes in nephrotic urine. The impact of storage 
conditions and preservation was assessed on yield and stability of the exosomal fraction and 
associated proteins (Zhou et al., 2006b). The study showed that some of the exosomal 
proteins can be susceptible to degradation if protease inhibitors are not added at the time of 
sample collection. However, this was done on two different samples and not on the same 
sample which had been divided into two parts thus it may be subject to sample-to-sample 
variations. Freezing urine samples at -80°C was better for recovery of exosomes by 
ultracentrifugation compared to freezing at –20°C and extensive vortexing improves the 
recovery after freezing. Finally, first and second morning urine is comparable in terms of 
content and recovery of exosomes and associated proteins. Adjustment of pH before freezing 
the samples did not affect protein stability (Miki & Sudo, 1998).  
1.2.4.3 Proteomic analysis of urinary exosomes and other vesicles 
Proteomic analysis is an important tool which helps to annotate and understand the function 
of exosomes as well as presenting avenues for biomarker discovery by enabling differential 
protein analysis between normal and pathologic patient samples. Exosomal composition 
varies according to the cell type of origin but some components appear to be present in all 
exosomes which reflects their secretion pathway and common origin. The presence of 
tetraspanins (CD63, CD9, CD81 and CD82) in exosomes, regardless of their cell of origin, is 
such a typical characteristic. Exosomes also contain heat shock proteins Hsp70 and Hsp90 
which assist loading of peptide onto the major histocompatibility complexes MHCI and 
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MHCII, among other functions. Exosomes are also enriched in proteins involved in vesicle 
formation and trafficking, like Alix and Tsg101 among others. Proteins involved in 
membrane fusion and exosome docking, like Rabs and annexins including I, II, V, VI are also 
present (Mears et al., 2004; Futter & White, 2007) common to most exosomes from various 
cells. A variety of adhesion molecules, like CD146, CD9, CD18, CD11a, b and c, milk-fat-
globule EGF factor-VIII (MFG-E8), intercellular adhesion molecule-1 and CD58, have been 
found in exosomal fractions (Thery et al., 2001; Mears et al., 2004). Proteins involved in 
apoptosis such as 14-3-3, galectin-3 and thioredoxin peroxidise have also been found. 
Metabolic enzymes including enolase-1, pyruvate and lipid kinases and peroxidases are also 
commonly found (Hegmans et al., 2004).  Figure 1.11 is a schematic showing protein 
composition found in exosomes from various sources along with their function for some of 
them. 
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Figure 1.11: Schematic representation of typical proteome content of exosomes derived from 
various types of cells. This figure has been taken from (Schorey & Bhatnagar, 2008) 
There have been a number of proteomic studies of different types of urine vesicles such as 
membrane particles and urinary exosomes. One of the earliest was by Pistikun et al., 
(Pisitkun, Shen & Knepper, 2004) who isolated low density membrane vesicles by 
differential centrifugation followed by DTT treatment to remove interference of THP and 
they termed these vesicles “exosomes”. They identified 295 unique proteins, from which 73 
are known to be involved in membrane trafficking including endosomal traffic. Forty-eight 
proteins were integral membrane proteins, eight were GPI-anchored and twenty three were 
peripheral membrane proteins. All the integral proteins identified were from the apical side of 
plasma membrane and none were from the baso-lateral side suggesting that exocytosis of 
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vesicles found in urine occurs at the apical side of cells. Additionally a number of high-
molecular weight ubiquitin bands were observed in the immunoblot (Figure 1.12) suggesting 
these membranes consist of ubiquitinated proteins.  
 
 
 
Figure 1.12: Instances of identification of ubiquitin and immunoblot using anti-ubiquitin 
antibodies. Part A shows the numbers of different ubiquitin peptides were identified at a 
given molecular weight; x-axis is the number of ubiquitin peptides identified and the y-axis is 
the molecular weight corresponding to the gel segment from where the band was cut. Part B 
is the western blot of high-speed pellet (P200,000g) using anti-ubiquitin antibodies. The 
figure is taken from (Pisitkun, Shen & Knepper, 2004) 
A number of solute and water transporters were also identified. Readers are directed to the 
original study for complete list of the proteins. Polycystin-1, which codes for protein product 
of the gene responsible for autosomal dominant polycystic kidney disease, was also 
identified. Shortly thereafter the same group published a large-scale proteomics and 
phosphoproteomics study on urinary exosomes isolated by the same method as their previous 
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study (Gonzales et al., 2009). The list of phosphoproteins identified and the phosphorylation 
site is provided in the following section about post-translational modifications. They 
identified 1132 proteins unambiguously including 205 proteins from the previous study and 
927 new proteins. A large number of integral membrane proteins, mainly apical solute and 
water transporters were identified from every kidney tubule segment including the proximal 
tubule (sodium-hydrogen exchanger 3, sodium-glucose co-transporter 1 and 2, and 
aquaporin-1 [AQP1]), the thick ascending limb (sodium-potassium-chloride co-transporter 2 
[NKCC2]), the distal convoluted tubule (thiazide-sensitive Na-Cl co-transporter [NCC]), and 
connecting tubule/collecting duct (AQP2, rhesus blood group C glycoprotein [RhCG, an 
ammonia channel], B1 subunit of vacuolar H
+
-ATPase, and pendrin). Twenty two proteins, 
part of the ESCRT-0, ESCRT-I, ESCRT-II, and ESCRT-III complexes involved in 
multivesicular body formation, were also identified. These proteins cover 75% of total 
ESCRT machinery. This original study was followed by another study published by Hogan et 
al., (Hogan et al., 2009), who isolated a urinary exosomal fraction by a traditional 
centrifugation method and this fraction was subfractionated by density gradient 
ultracentrifugation (5-30% sucrose gradient). This resulted in three fractions representing 
markers aquaporin-2, polycystin-1 (PC-1) and podocin. These PKD vesicles were analysed 
by proteomic methodology and 552 proteins were identified including 232 proteins not 
reported in urinary proteomic databases. They also identified polycystin-2 (PC-2) and 
fibrocystin (FCP) in their PKD vesicle preparations. They identified the in vivo cleavage 
products of PC-1 and FCP which confirmed the previous in vitro studies (Ponting, Hofmann 
& Bork 1999; Qian et al., 2002; Kaimori et al., 2007). They also demonstrated the interaction 
of PKD vesicles with primary cilia of kidney and biliary epithelial cells. In addition to these 
studies, another study has shown isolation of podocyte membrane vesicles from normal and 
pathological (several types of nephropathies) urine by immunoadsorption onto anti-
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complement receptor-1 (CR-1) antibody-bound magnetic beads (Lescuyer et al., 2008). They 
identified 76 proteins out of which 37 were identified only in pathological urine. 
Interestingly, 55 proteins of the 76 were plasma proteins and one could speculate about 
proteinuric states in these nephropathic samples. Paraoxanase-1 (PON-1) was identified in 
human urine for the first time from a patient with severe lupus nephritis and renal 
insufficiency.  
A comparison of proteins identified in all these proteomic studies of urinary vesicles with the 
most comprehensive urine protoemics study to date (Marimuthu et al., 2011) and with each 
other is presented in Figure 1.13. CR-1 immunopurified vesicles proteomics is marked as 
ectosomes and all other studies are marked with the first author of the studies.  
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Figure 1.13: exosomal proteomics studies (Combined  (Pisitkun, Shen & Knepper, 2004) and 
(Gonzales et al., 2009)), exosome-like vesicles  (Hogan et al., 2009), CR-1 immuno-isolated 
vesicles (ectosomes (Lescuyer et al., 2008)) and whole urine proteomic study (Marimuthu et 
al., 2011) are compared to each other. 
Pistikun and Gonzalez et al., have worked with crude vesicle preparations. Therefore, their 
exosomal fraction is probably a mixture of many different types of vesicles like exosomes, 
ectosome/shed vesicles and membrane particles. Hence, they are likely to have overlaps with 
all other studies which are illustrated in figure 1.13. On the other hand Hogan et al., purified 
vesicles which have a significant fraction of proteins not covered by any of the earlier studies. 
Apart from the highly dynamic nature of exosomes, this suggests that theirs is a novel protein 
set with possible different functions than other exosomal and ectosomal vesicles. 
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1.3 Post-translational modification and proteomic analysis 
The function of a cell is dependent on a multitude of biochemical reaction cycles, going on 
simultaneously in the cell, at various locations. A very high degree of diversity in proteins 
involved in these reactions is needed to temporally and spatially regulate the respective 
activities at different sub-cellular microdomains. Altered and sometimes many different 
localisation of a same protein may be needed for different pathways. The same protein might 
be required, for example, in cytoplasm or plasma membrane to execute the signals 
propagated by different stimuli. This extremely high level of diversity is not possible with 
only approximately 25,000 genes coding for proteins in humans (U.S. Human Genome 
Project, http://www.ornl.gov/sci/techresources/Human_Genome/home.shtml). One of the 
major ways to generate such diversity is through covalent post-translational modifications 
(PTMs) of the proteins at one or more sites (Walsh, Garneau-Tsodikova & Gatto, 2005). 
Because α-carboxy and amino group of an amino acid are involved in bonding to make 
peptide bond in protein backbone, these modifications mainly occur at amino acid side chains 
and/or at the amino- or carboxy-terminus of the proteins. Table 1.3 lists some of the major 
PTMs of the different amino acid side chains.  
Table 1.3: Common post-translational modifications of amino acid side chains. This table 
has been adapted from  (Walsh, Garneau-Tsodikova & Gatto, 2005) 
Residues Reaction  Example 
Multiple residues Proteolysis Signal peptide cleavage, 
activation of proteases 
Asp Phosphorylation Protein tyrosine phosphotases, 
response regulators in two-
component systems 
 Isomerisation to isoAsp 
Glu Methylation  Chemotaxis receptor proteins 
 Carboxylation  Gla residues in blood 
coagulation 
 Polyglycination  Tubulin  
 Polyglutamylation  Tubulin 
Ser Phosphorylation Protein serine kinases and 
phosphotases 
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 O-glycosylation Notch O-glycosylation 
 Phosphopantetheinylation  Fatty acid synthase 
 Autocleavages  Pyruvamidyl enzyme formation 
Thr Phosphorylation  Protein threonine 
kinases/phosphatses  O-glycosylation 
Tyr Phosphorylation Tyrosine kinases/phosphatses 
 Sulfation  CCR5 receptor maturation 
 Ortho-nitration Inflammatory responses 
 TOPA quinine Amine oxidase maturation 
His Phosphorylation Sesnsor protein kinases in two-
cmoponent regulatory systems 
 Aminocarboxypropylation  Dipthamide formation 
 N-methylation Methyl CoM reductase 
Lys N-methylation  
 N-acylation by acetyl, biotinyl, 
lipoyl, ubiquityl groups 
Histone acetylation, swinging-
arm prosthetic gropus, 
ubiquitin, SUMO tagging of 
proteins 
 C-hydroxylation Collagen maturation 
Cys S-hydroxylation (S-OH) Sufenate intermediates 
 Disulfide bond formation Protein in oxidising 
environments 
 Phosphorylation PTPases 
 S-acylation Ras 
 S-prenylation Ras 
 Protein splicing Intein excisions 
Met Oxidation to sulfoxide Met sulfoxide reductase 
Arg N-methylation Histones 
 N-ADP ribosylation Gsα 
Asn N-glycosylation N-glycoproteins 
 N-ADP ribosylation eEF-2 
 Protein splicing Intein excision step 
Gln Transglutamination Protein cross-linking 
Trp C-mannosylation Plasma membrane proteins 
Pro C-hydroxylation Collagen, HIF-1α 
 Cis-trans isomerisation Protein prolyl isomerases 
Gly C-hydroxylation C-terminal amide formation 
 
These PTMs can potentially change the activity and/or localisation of the proteins acting as 
regulators of various biological processes in the cell. Exosomes/microvesicles originate from 
specialised compartments of the cells involved in regulatory and communication processes of 
the various target cells. It is, therefore, extremely important to characterise PTMs of proteins 
found in exosomes/microvesicles because they will reflect upon the functions of these 
vesicles and also provide information about classes of proteins sorted to these vesicles. 
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Protein modifications are not homogenous and a single gene can give rise to many sub-
populations of a protein by alternative splicing of the gene and a single or multiple 
modifications of the protein residues. Usually only a fraction of a protein is modified by 
PTMs. Therefore, the amount of modified protein is often not sufficient for complete 
characterization by MS. As a result, recombinant proteins are often used as a source for such 
studies. However in vitro-modified proteins can be significantly different from the in vivo 
modifications. Two-dimensional electrophoresis (2DE) is often used to separate different 
modification states of a protein population followed by their characterization by MS. For 
example, phosphorylated proteins on 2DE leave a horizontal trail owing to charge differences 
among modified and non-modified forms. N- and C-terminal processing of enolase was 
studied with a combination of 2DE and MS and more than 10 different forms were defined 
(Larsen et al., 2001). Antibody precipitation and chromatographic methods are also used to 
enrich the modified proteins followed by their identification or characterization by MS. The 
isolation method selection mainly depends upon the type of modification in question. Anti-
phosphotyrosine antibody can enrich phosphorylated tyrosine-containing proteins (Pandey et 
al., 2000) while an anti-phosphoamino acid antibody can be used for detection of 
phosphoserine or phosphothreonine (Gronborg et al., 2002). However, 
glycosylphosphatidylinositol (GPI)-anchored proteins are usually released by specific 
enzymes from the cell surfaces and, after removing the cells by centrifugation, proteins in the 
supernatant can be identified. This type of analysis will yield a global identification of GPI-
anchored proteins. Transfection of cells with a tagged version of ubiquitin or SUMO proteins 
and subsequent tag-based purification yields all proteins covalently attached to these 
modifiers (Vertegaal et al., 2006) which can be subsequently identified by MS. If the 
enrichment protocol is designed carefully it eliminates the need for further complex 
characterization by MS and only identification of enriched proteins is often sufficient. There 
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have been very few studies characterising PTM of the exosomal/microvesicle proteins. These 
are discussed according to the type of PTM involved. 
1.3.1 Glycosylation 
One of the most common and important type of PTM is glycosylation in which proteins 
contain one or more heterosaccharides covalently bound to the polypepide backbone. These 
conjugated proteins are called glycoproteins. These proteins are present in all forms of life 
and almost every type of tissues and cells as well as in cell secretion products. These 
heterosachharides conjugated to proteins are called glycans and they make upto 10-60% of 
the weight of glycoproteins. Two major types of glycosylations are N-linked and O-linked 
glycosylation. The N-linked refers to the bond of glycan with a nitrogen atom in the amino 
acid asparagine while O-linked refers to bonding of glycans to oxygen atom in serine or 
threonine. N-linked glycoproteins contains β-glycosidic linkage between a GlcNAc residue 
and the δ amide N of an asparagine (Asn) side chain. The common feature between different 
types of N-linked glycans is a pentasaccharide (Man3 GlcNAc 2) core which reflects common 
precursors to all forms. N-linked glycans fall into three main subclasses as shown in Figure 
1.14. 
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Figure 1.14: Structural varieties in N-glycosylation. 
 Polylactosamine extensions are composed of number of (Galβ1-4GlcNAcβ1-)n disaccharide 
units within one of the antenna.  Alternatively, GlcNAc residue directly attached to the Asn 
residue or on the antennae could be derivatised with the monosaccharide fucose. Despite the 
structural composition of each antenna, all N-linked glycans may be capped with an N-
acetylneuraminic acid- galactose (NeuAc-Gal) disaccharide. The variety of sialic acids, 
containing NeuAc residue, is either α2-3 or α2-6 linked to the penultimate galactose.  A 
summary of the various potential modifications that can occur are shown in Figure 1.15. 
High Mannose
Complex
Triantennary
Antenna
Antenna
Antenna
BiantennaryAntenna
Antenna
Hybrid
Antenna
Tetraantennary
Antenna
Antenna
Antenna
Antenna
N-acetylglucosamine
Mannose
Galactose
57 
 
 
Figure 1.15: Possible modifications of the N-glycosylation glycan structure. 
O-linked glycans are formed by an α-glycosidic linkage between a GalNAc and the hydroxyl 
group of a Ser or Thr residue.  Following attachment of the GalNAc residue to Ser/Thr, a 
Galβ1-3 attachment to the GalNac forms what is termed a core 1 O-linked glycan.  This is 
either disialyated to complete the core 1 structure or further extended to produce a core 2 O-
linked glycan.  Core 1 and 2 structures may be seen in Figure 1.16. 
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Figure 1.16: various core structures of O-glycosylation. 
Unlike N-glycosylation, there is no preformed core structure that is formed before the final 
glycan structure is established. O-linked glycosylation unlike N-linked glycosylation takes 
place completely in golgi apparatus. O-linked glycans contain non-reducing α-linked sugars 
(sialic acid and fucose) while mannose and glucose are absent. 
Glycosylation is a dynamic PTM and it is believed that it changes upon alterations in 
physiological state of an organism are reflected in altered expression of glycans or a change 
in their type. Several hereditary diseases show alterations in glycosylation associated with 
mutant phenotype. For example, persons with Carbohydrate Deficiency Glycoprotein 
Syndrome (CDGS) exhibit abnormal glycosylation of proteins like α-1 antitrypsin and 
transferrin (Jaeken & Carchon, 1993). For other diseases, increase in sialylation and 
branching of glycans expressed by cancer cells has been widely observed and it correlates 
directly with metastatic capacity of these cells (Troy, 1992). The glycans on Fc region of 
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immunoglobulins (IgG) lacking in galactose have been observed to be increased in 
rheumatoid arthritis (Youings et al., 1996). Incomplete N-glycosylation in cystic fibrosis 
transmembrane conductance regulator (CFTR) protein leads to ER retention of the protein 
and premature degradation (Jilling & Kirk, 1997) and this contributes to symptoms of cystic 
fibrotic. In case of cardiovascular diseases, abnormal glycosylation of fibrinogen in hepatoma 
can lead to dysfibrinogenemia (Gralnick, Givelber & Abrams, 1978) and also impaired fibrin 
polymerization (Maekawa et al., 1992; Ridgway et al., 1997). In case of IgA nephropathy it 
has been found that there is overrepresentation of IgA1 O-glycoforms in serum which are 
poorly galactosylated. It is suggested that these glycoforms either act as autoantigens driving 
the formation of glycan specific antibodies or as antigens for cross reacting antimicrobial 
antibodies and subsequent formation of immune complexes which take part in pathogenesis 
of the disease (Barrett & Feehally, 2011). Efficient and appropriate glycosylation of several 
kidney proteins is essential for their function. For example, altered glycosylation of rat 
thiazide-sensitive Na-Cl cotransporter (rNCC) affects its normal function and cell surface 
expression in rat renal distal convoluted tubule (Hoover et al., 2003). Glycosylation is an 
important PTM to be studied as it can lead to novel biomarkers of various diseases as well as 
enhanced understanding of the pathogenesis. 
1.3.1.1 Glycomic approaches to study glycosylation 
There is an increasing amount of interest in characterizing glycans of various glycoproteins 
coupled with identification of these proteins. There are LC and MS approaches to study of 
glycans either in purified proteins or from a complex mixture like cell lysates or body fluids. 
This, however, requires liberation of glycans from their corresponding proteins followed by 
reducing terminal labelling for detection and separation. Inability of these techniques to 
assign whole cell or body fluid glycans to their corresponding proteins is one major 
drawback. If one protein at a time is analysed, it reduces the throughput and requires purified 
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proteins in sufficient amount because glycans usually are a small but distinctive portion of a 
whole protein’s mass. Moreover, this procedure is not helpful in the case of O-linked glycans 
as protocols for their liberation are based on chemical removal and the reproducibility of such 
techniques is low. In addition, glycans of glycoproteins show high degree of heterogeneity.  
Another approach to glycomic  analysis is the use of carbohydrate binding proteins (anti-
carbohydrate antibodies and lectins) to fractionate the proteins prior to identification with 
MS. Antibodies are not very useful for this prupose as most of the glycans and components 
thereof are evolutionarily conserved and evoke minimal immunogenicity in antibody-
producing host species. A notable exception is the natural antibodies to blood group 
determinants different than the host blood group. Lectins are sugar-binding proteins having 
distinct specificity to one type of sugar conjugate over others. This specificity varies among 
different lectins. Use of lectins also has limitations in identifying the composition of glycans 
attached to target proteins. These limitations include the inability to infer complete glycan 
composition from lectin binding. Lectin microarray is one rapidly emerging technology for 
profiling of total glycans of complex mixtures like cell lysates and differences among 
pathological states compared to the normal physiological state, present an avenue for 
development of highly sensitive glyco-biomarkers. A definite advantage is the possibility for 
high-throughput analysis of glycans by the lectin microarrays. The respective biomarkers 
discovered have an advantage over protein biomarkers as changes in glycan profile e.g. in 
response to a disease course are rapid and early detection of anomalous structures is possible. 
However, there are many challenges associated with technical and biological variabilities. 
Typically lectins are immobilised or printed (using techniques like that of ink-jet printing) on 
a substrate surface or glass slide and pre-labelled glycoprotein, or a mixture thereof, is 
hybridised to them (Hirabayashi, Kuno & Tateno, 2011). Fluorescence intensity can be 
measured to obtain quantitative information about type of glycans present on a purified 
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protein or the whole glycans of a mixture like a cell lysate. Controls can be compared to a test 
population of samples to evaluate differences and similarities among them. Figure 1.17 
presents various schemes that can be implemented in lectin microarray. 
 
Figure 1.17: Various schemes of lectin microarray including direct cell glycan profiling and 
direct and indirect glycoprotein profiling. Lectins are immobilised on a substrate and labelled 
cells (direct cell profiling) or glycoprotein (s) (direct glycoprotein profiling) are added. In 
another approach glycoproteins captured by lectins can be probed further with a specific 
antibody (indirect glycoprotein profiling). The figure has been taken from  (Hirabayashi, 
Kuno & Tateno, 2011) 
Lectin affinity chromatography coupled to MS can also be used to determine the nature of 
glycans along with corresponding glycoproteins. This is important because, once native 
glycosylation of a protein is known; it becomes much easier to develop antibody and lectin-
based hybrid microtitre plate assays to determine rapidly whether glycosylation of target 
protein is changing in a given pathological state. Lectins have affinity for distinct glycan 
epitopes (Sharon & Lis, 1989) and this property can be used to isolate, fractionate and 
analyse complex mixtures of glycoproteins using e.g. lectin-agarose or magnetic beads with 
immobilised lectins (Wiener & vanHoek, 1996; Bundy & Fenselau, 2001). Lectins only 
enrich a selective fraction of glycoproteins and, therefore, broad specificity lectins are 
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generally used (Mechref et al., 2000; Yamamoto, Tsuji & Osawa, 1998). However, to enable 
complete analysis of most glycoproteins present in a complex biological sample like 
biofluids, multi-lectin columns are needed (Yang & Hancock, 2004; Wang, Wu & Hancock, 
2006). Another method based on hydrazide chemistry can also be used which oxidises the 
carbohydrates attached to glycoproteins and enables their subsequent attachment to a 
hydrazide resin. The N-linked proteins or peptides can subsequently be released by peptide 
N-glycosidase F (PNGase F) (Zhang et al., 2003; Tian et al., 2007). Lectin and hydrazide 
chemistry-based enrichment both have their advantages and disadvantages. For example, in a 
comparative study to analyse rat liver membrane proteins, it was found that lectins mostly 
enriched high molecular weight glycoproteins while the hydrazide method enriched mostly 
low molecular weight proteins (Lee et al., 2009). Therefore, both these methods should be 
used in tandem if possible for optimal results. Reaction with boronic acid can also be used to 
enrich glycoproteins and it was applied to enrich low-abundance glycoproteins from human 
blood samples (Sparbier, Wenzel & Kostrzewa, 2006). Coupling of high-resolution MS 
instruments to these enrichment methods can be used for qualitative and/or quantitative 
analysis of glycoproteins (Wang, Wu & Hancock, 2006). 
1.3.1.2 Exosome/Microvesicle glycosylation 
The glycan signature of the exosome/microvesicle reflects the cell secreting them and 
differences among and between cells and between cells and the vesicles, respectively. 
SKOV3 ovarian carcinoma cell-derived exosomes are remarkably enriched in high-mannose 
or NeuAcα2, 3/6-containing proteins compared to parent cells (Escrevente et al., 2011) 
although the full identity of these proteins is not yet known. Exosome uptake by dendritic 
cells can be specifically inhibited by mannose and N-acetylglucosamine where interaction 
between cell and exosome is mediated by a C-type lectin (Hao et al., 2007). Galectin-5 
mediates the uptake of exosomes by macrophages and this process can be inhibited by 
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supplying lactose, the nominal glycan specificity of this lectin, to the medium (Barres et al., 
2010). This suggests that glycosylation affects the uptake of exosome/microvesicles in a cell 
type-dependent manner. Glycosylation is also an important “address code” signal for 
microvesicle cargo. This is supported by the fact that distinct glycoforms of prion protein 
(PrP) are incorporated preferentially over other forms into exosomes (Vella et al., 2007).  
Lectin microarrays were employed to reveal the glycan expression pattern of microvesicles, 
cell membranes and HIV-1 particles from matched cells. Notably, it was found that HIV-1 
particles and microvesicles (MV) share similar glycosylation, different from the parent cells 
(Krishnamoorthy et al., 2009). Microvesicles and HIV-1 particles were enriched in high-
mannose epitopes (Galanthus nivalis lectin {GNA, Narcissus pseudonarcissus lectin {NPA, 
Hippeastrum hybrid lectin {HHL, Concanavalin-A {Con-A, Pisum sativum agglutinin {PSA, 
cyanovirin-N {CVN, scytovirin {SVN} and griffithsin {GRFT) compared to parent H9 cell 
membrane. MV and HIV were also enriched in complex N-linked glycans (Phaseolus 
vulgaris erythroagglutinin {PHA-E} and leukoagglutinin {PHA-L), N-acetyllactosamine 
(Datura stramonium agglutinin {DSA, Maackia amurensis lectin {MAL-I, Ricinus communis 
agglutinin {RCA, Solanum tuberosum lectin {STA, Wheat Germ agglutinin {WGA), sialic 
acid (Sambucus nigra lectin {SNA, MAA, MAL-II), and fucosylated (Ulex europaeus 
agglutinin I {UEA-I, Psophocarpus tetragonolobus lectin II {PTL-II, Aleuria aurantia lectin 
{AAL) epitopes. Moreover blood antigens A/B (Euonymus europaeus lectin {EEA, 
Phaseolus lunatus lectin {LBA) were absent in microvesicles and HIV-1 while being present 
on the cell membrane. These glycan epitopes enriched in MV and HIV-1 colocalized to 
specific membrane microdomains suggesting that MV arise from specific domains on PM 
and HIV-1 hijacks the glycosylation machinery of MV for its advantage. The immune system 
would see HIV-1 glycans as MV and would not attack the viral particles. The glycan 
signatures among different cell lines (all T-cell lines) were similar in MV but some 
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differences were also present while in the parent cell membrane glycosylation was different 
among cells. It suggests that sorting of glycoproteins to these vesicles is at least in some ways 
glycosylation-specific and may serve as an important mediator of communication between 
cells including that mediated by exosome/microvesicle uptake. Another study by the same 
group, this time using a wide variety of cell line and human breast milk as source of MV, 
reinforced these results showing that MV have a conserved glycan pattern which is different 
from the parent cell membrane (Batista et al., 2011). No other studies have been done on 
glycosignature of exosome/microvesicles or glycoproteomics. Notably these studies did not 
identify the glycoprotein constituents of the vesicles. 
1.3.2 Phosphorylation 
Mammalian phosphoproteome (all the proteins modified by phosphorylation of at least one or 
more amino acids) typically contains phosphoSerine (pS), phosphoThreonine (pT) and 
phosphoTyrosine (pY) residues with the majority being pS and pT (90:10 pS,pT/pY) while 
bacteria and fungi also have phosphoHistidine (pHis) and phosphoAspartic acid (pAsp) 
(Mann et al., 2002). pAsp is also found in some mammalian proteins but it is rare in 
mammals. These phosphorylated amino acids are shown in Figure 1.18.  
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Figure 1.18: Various phosphorylated amino acid structures (Walsh, Garneau-Tsodikova & 
Gatto, 2005). 
One protein can be phosphorylated at multiple residues making the phosphoproteome very 
complex. Over 500 different kinases (Phoshorylating enzymes) are known in the human 
proteome capable of influencing the phosphoprotein outcome, making this network even 
more complex. Introduction of phosphate group(s) to a protein can lead to altered 
conformation and, thus, also protein function  (Johnson & Lewis, 2001) e.g. inducing 
initiation or termination of a signal in a signalling cascade. There has been only one study in 
exosomes which has identified phosphoproteins and their site of modification in urinary 
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exosomes (Gonzales et al., 2009). Gonzalez et al., used mass spectrometric technique of 
neutral loss scanning with high-stringency target-decoy analysis to identify phosphorylation 
sites in urinary exosomal proteins. Nineteen phosphorylation sites corresponding to fourteen 
exosomal proteins were identified in the study. Orphan G-protein coupled receptors 
(GPRC5B and GPRC5C) were among the proteins on which these sites were identified 
including one new site in GPRC5B (T389) and three new sites in GPRC5C (T435, S395 and 
Y426). S811 was identified as a previously unknown phosphorylation site on carboxy 
terminal of thiazide-sentitive co-transporter (NCC) which is proposed to regulate transport. 
S256 was identified in aquaporin-2 (AQP-2) which was further confirmed by immunoblotting 
the exosomal sample with specific anti-AQP-2 antibodies. A list of all the indentified 
phosphorylation sites with corresponding proteins is shown in Table 1.4. 
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Table 1.4: Phosphoproteins identified in urinary exosomes by (Gonzales et al., 2009) 
Ref Seq Protein Name, Sequence Site Gene Novel site 
NP_061123 G protein-coupled receptor family 
C, group 5, member C isoform b  
 GPRC5C  
 R.AEDMYSAQSHQAA 
(T*)PPKDGK.N 
T435  Yes 
 K.VP (S*)EGAYDIILPR.A S395  Yes 
 R.AEDM 
(Y*)SAQSHQAATPPKDGK.N 
Y426  Yes 
NP_001035149 secreted phosphoprotein 1 isoform 
C 
 SPP1  
 K.AIPVAQDLNAPSDWD 
(S*)R.G 
S192  No 
 R.GKD 
(S*)YETSQLDDQSAETHSHK.Q 
S197   
 R.GKDSYETSQLDDQ 
(S*)AETHSHK.Q 
S207   
NP_057319 G protein-coupled receptor family 
C, group 5, member b precursor 
 GPRC5B  
 R.SNVYQPTEMAVVLNGG 
(T*)IPTAPPSHTGR.H 
T389  Yes 
NP_000477 Aquaporin 2  AQP2  
 R.RQ (S*)VELHSPQSLPR.G S256  No 
NP_004860 Vacuolar protein sorting factor 4B  VPS4B  
 K.EGQPSPADEKGND 
(S*)DGEGESDDPEKKK.L 
S102  Yes 
NP_054762 Chromatin modifying protein 2B  CHMP2B  
 K.ATI (S*)DEEIER.Q S199  No 
NP_687033 Proteasome α 3 subunit isoform 2  PSAM3  
 K.ESLKEEDE (S*)DDDNM S243  No 
NP_036382 Related RAS viral (r-ras) 
oncogene homolog 2 
 RRAS2  
 R.KFQEQECPP (S*)PEPTRK.E S186  Yes 
NP_031381 Heat-shock 90-kD protein 1, β  HSP90AB1  
 K.IEDVG 
(S*)DEEDDSGKDKK.K 
S255  No 
NP_612433 Kinesin family member 12  KIF12  
 R.VTTRPQAPK (S*)PVAK.Q S236  Yes 
NP_079119 Cytochrome b reductase 1  CYBRD1  
 R.NLALDEAGQRS (T*)M. T285  Yes 
NP_001037857 Mucin 1 isoform 7 precursor  MUC1  
 R.DTYHPMSEYPTYH 
(T*)HGR.Y 
T118  Yes 
NP_000330 Solute carrier family 12 
(sodium/chloride transporters), 
member 3 
 SLC12A3  
 R.GARP (S*)VSGALDPK.A S811  Yes 
NP_000329 Sodium potassium chloride co-
transporter 2 
 SLC12A1  
 K.IEYYRN (T*)GSISGPK.V T118  No 
 K.IEYYRNTG (S*)ISGPK.V S120  No 
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AIMS OF THE STUDY 
 
The aims of the study were following: 
1. To develop alternative and/or novel methods for isolation and purification of urinary 
membrane vesicles including the search for novel affinity-ligand-based methods for 
urinary membrane vesicles isolation.  
 
2. To characterise urinary membrane vesicles and their content using proteomic ‘gel-
based’ and ‘off-gel’ proteomic analysis. 
 
3. To profile glycoproteins of urinary membrane vesicles. To establish the surface 
glycan signature of urinary membrane vesicles followed by identification of the 
constituent glycoproteins of urinary membrane vesicles. 
 
4. To profile the other post-translational modifications like palmitoylation and 
ubiquitination of protein constituents of urinary membrane vesicles and identification 
of these proteins. 
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2.1 Introduction  
The discovery of exosome vesicles in urine (Pisitkun, Shen & Knepper, 2004) has rapidly 
opened new possibilities for the mechanistic understanding of biological processes and, 
importantly, has served as a source for novel biomarkers (Simpson et al., 2009). 
Consequently, exhaustive proteomic profiling of urinary exosomes has identified more than 
1100 gene products, including 177 disease-related proteins derived from all nephron 
segments (Gonzales et al., 2009) and from the urogenital tract (Mitchell et al., 2009; Welton 
et al., 2010). The identification from urine of distinct exosomal transcription factors (Zhou et 
al., 2008) and nucleic acids encoding proteins native to all nephron segments (Miranda et al., 
2010) is groundbreaking, and highlights the need to precisely understand their biology which 
plausibly reflects new aspects of disease pathways.  
The aim of this study was to optimise the currently-available techniques and remove the 
abundant confounding urinary proteins which seriously interfere with the exosomal vesicle 
recovery, thus influencing the final yield and subsequent analytical power. The treatment of 
the exosomal pellet obtained by the serial centrifugation protocol with dithiothreitol (DTT) 
has previously been proposed as a solution to reduce such interference (Gonzales et al., 
2009). After treatment with DTT, exosomal markers, CD9, Alix and TSG101 pelleted down 
in the high-speed pellet (P200,000g) but not in the low speed pellet (18,000g). Therefore, the 
yield of exosomes increased, however, Tamm-Horsfall protein, which is the most abundant 
protein in urine and a contaminant in urinary exosome isolation, pelleted down at high speed. 
This might interfere in obtaining pure exosomal pellet (200,000g) and complicate further 
proteomic analysis. 
Furthermore, previous proteomic profiling studies have also identified a number of receptor 
proteins whose three-dimensional folding is stabilised by disulfide bridges. Accordingly, 
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sortilin-related receptor, for example, has 33 predicted disulfide bridges and megalin has 159 
predicted disulfide bridges (Westergaard et al., 2004; Bajari et al., 2005) fixing their 
respective molecular structures. Any study attempting to evaluate functions of exosomes 
should optimally follow an isolation protocol which preserves the correct folding and 
therefore, the functionality of the respective proteins.  DTT is a strong reducing agent, 
however, and the exosomal proteins may accordingly be reduced and unable to refold 
properly upon reoxidation, hampering relevant functional studies leading to loss of biomarker 
promise  
Here, we hypothesized that interference of soluble proteins in the exosomal isolation process 
occurs due to aggregation, non-specific interactions as well as their gelling properties (as e.g. 
for Tamm-Horsfall glycoprotein {THP}). Any chemical agent which solubilises these 
aggregates may also reduce contamination of the ultracentrifugation pellet by these proteins. 
For these benefits, we have used 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonic (CHAPS) as mild detergent which is known to solubilise THP (Kobayashi & 
Fukuoka, 2001) to largely exclude this interference. Mild non-ionic or zwitterionic detergents 
can solubilise the polymers of THP which might lead to pelletting down of THP at low speed 
(18,000g). This would be expected to remove contamination of high speed pellet (200,000g) 
with THP. We then compared results after CHAPS treatment with those after the DTT 
treatment. 
Furthermore, we also compared the preservation of two key protease activities, including 
dipeptidyl peptidase IV (DPP IV) and nephrilysin (NEP), both previously shown to be 
associated with urinary exosomes (Pisitkun, Shen & Knepper, 2004; Gonzales et al., 2009). 
These two enzymes are stabilised by 5 and 6 disulfide bonds, respectively (Erdos & Skidgel, 
1989; Busek, Malik & Sedo, 2004). Furthermore, we reveal for the first time the overlapping 
proteome subsets following CHAPS and DTT treatments (SN200,000g). Proteomic profiling 
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of the SN200,000g would shed light on the types of proteins whose interference will be 
reduced in the P200,000g.  The proteomic profiling revealed that both CHAPS and DTT 
methods result in closely-related protein profiles, fully validating our method while CHAPS 
was found to be superior in maintaining functional protein integrity. Our method should 
greatly improve the exosome functional yield and, thus, possibilities to fully exploit the 
biomarker potential of exosomes. 
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2.2 Materials and Methods 
2.2.1 Urine collection 
Urine samples were collected from ten non-smoking healthy laboratory volunteers (5 female 
and 5 male) whose ages ranged from between 20 to 40 years.  There was no history of renal 
dysfunction in any of the subjects or drug administration during sample collection. The first 
morning urine was processed within 3 hours of collection. At collection, the first 50 mls were 
discarded and the remaining void urine was collected for analysis. Each urine specimen was 
subsequently tested by the Combur 10 Test®D dipstick (Roche Diagnostics; Mannheim, 
Germany). 
2.2.2 Vesicle purification 
All the chemicals were purchased from SIGMA, St. Louis unless otherwise specified. A 
schematic representation of the methodology used to isolate nano vesicles is shown in Figure 
2.1.  In summary, pooled urine samples were initially centrifuged at a relative centrifugal 
force (RCF) of 1,000g for 20 minutes. The resultant supernatant (SN) was retained and split 
into aliquots of 500mL. Upon thawing, these samples presented with cryo-precipitate, which 
was completely dissolved by vortexing the sample at room temperature (RT) until complete 
the solution became clear. Next, 500mL aliquots of SN1 were dialysed at 4ºC against 
deionised water (3 changes of 10L each over 24hours) and the volume was subsequently 
reduced up to 20mL using vacuum concentration (miVac, GeneVac, Suffolk, Ipswich, UK). 
The concentrated SN1 was centrifuged (Avanti®J-26 XP centrifuge, Beckman Coulter, 
Fullerton, CA) at 18,000g for 30 minutes at RT in a fixed angle rotor (Beckman JA-20, 
Fullerton, CA). The 18,000g SN (SN18) fraction was subjected to an ultracentrifugation step 
using the OptimaTM L-90 K preparative ultracentrifuge (Beckman Coulter) at 200,000g for 2 
hours at RT in a fixed-angle rotor (Beckman 70Ti, Beckman). The pellet (P200) was 
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resuspended in 3 mL of deionized water. Aliquots (2mg of total protein) of resolubilised 
crude P18 and P200 were treated with either 1% (w/v) of 3-[ (3-
cholamidopropyl)dimethylammonio]-1-propanesulfonic acid (CHAPS) overnight (ON) with 
end-over-end agitation at 4°C (5mL final volume) or with 200mg/mL of dithiothreitol (DTT), 
independently of one another, for 30 minutes at 37°C in accordance with the 
recommendations of Fernández-Llama et al., (Fernandez-Llama et al., 2010) with vortexing 
every five minutes. Here, a final volume of 5mL was also used. These two solutions (i.e. P18 
and P200, CHAPS and DTT-treated pellet) were subjected to a second series of 
centrifugations at 18,000g followed by an ultracentrifugation at 200,000g as shown in Figure 
1. After the first centrifugation at low-speed (18,000g), the SNs from same treatment were 
pooled together (10mL final volume) and centrifuged at 200,000g. For method 2, 0.5mg of 
crude protein obtained from P18 and P200, respectively, was treated with CHAPS as in 
method 1 without pooling the SN after the first low-speed pellet (18,000g). Instead, they were 
subjected individually to an ultracentrifugation step at 200,000g. 
2.2.3 Protein quantification, SDS-PAGE and Western Blotting 
The protein concentrations in all urine fractions were measured by Coomassie Protein Assay 
(M., Bradford, 1976). SDS-PAGE was carried out according to the recommendations of 
Laemmli (Laemmli, 1970). Gels were either stained by homemade colloidal Coomassie blue 
staining (Candiano et al., 2004) or transferred to a nitrocellulose membrane (Towbin, 
Staehelin & Gordon, 1979). Membranes were blocked overnight (ON) at room temperature 
(RT) with the Odyssey blocking buffer solution (LI-COR Biosciences, Lincoln, NE). All 
incubation steps with antibodies were performed in a 1:1 (v/v) mixture of Odyssey blocking 
buffer and PBS with 0.1% (v/v) Tween 20 (PBST). Antibodies were diluted in accordance 
with supplier’s guidelines for 2 hours at room temperature. Rabbit anti-CD63 (H193) 
sc15363 (Santa Cruz, Santa Cruz, CA), dilution 1:500 (v/v); rabbit anti-TSG101 (Sigma) 
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0.5μg/mL dilution; rabbit anti-MFG-E8/lactadherin (H60); sc-33545v (Santa Cruz) 1:500 
(v/v) dilution; rabbit anti-nephrin (in house) 1:500 (v/v). Secondary antibody goat anti-rabbit 
IRDye-800 (LI-COR Biosciences) was diluted 1:5000 (v/v) in PBS tween 0.1% (v/v) plus 
0.01% (w/v) SDS for 2 hours at room temperature. Western blot images were acquired by 
Odyssey infrared laser scanner (LI-COR Biosciences, Lincoln, NE) 
2.2.4 Negative Transmission Electron Microscopy  
Fifty μg of vesicle preparations were fixed with 1% (v/v) glutaraldehyde (Sigma Aldrich) in 
water. Fixed vesicle preparations were spotted onto a Formvar/Carbon 300 mesh grid (Agar 
Scientific, Stansted, UK) and dried at RT. The grids were washed twice in 0.1M PBS and 
incubated in 1% (w/v) OsO4 in 0.1M PBS for 30 min on ice. After five 5 min washes (3 with 
PBS and 2 with water), exosomes were stained with 5% (w/v) uranyl acetate in water for 10 
min (Mathias et al., 2009). After staining, vesicle populations were monitored by JEM-2100 
transmission electron microscopy (Jeol Ltd, Tokyo, Japan). 
2.2.5 LC-MS/MS analysis 
100μg of protein were reduced by 10mM tris (2-carboxyethyl)phosphine (TCEP) in 100mM 
Tris–HCl,  pH 8.8 , 8M Urea, 0.1mM EDTA and 1% (w/v) sodium deoxycholate (DOC) for 
1.5 h at room temperature (RT) in the dark. Alkylation was carried out by 20mM 
iodoacetamide (IAA) in 100mM Tris–HCl, pH 8.8, 0.1mM EDTA for 1.5 h at RT in the dark. 
Excess of IAA was quenched by 20mM N-acetyl cysteine in 100mM Tris–HCl, pH 8.8, 
0.1mM EDTA for 0.5 h at RT in the dark. Reduced and alkylated samples were 
concentrated/delipidated by chloroform/methanol precipitation according to Wessel and 
Fugge (Wessel & Flugge, 1984) before trypsin digestion. Briefly, to 150µl of sample solution 
were added first 400µl of 100% (v/v) MeOH, and then 200µl of chloroform and after 
vortexing well, 400µl of mQ water was added and then centrifuged at 5,000g for 5 min at RT. 
The upper layer was removed and 600µl of 100% (v/v) MeOH was added to the tube. Finally, 
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protein was recovered by centrifugation at 15,000g for 30 min and the pellet dried by speed 
vac.  Digestion was carried out using trypsin (modified sequencing grade; Promega, Madison, 
WI) at 37°C for 16 h in 50mM Tris-HCL, pH 8.0 and 1% (w/v) DOC which is compatible 
with trypsin activity (Lin et al., 2008). The digested solutions were acidified with 1% (v/v) 
formic acid (up to around pH 2) and centrifuged at 15,000g for 20 min. The supernatant was 
collected and the pellet were washed for with 1% (v/v) formic acid and sonicated for 5 
minutes and centrifuged at 15,000g for 20 min. This was repeated twice (Lin et al., 2010). All 
the SNs were pooled together and were then desalted and concentrated by using reverse phase 
cartridges (Sep-Pak C18) according to the manufacturer's instructions (Waters, Mississauga, 
ON). Briefly, the columns were conditioned and equilibrated with 1mL 100% methanol (v/v) 
and 1mL 80% (v/v) acetonitrile (ACN), respectively, and successively washed with 4 mL of 
0.1% (v/v) formic acid. The sample solution was then loaded onto the column, and the 
columns were washed with 6 mL of 0.1% (v/v) formic acid. The tryptic digestions were 
eluted with 1 mL 80% (v/v) ACN, 0.1% (v/v) formic acid and lyophilized (Thermo). 
Lyophilized samples were rehydrated with 0.1% (v/v) formic acid to give 1μg/μL 
concentration of the equivalent starting protein amount. Nanoflow electrospray ionization 
tandem mass spectrometric analysis of peptide samples was carried out using LTQ-Orbitrap 
Velos (Thermo Scientific, Bremen, Germany) interfaced with the Agilent 1200 Series 
nanoflow LC system. The chromatographic capillary columns were used with a flow rate of 
300nL per min. The peptides were eluted using a linear gradient of 7-30% (v/v in water) 
acetonitrile over 50 min. Mass spectrometry analysis was carried out in a data-dependent 
manner with full scans acquired using the Orbitrap mass analyzer at a mass resolution of 
60,000 at 400 m/z. For each cycle, the twenty most intense precursor ions from a survey scan 
were selected for MS/MS and detected at a mass resolution of 15,000 at m/z 400. The 
fragmentation was carried out using higher-energy collision dissociation as the activation 
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method, with 40% normalized collision energy. The ions selected for fragmentation were 
excluded for 30 seconds. The automatic gain control for full FT MS was set to 1 million ions 
and for FT MS/MS was set to 0.1 million ions with a maximum time of accumulation of 750 
and 100ms, respectively. 
2.2.6 Data Analysis 
The mass spectrometry data was processed using Proteome Discoverer (Version 1.2.0.208) 
software (Thermo Fisher Scientific) and searched using Mascot. The search parameters used 
were: oxidation of methionine, deamidation at N and Q, protein N-terminal acetylation, N-
pyroglutamate for N-terminal Q/N and carbamidomethylation of cysteine residues as variable 
modifications. A maximum of one missed cleavage was allowed for tryptic peptides with a 
minimum length of 7 amino acids. The peptide and protein data were extracted using high 
peptide confidence and top one peptide rank filters. False discovery rate (FDR) was 
calculated by enabling the peptide sequence analysis using the decoy database. A mass error 
window of 20 ppm and 0.1Da were allowed for MS and MS/MS, respectively. FDR was kept 
at 1% to be used as a ‘cut-off’ value for reporting identified peptides. In addition to the 
target-decoy approach, the quality of proteins identified was validated by manually checking 
the spectra of those proteins with at least one unique peptide. 
2.2.7 Determination of Dipeptidyl peptidase (DPP IV) and Nephrilysin (NEP) catalytic 
activity 
DPP IV activity was measured in triplicate by using HGly- pro-β-naphthylamide as substrate, 
following the method of Liu and Hansen (Liu & Hansen, 1995). The NEP assay was carried 
out by incubating samples with N-dansyl-D-Ala-Gly-p-nitro-Phe-Gly ([D]AG (pN)PG, a 
dansyl derivative), following the protocol of Florentin et al., (Florentin, Sassi & Roques, 
1984). 
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2.2.8 THP purification 
THP was purified from resolubilised P1 (Musante et al., 2012) by filtration through a 
diatomaceous earth filter (DEF) (Serafinicessi et al., 1989).  In summary, PBS containing 
NaCl (0.2M) and CaCl2 (1mM) was added to P1 before being transferred to a diatomaceous 
earth layer (5mL) placed on a Büchner funnel.  After washing with 500mLs of 0.02mM 
phosphate buffer (pH 7.5) containing 0.2M NaCl and 1mM CaCl2, the diatomaceous earth 
was retained and transferred into a 50mL centrifugation tube.  This was subsequently washed 
twice with 50mL of 1mM ethylenediaminetetraacetic acid (EDTA) in water.  This facilitated 
the extraction of THP entrapped within the diatomaceous earth.  Non-bound and bound 
fractions were dialysed three times against deionised water (10L) independently of one 
another, and the volumes reduced to 5mL by vacuum drying (MiVac, Mason Technology, 
Suffolk, Ipswich, UK). 
2.2.9 Purification of monomeric HSA 
High-performance liquid chromatography (HPLC) assays were performed on an Agilent 1200 
system (Agilent technologies, Palo Alto, California, USA), and all water selected for use was 
of HPLC grade (18.2 M) and purified using a TKA-Gen-Pure purification system (Mason 
Technologies, Suffolk, Ipswich, UK).  The species composition of human albumin was 
determined by SEC.  Separations were performed using a Bio-Sil-SEC 400-5 stationary phase 
(Bio-Rad, Richmond, CA; 300x7.8mm), with 20mM PBS containing 0.15M NaCl (pH 7.5) 
selected as a mobile phase.  For enhanced resolution of monomeric and dimeric fractions of 
HSA, three stationary phases were inter-connected with steel fittings. All samples were 
assayed at a flow rate of 1.0mL/minute using UV detection at 280nm, with 100µL sample 
volumes (1mg of protein) selected for injection. Species composition was determined through 
the use of a gel filtration standard consisting of thyroglobulin (670kDa), immunoglobulin G 
(158kDa), ovalbumin (44kDa), myoglobin (17kDa) and vitamin B12 (1.35kDa) (Bio-Rad).  
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Monomeric fractions of HSA for use in FLISA and SPR binding analysis (vide infra) were 
retained manually and screened by SDS-PAGE. 
2.2.10 Fluorophore-Linked Immuno Sorbent Assay (FLISA) 
As a preliminary method to ascertain whether HSA was binding to ultracentrifugation pellets 
prior to more rigorous SPR analysis, the P18+200CP200 vesicle fraction (100μg/mL) was 
passively immobilised in triplicate on a 96-well plate (Nunc Maxisorp, Nunc, Roskilde, 
Denmark) in 100μL volumes and incubated overnight at 4°C.  Next, plates were washed five 
times with PBS (pH 7.4) and all wells selected for analysis were subsequently blocked with 
400μL of Odyssey blocking solution diluted 1:1 in PBS (pH 7.4) for 1 hour at room 
temperature.  After washing with PBS as before, monomeric HSA (100µl of a 20µg/mL stock 
solution) was added and wells were incubated for 1 hour at room temperature.  Wells were 
subsequently washed five times with PBS containing 0.1% (v/v) tween (PBST).  For 
detection, monoclonal mouse anti-HSA clone 6501 (100µL of a 10µg/mL stock solution), 
diluted in Odyssey blocking solution (1:1) was added before incubating for 2 hours at room 
temperature.  Wells selected for analysis were washed again in PBST (5x).  Next, 100µL of 
anti-mouse-IRdye 800 secondary antibody, diluted 1:5000 in Odyssey blocking solution, was 
added and allowed to incubate for 1 hour at room temperature.  Non-bound antibody was 
removed by additional washes (5x) in PBST.  Binding was determined through the use of the 
Odyssey infrared imaging system (Li-COR Biosciences, Lincoln, NE). Albumin interaction 
was evaluated at a physiological pH (7.4) and at a pH more representative of that seen in 
urine (pH 6.0).  As a negative control, nano vesicle populations were immobilised as before, 
and subsequently probed with primary and secondary antibodies in the absence of albumin. 
The signal obtained here was then subtracted from that seen for analytical samples at pH 6.0 
and pH 7.4. 
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2.2.11 Immunoprecipitation of membrane vesicles using anti-albumin antibody 
Anti-albumin antibody was immobilised on Dynabeads (Dynal, M270 amine) according to 
manufacturer’s instructions using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide) and N-
hydroxysulfosuccinimide (EDC/SNHS) chemistry (Invitrogen, Carlsbad, CA). 100µg of 
antibodies were coupled to 150µL of amine-functionalised Dynabeads (M-270 amine, Dynal, 
Invitrogen) using EDC-Sulfo-NHS. Briefly, antibodies were diluted to a final concentration 
of 1mg/mL antibody in MES buffer (0.1M MES + .9% (w/v) NaCl pH 6.0). EDC/SNHS were 
prepared in MES buffer at concentration of 10/15 mg/mL. EDC/SNHS solution (100µL/1mg 
protein) was added to the antibody and incubated at RT for 15 min. Following antibody 
activation by EDC/SNHS, the antibodies were added to 150µL Dynal M270-amine beads 
(2x10
9 
beads/mL) and mixture was incubated at 4°C overnight while rotating. Next day, the 
beads were washed with PBS to remove non-bound antibodies and incubated with 100mM 
Tris, pH 7.2, for 15 min to quench any remaining active groups. The anti-albumin beads were 
incubated with 1mg of P200CHAPSP200 in binding buffer (phosphate buffer pH 7.2). The 
next day non-bound fraction was collected and beads were washed with binding buffer three 
times. The bound fraction was eluted from the beads by elution with 100mM glycine buffer 
(pH 2.3) for 1 hour while rotating at RT. 
2.2.12 Biacore-based analysis of interactions 
All surface-plasmon resonance (SPR) assays were performed on a Biacore 3000TM 
instrument using a CM5 carboxymethylated dextran sensor chip (GE Healthcare) in 
accordance with the recommendations of Reeves et al., (Reeves et al., 2010).  In summary, 
HEPES-buffered saline (HBS: 10mM 4-2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), 3mM EDTA, 150mM NaCl and 0.005% (v/v) Tween 20, pH 7.4 or 6.3), selected 
as a running buffer, was filtered through a 0.2µM filter (Supelco Inc., Bellefonte, PA) and de-
gassed overnight in a sintered glass funnel apparatus (AGB Scientific Apparatus Ltd., 
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Belfast, UK) before use.  Pre-concentration analysis in 10mM sodium acetate was used to 
determine the optimal pH for the capture of 100µg/mL of vesicle preparation on flow cells 
(FC) 2 (P18+170DP170) and 4 (P18+170CP170), respectively.  Subsequent immobilisation 
was permitted by surface activation using standard EDC/NHS coupling.  Here, 70µL of EDC 
(400mM) was mixed with 70µL of NHS (100mM) and 80µL was injected over the sensor 
surface at a flow rate of 10µL/min. A 100µg/mL solution of the relevant ligand was then 
captured on the activated surface for 20 minutes.  Any un-reacted succinimide esters were 
subsequently deactivated by capping for 7 minutes with 1M ethanolamine (pH 8.5).  Flow 
cells 1 and 3 were used for online reference subtraction, and each five-minute injection (50µL 
of analyte at a flow-rate of 10µL/minute) was immediately followed by regeneration using 
conditions optimised through regeneration scouting (see below).  All analyses were 
performed in triplicate on three consecutive days (interday), and binding responses were 
monitored as a function of analyte (e.g. albumin) concentration.  A negative control of HBS 
buffer was included for each assay.  The response units (RU) value obtained here was then 
subtracted from that obtained for each analyte-ligand biomolecular interaction, thereby 
providing an accurate representation of the true binding event.  Biaevaluation software (GE 
Heathcare, Buckinghamshire, UK) was used for all data analysis. 
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2.3 Results 
2.3.1 Vesicle purification 
A schematic representation of the workflow used to isolated urine exosomal vesicles and 
abbreviations used for each product step is shown in Figure 2.1.  For the analysis, pooled 
urine samples were initially centrifuged at a RCF of 1,000g for 20 min. The resultant SN was 
dialysed against deionized water water and sample volume reduced to 1:20 by vacuum 
concentration. The concentrated SN was centrifuged at 18,000g and the resulting supernatant 
at 200,000g. Both pellets (P18 and P200) were resuspended in a minimal volume of 
200mg/mL DTT or 1% (w/v) CHAPS and re-centrifuged again at 18,000g. The two SNs were 
combined and further centrifuged at 200,000g. Alternatively, CHAPS 18,000g SNs were not 
pooled but centrifuged individually at 200,000g to check THP sedimentation behaviour 
following CHAPS treatment. 
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Figure 2.1: Urine vesicle enrichment workflow. a. Dialysis followed by vacuum 
concentration (approx.1:25); b. either 1% (w/v) CHAPS, ON at 4ºC or 200mg/mL DTT, 30 
minutes at 37ºC. The type of treatment is reflected in the sample name: the x is replaced by C 
in case of CHAPS treatment and by D in the case of DTT. SAMPLE NOMENCATURE: P: 
Pellet; SN: Supernatant; x: Detergent used for treatment b C: CHAPS, D: DTT. Generally, 
P/SN are followed by the shortened centrifugational speed (e.g. P1 means pellet of 1,000g; 18 
for 18,000g and 200 for 200,000g), after detergent treatment C/D will be used as prefix of the 
fraction which underwent treatment. If double centrifugation has been performed, the sample 
name will reflect the chronological order of events with the last step first. 
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2.3.2 Transmission electron Microscopy (TEM)  
Transmission electron microscopy was used to verify the presence and to evaluate qualitative 
features of the vesicles present in the crude preparation P18 and P200 (for abbreviations, see 
Fig 2.1) and in CHAPS/DTT-treated fractions (Figure 2.2), as well as to assess the integrity 
of these vesicles following the respective treatments.  
 
Figure 2.2: TEM analysis Transmission electron micrographs of P18 (Panel A) and P200 
(Panel B) at 10,000x and 5,000x magnifications, respectively. High-magnification (50,000x) 
of CHAPS- (Panels C-F) and DTT-treated (Panels G-I) vesicle preparations are represented. 
The bar below the pictures is 500nm for panels A and B and 100nm for panels, C-I. 
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It can be seen in Fig. 2.2A that, the P18 preparation contained a heterogeneous population of 
vesicles ranging in size from 50-100nm in diameter. Furthermore, long polymeric filaments 
closely resembling THP polymers were detected along with associated vesicles (Fernandez-
Llama et al., 2010), despite the fact that dialysis should remove factors favouring the 
tendency of THP to aggregate (McQueen & Engel, 1966). Crude P200 (Fig. 2.2, Panel B) 
showed a heterogeneous population of vesicles whose size distribution (10-300nm) and shape 
are consistent with those of exosomes and ‘exosome-like’ vesicles previously described in 
urine (Pisitkun, Shen & Knepper, 2004; Hogan et al., 2009). TEM images revealed that the 
preparations obtained after CHAPS or DTT treatments in method 1 yielded intact vesicles 
ranging from approximately 20 to 200nm, dimensions which are characteristic for urinary 
exosomes (Pisitkun, Shen & Knepper, 2004), ‘exosome-like’ (Hogan et al., 2009) and 
apically-shed vesicles (Hara et al., 2010). High magnification images (50,000x) after CHAPS 
(Fig. 2.2, panels C, D, E and F) and DTT treatments (Fig. 2.2, panels G, H and I) showed 
closely related morphologies and sizes. Another interesting observation was the detection of 
vesicles sized between 5 and 10 nm enriched in the P200C preparation, further highlighting 
the wide complexity, size distribution and heterogeneity of these fractions (Fig. 2.2, panel C). 
2.3.3 SDS-PAGE analysis 
Figure 3 shows colloidal Coomassie-stained gels of crude fractions (Fig. 2.3, panel A), DTT 
fractions and CHAPS fractions obtained in method 1 (Fig. 2.3, Panel B) and CHAPS 
fractions obtained in method 2 (Fig. 2.3, panel C).  
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Figure 2.3: SDS-PAGE three panels are separated from each other by thick black lines. From 
left to right: Panel A: Gel Acrylamide T 12% Constant. 15µg of protein per lane of crude 
preparation Panel B: Gel Acrylamide T 8% Constant. 10µg of protein per fraction obtained 
in Method 1. Panel C: Gel Acrylamide T 12% constant. 10µg of protein per fraction obtained 
in Method 2. M: Molecular weight markers (in kDa), 1: P1, 2: P18, 3: P200, 4: SN200, 5: 
P18CP18, 6: P18DP18 7: P18CP200, 8: P18DP200, 9: P200C, 10: P200D, 11: SN200C, 12: 
SN200D, 13: SN200CP200, 14: P200CP200, 15: SN200CP18, 16: P200CP18. 
The large band at around 100kDa is the monomeric form of Tamm-Horsfall Protein (THP). It 
abundantly sediments at a low-speed (1000g) and then progressively, in decreasing amount is 
recovered in the following centrifugation steps (P18 and P200), with traces left in the final 
supernatant (SN200) (Figure 2.3 Panel A). After either DTT or CHAPS treatment of the 
crude P18 and P200 sediments, respectively, the pellet recovered again at a relatively low 
RCF (P18CP18, P18DP18, P18CP200 and P18DP200; for abbreviations, see Fig. 2.1) 
showed only traces of THP. Surprisingly, after CHAPS treatment, in method 1 where the SNs 
were combined (Fig. 2.1), all the THP was recovered in the ultracentrifugation pellet (Fig. 
2.3, Panel B P200C) instead of being in the SN (Fig. 2.3, Panel B SN200C) as was observed 
for DTT treatment (Fig. 2.3, Panel B P200D and SN220D). Interestingly, without pooling the 
SNs, THP present in the crude pellet (P18) after CHAPS treatment was no longer recovered 
at 18,000g, but at 200,000g (Fig. 2.3, Panel C P200CP18). CHAPS treatment of crude P200 
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pellet without pooling gave a final sediment (Panel C, P200CP200) in which Tamm-Horsfall 
protein was present at the same amount with respect to the DTT pellet (Panel B P200D). 
Moreover, albumin (~66kDa), found in abundance in the crude pellet (Panel A, P200), was 
instead detectable in the supernatant after CHAPS treatment (Fig. 2.3, Panel C 
SN200CP200), with traces remaining in the 200,000g pellet (Panel C, P200CP200). 
2.3.4 Profiling of urinary markers by Western Blotting  
Figure 2.4 shows the Western blotting of exosomal and podocyte markers.  
2.3.4.1 CD63 
CD63 was abundantly found in P18 and in the corresponding low-speed detergent-treated and 
DTT precipitates (Panel A; Figure 2.4).  
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Figure 2.4: Western blotting analysis. A: Rabbit anti-CD63, B: Rabbit anti-TSG101, C: 
rabbit anti-MGF-E8/Lactaderin and D: rabbit anti-nephrin (Hara et al., 2010). 10µg of protein 
of fractions obtained in Method 1 were loaded on the gels. M: Molecular weight markers (in 
kDa), 1: P18, 2: P18CP18, 3:P18DP18, 4: P18DP200, 5: P18CP200, 6: P200D, 7: P200C, 8: 
P200, 9: SN200 10: SN200C, 11: SN200D. 
The CD63 isoform profiles exhibit a distinct distribution in these vesicle preparations, with 
sizes of approximately 65, 45 and 35kDa, respectively, consistent with a heavy glycosylation 
pattern (Ageberg & Lindmark, 2003). In treated high-speed pellets (P200C and P200D) and 
the crude P200 fraction, CD63 was observed mainly at higher molecular weights (75 to 
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100kDa). The broad band seen in Western blotting is most likely due to the high-degree of 
glycosylation by poly N-acetyl lactosamine, as reported by Engering et al., (Engering et al., 
2003). Heavy glycosylation can cause streaking and smearing of glycoproteins in the SDS-
PAGE system.  
2.3.4.2 TSG101 
TSG101 was detected in the exosome fraction as a single band of approximately 46 kDa in 
P18 and P200 crude preparations but, significantly, after this fraction was treated (CHAPS or 
DTT), the antigen was recovered in the low-speed centrifugation preparations, namely 
P18CP200 and P18DP200. In the latter two samples, in addition to the main band of 
approximately 46kDa, four other lower molecular weight isoforms were also detected. It 
appears that the lower molecular weight bands are a specific feature of these two samples, 
especially of the CHAPS-treated fraction.  
2.3.4.3 LACTADHERIN/MFG-E8 
In the P18 preparation, two main bands were visible with molecular weights of approximately 
48kDa and 35kDa of lactadherin. Interestingly, after CHAPS treatment, only the 35kDa band 
was detected (P18CP18 and P18CP200). Notably, in the corresponding DTT pellet, 
(P18DP18), both the 46 and 35kDa bands were present, in addition to two extra isoforms of 
approximately 77 and 100kDa, specifically enriched in this fraction. The analysis of the crude 
P200 preparation revealed three main bands whose molecular masses were approximately 53, 
62 and 70kDa. Interestingly, the 53 and 70kDa forms were specifically enriched in both DTT 
preparations originating from the P200 samples.  
2.3.4.4 NEPHRIN 
A recent report has described the ability of glomerular podocyte microvilli to secrete non-
exosomal vesicles by tip vesiculation (Hara et al., 2010). This finding led us to explore this 
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podocyte-specific marker of the slit-diaphragm in detail in the vesicle preparations, especially 
in the CHAPS or DTT-treated vesicles, in order to scout for specific functional features 
reflecting the critical elements of the glomerular filtration barrier. The whole array of samples 
was probed with an anti-nephrin antibody raised against the intra-cytoplasmic domain of the 
protein (Ahola et al., 1999). Surprisingly, the bulk of the nephrin-containing vesicles were 
recovered at low RCF, (P18CP18, P18DP18, P18CP200 and P18DP200). In the whole 
sample set, no full-length nephrin was observed, although different nephrin fragments were 
detected in the diverse preparations. This is in line with previous results from our group 
(Patari et al., 2003). In the soluble fractions, nephrin was detectable only in the SN170 
fraction as 75, 65 and 48kDa bands, while in the vesicle preparations, a wider range of bands 
was detected at 75, 65, 48 and 35 and 25kDa.  
2.3.5 Dipeptidyl peptidase IV (DDPIV) and nephrilysin (NEP) activity in CHAPS and 
DTT fractions  
Figure 2.5 shows DPP IV and NEP activities measured in pellet and SN after CHAPS and 
DTT treatments. Before measuring the activity, samples were dialysed with a membrane with 
a molecular weight ‘cut-off’ of 300kDa to remove DTT, CHAPS and potential soluble 
isoforms of these two proteases. Figure 2.5B shows Coomassie staining and the 
immunodetection of DPP IV after dialysis. In DTT 200,000g pellets and SNs (Anti DPP IV, 
Panel B lane 1 and 3), DPP IV is visible at 110 kDa, while in CHAPS fractions two specific 
bands were detected whose molecular weights were approximately 52 and 25kDa  (Anti DPP 
IV, Panel B lane 2 and 4). Activity was recorded as pmol of product/min/mg protein (UP/mg 
protein). When compared, DPP IV activity in DTT and CHAPS fractions were similar despite 
the difference in the respective western blotting patterns as shown in Figure 2.5A.  
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Figure 2.5: Protease activity. Membrane-bound DPP IV (Panel A) and NEP (Panel C) 
peptidase activity profiles recorded in absence and presence of 10 mM DTT. Samples were 
dialysed at a MWCO of 300kDa. DTT pellet 200,000g (sample 1), DTT SN 200,000g 
(sample 3), CHAPS pellet 200,000g (sample 2) and CHAPS SN 200,000g (sample 4) are 
represented. Columns compare DTT vs CHAPS after dialysis with a membrane of MWCO 
300kDa and in the presence of 10mM DTT. Values represent mean ± SD of units of 
peptidase (UP) per milligram of protein per minute. Panel B represents the Coomassie gel 
and DPP-IV immunodetection of the same samples. 10µg of protein per fraction obtained in 
Method 1 were loaded on the gels after 300kDa MWCO dialysis. 
Activity drastically decreased in the presence of DTT, suggesting that, although disulfide 
bond reduction affects the activity, during dialysis DPP IV is able to regain its native 
106 
 
conformation with a good recovery of its activity. For NEP, the activity decreased 
significantly (around 4-fold) in the DTT fractions when compared with the corresponding 
CHAPS fraction. This result shows that although DTT was removed by dialysis, there was a 
detrimental and irreversible effect of the reducing agent on the folding of NEP which led to a 
loss of the enzymatic activity. Once again, as a control, in the presence of DTT the activity 
decreased substantially in all the fractions. The activity recorded in the SNs after dialysis 
with a molecular weight ‘cut-off’ membrane of 300kDa, along with CD63 signals detected in 
Western blotting (Figure 2.4) indirectly points to the presence of nano-vesicles in these 
fractions which were not collected in the pellet after the second ultracentrifugation 
(200,000g). 
2.3.6 MS-based identification of proteins released in the supernatant after DTT and 
CHAPS treatments 
The supplemental tables list the proteins identified by the systematic MS analysis of the final 
200,000g supernatant after DTT (Supplementary Table S2.1 and S2.2, 274 unique proteins) 
and CHAPS (Supplementary Table S2.3, 234 unique proteins) treatments. Figure 2.5 shows 
the analysis in comparison to the two published data sets of proteins identified in the 
200,000g pellet (Gonzales et al., 2009) and SN (Kentsis et al., 2009), respectively.  
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Figure 2.6: Protein identification comparisons. Venn diagram showing the distribution of the 
number of identified proteins presents in SN 200,000g after CHAPS and DTT treatments. 
Protein identifications from the current study were compared to two other studies which were 
carried out using high-resolution mass spectrometers in gels on 200,000g pellets after DTT 
treatment (Gonzales et al., (Gonzales et al., 2009)) and 200,000g supernatants (Kentsis et al., 
(Kentsis et al., 2009)). 
The Venn diagram shows that 76.2 % of proteins found in the CHAPS fraction are common 
to the corresponding DTT fraction. This result confirms the close similarity between the two 
methods in respect to the preservation of major protein components. Interestingly, 
approximately 9.7% and 6.9% of protein in CHAPS and DTT supernatants, respectively, are 
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consistent with the observations made by Gonzales (Gonzales et al., 2009), while 33.7% and 
31% of proteins in CHAPS and DTT supernatants, respectively, are common to the Kentsis 
(Kentsis et al., 2009) data-set while 40.9% and 45.6% of the proteins in CHAPS and DTT 
SN, respectively, overlap with the two reference data sets. Finally, around 10% of proteins 
detected in our study are unique for both CHAPS and DTT supernatants. 
The bulk of identified proteins were found to be already annotated in the whole urine, but 
others, like Ig gamma-4 chain, Ig gamma-3 chain C region and Ig alpha-2 chain, have 
specifically been shown to associate with exosomes. Others, including Tumor Necrosis 
Factor receptor superfamily member 19L or palmitoyl-protein thioesterase 1 have all the 
potentiality to be part of the exosome proteome (Table 2.1).  
Table 2.1: Protein identification in DTT and CHAPS supernatants. Fractions in which 
proteins were obtained, Uniprot accession, % sequence coverage, peptides, mascot score, 
protein name description, presence in Exocarta and Adachi et al., (Adachi et al., 2006) and 
Marimuthu et al., (Marimuthu et al., 2011) is indicated in the table. 
Fraction Accession Coverage 
% 
Peptides Mascot 
score 
Descriptions Exocarta Adachi Marimuthu 
CHAPS O95497 10.33 4/4 180.32 Pantetheinas
e  
GN=VNN1 
N Y Y 
CHAPS P50897 9.15 2/2 97.96 Palmitoyl-
protein 
thioesterase 
1 GN=PPT 
N N Y 
CHAPS P01040 30.61 2/2 109.9 Cystatin-A  
GN=CSTA 
N N Y 
CHAPS Q86SR0 45.36 2/2 114.84 Secreted Ly-
6/uPAR-
related 
protein 2 
GN=SLURP
N N N 
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2 
CHAPS Q969Z4 2.56 2/2 109.04 Tumor 
necrosis 
factor 
receptor 
superfamily 
member 19L 
GN=RELT 
N Y Y 
CHAPS P61916 10.60 1/1 66.37 Epididymal 
secretory 
protein E1 
GN=NPC2 
N Y Y 
CHAPS/
DTT 
P01861 18.35 7/4 354.82 Ig gamma-4 
chain C 
region 
GN=IGHG4 
Y N N 
CHAPS/
DTT 
P01877 18.53 7/5 360.53 Ig alpha-2 
chain 
GN=IGHA2 
Y N N 
CHAPS/
DTT 
P37235 6.22 1/1 81.02 Hippocalcin-
like protein 
1 
GN=HPCAL
1 
Y N Y 
CHAPS/
DTT 
P15289 8.09 2/2 123.11 Arylsulfatas
e A  
GN=ARSA 
N N Y 
CHAPS/
DTT 
P41222 24.74 6/4 304.59 Prostaglandi
n-H2 D-
isomerase 
GN=PTGDS 
N Y Y 
CHAPS/
DTT 
Q14508 38.71 4/3 216.44 WAP four-
disulfide 
core domain 
protein 2 
GN=WFDC
2 
N Y Y 
CHAPS/
DTT 
P31949 15.24 1/1 80.02 Protein 
S100-A11 
GN=S100A1
Y Y Y 
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1 
DTT P02788 6.48 5/4 227.66 Lactotransfe
rrin 
GN=LTF 
Y Y Y 
DTT P19835 16.61 7/7 339.62 Bile salt-
activated 
lipase 
GN=CEL 
Y N Y 
DTT Q9Y646 16.95 6/6 334.27 Plasma 
glutamate 
carboxypepti
dase  
GN=PGCP 
N N Y 
DTT P55259 4.28 2/2 136.92 Pancreatic 
secretory 
granule 
membrane 
major 
glycoprotein 
GP2  
GN=GP2 
N N Y 
DTT P01860 13.79 5/4 256.39 Ig gamma-3 
chain C 
region 
GN=IGHG3 
Y N N 
 
These results suggest that in specific subpopulations of exosome vesicles, unique features can 
still be recovered in the SN after DTT and CHAPS treatments. This finding has practical 
consequences for their use. Figure 2.7 reports the gene ontology distribution per protein class 
of identified proteins by the Panther classification system (www.panther.org) (Thomas et al., 
2003). Once again the distribution of the protein classes is very similar in the 200,000g 
CHAPS and DTT supernatants.  
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Figure 2.7: Gene ontology based classification (www.panther.org) of proteins identified in 
DTT and CHAPS SN200,000g. 
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2.3.7 Interaction of abundant proteins like albumin, THP and IgG with nano vesicles 
treated with either DTT or CHAPS 
High-abundance proteins in membrane vesicle fractions were investigated by western blotting 
in various membrane vesicle fractions. The results are shown in Figure 2.8. 
 
Figure 2.8: Western blot analyses of nano vesicle pellets and SN in crude preparations and 
after CHAPS and DTT treatment.  Lane 1 18,000g pellet; lane 2 18,000g pellet CHAPS 
18,000g pellet;  lane 3 18,000g pellet DTT 18,000g pellet; lane 4 200,000g pellet DTT 
18,000g pellet; lane 5 200,000g pellet CHAPS 18,000g pellet; lane 6 SN 18,000g CHAPS 
200,000g pellet; lane 7 SN 18,000g DTT 200,000g pellet; lane 8 200,000g pellet; lane 9 SN 
200,000g;  lane 10 SN 18,000g  CHAPS SN 200,000g; lane 11 SN 18,000g  DTT  SN 
200,000g. Polyclonal anti-HSA and monoclonal anti-HAS clone 6501 and 6502. Polyclonal 
anti-IgG and polyclonal anti-THP diluted 1:1,000 overnight RT. 
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Albumin detection with two separate monoclonal antibodies showed that albumin is 
distributed in all fractions even after CHAPS and DTT treatment. Although the signal is 
present in the SN 18,000g CHAPS/DTT SN 200,000g (lane 9 and 10), signal was still visible 
in the respective pellets (lane 6 and 7). Notably, treatment with CHAPS and DTT could not 
affect the precipitation of albumin into the soluble phase. It is also interesting to note that 
HSA, which co-precipitated in the 18,000g pellet (lane1, 2 and 3) did not reveal a 
fragmentation pattern consistent with that of the 18,000g and 200,000g pellets resulting from 
CHAPS and DTT treatment of the crude 200,000g pellet (lane 4, 5, 6 and 7). This postulates 
that these different fractions of membrane vesicles have different patterns of albumin 
fragmentation which co-precipitate specifically with sub populations of nano vesicles. It 
could be due to a specific protease present in these sub-populations or differential PTMs of 
albumin. Full-length IgG was found to be present in P18,000g (Lane 1-3) while extensive 
fragmentation as well as full length IgG was seen in P200,000g pellets both crude and treated 
(Lane 6 & 8). THP similarly was present to significant levels in the P200,000g (Lane  6-8). 
This prompted us to investigate whether these abundant proteins are present with membrane 
vesicle fractions in a non-specific manner or if there is a specific interaction of these proteins 
with membrane vesicles. 
Our preliminary investigations were focused on verifying whether a biomolecular interaction 
was occurring between both sets of detergent-treated nano vesicle populations (e.g. CHAPS- 
and DTT-treated) and albumin, as suggested by Western blotting analysis (Figure 2.8 anti-
albumin antibodies, polyclonal and monoclonal). For the separation of monomeric and 
dimeric fractions of HSA by SEC, a significant improvement in resolution was seen when 
three inter-connected stationary phases were selected instead of one and, hence, this system 
was implemented during this study.  Dimeric and monomeric species with retention times of 
26.8 and 28.4 minutes, respectively, were readily identified using the gel filtration standard 
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for size determination (Figure 2.9 A), while the ratio of monomer:dimer was estimated to be 
12.4:1 based on the calculation of peak areas (Figure 2.9 B).  Monomeric fractions, estimated 
to be approximately 40-45kDa in size, were manually collected and analysed by SDS-PAGE 
to monitor purity and verify the absence of superfluous albumin fractions (Figure 2.9 C).   
Interaction analysis studies were firstly performed by FLISA before proceeding to more in-
depth SPR analysis.  Here, the CHAPS-treated 200,000g pellet (P18+200CP200) was coated 
in triplicate on individual wells of a 96-well plate and after blocking and washing, was 
subsequently probed with the retained monomeric albumin fraction and detected as described 
in the methods section.  Comparative analysis of binding at pH 6.0 and pH 7.4 revealed that 
more favourable binding was seen at the higher pH (Figure 2.9 D), so subsequent SPR 
interaction studies were performed using a running buffer (HBS) at a physiological pH (7.4). 
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Figure 2.9: Species composition of human albumin and preliminary binding studies. (A) 
Retention times for individual components in the gel filtration standard were as follows: 
bovine thyroglobulin (i; 22.8mins), IgG (ii; 27.9mins), ovalbumin (iii; 29.5mins) myoglobin 
(iv; 31.4mins) and vitamin B12 (v; 33.1mins). (B) Dimeric (vi) and monomeric (vii) species 
of commercial human albumin was readily detected by SEC, and subsequently analysed by 
SDS-PAGE to ascertain purity of retained fractions (40-45kDa). (D) A pilot study using 
CHAPS-treated nano vesicle populations demonstrated more favourable binding at 
physiological pH by FLISA. The background fluorescence signal for the negative control was 
subtracted from those obtained at pH values of 6.0 and 7.4, respectively. 
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Aliquots of DTT- and CHAPS-treated nano vesicle preparations were reconstituted in HPLC-
grade de-ionised water (filter-sterilised) to 980g/mL and 509g/mL, respectively, before 
being diluted to a final concentration of 100g/mL.  Next, pre-concentration studies were 
used to determine the optimal pH for the immobilisation of DTT- (pH3.6) and CHAPS-
treated populations (pH3.8) on flow cells 2 and 4, respectively.  EDC/NHS-based coupling 
and ethanolamine capping resulted in the capture of 15,952.7RU of DTT-treated exosomes, 
while 8,530RU of CHAPS-treated exosomes were captured. Nano vesicle populations were 
previously shown by TEM analysis to be comprised of a panel of entities whose sizes ranged 
from 20-200nm. It suggests that heterogenous surfaces (having vesicles of multiple sizes) 
were therefore presented for interaction analysis with high-abundance proteins.  Regeneration 
scouting was used to verify that 2.5mM NaOH could be selected to ensure a stable baseline 
on both flow cells, with 20 regenerations (5L injections) resulting in a loss of 15RU and 
18RU from FC2 and FC4, respectively.  Hence, these conditions were deemed to be 
appropriate and were selected for albumin binding studies. 
We initially investigated whether the nano vesicle populations isolated by CHAPS- and DTT-
treatments were already coupled to albumin at the time of their immobilisation, which would 
also suggest an interaction prior to cross-linking. To test this hypothesis, a dose-response 
curve with polyclonal anti-albumin antibody at five concentrations, namely 10µg/mL, 
20µg/mL, 50µg/mL, 100µg/mL and 200µg/mL, was tested on both flow cells by interday 
analysis.  The antibody bound to both CHAPS- and DTT-treated populations, with apparent 
saturation seen at the lowest concentration selected (10µg/mL).  In contrast, binding to DTT-
treated populations was in a concentration-dependent manner, with the introduction of 
elevated concentrations of analyte correlating with an increase in RU (Figure 2.10 A). 
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Figure 2.10: Comparative binding analysis of albumin to CHAPS-treated nano vesicle 
populations at two pH values by SPR. Comparative analysis of the binding of anti-albumin 
(A) and albumin (B) to DTT-and CHAPS-treated nano vesicle populations immobilised on 
flow cells 2 and 4, respectively.  Signals shown are for interday analysis, with the signal 
obtained from the HBS negative control (analyte-free) and the reference flow cells (e.g. flow 
cell 1 for DTT-nano vesicles and flow cell 3 for CHAPS) subtracted so as to show true 
binding to immobilised populations. Erros bars represent standard deviation from the mean. 
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These observations suggested that the immobilised nano vesicles were coupled with albumin, 
and that detergent treatment did not effect the removal of this soluble protein from either 
population (DTT and CHAPS trated vesicles). Next, as a further verification of the 
occurrence of a binding event between albumin and both vesicle populations independently 
of one another, the monomeric fraction of human albumin previously selected for FLISA-
based analysis was tested on both flow cells using the same dose-dependence response curve 
as previously used for anti-albumin.  More favourable binding was evident for the CHAPS-
treated population, and apparent saturation was seen at an analyte concentration of 20µg/mL 
for each ligand (Figure 2.10 B). 
Based on these observations, we investigated whether an anti-albumin immunoprecipitation 
(IP) could be performed with the objective of selectively enriching exosomes from the nano 
vesicle population, with polyclonal anti-HSA antibody selected as a biorecognition element 
and a monoclonal anti-HSA antibody implemented for detection purposes. Nano vesicles 
isolated by treatment with CHAPS (P18+170CP170) were selected as an analyte, primarily 
due to the observation in SPR analysis of more favourable binding to albumin.  
Immunoprecipitation of the full-lenght HSA molecule, and not proteolysis-derived fragments, 
was seen when captured fractions were eluted, analysed by SDS-PAGE (Figure 2.11 A) and 
subsequently probed with monoclonal anti-HSA antibody (Figure 2.11 B). However, 
proteolysed fragments of albumin were present in the unbound fraction.  
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Figure 2.11: Immunoprecipitation of urinary nano vesicles using monoclonal anti-albumin 
antibody for biorecognition. Silver staining (A) and Western blotting (B) analysis of non-
bound (Lane 1), wash (Lane 2) and elution fractions (Lane 3), verifying the presence of three 
isoforms of albumin. 
In our previous report, we outlined that in the aforementioned CHAPS-treated nano vesicle 
population (P18+200CP200) CD63, a well-established exosomal marker (Logozzi et al., 
2009; Nilsson et al., 2009), was detected in relatively low intensities by Western blotting 
(Musante et al., 2012). Interday SPR analysis using a single concentration of anti-CD63 
antibody (10µg/mL) was performed to verify this result with respect to binding to both nano 
vesicle populations, and determine whether this antibody could also be selected as an 
alternative to anti-albumin for immunoprecipitation.  Here, it was observed that weak binding 
was occurring between anti-CD63 and DTT-treated exosomes (µ=16.9RU; = 1.34), with 
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comparable results (µ=15.1RU; = 4.31) obtained for vesicles treated with CHAPS.  
Subsequent analysis of immunoprecipitation fractions using anti-CD63 demonstrated a clear 
enrichment of CD63 in the eluate fraction (approximately 50-55kDa), which was not detected 
in the non-bound and washing fractions (Figure 2.12). 
 
Figure 2.12: Immunoprecipitation of urinary nano vesicles (using anti-albumin antibody) and 
detection in a western blot using anti-CD63 antibody. Western blotting analysis of non-bound 
(Lane 1), wash (Lane 2) and elution fractions (Lane 3); CD63 (~55kDa) is present in the 
elution fraction but not in other fractions.  
   
It is well-established that the co-precipitation of THP, with urinary nano vesicles during 
exosome/urinary nano vesicle isolation, is problematic when attempting to isolate populations 
for proteomic, glycomic or transcriptomic analysis.  Moreover, THP polymers are known to 
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interact with urinary nano vesicles (Fernandez-Llama et al., 2010). Furthermore, in our 
previous analysis we demonstrated that sedimentation of this protein in the 1,000g pellet 
significantly reduced the quantity of THP in subsequent fractions, which permitted us to 
obtained improved yields of pure nano vesicles (Figure 2.3).  As a demonstration of the 
ability of this soluble protein to bind to both CHAPS- and DTT-treated populations, DEF-
extracted THP was selected as an analyte and assayed on both nano vesicle populations by 
SPR, using the same dose-response curve as described previously.  For DTT-treated vesicles, 
an increase in analyte concentration correlated with higher RU values.  Notably, for vesicles 
isolated using a CHAPS-treatment, an inverse trend was seen.  Here, binding to THP was 
significantly lower for each concentration selected for analysis.  Furthermore, introducing 
increased concentrations of analyte resulted in reduced binding to surface-immobilised nano 
vesicles (Figure 2.13).  
 
Figure 2.13: Biomolecular interactions with THP. Comparative analysis of the binding of 
DEF-purified THP in solution to DTT- and CHAPS-treated populations by SPR, using a 
dose-dependent response curve and interday analysis. X-axis is the THP concentration and Y-
axis is the response unit obtained upon interaction with vesicles. 
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This inverse trend of reduced binding seen upon introduction of increasing concentrations of 
THP to the CHAPS-treated fraction could be due to the apparent Hooks effect. Western 
blotting using anti-IgG demonstrated that this immunoglobulin was resident to both CHAPS- 
and DTT-treated nano vesicle populations (Figure 2.8, polyclonal IgG). To verify whether 
IgG could interact with the nano vesicle fractions selected herein for binding studies, human 
IgG was selected as an analyte and assayed using identical conditions to the aforementioned 
interaction analyses.  In contrast to what was observed for THP binding studies, an increase 
in RU as a function of IgG concentration was observed for ligands on flow cells 2 and 4, 
respectively, while no apparent saturation was observed during this analysis (Figure 2.14). 
The reference flow cells 1 and 3 were used as a control by passing equal amounts of IgG over 
them and subtracting their value from the interaction shown here. 
 
Figure 2.14: Biomolecular interactions with IgG. Comparative analysis of the binding of IgG 
in solution to both nano vesicle populations (DTT-treated and CHAPS-treated) by interday 
SPR analysis.   
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2.4 Discussion 
Exosomes found in all biological fluids, including the urine, are emerging as a novel class of 
cell products plausibly revolutionising our views of cell behaviour and processes like 
intercellular communication (Van Niel et al., 2006). While an increasing variety of exosome 
constituents including specific proteins, DNA and RNA species are being identified, little is 
still understood of their precise biological roles. Likewise, the optimal method for exosomal 
isolation and to determine of thier interactions, to appreciate their distinct roles in biology 
remains to be characterised in detail. The aim of this study was to optimize methods which 
increase the recovery of urinary exosomal vesicles and optimise their preservation for 
functionality without notable interference with inherent soluble protein constituents of urine.  
Tamm-Horsfall protein (THP) is the most abundant glycoprotein normally found in urine 
(Tamm & Horsfall, 1952). It is expressed abundantly in the thick ascending limb of the loop 
of Henle and the early distal convoluted tubule (Kumar et al., 1985). THP contains the most 
varied array of linked glycans of any human glycoprotein, which suggests a capacity for 
adhesion to a variety of ligands (Hard et al., 1992). In the urine, THP may precipitate due to 
many factors of the immediate physico-chemical microenvironment and, accordingly, THP is 
the main constituent of hyaline urinary casts (Fairley, Owen & Birch, 1983). More recently, 
Fernández-Llama and colleagues (Fernandez-Llama et al., 2010) demonstrated that abundant 
exosome vesicles are entrapped within urinary THP polymers. In order to overcome such an 
interference in the analysis of the total exosome proteome, a strong denaturation of its 24-
disulfide bridges by DTT have been proposed (Gonzales et al., 2009; Fernandez-Llama et al., 
2010). This leads to defolding of the zona pellucida (ZP) domain responsible for protein 
polymerization (Gonzales et al., 2010). Alternatively, use of ultracentrifugation, 
incorporating a sucrose gradient or a cushion in deuterated buffer, to remove THP has been 
proposed (Mitchell et al., 2009; Hogan et al., 2009). 
124 
 
We introduce here distinct modifications, as summarised in Figure 1, to the well-established 
method of exosome isolation which is based on serial differential centrifugations (Gonzales et 
al., 2010). Firstly, a very low-speed centrifugation at 1,000g was introduced to remove 
abundant cells, cell debris, nuclei, bacteria and the bulk of THP which interferes by 
entrapping the exosomes. As evident by SDS-PAGE analysis of this fraction, the approach 
was efficient (Figure 2.3). Although we cannot fully appreciate the fact that a fraction of 
vesicles retained at this point may have been entrapped within THP polymers, the 
introduction of this low-speed centrifugation step avoided a potential contamination resulting 
from intracellular vesicle release as a result of cytolysis following freeze-thaw cycles and 
hypotonic shock during dialysis. Furthermore, a dialysis step was introduced to decrease the 
salt concentration in order to favour the de-polymerization of THP and avoid its precipitation 
during the following centrifugation steps. Nonetheless, THP fibrils were still present in the 
low-speed centrifugation pellet, as shown in Figure 2.2, possibly due to the increased THP 
concentration following the reduction of the starting volume by sppedvac. This step was 
introduced with the double aim of handling a large amount of urine in a small volume and, 
secondly, to mimic a proteinuric condition and, thus, to evaluate the extent of albumin 
interference which is well-represented in the first crude pellets along with THP (section 
2.3.3). To overcome these barriers, our protocol was modified particularly to facilitate the 
release of entrapped vesicles from THP polymers, and simultaneously removing the 
interference of soluble proteins like albumin.  
After systematic trials, we selected two approaches to manage THP interference. The first 
involved the well-established DTT treatment (Pisitkun, Shen & Knepper, 2004; Gonzales et 
al., 2009; Fernandez-Llama et al., 2010; Gonzales et al., 2010) which unfolds the zona 
pellucida (ZP) domain responsible for protein polymerization (Jovine et al., 2002). The 
second method involved the addition of a mild detergent which has previously been shown to 
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solubilise THP efficiently (Kobayashi & Fukuoka, 2001). CHAPS, a non-denaturating 
zwitterionic detergent is ideally suited for the disruption of non-specific protein interactions, 
while also protecting the conformation of the protein (s) of interest (Hjelmeland, 1980).  The 
bulk of THP and albumin were successfully removed from the exosomal pellet and after the 
treatment with CHAPS, were found in the supernatant, as shown in Figure 3. CHAPS is 
known to break protein-protein interactions (Hjelmeland, 1980; Labeta, Fernandez & 
Festenstein, 1988). However, depending on the microenvironment, the strongest protein-
protein interactions, such as those found in the tetraspanin web (Levy & Shoham, 2005), are 
preserved. 
When analysed by electron microscopy, pellets retained after both low and high-speed 
centrifugations treated with CHAPS and/or DTT showed a characteristic spherical 
morphology limited by a bilipidic layer (Figure 2.2) and with diameters ranging from 
between 30 to 150 nm. These characteristics are consistent with the observed size and 
morphology of vesicles previously described in urine (Pisitkun, Shen & Knepper, 2004; 
Cheruvanky et al., 2007; Gonzales et al., 2009; Hogan et al., 2009; Hara et al., 2010; 
Gonzales et al., 2010; Merchant et al., 2010; Rood et al., 2010). Indeed, it is clear that 
urinary vesicles represent a tremendous heterogeneity in size and in the exosomes, marker 
patterns are evident as shown in the Western blot analysis. The concomitant presence of other 
specific markers, like nephrin and lactadherin, complicate the semantic definition of such 
urinary fractions which can include what are generally called microparticles, ectosomes, 
exosomes, ‘exosome-like’ vesicles and shed vesicles. Furthermore, these results clearly 
suggest that the whole vesicle is a structure resistant to treatment with a detergent such as 
CHAPS, which in turn demonstrates that this may be used for vesicle isolation without 
having a deleterious effect on the structural conformation of vesicles.  
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In our analysis, after an ON incubation in 1% (w/v) CHAPS, which is able to solubilise a 
detergent-resistant domain almost completely within one hour of incubation (Garner, Smith 
& Hooper, 2008), we were able to perform comparative analysis of CHAPS- and DTT-
treated vesicle populations by TEM (Figure 2.2). This suggests that urinary vesicles are 
detergent (CHAPS)-resistant. Furthermore, the MS-based proteomic profiling led to the 
identification of 247 unique proteins in CHAPS SN and 274 in DTT SN, respectively. This 
finding indirectly confirms the resistance of these vesicles to detergent solubilisation. The 
Venn diagram in Figure 2.6 shows that around 75% of identifications in CHAPS or DTT are 
shared. This evidence clearly highlights the detergent-resistant features of urinary nano 
vesicles. In fact, if CHAPS had lysed and solubilised the vesicle contents, it would be 
expected to find a protein data set which would be highly biased toward the exosomal 
proteome. Furthermore, the distribution of the protein classes by the Panther classification 
system (Fig. 2.7) was similar between CHAPS and DTT in respect to several exosomal 
proteins. Comparison of our results with the published proteomic data on exosomes and 
exosome free supernatants (Gonzales et al., 2009; Kentsis et al., 2009) showed that more than 
50% -exosomes pellet- and 70% -SN exosome-free of the identified proteins were shared, 
respectively. Interestingly, around 40% of identified proteins are common to the 4 data sets.  
In spite of differences in the methodological approach, the ‘off-gel’ utilized in this study with 
respect to the ‘in-gel’ method utilized in the comparative protein data set (Gonzales et al., 
2009; Kentsis et al., 2009), instrumentation and bioinformatics tools, the 3 data sets showed 
high concordance in the identifications. One of the reasons for it oculd be the stringency of 
MS identification criteria used (described in detail in the original publications on each 
dataset), was reasonably high in each case. Therefore, false-positive identifications should 
represent less than 1% of the entries.  Keeping in mind that these vesicles were found to be 
resistant to harsh treatments, this evidence shows an incomplete recovery of vesicles by the 
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classical ultracentrifugation protocols which may lead to a preferential enrichment of 
vesicular subpopulations which plainly share a common set of proteins (exosomal markers) 
along with some specific ones (inherent to a possible sub-population).  This is of significant 
practical importance as the increased yield of vesicles isolated and the confidence in the MS 
identification and quantification of low-abundant proteins from vesicle pellets could be of 
crucial importance to identify biomarkers represented in very low amounts. Currently, 
modern proteomics aim for the analysis of sub-cellular proteomes for markers discovery. In 
this regard, two special kinds of extracellular vesicles such as exosomes and membrane 
plasma shedding vesicles are emerging as excellent biological sources to be applied in the 
discovery of non-invasive organ-specific disease biomarkers.  
Protease activity of dipeptidyl peptidase (DPP IV) and nephrilysin (NEP) showed that the 
CHAPS method is a useful alternative to DTT when full preservation of biological activity of 
all the disulfide bridge-containing proteins is needed. In particular, the NEP structure consists 
of a short N-terminal cytoplasmic domain, followed by a single trans-membrane helix, and a 
large C-terminal extracellular domain that contains the active site (Lee et al., 1991; Shimada, 
Takahashi & Tanzawa, 1994). The extracellular domain of NEP contains 12 cysteine 
residues, all components of six disulfide bridges. Four of these are located within the catalytic 
domain. A single disulfide bridge is found within the inter-domain linker fragments, and 
another one is present within domain 2. All of these participate in maintaining the structure 
consisting of two multiply-connected folding domains which embrace a large central cavity 
containing the active site (Emoto & Yanagisawa, 1995). Evaluation of NEP proteolytic 
activity after reduction and re-oxidation (DTT treatment and subsequent removal of DTT) of 
disulfide bridges highlights that this may result in a severe misfolding, leading to an 
impairment of NEP activity. NEP activity is better preserved in the CHAPS protocol as 
shown by our results.  
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Western blotting of CHAPS and DTT fractions revealed very similar patterns. Firstly, after 
both treatments, the bulk of the tetraspanin family exosomal marker associated with late 
multivesicular endosomes, CD63 (Kobayashi et al., 2000) was recovered at a low centrifugal 
speed (18,000g) with a broad distribution of isoforms. During urine formation, the final 
product for voiding contains vesicles originating from a wide range of different cellular 
origins and hence, it was not a surprise to find such a heterogeneity which is a reflection of 
specific cell-sorting and trafficking pathways, but also of distinct origin upstream in the 
podocyte by finding fractions of nephrin in exosomes.  Finally, although protease degradation 
cannot be excluded, at the time of its occurrence this activity seemed to be very specific and 
related to all those fractions which were retained at a low-speed centrifugation (18,000g). In 
support of this evidence, immunodetection of cytosolic TSG-101 showed a fragmentation 
pattern in only one fraction P18CP200, which was not seen in other fractions where the 
signal was equally intense for full length protein (Figure 2.4). Furthermore, the ability to 
detect the intra-vesicular localised marker TSG101 (Babst et al., 2000; Thery et al., 2001; 
Khatua et al., 2009) underlines the retained integrity of the vesicles during the whole 
purification methodology. 
Lactadherin (MFG-E8 or SED1) is known to participate in a wide variety of cellular 
interactions (Raymond, Ensslin & Shur, 2009) and was previously shown to be released in 
association with exosomes (Oshima et al., 2002). An interaction was reported between the 
discoidin/C domains and the pellucida zone (Ensslin & Shur, 2003) and one could speculate 
about a possible interaction with THP (ZP domain).  Finally, lactadherin isoforms have been 
previously identified which are reflections of physiological state and distinct cell type origins 
(Veron et al., 2005; Watanabe et al., 2005). MFG-E8 immunodetection (Figure 2.4) reveals a 
wide distribution of bands with specific signatures for each pellet. Proteomic profiling 
(Pisitkun, Shen & Knepper, 2004; Gonzales et al., 2009) has identified potential interacting 
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partners of MFGE-E8 (such as β-integrin) in exosomes. On the other hand, shed vesicles and 
apoptotic bodies have phosphatidyl-serine on the surface and MFG-E8 could mediate 
interactions between these vesicles and exosomes, and as well as THP. However, this remains 
to be fully established. 
Surprisingly, immunodetection with anti-nephrin antibody revealed a comparable distribution 
of fragments to those seen in nephrinuria patients (Patari et al., 2003). Examination of the 
western blot molecular weights and the intracellular location of the specific epitope 
recognised by our antibody led us to propose that this vesicle preparation contains 
membrane-associated nephrin fragments. Whether these fragments were orientated ‘right-
side-out’ (extracellular part on surface) or ‘inside-out’ (cytosolic part on surface) has to be 
confirmed by further analyses. Identification of shed podocytes in the urines of healthy 
subjects and patients affected by glomerular diseases has also been proposed previously 
(Vogelmann et al., 2003; Hara et al., 2005). More recently, it was reported that small 
podocalyxin-positive vesicles which are negative for exosomal markers originate from 
microvilli of podocytes in both healthy samples and those from patients with glomerular 
diseases (Hara et al., 2010).  Detection of nephrin and exosomal markers in the same fraction 
may suggest a protein turnover through clathrin- or raft-mediated endocytosis (Veron et al., 
2005). After internalisation by either mechanism, vesicles are sorted into the endosomal 
pathway which could redirect vesicles to be either degraded or secreted as exosomes. The 
minute amount of nephrin excreted into urine of healthy subjects could reflect a physiological 
turnover of the slit diaphragm. In support to this, nephrin has been detected by immuno-
electron microscopy not solely at the slit diaphragm area but also along lateral podocyte 
membranes and, eventually, in the urine (Patari et al., 2003). The detection of the same 
nephrin fragmentation pattern in the whole urine of diabetic nephropathic patients (Patari et 
al., 2003) suggests that an increase in this dynamic process may accurately reflect worsening 
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podocyte injury. A better understanding of the mechanism (s) which accelerates the turnover 
of this key structure of the glomerular filtration barrier may provide a critical new insight into 
the identification of early markers of glomerular impairment during disease progression.   
It was found that despite the efforts to exclude high-abundant proteins like THP and albumin 
from nano vesicle isolation, these proteins are present in significant quantities in final pellet 
(Musante et al., 2012). DTT and CHAPS treatment seem to get rid of these proteins but only 
to a certain extent. Therefore, the resilient behaviour of these proteins led us to speculate 
whether these proteins could be interacting specifically with the vesicle populations. We 
sought to establish this interaction using FLISA, IP and SPR. Preliminary FLISA and IP 
analysis was performed using CHAPS-treated nano vesicle populations only, and the 
monomeric fraction of commercial human albumin, as purified by SEC and analysed by 
SDS-PAGE (Figures 2.9 and 2.12), which demonstrated more favourable binding to albumin 
at a physiological pH. The demonstration of this biomolecular interaction was one of the 
primary objectives of these analyses. This FLISA and IP study was not repeated for DTT-
populations as a significant amount of effort was required for the isolation of nano vesicles 
and hence, we elected to conserve this material for SPR analysis, using the FLISA and IP as a 
preliminary study to ascertain whether there was a justification for proceeding.   
For our SPR studies, we elected to capture nano vesicles using a carboxymethylated dextran 
surface and EDC/NHS-based coupling through the selection of a CM5 sensor chip.  It is well 
established that L1 sensor chips, supplied by the manufacturer of Biacore technology (GE 
Healthcare), are particularly suited for the capture of lipid-containing ligands (Anderluh et 
al., 2005).   However, our preconcentration and immobilisation studies performed initially on 
the CM5 surface allowed us to capture suitable quantities of analyte for interaction studies, 
with nano vesicles retaining stability on immobilised surfaces when subjected to regeneration 
scouting with NaOH.  We propose that the CHAPS- and DTT-treated vesicles selected as 
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ligands were coupled to this surface via their associated proteins, which in turn permitted 
covalent capture.  It should also be noted that at the completion of this analysis, only a 4.3% 
loss in captured ligand was observed, which suggested stability. For the purpose of our 
studies, we elected to proceed with comparative binding of a panel of different analytes with 
both nano vesicle populations, which explains why these were immobilised as opposed to e.g. 
albumin or THP. While identical ligand concentrations (100µg/mL) were selected for capture 
using the same immobilisation and capping cycle times, different amounts of ligand were 
captured on flow cells 2 and 4, respectively. It is a challenge to have identical amounts of 
ligand captured on adjacent surfaces. However, the objective of our analysis was simply to 
demonstrate qualitative binding primarily using a dose-dependent response curve of analyte.  
Hence, as the same amount of analyte was passing over both surfaces, it was possible to 
determine relative comparative binding. 
For our studies, the immobilisation of nano vesicles previously shown to be comprised of a 
population of entities with differing sizes (Musante et al., 2012) presented a heterologous 
surface, which would prevent accurate 1:1 interaction analyses to be performed.  In addition 
to this, our objectives were not to obtain comparative affinity measurements between each 
analyte selected for analysis and individual nano vesicle populations, but simply to 
demonstrate the occurrence in nature of this biomolecular interaction and deduce the 
biological importance of this interaction.  Furthermore, if an analyte such as albumin was 
selected for capture, it would not have been possible to perform kinetic analysis due to the 
heterogenous nature of these populations, inferring that is would not be possible to determine 
the size of the analyte.  This could only be performed by isolating individual populations of 
nano vesicles of a defined size, which is problematic given the nature of these analytical 
matrices.  Hence, no kinetic analysis was performed. 
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Preliminary SPR studies were undertaken to demonstrate an interaction between each nano 
vesicle population and albumin.  More specifically, we initially chose to investigate whether 
the nano vesicles immobilised were already coupled with albumin by selecting an anti-
albumin antibody for biorecognition purposes. For CHAPS-treated exosomes, the observation 
of a concentration-dependent increase in RU, taking online reference subtraction and the 
HBS negative control into consideration, suggested that albumin was already present and 
coupled with these vesicles.  In contrast, the introduction of a low analyte concentration 
(10µg/mL) to DTT nano vesicles resulted in favourable binding (µ=76.2RU), albeit without 
an increase in binding as elevated amounts of anti-albumin antibody were subsequently 
introduced (Figure 2.10 A). This suggested that saturation was occurring at this 
concentration. In contrast, when SEC-purified monomeric albumin was tested (Figure 2.10 
B), more favourable binding was observed for CHAPS populations, with signal saturation 
seen for both ligands at an analyte concentration of 50µg/mL. Based on the observations of 
these two interday SPR assays, we postulate that there is an interaction between albumin and 
both nano vesicle populations independent of one another, which is evident at the time of 
isolation from urine. Furthermore, we can speculate that there is a higher amount of albumin 
coupled to the DTT-population, which in turn results in increased binding of anti-albumin 
antibody at the lowest analyte concentration selected for analysis, namely 10µg/mL. 
Notwithstanding the tendency of human serum albumin to aggregate (Lin et al., 2000), this in 
theory would mean that there is limited space available for albumin to bind to these vesicles, 
which is reflected by lower binding and, consequently, reduced RU values. The opposite 
effect appears to be evident for CHAPS-treated nano vesicles, where significantly increased 
albumin binding is observed, presumably to the presence of lower amounts on the 
immobilised vesicles which, in turn, accommodates interaction with free albumin in solution. 
It should also be mentioned that there is approximately twice as much ligand captured on 
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FC2 (DTT) than on the corresponding CHAPS surface (FC4). This may, in theory, mean a 
twofold increase in albumin binding sites availability on this surface which could mean that 
actual albumin interaction with DTT vesicles was even lower than what was observed. 
Finally, it must also be acknowledged that the detergent treatments may have different effects 
on the conformational structure of surface proteins/epitopes which may in turn compromise 
binding. IP, using anti-albumin antibodies, were able to isolate nano vesicles as evidenced by 
detection of CD63 in the elution fraction of IP (Figure 2.12). These results of SPR and IP 
seem to complement each other. 
We and others have already outlined the fact that THP co-precipitation is problematic for 
urinary exosome isolation (Fernandez-Llama et al., 2010; Musante et al., 2012), although we 
present the first direct binding studies using DEF-purified THP. For CHAPS-treated nano 
vesicles, increased concentrations of this soluble protein correlated with an increase in 
binding, as seen previously for albumin.  However, a contrasting binding profile was seen for 
DTT-populations, where analyte concentration was inversely proportional to surface binding. 
DTT-populations have less THP as compared to the CHAPS-populations (Figure 2.8). This 
could be due to the apparent Hooks effect. 
Subsequent profiling using anti-IgG revealed that both populations contained this 
immunoglobulin as an external epitope, as TEM analysis revealed that structural integrity 
was not compromised as a result of detergent treatment (Figure 2.2).  A typical concentration-
dependent increase in binding was observed, albeit with more favourable binding to CHAPS-
treated nano vesicle populations (Figure 2.14). In summary, through the implementation of 
FLISA and IP, as preliminary methodologies, and SPR analysis, through the application of 
the Biacore 3000 analytical platform, we have been able to provide key information on the 
biomolecular interactions that take place between high-abundance proteins such as THP, 
albumin and IgG and nano vesicles.  
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In conclusion, an improved method was developed to exclude most of the interference of 
soluble proteins present in urinary vesicle isolation. CHAPS treatment appears superior in 
preserving the activity of constituent proteins of membrane vesicles while simultaneously 
removing interference of soluble proteins (THP, albumin). Thus, our method offers a new 
protocol to prepare urinary vesicles for –omics, analytical or functional studies. Moreover, 
interactions between high abundant proteins and membrane vesicles were established. This, 
in part, explains why these proteins are so difficult to remove from the nano vesicle 
populations when isolated from whole urine.  
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Supplementary table S2.1: Identification of proteins in (P18+P200) DTT SN200 sample 1. 
Accession of the protein, sequence coverage, PSM (Match between a fragmentation mass 
spectrum and peptide), number of peptides found, number of amino acid in the protein, 
molecular weight, calculated PI and mascot score along with the description of the protein are 
indicated in the table. 
Accession Coverage 
% 
# 
PSMs 
# 
Peptides 
# 
AAs 
MW 
[kDa] 
calc. pI Score Description 
P62258 12.16 2 2 255 29.2 4.74 118.92 14-3-3 protein epsilon OS=Homo 
sapiens GN=YWHAE PE=1 SV=1 - 
[1433E_HUMAN] 
P63104 4.90 1 1 245 27.7 4.79 65.24 14-3-3 protein zeta/delta 
OS=Homo sapiens GN=YWHAZ 
PE=1 SV=1 - [1433Z_HUMAN] 
P08195 4.44 2 2 630 68.0 5.01 76.24 4F2 cell-surface antigen heavy 
chain OS=Homo sapiens 
GN=SLC3A2 PE=1 SV=3 - 
[4F2_HUMAN] 
O95336 6.20 1 1 258 27.5 6.05 98.20 6-phosphogluconolactonase 
OS=Homo sapiens GN=PGLS PE=1 
SV=2 - [6PGL_HUMAN] 
Q13510 26.08 9 8 395 44.6 7.62 555.66 Acid ceramidase OS=Homo sapiens 
GN=ASAH1 PE=1 SV=5 - 
[ASAH1_HUMAN] 
P60709 9.60 3 3 375 41.7 5.48 191.73 Actin, cytoplasmic 1 OS=Homo 
sapiens GN=ACTB PE=1 SV=1 - 
[ACTB_HUMAN] 
P13798 1.64 1 1 732 81.2 5.48 68.22 Acylamino-acid-releasing enzyme 
OS=Homo sapiens GN=APEH PE=1 
SV=4 - [ACPH_HUMAN] 
P02763 30.35 5 5 201 23.5 5.02 279.23 Alpha-1-acid glycoprotein 1 
OS=Homo sapiens GN=ORM1 
PE=1 SV=1 - [A1AG1_HUMAN] 
P19652 16.92 3 3 201 23.6 5.11 131.95 Alpha-1-acid glycoprotein 2 
OS=Homo sapiens GN=ORM2 
PE=1 SV=2 - [A1AG2_HUMAN] 
P01011 17.02 5 5 423 47.6 5.52 326.04 Alpha-1-antichymotrypsin 
OS=Homo sapiens GN=SERPINA3 
PE=1 SV=2 - [AACT_HUMAN] 
P01009 37.80 14 12 418 46.7 5.59 838.83 Alpha-1-antitrypsin OS=Homo 
sapiens GN=SERPINA1 PE=1 SV=3 
- [A1AT_HUMAN] 
P04217 5.86 2 2 495 54.2 5.87 109.18 Alpha-1B-glycoprotein OS=Homo 
sapiens GN=A1BG PE=1 SV=3 - 
[A1BG_HUMAN] 
P02765 5.72 3 2 367 39.3 5.72 179.74 Alpha-2-HS-glycoprotein OS=Homo 
sapiens GN=AHSG PE=1 SV=1 - 
[FETUA_HUMAN] 
P01023 1.97 2 2 1474 163.2 6.42 115.80 Alpha-2-macroglobulin OS=Homo 
sapiens GN=A2M PE=1 SV=2 - 
[A2MG_HUMAN] 
O43707 5.93 5 5 911 104.8 5.44 274.72 Alpha-actinin-4 OS=Homo sapiens 
GN=ACTN4 PE=1 SV=2 - 
[ACTN4_HUMAN] 
P04745 37.77 12 12 511 57.7 6.93 628.87 Alpha-amylase 1 OS=Homo sapiens 
GN=AMY1A PE=1 SV=2 - 
[AMY1_HUMAN] 
P19961 31.51 11 11 511 57.7 7.09 601.37 Alpha-amylase 2B OS=Homo 
sapiens GN=AMY2B PE=1 SV=1 - 
[AMY2B_HUMAN] 
P06733 10.60 3 3 434 47.1 7.39 151.89 Alpha-enolase OS=Homo sapiens 
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GN=ENO1 PE=1 SV=2 - 
[ENOA_HUMAN] 
P54802 32.17 19 16 743 82.1 6.54 1058.5
0 
Alpha-N-acetylglucosaminidase 
OS=Homo sapiens GN=NAGLU 
PE=1 SV=1 - [ANAG_HUMAN] 
P15144 29.16 30 21 967 109.5 5.48 1641.0
3 
Aminopeptidase N OS=Homo 
sapiens GN=ANPEP PE=1 SV=4 - 
[AMPN_HUMAN] 
P12821 1.07 1 1 1306 149.6 6.39 63.12 Angiotensin-converting enzyme 
OS=Homo sapiens GN=ACE PE=1 
SV=1 - [ACE_HUMAN] 
P01019 6.39 3 2 485 53.1 6.32 163.68 Angiotensinogen OS=Homo sapiens 
GN=AGT PE=1 SV=1 - 
[ANGT_HUMAN] 
P04083 8.09 2 2 346 38.7 7.02 70.17 Annexin A1 OS=Homo sapiens 
GN=ANXA1 PE=1 SV=2 - 
[ANXA1_HUMAN] 
P07355 4.13 1 1 339 38.6 7.75 95.63 Annexin A2 OS=Homo sapiens 
GN=ANXA2 PE=1 SV=2 - 
[ANXA2_HUMAN] 
P08758 9.69 2 2 320 35.9 5.05 118.17 Annexin A5 OS=Homo sapiens 
GN=ANXA5 PE=1 SV=2 - 
[ANXA5_HUMAN] 
P01008 2.80 1 1 464 52.6 6.71 72.00 Antithrombin-III OS=Homo sapiens 
GN=SERPINC1 PE=1 SV=1 - 
[ANT3_HUMAN] 
P02647 23.97 5 5 267 30.8 5.76 312.30 Apolipoprotein A-I OS=Homo 
sapiens GN=APOA1 PE=1 SV=1 - 
[APOA1_HUMAN] 
P02652 20.00 1 1 100 11.2 6.62 91.59 Apolipoprotein A-II OS=Homo 
sapiens GN=APOA2 PE=1 SV=1 - 
[APOA2_HUMAN] 
P06727 6.31 2 2 396 45.4 5.38 134.56 Apolipoprotein A-IV OS=Homo 
sapiens GN=APOA4 PE=1 SV=3 - 
[APOA4_HUMAN] 
P05090 35.98 16 8 189 21.3 5.15 831.21 Apolipoprotein D OS=Homo sapiens 
GN=APOD PE=1 SV=1 - 
[APOD_HUMAN] 
P02649 23.34 6 5 317 36.1 5.73 353.72 Apolipoprotein E OS=Homo sapiens 
GN=APOE PE=1 SV=1 - 
[APOE_HUMAN] 
P15289 14.00 5 4 507 53.6 6.07 293.32 Arylsulfatase A OS=Homo sapiens 
GN=ARSA PE=1 SV=3 - 
[ARSA_HUMAN] 
O75882 7.42 10 10 1429 158.4 7.31 500.96 Attractin OS=Homo sapiens 
GN=ATRN PE=1 SV=2 - 
[ATRN_HUMAN] 
P98160 1.34 5 5 4391 468.5 6.51 241.11 Basement membrane-specific 
heparan sulfate proteoglycan core 
protein OS=Homo sapiens 
GN=HSPG2 PE=1 SV=3 - 
[PGBM_HUMAN] 
P02749 4.35 1 1 345 38.3 7.97 77.13 Beta-2-glycoprotein 1 OS=Homo 
sapiens GN=APOH PE=1 SV=3 - 
[APOH_HUMAN] 
P61769 8.40 1 1 119 13.7 6.52 75.04 Beta-2-microglobulin OS=Homo 
sapiens GN=B2M PE=1 SV=1 - 
[B2MG_HUMAN] 
P16278 7.98 4 4 677 76.0 6.57 287.86 Beta-galactosidase OS=Homo 
sapiens GN=GLB1 PE=1 SV=2 - 
[BGAL_HUMAN] 
P08236 11.21 4 4 651 74.7 7.02 279.58 Beta-glucuronidase OS=Homo 
sapiens GN=GUSB PE=1 SV=2 - 
[BGLR_HUMAN] 
Q93088 14.53 4 4 406 45.0 7.03 297.42 Betaine--homocysteine S-
methyltransferase 1 OS=Homo 
sapiens GN=BHMT PE=1 SV=2 - 
[BHMT1_HUMAN] 
P19835 14.61 7 7 753 79.3 5.34 339.62 Bile salt-activated lipase OS=Homo 
sapiens GN=CEL PE=1 SV=3 - 
[CEL_HUMAN] 
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P43251 4.79 2 2 543 61.1 6.25 140.86 Biotinidase OS=Homo sapiens 
GN=BTD PE=1 SV=2 - 
[BTD_HUMAN] 
Q5VW32 3.89 2 1 411 46.4 7.65 80.70 BRO1 domain-containing protein 
BROX OS=Homo sapiens 
GN=BROX PE=1 SV=1 - 
[BROX_HUMAN] 
Q8WVV5 2.10 1 1 523 59.0 6.01 66.10 Butyrophilin subfamily 2 member 
A2 OS=Homo sapiens GN=BTN2A2 
PE=2 SV=2 - [BT2A2_HUMAN] 
P12830 7.94 4 4 882 97.4 4.73 235.86 Cadherin-1 OS=Homo sapiens 
GN=CDH1 PE=1 SV=3 - 
[CADH1_HUMAN] 
P55290 1.68 1 1 713 78.2 4.98 67.16 Cadherin-13 OS=Homo sapiens 
GN=CDH13 PE=1 SV=1 - 
[CAD13_HUMAN] 
P19022 4.08 2 2 906 99.7 4.81 196.12 Cadherin-2 OS=Homo sapiens 
GN=CDH2 PE=1 SV=4 - 
[CADH2_HUMAN] 
Q9BYE9 3.66 4 4 1310 141.5 4.50 183.49 Cadherin-related family member 2 
OS=Homo sapiens GN=CDHR2 
PE=1 SV=2 - [CDHR2_HUMAN] 
Q9HBB8 2.13 1 1 845 88.2 4.93 76.63 Cadherin-related family member 5 
OS=Homo sapiens GN=CDHR5 
PE=1 SV=3 - [CDHR5_HUMAN] 
P05937 4.98 1 1 261 30.0 4.83 78.51 Calbindin OS=Homo sapiens 
GN=CALB1 PE=1 SV=2 - 
[CALB1_HUMAN] 
P22792 3.30 1 1 545 60.6 5.99 128.50 Carboxypeptidase N subunit 2 
OS=Homo sapiens GN=CPN2 PE=1 
SV=2 - [CPN2_HUMAN] 
P31944 5.79 1 1 242 27.7 5.58 64.58 Caspase-14 OS=Homo sapiens 
GN=CASP14 PE=1 SV=2 - 
[CASPE_HUMAN] 
P07339 15.53 4 4 412 44.5 6.54 301.14 Cathepsin D OS=Homo sapiens 
GN=CTSD PE=1 SV=1 - 
[CATD_HUMAN] 
P16070 1.62 1 1 742 81.5 5.33 95.82 CD44 antigen OS=Homo sapiens 
GN=CD44 PE=1 SV=2 - 
[CD44_HUMAN] 
P13987 15.63 3 2 128 14.2 6.48 176.85 CD59 glycoprotein OS=Homo 
sapiens GN=CD59 PE=1 SV=1 - 
[CD59_HUMAN] 
Q8NFZ8 6.19 2 2 388 42.8 6.30 128.19 Cell adhesion molecule 4 OS=Homo 
sapiens GN=CADM4 PE=1 SV=1 - 
[CADM4_HUMAN] 
P00450 13.90 10 10 1065 122.1 5.72 570.61 Ceruloplasmin OS=Homo sapiens 
GN=CP PE=1 SV=1 - 
[CERU_HUMAN] 
Q53GD3 1.97 1 1 710 79.2 8.59 99.06 Choline transporter-like protein 4 
OS=Homo sapiens GN=SLC44A4 
PE=2 SV=1 - [CTL4_HUMAN] 
P10909 19.60 6 6 449 52.5 6.27 452.74 Clusterin OS=Homo sapiens 
GN=CLU PE=1 SV=1 - 
[CLUS_HUMAN] 
Q9UGN4 6.02 1 1 299 33.2 5.49 63.42 CMRF35-like molecule 8 OS=Homo 
sapiens GN=CD300A PE=1 SV=2 - 
[CLM8_HUMAN] 
P12109 5.45 4 4 1028 108.5 5.43 330.05 Collagen alpha-1(VI) chain 
OS=Homo sapiens GN=COL6A1 
PE=1 SV=3 - [CO6A1_HUMAN] 
P39059 0.94 1 1 1388 141.6 5.00 133.46 Collagen alpha-1(XV) chain 
OS=Homo sapiens GN=COL15A1 
PE=1 SV=2 - [COFA1_HUMAN] 
P12111 1.51 3 3 3177 343.5 6.68 260.70 Collagen alpha-3(VI) chain 
OS=Homo sapiens GN=COL6A3 
PE=1 SV=4 - [CO6A3_HUMAN] 
P01024 1.68 2 2 1663 187.0 6.40 120.26 Complement C3 OS=Homo sapiens 
GN=C3 PE=1 SV=2 - 
[CO3_HUMAN] 
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P0C0L4 1.49 2 2 1744 192.7 7.08 122.10 Complement C4-A OS=Homo 
sapiens GN=C4A PE=1 SV=1 - 
[CO4A_HUMAN] 
P08185 3.95 1 1 405 45.1 6.04 75.37 Corticosteroid-binding globulin 
OS=Homo sapiens GN=SERPINA6 
PE=1 SV=1 - [CBG_HUMAN] 
P12277 4.46 1 1 381 42.6 5.59 101.91 Creatine kinase B-type OS=Homo 
sapiens GN=CKB PE=1 SV=1 - 
[KCRB_HUMAN] 
Q86T13 3.47 1 1 490 51.6 6.35 58.87 C-type lectin domain family 14 
member A OS=Homo sapiens 
GN=CLEC14A PE=1 SV=1 - 
[CLC14_HUMAN] 
O60494 9.33 23 23 3623 398.4 5.35 1695.1
4 
Cubilin OS=Homo sapiens 
GN=CUBN PE=1 SV=4 - 
[CUBN_HUMAN] 
P15924 0.49 1 1 2871 331.6 6.81 69.25 Desmoplakin OS=Homo sapiens 
GN=DSP PE=1 SV=3 - 
[DESP_HUMAN] 
P16444 11.19 3 3 411 45.6 6.15 189.46 Dipeptidase 1 OS=Homo sapiens 
GN=DPEP1 PE=1 SV=3 - 
[DPEP1_HUMAN] 
P53634 9.72 3 3 463 51.8 6.99 234.33 Dipeptidyl peptidase 1 OS=Homo 
sapiens GN=CTSC PE=1 SV=1 - 
[CATC_HUMAN] 
Q9UHL4 4.47 2 2 492 54.3 6.32 90.75 Dipeptidyl peptidase 2 OS=Homo 
sapiens GN=DPP7 PE=1 SV=3 - 
[DPP2_HUMAN] 
P27487 13.45 9 8 766 88.2 6.04 625.03 Dipeptidyl peptidase 4 OS=Homo 
sapiens GN=DPP4 PE=1 SV=2 - 
[DPP4_HUMAN] 
Q12805 14.00 5 5 493 54.6 5.07 292.78 EGF-containing fibulin-like 
extracellular matrix protein 1 
OS=Homo sapiens GN=EFEMP1 
PE=1 SV=2 - [FBLN3_HUMAN] 
Q9UNN8 16.81 3 3 238 26.7 7.18 130.75 Endothelial protein C receptor 
OS=Homo sapiens GN=PROCR 
PE=1 SV=1 - [EPCR_HUMAN] 
P08294 16.67 3 3 240 25.8 6.61 176.52 Extracellular superoxide dismutase 
[Cu-Zn] OS=Homo sapiens 
GN=SOD3 PE=1 SV=2 - 
[SODE_HUMAN] 
P15311 7.34 5 4 586 69.4 6.27 228.20 Ezrin OS=Homo sapiens GN=EZR 
PE=1 SV=4 - [EZRI_HUMAN] 
P02671 1.96 1 1 866 94.9 6.01 86.31 Fibrinogen alpha chain OS=Homo 
sapiens GN=FGA PE=1 SV=2 - 
[FIBA_HUMAN] 
Q14314 3.64 1 1 439 50.2 7.39 94.43 Fibroleukin OS=Homo sapiens 
GN=FGL2 PE=1 SV=1 - 
[FGL2_HUMAN] 
P02751 4.86 8 7 2386 262.5 5.71 496.46 Fibronectin OS=Homo sapiens 
GN=FN1 PE=1 SV=4 - 
[FINC_HUMAN] 
Q5D862 0.46 1 1 2391 247.9 8.31 62.00 Filaggrin-2 OS=Homo sapiens 
GN=FLG2 PE=1 SV=1 - 
[FILA2_HUMAN] 
Q14315 0.48 1 1 2725 290.8 5.97 74.24 Filamin-C OS=Homo sapiens 
GN=FLNC PE=1 SV=3 - 
[FLNC_HUMAN] 
P09467 5.03 1 1 338 36.8 6.99 78.68 Fructose-1,6-bisphosphatase 1 
OS=Homo sapiens GN=FBP1 PE=1 
SV=4 - [F16P1_HUMAN] 
P04075 1.92 2 1 364 39.4 8.09 69.67 Fructose-bisphosphate aldolase A 
OS=Homo sapiens GN=ALDOA 
PE=1 SV=2 - [ALDOA_HUMAN] 
Q08380 29.74 26 12 585 65.3 5.27 1515.6
9 
Galectin-3-binding protein 
OS=Homo sapiens GN=LGALS3BP 
PE=1 SV=1 - [LG3BP_HUMAN] 
Q92820 16.35 4 4 318 35.9 7.11 280.60 Gamma-glutamyl hydrolase 
OS=Homo sapiens GN=GGH PE=1 
SV=2 - [GGH_HUMAN] 
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P19440 6.85 3 3 569 61.4 7.12 228.32 Gamma-glutamyltranspeptidase 1 
OS=Homo sapiens GN=GGT1 PE=1 
SV=2 - [GGT1_HUMAN] 
P17900 10.36 1 1 193 20.8 5.31 79.14 Ganglioside GM2 activator 
OS=Homo sapiens GN=GM2A PE=1 
SV=4 - [SAP3_HUMAN] 
P06396 9.72 5 5 782 85.6 6.28 384.59 Gelsolin OS=Homo sapiens 
GN=GSN PE=1 SV=1 - 
[GELS_HUMAN] 
Q16769 26.04 6 6 361 40.9 6.61 419.14 Glutaminyl-peptide cyclotransferase 
OS=Homo sapiens GN=QPCT PE=1 
SV=1 - [QPCT_HUMAN] 
Q07075 5.85 4 4 957 109.2 5.47 216.96 Glutamyl aminopeptidase 
OS=Homo sapiens GN=ENPEP 
PE=1 SV=3 - [AMPE_HUMAN] 
P22352 15.49 3 3 226 25.5 8.13 184.78 Glutathione peroxidase 3 
OS=Homo sapiens GN=GPX3 PE=1 
SV=2 - [GPX3_HUMAN] 
P08263 9.01 2 2 222 25.6 8.88 88.98 Glutathione S-transferase A1 
OS=Homo sapiens GN=GSTA1 
PE=1 SV=3 - [GSTA1_HUMAN] 
P09211 7.62 1 1 210 23.3 5.64 150.04 Glutathione S-transferase P 
OS=Homo sapiens GN=GSTP1 
PE=1 SV=2 - [GSTP1_HUMAN] 
P04406 16.42 3 3 335 36.0 8.46 176.18 Glyceraldehyde-3-phosphate 
dehydrogenase OS=Homo sapiens 
GN=GAPDH PE=1 SV=3 - 
[G3P_HUMAN] 
P28799 2.53 2 1 593 63.5 6.83 151.06 Granulins OS=Homo sapiens 
GN=GRN PE=1 SV=2 - 
[GRN_HUMAN] 
Q8NHV1 2.00 2 1 300 34.5 6.46 65.83 GTPase IMAP family member 7 
OS=Homo sapiens GN=GIMAP7 
PE=2 SV=1 - [GIMA7_HUMAN] 
P00738 8.62 3 3 406 45.2 6.58 202.09 Haptoglobin OS=Homo sapiens 
GN=HP PE=1 SV=1 - 
[HPT_HUMAN] 
P08107 1.25 1 1 641 70.0 5.66 87.09 Heat shock 70 kDa protein 1A/1B 
OS=Homo sapiens GN=HSPA1A 
PE=1 SV=5 - [HSP71_HUMAN] 
P11142 1.70 1 1 646 70.9 5.52 83.24 Heat shock cognate 71 kDa protein 
OS=Homo sapiens GN=HSPA8 
PE=1 SV=1 - [HSP7C_HUMAN] 
P68871 6.80 1 1 147 16.0 7.28 71.11 Hemoglobin subunit beta 
OS=Homo sapiens GN=HBB PE=1 
SV=2 - [HBB_HUMAN] 
P02790 2.38 1 1 462 51.6 7.02 67.77 Hemopexin OS=Homo sapiens 
GN=HPX PE=1 SV=2 - 
[HEMO_HUMAN] 
P04196 5.71 2 2 525 59.5 7.50 137.19 Histidine-rich glycoprotein 
OS=Homo sapiens GN=HRG PE=1 
SV=1 - [HRG_HUMAN] 
Q86YZ3 5.09 4 3 2850 282.2 10.04 203.97 Hornerin OS=Homo sapiens 
GN=HRNR PE=1 SV=2 - 
[HORN_HUMAN] 
Q12794 8.74 2 2 435 48.3 6.77 136.32 Hyaluronidase-1 OS=Homo sapiens 
GN=HYAL1 PE=1 SV=2 - 
[HYAL1_HUMAN] 
O75144 8.61 2 2 302 33.3 5.31 104.86 ICOS ligand OS=Homo sapiens 
GN=ICOSLG PE=1 SV=2 - 
[ICOSL_HUMAN] 
P01876 24.36 8 6 353 37.6 6.51 527.15 Ig alpha-1 chain C region 
OS=Homo sapiens GN=IGHA1 
PE=1 SV=2 - [IGHA1_HUMAN] 
P01877 28.82 7 6 340 36.5 6.10 384.08 Ig alpha-2 chain C region 
OS=Homo sapiens GN=IGHA2 
PE=1 SV=3 - [IGHA2_HUMAN] 
P01857 32.42 8 7 330 36.1 8.19 432.82 Ig gamma-1 chain C region 
OS=Homo sapiens GN=IGHG1 
PE=1 SV=1 - [IGHG1_HUMAN] 
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P01859 7.98 2 2 326 35.9 7.59 204.22 Ig gamma-2 chain C region 
OS=Homo sapiens GN=IGHG2 
PE=1 SV=2 - [IGHG2_HUMAN] 
P01825 13.68 1 1 117 12.8 7.08 67.11 Ig heavy chain V-II region NEWM 
OS=Homo sapiens PE=1 SV=1 - 
[HV207_HUMAN] 
P01781 17.24 2 2 116 12.7 8.48 109.19 Ig heavy chain V-III region GAL 
OS=Homo sapiens PE=1 SV=1 - 
[HV320_HUMAN] 
P01777 15.97 1 1 119 12.8 8.50 103.30 Ig heavy chain V-III region TEI 
OS=Homo sapiens PE=1 SV=1 - 
[HV316_HUMAN] 
P01765 16.52 1 1 115 12.3 9.13 118.42 Ig heavy chain V-III region TIL 
OS=Homo sapiens PE=1 SV=1 - 
[HV304_HUMAN] 
P01764 9.40 1 1 117 12.6 8.28 58.96 Ig heavy chain V-III region VH26 
OS=Homo sapiens PE=1 SV=1 - 
[HV303_HUMAN] 
P01834 80.19 6 5 106 11.6 5.87 417.81 Ig kappa chain C region OS=Homo 
sapiens GN=IGKC PE=1 SV=1 - 
[IGKC_HUMAN] 
P01593 31.48 2 2 108 12.0 5.99 77.87 Ig kappa chain V-I region AG 
OS=Homo sapiens PE=1 SV=1 - 
[KV101_HUMAN] 
P01598 26.85 2 2 108 11.8 8.44 137.52 Ig kappa chain V-I region EU 
OS=Homo sapiens PE=1 SV=1 - 
[KV106_HUMAN] 
P01602 13.68 1 1 117 12.8 6.51 103.59 Ig kappa chain V-I region HK102 
(Fragment) OS=Homo sapiens 
GN=IGKV1-5 PE=4 SV=1 - 
[KV110_HUMAN] 
P01609 27.78 2 2 108 11.8 6.00 78.57 Ig kappa chain V-I region Scw 
OS=Homo sapiens PE=1 SV=1 - 
[KV117_HUMAN] 
P01611 16.67 1 1 108 11.6 7.28 59.70 Ig kappa chain V-I region Wes 
OS=Homo sapiens PE=1 SV=1 - 
[KV119_HUMAN] 
P01617 32.74 2 2 113 12.3 6.00 129.82 Ig kappa chain V-II region TEW 
OS=Homo sapiens PE=1 SV=1 - 
[KV204_HUMAN] 
P01620 31.19 2 2 109 11.8 8.48 159.32 Ig kappa chain V-III region SIE 
OS=Homo sapiens PE=1 SV=1 - 
[KV302_HUMAN] 
P01625 23.68 3 2 114 12.6 7.93 160.18 Ig kappa chain V-IV region Len 
OS=Homo sapiens PE=1 SV=2 - 
[KV402_HUMAN] 
P0CG05 47.17 4 3 106 11.3 7.24 182.41 Ig lambda-2 chain C regions 
OS=Homo sapiens GN=IGLC2 
PE=1 SV=1 - [LAC2_HUMAN] 
P01871 3.54 1 1 452 49.3 6.77 83.13 Ig mu chain C region OS=Homo 
sapiens GN=IGHM PE=1 SV=3 - 
[IGHM_HUMAN] 
Q9Y6R7 2.52 5 5 5405 571.6 5.34 331.41 IgGFc-binding protein OS=Homo 
sapiens GN=FCGBP PE=1 SV=3 - 
[FCGBP_HUMAN] 
P01591 13.84 2 2 159 18.1 5.24 144.29 Immunoglobulin J chain OS=Homo 
sapiens GN=IGJ PE=1 SV=4 - 
[IGJ_HUMAN] 
Q16270 18.44 3 3 282 29.1 7.90 139.57 Insulin-like growth factor-binding 
protein 7 OS=Homo sapiens 
GN=IGFBP7 PE=1 SV=1 - 
[IBP7_HUMAN] 
Q14624 13.12 9 7 930 103.3 6.98 442.57 Inter-alpha-trypsin inhibitor heavy 
chain H4 OS=Homo sapiens 
GN=ITIH4 PE=1 SV=4 - 
[ITIH4_HUMAN] 
O75874 4.11 1 1 414 46.6 7.01 110.66 Isocitrate dehydrogenase [NADP] 
cytoplasmic OS=Homo sapiens 
GN=IDH1 PE=1 SV=2 - 
[IDHC_HUMAN] 
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P53990 7.69 2 2 364 39.7 5.35 133.33 IST1 homolog OS=Homo sapiens 
GN=KIAA0174 PE=1 SV=1 - 
[IST1_HUMAN] 
P06870 14.50 3 3 262 28.9 4.83 177.21 Kallikrein-1 OS=Homo sapiens 
GN=KLK1 PE=1 SV=2 - 
[KLK1_HUMAN] 
P29622 5.62 2 2 427 48.5 7.75 92.82 Kallistatin OS=Homo sapiens 
GN=SERPINA4 PE=1 SV=3 - 
[KAIN_HUMAN] 
P13645 51.20 28 21 584 58.8 5.21 1584.7
7 
Keratin, type I cytoskeletal 10 
OS=Homo sapiens GN=KRT10 
PE=1 SV=6 - [K1C10_HUMAN] 
P13646 10.26 4 4 458 49.6 4.96 307.14 Keratin, type I cytoskeletal 13 
OS=Homo sapiens GN=KRT13 
PE=1 SV=4 - [K1C13_HUMAN] 
P02533 15.89 6 6 472 51.5 5.16 443.14 Keratin, type I cytoskeletal 14 
OS=Homo sapiens GN=KRT14 
PE=1 SV=4 - [K1C14_HUMAN] 
P08779 12.68 5 5 473 51.2 5.05 369.46 Keratin, type I cytoskeletal 16 
OS=Homo sapiens GN=KRT16 
PE=1 SV=4 - [K1C16_HUMAN] 
P35527 38.04 15 12 623 62.0 5.24 1073.3
7 
Keratin, type I cytoskeletal 9 
OS=Homo sapiens GN=KRT9 PE=1 
SV=3 - [K1C9_HUMAN] 
P04264 30.28 22 16 644 66.0 8.12 1362.9
8 
Keratin, type II cytoskeletal 1 
OS=Homo sapiens GN=KRT1 PE=1 
SV=6 - [K2C1_HUMAN] 
P35908 34.12 19 18 639 65.4 8.00 1050.6
2 
Keratin, type II cytoskeletal 2 
epidermal OS=Homo sapiens 
GN=KRT2 PE=1 SV=2 - 
[K22E_HUMAN] 
P19013 5.99 3 3 534 57.2 6.61 156.75 Keratin, type II cytoskeletal 4 
OS=Homo sapiens GN=KRT4 PE=1 
SV=4 - [K2C4_HUMAN] 
P13647 13.22 8 7 590 62.3 7.74 381.72 Keratin, type II cytoskeletal 5 
OS=Homo sapiens GN=KRT5 PE=1 
SV=3 - [K2C5_HUMAN] 
P02538 11.52 7 6 564 60.0 8.00 343.84 Keratin, type II cytoskeletal 6A 
OS=Homo sapiens GN=KRT6A 
PE=1 SV=3 - [K2C6A_HUMAN] 
P04259 11.52 7 6 564 60.0 8.00 348.29 Keratin, type II cytoskeletal 6B 
OS=Homo sapiens GN=KRT6B 
PE=1 SV=5 - [K2C6B_HUMAN] 
P01042 20.03 13 11 644 71.9 6.81 644.90 Kininogen-1 OS=Homo sapiens 
GN=KNG1 PE=1 SV=2 - 
[KNG1_HUMAN] 
P02788 6.06 5 4 710 78.1 8.12 228.88 Lactotransferrin OS=Homo sapiens 
GN=LTF PE=1 SV=6 - 
[TRFL_HUMAN] 
Q6GTX8 9.06 2 2 287 31.4 5.63 168.04 Leukocyte-associated 
immunoglobulin-like receptor 1 
OS=Homo sapiens GN=LAIR1 
PE=1 SV=1 - [LAIR1_HUMAN] 
P00338 13.25 3 3 332 36.7 8.27 163.05 L-lactate dehydrogenase A chain 
OS=Homo sapiens GN=LDHA PE=1 
SV=2 - [LDHA_HUMAN] 
P07195 8.08 2 2 334 36.6 6.05 119.54 L-lactate dehydrogenase B chain 
OS=Homo sapiens GN=LDHB PE=1 
SV=2 - [LDHB_HUMAN] 
P98164 8.31 33 28 4655 521.6 5.08 2042.7
1 
Low-density lipoprotein receptor-
related protein 2 OS=Homo sapiens 
GN=LRP2 PE=1 SV=3 - 
[LRP2_HUMAN] 
P11117 4.49 2 2 423 48.3 6.74 134.44 Lysosomal acid phosphatase 
OS=Homo sapiens GN=ACP2 PE=1 
SV=3 - [PPAL_HUMAN] 
P10253 15.65 12 10 952 105.3 5.99 823.12 Lysosomal alpha-glucosidase 
OS=Homo sapiens GN=GAA PE=1 
SV=3 - [LYAG_HUMAN] 
P10619 2.71 1 1 480 54.4 6.61 101.19 Lysosomal protective protein 
OS=Homo sapiens GN=CTSA PE=1 
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SV=2 - [PPGB_HUMAN] 
P42785 10.48 3 3 496 55.8 7.21 245.30 Lysosomal Pro-X carboxypeptidase 
OS=Homo sapiens GN=PRCP PE=1 
SV=1 - [PCP_HUMAN] 
P13473 7.07 3 3 410 44.9 5.63 136.85 Lysosome-associated membrane 
glycoprotein 2 OS=Homo sapiens 
GN=LAMP2 PE=1 SV=2 - 
[LAMP2_HUMAN] 
O43451 17.66 22 22 1857 209.7 5.50 1360.4
2 
Maltase-glucoamylase, intestinal 
OS=Homo sapiens GN=MGAM 
PE=1 SV=5 - [MGA_HUMAN] 
O00187 3.21 2 2 686 75.7 5.77 85.39 Mannan-binding lectin serine 
protease 2 OS=Homo sapiens 
GN=MASP2 PE=1 SV=3 - 
[MASP2_HUMAN] 
P02795 19.67 1 1 61 6.0 7.83 68.63 Metallothionein-2 OS=Homo 
sapiens GN=MT2A PE=1 SV=1 - 
[MT2_HUMAN] 
P26038 3.47 2 2 577 67.8 6.40 150.97 Moesin OS=Homo sapiens 
GN=MSN PE=1 SV=3 - 
[MOES_HUMAN] 
P08571 10.40 3 2 375 40.1 6.23 135.79 Monocyte differentiation antigen 
CD14 OS=Homo sapiens GN=CD14 
PE=1 SV=2 - [CD14_HUMAN] 
P15941 1.75 2 2 1255 122.0 7.47 138.62 Mucin-1 OS=Homo sapiens 
GN=MUC1 PE=1 SV=3 - 
[MUC1_HUMAN] 
Q9HC84 2.03 3 3 5703 590.1 6.67 174.91 Mucin-5B OS=Homo sapiens 
GN=MUC5B PE=1 SV=2 - 
[MUC5B_HUMAN] 
Q9H8L6 2.53 1 1 949 104.3 5.86 167.81 Multimerin-2 OS=Homo sapiens 
GN=MMRN2 PE=1 SV=2 - 
[MMRN2_HUMAN] 
O95865 4.91 1 1 285 29.6 6.01 67.45 N(G),N(G)-dimethylarginine 
dimethylaminohydrolase 2 
OS=Homo sapiens GN=DDAH2 
PE=1 SV=1 - [DDAH2_HUMAN] 
P34059 4.79 2 2 522 58.0 6.74 113.61 N-acetylgalactosamine-6-sulfatase 
OS=Homo sapiens GN=GALNS 
PE=1 SV=1 - [GALNS_HUMAN] 
P15586 1.09 1 1 552 62.0 8.31 61.55 N-acetylglucosamine-6-sulfatase 
OS=Homo sapiens GN=GNS PE=1 
SV=3 - [GNS_HUMAN] 
O96009 9.52 3 3 420 45.4 6.61 154.35 Napsin-A OS=Homo sapiens 
GN=NAPSA PE=1 SV=1 - 
[NAPSA_HUMAN] 
P08473 7.60 4 4 750 85.5 5.73 244.91 Neprilysin OS=Homo sapiens 
GN=MME PE=1 SV=2 - 
[NEP_HUMAN] 
P59665 9.57 1 1 94 10.2 6.99 79.01 Neutrophil defensin 1 OS=Homo 
sapiens GN=DEFA1 PE=1 SV=1 - 
[DEF1_HUMAN] 
Q92542 1.69 1 1 709 78.4 5.99 71.10 Nicastrin OS=Homo sapiens 
GN=NCSTN PE=1 SV=2 - 
[NICA_HUMAN] 
P10153 10.56 2 1 161 18.3 8.73 133.16 Non-secretory ribonuclease 
OS=Homo sapiens GN=RNASE2 
PE=1 SV=2 - [RNAS2_HUMAN] 
P51688 7.37 3 3 502 56.7 6.95 144.60 N-sulphoglucosamine 
sulphohydrolase OS=Homo sapiens 
GN=SGSH PE=1 SV=1 - 
[SPHM_HUMAN] 
P61970 11.02 2 1 127 14.5 5.38 195.33 Nuclear transport factor 2 
OS=Homo sapiens GN=NUTF2 
PE=1 SV=1 - [NTF2_HUMAN] 
Q6UX06 16.27 7 6 510 57.2 5.69 366.99 Olfactomedin-4 OS=Homo sapiens 
GN=OLFM4 PE=1 SV=1 - 
[OLFM4_HUMAN] 
P04746 35.23 11 11 511 57.7 7.05 566.84 Pancreatic alpha-amylase 
OS=Homo sapiens GN=AMY2A 
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PE=1 SV=2 - [AMYP_HUMAN] 
P55259 4.28 2 2 537 59.4 5.24 136.92 Pancreatic secretory granule 
membrane major glycoprotein GP2 
OS=Homo sapiens GN=GP2 PE=2 
SV=3 - [GP2_HUMAN] 
Q9UBV8 7.39 2 2 284 30.4 6.54 130.49 Peflin OS=Homo sapiens GN=PEF1 
PE=1 SV=1 - [PEF1_HUMAN] 
O75594 39.29 7 4 196 21.7 8.59 362.59 Peptidoglycan recognition protein 1 
OS=Homo sapiens GN=PGLYRP1 
PE=1 SV=1 - [PGRP1_HUMAN] 
P62937 16.36 2 2 165 18.0 7.81 82.35 Peptidyl-prolyl cis-trans isomerase 
A OS=Homo sapiens GN=PPIA 
PE=1 SV=2 - [PPIA_HUMAN] 
Q06830 14.57 3 3 199 22.1 8.13 117.57 Peroxiredoxin-1 OS=Homo sapiens 
GN=PRDX1 PE=1 SV=1 - 
[PRDX1_HUMAN] 
P30086 40.11 5 5 187 21.0 7.53 256.82 Phosphatidylethanolamine-binding 
protein 1 OS=Homo sapiens 
GN=PEBP1 PE=1 SV=3 - 
[PEBP1_HUMAN] 
Q9Y646 15.04 5 5 472 51.9 6.18 308.83 Plasma glutamate carboxypeptidase 
OS=Homo sapiens GN=PGCP PE=1 
SV=1 - [PGCP_HUMAN] 
P05155 13.80 8 6 500 55.1 6.55 492.13 Plasma protease C1 inhibitor 
OS=Homo sapiens GN=SERPING1 
PE=1 SV=2 - [IC1_HUMAN] 
P05154 24.63 11 8 406 45.7 9.26 585.42 Plasma serine protease inhibitor 
OS=Homo sapiens GN=SERPINA5 
PE=1 SV=2 - [IPSP_HUMAN] 
P01833 30.24 20 16 764 83.2 5.74 1164.5
0 
Polymeric immunoglobulin receptor 
OS=Homo sapiens GN=PIGR PE=1 
SV=4 - [PIGR_HUMAN] 
P0CG48 21.02 1 1 685 77.0 7.66 107.44 Polyubiquitin-C OS=Homo sapiens 
GN=UBC PE=1 SV=1 - 
[UBC_HUMAN] 
P07602 12.60 7 4 524 58.1 5.17 483.56 Proactivator polypeptide OS=Homo 
sapiens GN=PSAP PE=1 SV=2 - 
[SAP_HUMAN] 
Q9H3G5 3.99 1 1 476 54.1 5.62 88.11 Probable serine carboxypeptidase 
CPVL OS=Homo sapiens GN=CPVL 
PE=1 SV=2 - [CPVL_HUMAN] 
P01133 18.31 18 16 1207 133.9 5.85 1086.3
2 
Pro-epidermal growth factor 
OS=Homo sapiens GN=EGF PE=1 
SV=2 - [EGF_HUMAN] 
Q8WUM4 3.23 2 2 868 96.0 6.52 126.10 Programmed cell death 6-
interacting protein OS=Homo 
sapiens GN=PDCD6IP PE=1 SV=1 - 
[PDC6I_HUMAN] 
O75340 12.04 2 2 191 21.9 5.40 179.17 Programmed cell death protein 6 
OS=Homo sapiens GN=PDCD6 
PE=1 SV=1 - [PDCD6_HUMAN] 
P12273 18.49 2 2 146 16.6 8.05 147.97 Prolactin-inducible protein 
OS=Homo sapiens GN=PIP PE=1 
SV=1 - [PIP_HUMAN] 
O43490 7.86 4 4 865 97.1 7.27 199.21 Prominin-1 OS=Homo sapiens 
GN=PROM1 PE=1 SV=1 - 
[PROM1_HUMAN] 
P41222 21.05 5 3 190 21.0 7.80 309.59 Prostaglandin-H2 D-isomerase 
OS=Homo sapiens GN=PTGDS 
PE=1 SV=1 - [PTGDS_HUMAN] 
Q16651 5.54 1 1 343 36.4 5.85 117.83 Prostasin OS=Homo sapiens 
GN=PRSS8 PE=1 SV=1 - 
[PRSS8_HUMAN] 
O43653 8.13 1 1 123 12.9 5.29 79.41 Prostate stem cell antigen 
OS=Homo sapiens GN=PSCA PE=1 
SV=1 - [PSCA_HUMAN] 
P15309 16.32 7 5 386 44.5 6.24 443.71 Prostatic acid phosphatase 
OS=Homo sapiens GN=ACPP PE=1 
SV=3 - [PPAP_HUMAN] 
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P02760 27.84 16 7 352 39.0 6.25 905.21 Protein AMBP OS=Homo sapiens 
GN=AMBP PE=1 SV=1 - 
[AMBP_HUMAN] 
P31949 15.24 1 1 105 11.7 7.12 95.47 Protein S100-A11 OS=Homo 
sapiens GN=S100A11 PE=1 SV=2 - 
[S10AB_HUMAN] 
P06703 8.89 1 1 90 10.2 5.48 91.52 Protein S100-A6 OS=Homo sapiens 
GN=S100A6 PE=1 SV=1 - 
[S10A6_HUMAN] 
P05109 8.60 1 1 93 10.8 7.03 67.99 Protein S100-A8 OS=Homo sapiens 
GN=S100A8 PE=1 SV=1 - 
[S10A8_HUMAN] 
P06702 26.32 2 2 114 13.2 6.13 144.59 Protein S100-A9 OS=Homo sapiens 
GN=S100A9 PE=1 SV=1 - 
[S10A9_HUMAN] 
P25815 13.68 1 1 95 10.4 4.88 90.65 Protein S100-P OS=Homo sapiens 
GN=S100P PE=1 SV=2 - 
[S100P_HUMAN] 
P00734 6.27 3 3 622 70.0 5.90 236.78 Prothrombin OS=Homo sapiens 
GN=F2 PE=1 SV=2 - 
[THRB_HUMAN] 
A6NIZ1 6.52 1 1 184 20.9 5.48 74.07 Ras-related protein Rap-1b-like 
protein OS=Homo sapiens PE=2 
SV=1 - [RP1BL_HUMAN] 
Q12913 4.26 4 4 1337 145.9 5.58 230.82 Receptor-type tyrosine-protein 
phosphatase eta OS=Homo sapiens 
GN=PTPRJ PE=1 SV=3 - 
[PTPRJ_HUMAN] 
Q13332 0.67 1 1 1948 217.0 6.51 78.02 Receptor-type tyrosine-protein 
phosphatase S OS=Homo sapiens 
GN=PTPRS PE=1 SV=2 - 
[PTPRS_HUMAN] 
O75787 2.57 1 1 350 39.0 6.10 78.18 Renin receptor OS=Homo sapiens 
GN=ATP6AP2 PE=1 SV=2 - 
[RENR_HUMAN] 
Q9HD89 40.74 3 3 108 11.4 6.86 202.08 Resistin OS=Homo sapiens 
GN=RETN PE=2 SV=1 - 
[RETN_HUMAN] 
P00352 2.99 1 1 501 54.8 6.73 96.77 Retinal dehydrogenase 1 OS=Homo 
sapiens GN=ALDH1A1 PE=1 SV=2 
- [AL1A1_HUMAN] 
Q9HB40 5.53 2 2 452 50.8 5.81 124.28 Retinoid-inducible serine 
carboxypeptidase OS=Homo 
sapiens GN=SCPEP1 PE=1 SV=1 - 
[RISC_HUMAN] 
P07998 13.46 1 1 156 17.6 8.79 112.46 Ribonuclease pancreatic OS=Homo 
sapiens GN=RNASE1 PE=1 SV=4 - 
[RNAS1_HUMAN] 
Q8WVN6 14.52 2 2 248 27.0 7.43 147.02 Secreted and transmembrane 
protein 1 OS=Homo sapiens 
GN=SECTM1 PE=1 SV=2 - 
[SCTM1_HUMAN] 
P04279 2.60 1 1 462 52.1 9.29 89.93 Semenogelin-1 OS=Homo sapiens 
GN=SEMG1 PE=1 SV=2 - 
[SEMG1_HUMAN] 
P02787 4.30 2 2 698 77.0 7.12 141.44 Serotransferrin OS=Homo sapiens 
GN=TF PE=1 SV=2 - 
[TRFE_HUMAN] 
P29508 12.56 4 4 390 44.5 6.81 151.58 Serpin B3 OS=Homo sapiens 
GN=SERPINB3 PE=1 SV=2 - 
[SPB3_HUMAN] 
P02768 61.25 47 31 609 69.3 6.28 2263.9
5 
Serum albumin OS=Homo sapiens 
GN=ALB PE=1 SV=2 - 
[ALBU_HUMAN] 
P02743 10.31 2 2 223 25.4 6.54 137.60 Serum amyloid P-component 
OS=Homo sapiens GN=APCS PE=1 
SV=2 - [SAMP_HUMAN] 
Q9HAT2 11.09 5 5 523 58.3 7.33 266.74 Sialate O-acetylesterase OS=Homo 
sapiens GN=SIAE PE=1 SV=1 - 
[SIAE_HUMAN] 
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P48061 15.05 1 1 93 10.7 9.88 70.33 Stromal cell-derived factor 1 
OS=Homo sapiens GN=CXCL12 
PE=1 SV=1 - [SDF1_HUMAN] 
O00391 5.09 4 3 747 82.5 8.92 210.97 Sulfhydryl oxidase 1 OS=Homo 
sapiens GN=QSOX1 PE=1 SV=3 - 
[QSOX1_HUMAN] 
Q9UGT4 1.70 1 1 822 90.1 6.28 91.80 Sushi domain-containing protein 2 
OS=Homo sapiens GN=SUSD2 
PE=1 SV=1 - [SUSD2_HUMAN] 
O00560 14.09 3 2 298 32.4 7.53 232.53 Syntenin-1 OS=Homo sapiens 
GN=SDCBP PE=1 SV=1 - 
[SDCB1_HUMAN] 
P10599 12.38 1 1 105 11.7 4.92 73.53 Thioredoxin OS=Homo sapiens 
GN=TXN PE=1 SV=3 - 
[THIO_HUMAN] 
P07996 0.94 1 1 1170 129.3 4.94 69.26 Thrombospondin-1 OS=Homo 
sapiens GN=THBS1 PE=1 SV=2 - 
[TSP1_HUMAN] 
Q9UKU6 0.78 1 1 1024 116.9 6.99 63.27 Thyrotropin-releasing hormone-
degrading ectoenzyme OS=Homo 
sapiens GN=TRHDE PE=2 SV=1 - 
[TRHDE_HUMAN] 
P05543 4.58 2 2 415 46.3 6.30 84.27 Thyroxine-binding globulin 
OS=Homo sapiens GN=SERPINA7 
PE=1 SV=2 - [THBG_HUMAN] 
P02766 48.30 6 5 147 15.9 5.76 308.51 Transthyretin OS=Homo sapiens 
GN=TTR PE=1 SV=1 - 
[TTHY_HUMAN] 
P60174 10.44 2 2 249 26.7 6.90 100.56 Triosephosphate isomerase 
OS=Homo sapiens GN=TPI1 PE=1 
SV=2 - [TPIS_HUMAN] 
O14773 9.77 4 3 563 61.2 6.48 231.93 Tripeptidyl-peptidase 1 OS=Homo 
sapiens GN=TPP1 PE=1 SV=2 - 
[TPP1_HUMAN] 
Q99816 2.56 1 1 390 43.9 6.46 77.45 Tumor susceptibility gene 101 
protein OS=Homo sapiens 
GN=TSG101 PE=1 SV=2 - 
[TS101_HUMAN] 
P30530 2.01 1 1 894 98.3 5.43 69.75 Tyrosine-protein kinase receptor 
UFO OS=Homo sapiens GN=AXL 
PE=1 SV=3 - [UFO_HUMAN] 
Q9H1C7 10.31 1 1 97 10.6 4.32 59.38 UPF0467 protein C5orf32 
OS=Homo sapiens GN=C5orf32 
PE=2 SV=1 - [CE032_HUMAN] 
Q6UX73 3.23 1 1 402 45.4 6.19 59.34 UPF0764 protein C16orf89 
OS=Homo sapiens GN=C16orf89 
PE=2 SV=2 - [CP089_HUMAN] 
P00749 11.83 4 4 431 48.5 8.41 248.62 Urokinase-type plasminogen 
activator OS=Homo sapiens 
GN=PLAU PE=1 SV=2 - 
[UROK_HUMAN] 
P07911 39.22 86 18 640 69.7 5.24 5301.6
7 
Uromodulin OS=Homo sapiens 
GN=UMOD PE=1 SV=1 - 
[UROM_HUMAN] 
Q9H9H4 6.32 1 1 285 31.3 7.34 63.69 Vacuolar protein sorting-associated 
protein 37B OS=Homo sapiens 
GN=VPS37B PE=1 SV=1 - 
[VP37B_HUMAN] 
Q9NP79 6.51 1 1 307 33.9 6.29 92.07 Vacuolar protein sorting-associated 
protein VTA1 homolog OS=Homo 
sapiens GN=VTA1 PE=1 SV=1 - 
[VTA1_HUMAN] 
Q6EMK4 12.04 5 5 673 71.7 7.39 290.65 Vasorin OS=Homo sapiens 
GN=VASN PE=1 SV=1 - 
[VASN_HUMAN] 
Q12907 28.37 6 6 356 40.2 6.95 362.95 Vesicular integral-membrane 
protein VIP36 OS=Homo sapiens 
GN=LMAN2 PE=1 SV=1 - 
[LMAN2_HUMAN] 
P22891 12.50 3 3 400 44.7 5.97 221.30 Vitamin K-dependent protein Z 
OS=Homo sapiens GN=PROZ PE=1 
152 
 
SV=2 - [PROZ_HUMAN] 
Q7Z5L0 49.50 6 5 202 21.5 5.07 308.24 Vitelline membrane outer layer 
protein 1 homolog OS=Homo 
sapiens GN=VMO1 PE=1 SV=1 - 
[VMO1_HUMAN] 
P04004 5.65 2 2 478 54.3 5.80 157.40 Vitronectin OS=Homo sapiens 
GN=VTN PE=1 SV=1 - 
[VTNC_HUMAN] 
O43895 4.45 2 2 674 75.6 6.04 88.15 Xaa-Pro aminopeptidase 2 
OS=Homo sapiens GN=XPNPEP2 
PE=1 SV=3 - [XPP2_HUMAN] 
P25311 26.51 7 7 298 34.2 6.05 437.07 Zinc-alpha-2-glycoprotein 
OS=Homo sapiens GN=AZGP1 
PE=1 SV=2 - [ZA2G_HUMAN] 
Q96DA0 30.77 5 5 208 22.7 7.39 304.14 Zymogen granule protein 16 
homolog B OS=Homo sapiens 
GN=ZG16B PE=1 SV=3 - 
[ZG16B_HUMAN] 
 
Supplementary table S2.2: Identification of proteins in (P18+P200) DTT SN200 sample 2. 
Accession of the protein, sequence coverage, PSM (Match between a fragmentation mass 
spectrum and peptide), number of peptides found, number of amino acid in the protein, 
molecular weight, calculated PI and mascot score along with the description of the protein are 
indicated in the table. 
Accession Coverage % # 
PSMs 
# 
Peptides 
# 
AAs 
MW 
[kDa] 
calc. 
pI 
Score Description 
P62258 7.45 1 1 255 29.2 4.74 122.69 14-3-3 protein epsilon OS=Homo 
sapiens GN=YWHAE PE=1 SV=1 
- [1433E_HUMAN] 
P63104 4.90 1 1 245 27.7 4.79 74.94 14-3-3 protein zeta/delta 
OS=Homo sapiens GN=YWHAZ 
PE=1 SV=1 - [1433Z_HUMAN] 
P08195 4.44 2 2 630 68.0 5.01 114.93 4F2 cell-surface antigen heavy 
chain OS=Homo sapiens 
GN=SLC3A2 PE=1 SV=3 - 
[4F2_HUMAN] 
O95336 6.20 1 1 258 27.5 6.05 77.20 6-phosphogluconolactonase 
OS=Homo sapiens GN=PGLS 
PE=1 SV=2 - [6PGL_HUMAN] 
Q13510 25.82 7 6 395 44.6 7.62 428.61 Acid ceramidase OS=Homo 
sapiens GN=ASAH1 PE=1 SV=5 - 
[ASAH1_HUMAN] 
P60709 9.87 3 3 375 41.7 5.48 203.53 Actin, cytoplasmic 1 OS=Homo 
sapiens GN=ACTB PE=1 SV=1 - 
[ACTB_HUMAN] 
P02763 26.37 4 4 201 23.5 5.02 176.91 Alpha-1-acid glycoprotein 1 
OS=Homo sapiens GN=ORM1 
PE=1 SV=1 - [A1AG1_HUMAN] 
P19652 4.48 1 1 201 23.6 5.11 86.48 Alpha-1-acid glycoprotein 2 
OS=Homo sapiens GN=ORM2 
PE=1 SV=2 - [A1AG2_HUMAN] 
P01011 17.02 5 5 423 47.6 5.52 284.75 Alpha-1-antichymotrypsin 
OS=Homo sapiens 
GN=SERPINA3 PE=1 SV=2 - 
[AACT_HUMAN] 
P01009 28.95 11 8 418 46.7 5.59 750.55 Alpha-1-antitrypsin OS=Homo 
sapiens GN=SERPINA1 PE=1 
SV=3 - [A1AT_HUMAN] 
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P04217 6.46 2 2 495 54.2 5.87 109.32 Alpha-1B-glycoprotein OS=Homo 
sapiens GN=A1BG PE=1 SV=3 - 
[A1BG_HUMAN] 
P02765 14.99 4 4 367 39.3 5.72 155.29 Alpha-2-HS-glycoprotein 
OS=Homo sapiens GN=AHSG 
PE=1 SV=1 - [FETUA_HUMAN] 
P01023 0.81 1 1 1474 163.2 6.42 91.94 Alpha-2-macroglobulin OS=Homo 
sapiens GN=A2M PE=1 SV=2 - 
[A2MG_HUMAN] 
O43707 4.83 4 4 911 104.8 5.44 221.54 Alpha-actinin-4 OS=Homo 
sapiens GN=ACTN4 PE=1 SV=2 - 
[ACTN4_HUMAN] 
P04745 21.92 9 8 511 57.7 6.93 578.84 Alpha-amylase 1 OS=Homo 
sapiens GN=AMY1A PE=1 SV=2 - 
[AMY1_HUMAN] 
P19961 21.92 9 8 511 57.7 7.09 565.89 Alpha-amylase 2B OS=Homo 
sapiens GN=AMY2B PE=1 SV=1 - 
[AMY2B_HUMAN] 
P06733 9.22 3 3 434 47.1 7.39 149.46 Alpha-enolase OS=Homo sapiens 
GN=ENO1 PE=1 SV=2 - 
[ENOA_HUMAN] 
P54802 28.13 15 14 743 82.1 6.54 855.70 Alpha-N-acetylglucosaminidase 
OS=Homo sapiens GN=NAGLU 
PE=1 SV=1 - [ANAG_HUMAN] 
Q96Q42 0.36 1 1 1657 183.5 6.27 67.00 Alsin OS=Homo sapiens 
GN=ALS2 PE=1 SV=2 - 
[ALS2_HUMAN] 
P15144 28.44 27 20 967 109.5 5.48 1477.51 Aminopeptidase N OS=Homo 
sapiens GN=ANPEP PE=1 SV=4 - 
[AMPN_HUMAN] 
P12821 1.07 1 1 1306 149.6 6.39 67.68 Angiotensin-converting enzyme 
OS=Homo sapiens GN=ACE 
PE=1 SV=1 - [ACE_HUMAN] 
P04083 3.76 1 1 346 38.7 7.02 92.17 Annexin A1 OS=Homo sapiens 
GN=ANXA1 PE=1 SV=2 - 
[ANXA1_HUMAN] 
P07355 8.85 2 2 339 38.6 7.75 95.33 Annexin A2 OS=Homo sapiens 
GN=ANXA2 PE=1 SV=2 - 
[ANXA2_HUMAN] 
P08758 5.00 1 1 320 35.9 5.05 73.02 Annexin A5 OS=Homo sapiens 
GN=ANXA5 PE=1 SV=2 - 
[ANXA5_HUMAN] 
P02647 28.09 6 6 267 30.8 5.76 326.83 Apolipoprotein A-I OS=Homo 
sapiens GN=APOA1 PE=1 SV=1 - 
[APOA1_HUMAN] 
P02652 20.00 1 1 100 11.2 6.62 103.82 Apolipoprotein A-II OS=Homo 
sapiens GN=APOA2 PE=1 SV=1 - 
[APOA2_HUMAN] 
P06727 3.54 1 1 396 45.4 5.38 87.66 Apolipoprotein A-IV OS=Homo 
sapiens GN=APOA4 PE=1 SV=3 - 
[APOA4_HUMAN] 
P05090 34.92 17 7 189 21.3 5.15 781.10 Apolipoprotein D OS=Homo 
sapiens GN=APOD PE=1 SV=1 - 
[APOD_HUMAN] 
P02649 26.50 7 7 317 36.1 5.73 400.82 Apolipoprotein E OS=Homo 
sapiens GN=APOE PE=1 SV=1 - 
[APOE_HUMAN] 
P15289 14.00 4 4 507 53.6 6.07 302.58 Arylsulfatase A OS=Homo 
sapiens GN=ARSA PE=1 SV=3 - 
[ARSA_HUMAN] 
O75882 5.39 6 6 1429 158.4 7.31 405.43 Attractin OS=Homo sapiens 
GN=ATRN PE=1 SV=2 - 
[ATRN_HUMAN] 
P98160 0.91 3 3 4391 468.5 6.51 177.74 Basement membrane-specific 
heparan sulfate proteoglycan 
core protein OS=Homo sapiens 
GN=HSPG2 PE=1 SV=3 - 
[PGBM_HUMAN] 
P16278 8.42 5 5 677 76.0 6.57 257.83 Beta-galactosidase OS=Homo 
sapiens GN=GLB1 PE=1 SV=2 - 
[BGAL_HUMAN] 
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P08236 10.29 4 4 651 74.7 7.02 273.62 Beta-glucuronidase OS=Homo 
sapiens GN=GUSB PE=1 SV=2 - 
[BGLR_HUMAN] 
Q93088 14.53 4 4 406 45.0 7.03 227.22 Betaine--homocysteine S-
methyltransferase 1 OS=Homo 
sapiens GN=BHMT PE=1 SV=2 - 
[BHMT1_HUMAN] 
P19835 10.36 5 5 753 79.3 5.34 284.94 Bile salt-activated lipase 
OS=Homo sapiens GN=CEL PE=1 
SV=3 - [CEL_HUMAN] 
P43251 4.79 2 2 543 61.1 6.25 112.26 Biotinidase OS=Homo sapiens 
GN=BTD PE=1 SV=2 - 
[BTD_HUMAN] 
Q5VW32 3.89 2 1 411 46.4 7.65 112.05 BRO1 domain-containing protein 
BROX OS=Homo sapiens 
GN=BROX PE=1 SV=1 - 
[BROX_HUMAN] 
Q8WVV5 2.10 1 1 523 59.0 6.01 67.62 Butyrophilin subfamily 2 member 
A2 OS=Homo sapiens 
GN=BTN2A2 PE=2 SV=2 - 
[BT2A2_HUMAN] 
P12830 7.94 4 4 882 97.4 4.73 211.52 Cadherin-1 OS=Homo sapiens 
GN=CDH1 PE=1 SV=3 - 
[CADH1_HUMAN] 
P55290 1.68 1 1 713 78.2 4.98 63.42 Cadherin-13 OS=Homo sapiens 
GN=CDH13 PE=1 SV=1 - 
[CAD13_HUMAN] 
P19022 4.08 3 2 906 99.7 4.81 196.74 Cadherin-2 OS=Homo sapiens 
GN=CDH2 PE=1 SV=4 - 
[CADH2_HUMAN] 
Q9BYE9 1.98 2 2 1310 141.5 4.50 165.71 Cadherin-related family member 
2 OS=Homo sapiens GN=CDHR2 
PE=1 SV=2 - [CDHR2_HUMAN] 
Q9HBB8 2.13 1 1 845 88.2 4.93 65.22 Cadherin-related family member 
5 OS=Homo sapiens GN=CDHR5 
PE=1 SV=3 - [CDHR5_HUMAN] 
P05937 4.98 1 1 261 30.0 4.83 81.70 Calbindin OS=Homo sapiens 
GN=CALB1 PE=1 SV=2 - 
[CALB1_HUMAN] 
P22792 3.30 1 1 545 60.6 5.99 98.38 Carboxypeptidase N subunit 2 
OS=Homo sapiens GN=CPN2 
PE=1 SV=2 - [CPN2_HUMAN] 
P07339 18.20 5 5 412 44.5 6.54 249.28 Cathepsin D OS=Homo sapiens 
GN=CTSD PE=1 SV=1 - 
[CATD_HUMAN] 
P16070 1.62 1 1 742 81.5 5.33 101.93 CD44 antigen OS=Homo sapiens 
GN=CD44 PE=1 SV=2 - 
[CD44_HUMAN] 
P13987 25.00 5 3 128 14.2 6.48 225.02 CD59 glycoprotein OS=Homo 
sapiens GN=CD59 PE=1 SV=1 - 
[CD59_HUMAN] 
P08962 4.20 1 1 238 25.6 7.81 63.44 CD63 antigen OS=Homo sapiens 
GN=CD63 PE=1 SV=2 - 
[CD63_HUMAN] 
Q8NFZ8 6.19 2 2 388 42.8 6.30 99.56 Cell adhesion molecule 4 
OS=Homo sapiens GN=CADM4 
PE=1 SV=1 - [CADM4_HUMAN] 
P00450 15.87 11 11 1065 122.1 5.72 563.68 Ceruloplasmin OS=Homo sapiens 
GN=CP PE=1 SV=1 - 
[CERU_HUMAN] 
Q53GD3 1.97 1 1 710 79.2 8.59 105.10 Choline transporter-like protein 4 
OS=Homo sapiens GN=SLC44A4 
PE=2 SV=1 - [CTL4_HUMAN] 
P10909 19.15 7 6 449 52.5 6.27 467.77 Clusterin OS=Homo sapiens 
GN=CLU PE=1 SV=1 - 
[CLUS_HUMAN] 
Q9UGN4 6.02 1 1 299 33.2 5.49 67.94 CMRF35-like molecule 8 
OS=Homo sapiens GN=CD300A 
PE=1 SV=2 - [CLM8_HUMAN] 
P12109 6.23 5 5 1028 108.5 5.43 332.93 Collagen alpha-1(VI) chain 
OS=Homo sapiens GN=COL6A1 
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PE=1 SV=3 - [CO6A1_HUMAN] 
P39059 2.45 3 3 1388 141.6 5.00 125.32 Collagen alpha-1(XV) chain 
OS=Homo sapiens GN=COL15A1 
PE=1 SV=2 - [COFA1_HUMAN] 
P12111 1.51 4 3 3177 343.5 6.68 243.42 Collagen alpha-3(VI) chain 
OS=Homo sapiens GN=COL6A3 
PE=1 SV=4 - [CO6A3_HUMAN] 
P01024 2.29 3 3 1663 187.0 6.40 169.26 Complement C3 OS=Homo 
sapiens GN=C3 PE=1 SV=2 - 
[CO3_HUMAN] 
P0C0L4 1.49 2 2 1744 192.7 7.08 115.04 Complement C4-A OS=Homo 
sapiens GN=C4A PE=1 SV=1 - 
[CO4A_HUMAN] 
Q12860 1.38 1 1 1018 113.2 5.90 59.76 Contactin-1 OS=Homo sapiens 
GN=CNTN1 PE=1 SV=1 - 
[CNTN1_HUMAN] 
Q9UBG3 3.03 1 1 495 53.5 6.10 92.70 Cornulin OS=Homo sapiens 
GN=CRNN PE=1 SV=1 - 
[CRNN_HUMAN] 
P12277 4.46 2 1 381 42.6 5.59 132.34 Creatine kinase B-type OS=Homo 
sapiens GN=CKB PE=1 SV=1 - 
[KCRB_HUMAN] 
O60494 11.15 27 26 3623 398.4 5.35 1549.07 Cubilin OS=Homo sapiens 
GN=CUBN PE=1 SV=4 - 
[CUBN_HUMAN] 
P01034 7.53 1 1 146 15.8 8.75 61.81 Cystatin-C OS=Homo sapiens 
GN=CST3 PE=1 SV=1 - 
[CYTC_HUMAN] 
P16444 2.43 1 1 411 45.6 6.15 141.33 Dipeptidase 1 OS=Homo sapiens 
GN=DPEP1 PE=1 SV=3 - 
[DPEP1_HUMAN] 
P53634 7.99 2 2 463 51.8 6.99 200.96 Dipeptidyl peptidase 1 OS=Homo 
sapiens GN=CTSC PE=1 SV=1 - 
[CATC_HUMAN] 
P27487 8.49 5 5 766 88.2 6.04 465.76 Dipeptidyl peptidase 4 OS=Homo 
sapiens GN=DPP4 PE=1 SV=2 - 
[DPP4_HUMAN] 
Q12805 16.63 6 6 493 54.6 5.07 278.96 EGF-containing fibulin-like 
extracellular matrix protein 1 
OS=Homo sapiens GN=EFEMP1 
PE=1 SV=2 - [FBLN3_HUMAN] 
Q9UNN8 16.81 3 3 238 26.7 7.18 129.82 Endothelial protein C receptor 
OS=Homo sapiens GN=PROCR 
PE=1 SV=1 - [EPCR_HUMAN] 
P08294 14.58 3 3 240 25.8 6.61 163.93 Extracellular superoxide 
dismutase [Cu-Zn] OS=Homo 
sapiens GN=SOD3 PE=1 SV=2 - 
[SODE_HUMAN] 
P15311 6.83 3 3 586 69.4 6.27 195.43 Ezrin OS=Homo sapiens GN=EZR 
PE=1 SV=4 - [EZRI_HUMAN] 
P02792 8.57 1 1 175 20.0 5.78 68.75 Ferritin light chain OS=Homo 
sapiens GN=FTL PE=1 SV=2 - 
[FRIL_HUMAN] 
Q14314 8.66 2 2 439 50.2 7.39 126.25 Fibroleukin OS=Homo sapiens 
GN=FGL2 PE=1 SV=1 - 
[FGL2_HUMAN] 
P02751 5.91 11 9 2386 262.5 5.71 557.56 Fibronectin OS=Homo sapiens 
GN=FN1 PE=1 SV=4 - 
[FINC_HUMAN] 
P09467 5.03 1 1 338 36.8 6.99 73.25 Fructose-1,6-bisphosphatase 1 
OS=Homo sapiens GN=FBP1 
PE=1 SV=4 - [F16P1_HUMAN] 
P05062 5.49 3 2 364 39.4 7.87 126.83 Fructose-bisphosphate aldolase B 
OS=Homo sapiens GN=ALDOB 
PE=1 SV=2 - [ALDOB_HUMAN] 
Q08380 32.48 25 12 585 65.3 5.27 1412.53 Galectin-3-binding protein 
OS=Homo sapiens 
GN=LGALS3BP PE=1 SV=1 - 
[LG3BP_HUMAN] 
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O00182 3.38 1 1 355 39.5 9.17 71.56 Galectin-9 OS=Homo sapiens 
GN=LGALS9 PE=1 SV=2 - 
[LEG9_HUMAN] 
Q92820 20.13 5 5 318 35.9 7.11 274.29 Gamma-glutamyl hydrolase 
OS=Homo sapiens GN=GGH 
PE=1 SV=2 - [GGH_HUMAN] 
Q6P531 4.26 1 1 493 50.5 6.07 68.32 Gamma-glutamyltransferase 6 
OS=Homo sapiens GN=GGT6 
PE=2 SV=2 - [GGT6_HUMAN] 
P19440 6.85 3 3 569 61.4 7.12 186.73 Gamma-glutamyltranspeptidase 1 
OS=Homo sapiens GN=GGT1 
PE=1 SV=2 - [GGT1_HUMAN] 
P06396 9.72 5 5 782 85.6 6.28 322.59 Gelsolin OS=Homo sapiens 
GN=GSN PE=1 SV=1 - 
[GELS_HUMAN] 
Q16769 20.50 6 5 361 40.9 6.61 369.01 Glutaminyl-peptide 
cyclotransferase OS=Homo 
sapiens GN=QPCT PE=1 SV=1 - 
[QPCT_HUMAN] 
Q07075 2.61 2 2 957 109.2 5.47 129.06 Glutamyl aminopeptidase 
OS=Homo sapiens GN=ENPEP 
PE=1 SV=3 - [AMPE_HUMAN] 
P22352 15.49 3 3 226 25.5 8.13 171.85 Glutathione peroxidase 3 
OS=Homo sapiens GN=GPX3 
PE=1 SV=2 - [GPX3_HUMAN] 
P09211 16.67 2 2 210 23.3 5.64 146.27 Glutathione S-transferase P 
OS=Homo sapiens GN=GSTP1 
PE=1 SV=2 - [GSTP1_HUMAN] 
P04406 20.60 4 4 335 36.0 8.46 245.42 Glyceraldehyde-3-phosphate 
dehydrogenase OS=Homo 
sapiens GN=GAPDH PE=1 SV=3 - 
[G3P_HUMAN] 
P28799 2.53 2 1 593 63.5 6.83 133.91 Granulins OS=Homo sapiens 
GN=GRN PE=1 SV=2 - 
[GRN_HUMAN] 
Q99988 5.19 1 1 308 34.1 9.66 64.66 Growth/differentiation factor 15 
OS=Homo sapiens GN=GDF15 
PE=1 SV=2 - [GDF15_HUMAN] 
Q8NHV1 2.00 2 1 300 34.5 6.46 81.04 GTPase IMAP family member 7 
OS=Homo sapiens GN=GIMAP7 
PE=2 SV=1 - [GIMA7_HUMAN] 
P00738 17.73 6 6 406 45.2 6.58 272.41 Haptoglobin OS=Homo sapiens 
GN=HP PE=1 SV=1 - 
[HPT_HUMAN] 
P11142 3.87 2 2 646 70.9 5.52 112.81 Heat shock cognate 71 kDa 
protein OS=Homo sapiens 
GN=HSPA8 PE=1 SV=1 - 
[HSP7C_HUMAN] 
P02790 2.38 1 1 462 51.6 7.02 64.63 Hemopexin OS=Homo sapiens 
GN=HPX PE=1 SV=2 - 
[HEMO_HUMAN] 
P37235 4.15 1 1 193 22.3 5.35 58.38 Hippocalcin-like protein 1 
OS=Homo sapiens GN=HPCAL1 
PE=1 SV=3 - [HPCL1_HUMAN] 
P04196 5.71 2 2 525 59.5 7.50 115.42 Histidine-rich glycoprotein 
OS=Homo sapiens GN=HRG 
PE=1 SV=1 - [HRG_HUMAN] 
Q86YZ3 1.68 1 1 2850 282.2 10.0
4 
94.15 Hornerin OS=Homo sapiens 
GN=HRNR PE=1 SV=2 - 
[HORN_HUMAN] 
Q12794 8.74 2 2 435 48.3 6.77 148.48 Hyaluronidase-1 OS=Homo 
sapiens GN=HYAL1 PE=1 SV=2 - 
[HYAL1_HUMAN] 
O75144 8.61 2 2 302 33.3 5.31 108.54 ICOS ligand OS=Homo sapiens 
GN=ICOSLG PE=1 SV=2 - 
[ICOSL_HUMAN] 
P01876 24.36 6 5 353 37.6 6.51 425.76 Ig alpha-1 chain C region 
OS=Homo sapiens GN=IGHA1 
PE=1 SV=2 - [IGHA1_HUMAN] 
P01877 18.53 4 4 340 36.5 6.10 307.52 Ig alpha-2 chain C region 
OS=Homo sapiens GN=IGHA2 
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PE=1 SV=3 - [IGHA2_HUMAN] 
P01857 28.79 9 6 330 36.1 8.19 470.52 Ig gamma-1 chain C region 
OS=Homo sapiens GN=IGHG1 
PE=1 SV=1 - [IGHG1_HUMAN] 
P01859 16.87 6 4 326 35.9 7.59 296.87 Ig gamma-2 chain C region 
OS=Homo sapiens GN=IGHG2 
PE=1 SV=2 - [IGHG2_HUMAN] 
P01860 13.79 5 4 377 41.3 7.90 256.39 Ig gamma-3 chain C region 
OS=Homo sapiens GN=IGHG3 
PE=1 SV=2 - [IGHG3_HUMAN] 
P01861 18.35 7 4 327 35.9 7.36 354.82 Ig gamma-4 chain C region 
OS=Homo sapiens GN=IGHG4 
PE=1 SV=1 - [IGHG4_HUMAN] 
P01742 10.26 1 1 117 12.5 6.57 79.09 Ig heavy chain V-I region EU 
OS=Homo sapiens PE=1 SV=1 - 
[HV101_HUMAN] 
P01766 25.00 2 2 120 13.2 6.57 117.64 Ig heavy chain V-III region BRO 
OS=Homo sapiens PE=1 SV=1 - 
[HV305_HUMAN] 
P01781 17.24 2 2 116 12.7 8.48 108.38 Ig heavy chain V-III region GAL 
OS=Homo sapiens PE=1 SV=1 - 
[HV320_HUMAN] 
P01765 16.52 2 1 115 12.3 9.13 129.56 Ig heavy chain V-III region TIL 
OS=Homo sapiens PE=1 SV=1 - 
[HV304_HUMAN] 
P01762 15.57 2 1 122 13.5 9.72 115.81 Ig heavy chain V-III region TRO 
OS=Homo sapiens PE=1 SV=1 - 
[HV301_HUMAN] 
P01834 63.21 11 5 106 11.6 5.87 554.19 Ig kappa chain C region 
OS=Homo sapiens GN=IGKC 
PE=1 SV=1 - [IGKC_HUMAN] 
P01593 16.67 2 1 108 12.0 5.99 165.90 Ig kappa chain V-I region AG 
OS=Homo sapiens PE=1 SV=1 - 
[KV101_HUMAN] 
P01596 16.82 1 1 107 11.7 9.41 96.06 Ig kappa chain V-I region CAR 
OS=Homo sapiens PE=1 SV=1 - 
[KV104_HUMAN] 
P01611 16.67 1 1 108 11.6 7.28 61.82 Ig kappa chain V-I region Wes 
OS=Homo sapiens PE=1 SV=1 - 
[KV119_HUMAN] 
P01616 11.61 1 1 112 12.0 9.29 73.34 Ig kappa chain V-II region MIL 
OS=Homo sapiens PE=1 SV=1 - 
[KV203_HUMAN] 
P01617 21.24 1 1 113 12.3 6.00 122.31 Ig kappa chain V-II region TEW 
OS=Homo sapiens PE=1 SV=1 - 
[KV204_HUMAN] 
P01620 14.68 1 1 109 11.8 8.48 78.40 Ig kappa chain V-III region SIE 
OS=Homo sapiens PE=1 SV=1 - 
[KV302_HUMAN] 
P06312 29.75 3 3 121 13.4 5.25 113.02 Ig kappa chain V-IV region 
(Fragment) OS=Homo sapiens 
GN=IGKV4-1 PE=4 SV=1 - 
[KV401_HUMAN] 
P01625 36.84 4 3 114 12.6 7.93 166.81 Ig kappa chain V-IV region Len 
OS=Homo sapiens PE=1 SV=2 - 
[KV402_HUMAN] 
P01702 7.21 1 1 111 11.4 4.89 58.86 Ig lambda chain V-I region NIG-
64 OS=Homo sapiens PE=1 
SV=1 - [LV104_HUMAN] 
P0CG05 50.94 4 3 106 11.3 7.24 249.63 Ig lambda-2 chain C regions 
OS=Homo sapiens GN=IGLC2 
PE=1 SV=1 - [LAC2_HUMAN] 
P01871 3.54 1 1 452 49.3 6.77 65.99 Ig mu chain C region OS=Homo 
sapiens GN=IGHM PE=1 SV=3 - 
[IGHM_HUMAN] 
Q9Y6R7 2.35 5 5 5405 571.6 5.34 256.55 IgGFc-binding protein OS=Homo 
sapiens GN=FCGBP PE=1 SV=3 - 
[FCGBP_HUMAN] 
P01591 23.27 3 3 159 18.1 5.24 188.95 Immunoglobulin J chain 
OS=Homo sapiens GN=IGJ PE=1 
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SV=4 - [IGJ_HUMAN] 
Q16270 17.73 4 3 282 29.1 7.90 205.49 Insulin-like growth factor-binding 
protein 7 OS=Homo sapiens 
GN=IGFBP7 PE=1 SV=1 - 
[IBP7_HUMAN] 
Q9Y287 3.76 1 1 266 30.3 5.14 58.87 Integral membrane protein 2B 
OS=Homo sapiens GN=ITM2B 
PE=1 SV=1 - [ITM2B_HUMAN] 
Q14624 9.89 6 6 930 103.3 6.98 390.41 Inter-alpha-trypsin inhibitor 
heavy chain H4 OS=Homo 
sapiens GN=ITIH4 PE=1 SV=4 - 
[ITIH4_HUMAN] 
P53990 5.22 1 1 364 39.7 5.35 102.01 IST1 homolog OS=Homo sapiens 
GN=KIAA0174 PE=1 SV=1 - 
[IST1_HUMAN] 
P06870 16.03 3 3 262 28.9 4.83 177.69 Kallikrein-1 OS=Homo sapiens 
GN=KLK1 PE=1 SV=2 - 
[KLK1_HUMAN] 
P29622 3.51 1 1 427 48.5 7.75 103.42 Kallistatin OS=Homo sapiens 
GN=SERPINA4 PE=1 SV=3 - 
[KAIN_HUMAN] 
P13645 42.47 24 19 584 58.8 5.21 1250.81 Keratin, type I cytoskeletal 10 
OS=Homo sapiens GN=KRT10 
PE=1 SV=6 - [K1C10_HUMAN] 
P13646 13.54 5 5 458 49.6 4.96 345.59 Keratin, type I cytoskeletal 13 
OS=Homo sapiens GN=KRT13 
PE=1 SV=4 - [K1C13_HUMAN] 
P02533 19.07 7 7 472 51.5 5.16 370.50 Keratin, type I cytoskeletal 14 
OS=Homo sapiens GN=KRT14 
PE=1 SV=4 - [K1C14_HUMAN] 
P08779 14.38 6 6 473 51.2 5.05 311.81 Keratin, type I cytoskeletal 16 
OS=Homo sapiens GN=KRT16 
PE=1 SV=4 - [K1C16_HUMAN] 
P35527 30.18 14 12 623 62.0 5.24 941.86 Keratin, type I cytoskeletal 9 
OS=Homo sapiens GN=KRT9 
PE=1 SV=3 - [K1C9_HUMAN] 
P04264 28.73 23 17 644 66.0 8.12 1050.10 Keratin, type II cytoskeletal 1 
OS=Homo sapiens GN=KRT1 
PE=1 SV=6 - [K2C1_HUMAN] 
P35908 28.64 16 14 639 65.4 8.00 827.60 Keratin, type II cytoskeletal 2 
epidermal OS=Homo sapiens 
GN=KRT2 PE=1 SV=2 - 
[K22E_HUMAN] 
P13647 11.86 7 6 590 62.3 7.74 349.88 Keratin, type II cytoskeletal 5 
OS=Homo sapiens GN=KRT5 
PE=1 SV=3 - [K2C5_HUMAN] 
P04259 8.51 5 4 564 60.0 8.00 295.13 Keratin, type II cytoskeletal 6B 
OS=Homo sapiens GN=KRT6B 
PE=1 SV=5 - [K2C6B_HUMAN] 
P01042 14.44 12 7 644 71.9 6.81 617.07 Kininogen-1 OS=Homo sapiens 
GN=KNG1 PE=1 SV=2 - 
[KNG1_HUMAN] 
P02788 6.48 5 4 710 78.1 8.12 227.66 Lactotransferrin OS=Homo 
sapiens GN=LTF PE=1 SV=6 - 
[TRFL_HUMAN] 
P02750 6.63 1 1 347 38.2 6.95 80.58 Leucine-rich alpha-2-glycoprotein 
OS=Homo sapiens GN=LRG1 
PE=1 SV=2 - [A2GL_HUMAN] 
Q6GTX8 9.06 2 2 287 31.4 5.63 120.39 Leukocyte-associated 
immunoglobulin-like receptor 1 
OS=Homo sapiens GN=LAIR1 
PE=1 SV=1 - [LAIR1_HUMAN] 
P00338 9.94 3 3 332 36.7 8.27 144.81 L-lactate dehydrogenase A chain 
OS=Homo sapiens GN=LDHA 
PE=1 SV=2 - [LDHA_HUMAN] 
P98164 7.82 28 27 4655 521.6 5.08 1723.08 Low-density lipoprotein receptor-
related protein 2 OS=Homo 
sapiens GN=LRP2 PE=1 SV=3 - 
[LRP2_HUMAN] 
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P11117 4.49 2 2 423 48.3 6.74 143.48 Lysosomal acid phosphatase 
OS=Homo sapiens GN=ACP2 
PE=1 SV=3 - [PPAL_HUMAN] 
P10253 18.59 17 11 952 105.3 5.99 898.30 Lysosomal alpha-glucosidase 
OS=Homo sapiens GN=GAA 
PE=1 SV=3 - [LYAG_HUMAN] 
P10619 2.71 1 1 480 54.4 6.61 105.17 Lysosomal protective protein 
OS=Homo sapiens GN=CTSA 
PE=1 SV=2 - [PPGB_HUMAN] 
P42785 10.48 3 3 496 55.8 7.21 200.30 Lysosomal Pro-X 
carboxypeptidase OS=Homo 
sapiens GN=PRCP PE=1 SV=1 - 
[PCP_HUMAN] 
P13473 4.88 2 2 410 44.9 5.63 100.58 Lysosome-associated membrane 
glycoprotein 2 OS=Homo sapiens 
GN=LAMP2 PE=1 SV=2 - 
[LAMP2_HUMAN] 
O43451 15.62 21 20 1857 209.7 5.50 1218.94 Maltase-glucoamylase, intestinal 
OS=Homo sapiens GN=MGAM 
PE=1 SV=5 - [MGA_HUMAN] 
O00187 3.21 2 2 686 75.7 5.77 82.18 Mannan-binding lectin serine 
protease 2 OS=Homo sapiens 
GN=MASP2 PE=1 SV=3 - 
[MASP2_HUMAN] 
Q9NR99 0.99 2 2 2828 312.1 8.32 103.53 Matrix-remodeling-associated 
protein 5 OS=Homo sapiens 
GN=MXRA5 PE=2 SV=2 - 
[MXRA5_HUMAN] 
P26038 1.91 1 1 577 67.8 6.40 108.62 Moesin OS=Homo sapiens 
GN=MSN PE=1 SV=3 - 
[MOES_HUMAN] 
P08571 14.40 3 3 375 40.1 6.23 136.45 Monocyte differentiation antigen 
CD14 OS=Homo sapiens 
GN=CD14 PE=1 SV=2 - 
[CD14_HUMAN] 
P15941 0.88 1 1 1255 122.0 7.47 135.46 Mucin-1 OS=Homo sapiens 
GN=MUC1 PE=1 SV=3 - 
[MUC1_HUMAN] 
Q9HC84 2.03 3 3 5703 590.1 6.67 145.40 Mucin-5B OS=Homo sapiens 
GN=MUC5B PE=1 SV=2 - 
[MUC5B_HUMAN] 
Q9H8L6 4.00 2 2 949 104.3 5.86 196.33 Multimerin-2 OS=Homo sapiens 
GN=MMRN2 PE=1 SV=2 - 
[MMRN2_HUMAN] 
P34059 3.07 1 1 522 58.0 6.74 70.13 N-acetylgalactosamine-6-
sulfatase OS=Homo sapiens 
GN=GALNS PE=1 SV=1 - 
[GALNS_HUMAN] 
O96009 9.52 3 3 420 45.4 6.61 142.51 Napsin-A OS=Homo sapiens 
GN=NAPSA PE=1 SV=1 - 
[NAPSA_HUMAN] 
P08473 5.20 3 3 750 85.5 5.73 221.46 Neprilysin OS=Homo sapiens 
GN=MME PE=1 SV=2 - 
[NEP_HUMAN] 
P80188 7.58 1 1 198 22.6 8.91 119.08 Neutrophil gelatinase-associated 
lipocalin OS=Homo sapiens 
GN=LCN2 PE=1 SV=2 - 
[NGAL_HUMAN] 
Q92542 1.69 1 1 709 78.4 5.99 73.57 Nicastrin OS=Homo sapiens 
GN=NCSTN PE=1 SV=2 - 
[NICA_HUMAN] 
P10153 10.56 2 1 161 18.3 8.73 126.91 Non-secretory ribonuclease 
OS=Homo sapiens GN=RNASE2 
PE=1 SV=2 - [RNAS2_HUMAN] 
P51688 7.37 3 3 502 56.7 6.95 163.74 N-sulphoglucosamine 
sulphohydrolase OS=Homo 
sapiens GN=SGSH PE=1 SV=1 - 
[SPHM_HUMAN] 
P61970 23.62 3 2 127 14.5 5.38 153.41 Nuclear transport factor 2 
OS=Homo sapiens GN=NUTF2 
PE=1 SV=1 - [NTF2_HUMAN] 
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Q6UX06 13.53 5 5 510 57.2 5.69 315.00 Olfactomedin-4 OS=Homo 
sapiens GN=OLFM4 PE=1 SV=1 - 
[OLFM4_HUMAN] 
P04746 19.37 8 7 511 57.7 7.05 560.45 Pancreatic alpha-amylase 
OS=Homo sapiens GN=AMY2A 
PE=1 SV=2 - [AMYP_HUMAN] 
P55259 4.28 2 2 537 59.4 5.24 88.99 Pancreatic secretory granule 
membrane major glycoprotein 
GP2 OS=Homo sapiens GN=GP2 
PE=2 SV=3 - [GP2_HUMAN] 
Q9UBV8 11.97 3 3 284 30.4 6.54 165.56 Peflin OS=Homo sapiens 
GN=PEF1 PE=1 SV=1 - 
[PEF1_HUMAN] 
O75594 39.29 5 4 196 21.7 8.59 301.86 Peptidoglycan recognition protein 
1 OS=Homo sapiens 
GN=PGLYRP1 PE=1 SV=1 - 
[PGRP1_HUMAN] 
Q06830 5.03 1 1 199 22.1 8.13 68.82 Peroxiredoxin-1 OS=Homo 
sapiens GN=PRDX1 PE=1 SV=1 - 
[PRDX1_HUMAN] 
P30086 32.09 4 4 187 21.0 7.53 229.60 Phosphatidylethanolamine-
binding protein 1 OS=Homo 
sapiens GN=PEBP1 PE=1 SV=3 - 
[PEBP1_HUMAN] 
Q9Y646 16.95 6 6 472 51.9 6.18 334.27 Plasma glutamate 
carboxypeptidase OS=Homo 
sapiens GN=PGCP PE=1 SV=1 - 
[PGCP_HUMAN] 
P05155 13.40 7 5 500 55.1 6.55 482.11 Plasma protease C1 inhibitor 
OS=Homo sapiens 
GN=SERPING1 PE=1 SV=2 - 
[IC1_HUMAN] 
P05154 21.43 10 7 406 45.7 9.26 546.80 Plasma serine protease inhibitor 
OS=Homo sapiens 
GN=SERPINA5 PE=1 SV=2 - 
[IPSP_HUMAN] 
P15151 3.12 1 1 417 45.3 6.52 78.42 Poliovirus receptor OS=Homo 
sapiens GN=PVR PE=1 SV=2 - 
[PVR_HUMAN] 
P01833 28.93 22 15 764 83.2 5.74 1225.49 Polymeric immunoglobulin 
receptor OS=Homo sapiens 
GN=PIGR PE=1 SV=4 - 
[PIGR_HUMAN] 
P0CG48 11.82 1 1 685 77.0 7.66 91.36 Polyubiquitin-C OS=Homo 
sapiens GN=UBC PE=1 SV=1 - 
[UBC_HUMAN] 
P07602 14.69 8 5 524 58.1 5.17 489.67 Proactivator polypeptide 
OS=Homo sapiens GN=PSAP 
PE=1 SV=2 - [SAP_HUMAN] 
P01133 16.74 16 14 1207 133.9 5.85 955.71 Pro-epidermal growth factor 
OS=Homo sapiens GN=EGF 
PE=1 SV=2 - [EGF_HUMAN] 
Q8WUM4 3.23 2 2 868 96.0 6.52 145.44 Programmed cell death 6-
interacting protein OS=Homo 
sapiens GN=PDCD6IP PE=1 
SV=1 - [PDC6I_HUMAN] 
O75340 16.75 3 3 191 21.9 5.40 178.08 Programmed cell death protein 6 
OS=Homo sapiens GN=PDCD6 
PE=1 SV=1 - [PDCD6_HUMAN] 
P12273 8.22 1 1 146 16.6 8.05 88.34 Prolactin-inducible protein 
OS=Homo sapiens GN=PIP PE=1 
SV=1 - [PIP_HUMAN] 
O43490 4.05 2 2 865 97.1 7.27 146.25 Prominin-1 OS=Homo sapiens 
GN=PROM1 PE=1 SV=1 - 
[PROM1_HUMAN] 
P41222 17.37 3 2 190 21.0 7.80 262.29 Prostaglandin-H2 D-isomerase 
OS=Homo sapiens GN=PTGDS 
PE=1 SV=1 - [PTGDS_HUMAN] 
Q16651 4.08 1 1 343 36.4 5.85 106.87 Prostasin OS=Homo sapiens 
GN=PRSS8 PE=1 SV=1 - 
[PRSS8_HUMAN] 
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O43653 8.13 1 1 123 12.9 5.29 61.64 Prostate stem cell antigen 
OS=Homo sapiens GN=PSCA 
PE=1 SV=1 - [PSCA_HUMAN] 
P15309 12.18 7 4 386 44.5 6.24 409.77 Prostatic acid phosphatase 
OS=Homo sapiens GN=ACPP 
PE=1 SV=3 - [PPAP_HUMAN] 
P02760 30.11 16 8 352 39.0 6.25 950.65 Protein AMBP OS=Homo sapiens 
GN=AMBP PE=1 SV=1 - 
[AMBP_HUMAN] 
P31949 15.24 1 1 105 11.7 7.12 92.18 Protein S100-A11 OS=Homo 
sapiens GN=S100A11 PE=1 
SV=2 - [S10AB_HUMAN] 
P06703 27.78 2 2 90 10.2 5.48 118.96 Protein S100-A6 OS=Homo 
sapiens GN=S100A6 PE=1 SV=1 
- [S10A6_HUMAN] 
P06702 26.32 2 2 114 13.2 6.13 120.97 Protein S100-A9 OS=Homo 
sapiens GN=S100A9 PE=1 SV=1 
- [S10A9_HUMAN] 
P25815 13.68 1 1 95 10.4 4.88 84.46 Protein S100-P OS=Homo 
sapiens GN=S100P PE=1 SV=2 - 
[S100P_HUMAN] 
P00734 5.95 2 2 622 70.0 5.90 190.38 Prothrombin OS=Homo sapiens 
GN=F2 PE=1 SV=2 - 
[THRB_HUMAN] 
A6NIZ1 6.52 1 1 184 20.9 5.48 74.32 Ras-related protein Rap-1b-like 
protein OS=Homo sapiens PE=2 
SV=1 - [RP1BL_HUMAN] 
Q12913 2.32 2 2 1337 145.9 5.58 182.06 Receptor-type tyrosine-protein 
phosphatase eta OS=Homo 
sapiens GN=PTPRJ PE=1 SV=3 - 
[PTPRJ_HUMAN] 
Q13332 0.67 1 1 1948 217.0 6.51 62.90 Receptor-type tyrosine-protein 
phosphatase S OS=Homo sapiens 
GN=PTPRS PE=1 SV=2 - 
[PTPRS_HUMAN] 
O75787 2.57 1 1 350 39.0 6.10 67.12 Renin receptor OS=Homo sapiens 
GN=ATP6AP2 PE=1 SV=2 - 
[RENR_HUMAN] 
Q9HD89 40.74 3 3 108 11.4 6.86 152.72 Resistin OS=Homo sapiens 
GN=RETN PE=2 SV=1 - 
[RETN_HUMAN] 
P00352 2.99 1 1 501 54.8 6.73 105.59 Retinal dehydrogenase 1 
OS=Homo sapiens GN=ALDH1A1 
PE=1 SV=2 - [AL1A1_HUMAN] 
Q9HB40 5.53 2 2 452 50.8 5.81 127.22 Retinoid-inducible serine 
carboxypeptidase OS=Homo 
sapiens GN=SCPEP1 PE=1 SV=1 
- [RISC_HUMAN] 
P07998 17.95 2 2 156 17.6 8.79 93.48 Ribonuclease pancreatic 
OS=Homo sapiens GN=RNASE1 
PE=1 SV=4 - [RNAS1_HUMAN] 
Q8WVN6 14.52 2 2 248 27.0 7.43 142.17 Secreted and transmembrane 
protein 1 OS=Homo sapiens 
GN=SECTM1 PE=1 SV=2 - 
[SCTM1_HUMAN] 
P04279 7.36 2 2 462 52.1 9.29 97.30 Semenogelin-1 OS=Homo 
sapiens GN=SEMG1 PE=1 SV=2 - 
[SEMG1_HUMAN] 
P02787 8.02 4 4 698 77.0 7.12 159.56 Serotransferrin OS=Homo 
sapiens GN=TF PE=1 SV=2 - 
[TRFE_HUMAN] 
P29508 5.90 2 2 390 44.5 6.81 126.41 Serpin B3 OS=Homo sapiens 
GN=SERPINB3 PE=1 SV=2 - 
[SPB3_HUMAN] 
P02768 49.26 40 23 609 69.3 6.28 2325.90 Serum albumin OS=Homo 
sapiens GN=ALB PE=1 SV=2 - 
[ALBU_HUMAN] 
P02743 20.63 4 4 223 25.4 6.54 178.81 Serum amyloid P-component 
OS=Homo sapiens GN=APCS 
PE=1 SV=2 - [SAMP_HUMAN] 
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Q9HAT2 7.65 3 3 523 58.3 7.33 188.56 Sialate O-acetylesterase 
OS=Homo sapiens GN=SIAE 
PE=1 SV=1 - [SIAE_HUMAN] 
P48061 15.05 1 1 93 10.7 9.88 66.94 Stromal cell-derived factor 1 
OS=Homo sapiens GN=CXCL12 
PE=1 SV=1 - [SDF1_HUMAN] 
P53597 4.34 1 1 346 36.2 8.79 62.08 Succinyl-CoA ligase [GDP-
forming] subunit alpha, 
mitochondrial OS=Homo sapiens 
GN=SUCLG1 PE=1 SV=4 - 
[SUCA_HUMAN] 
O00391 1.87 1 1 747 82.5 8.92 128.99 Sulfhydryl oxidase 1 OS=Homo 
sapiens GN=QSOX1 PE=1 SV=3 - 
[QSOX1_HUMAN] 
Q9UGT4 1.70 1 1 822 90.1 6.28 83.61 Sushi domain-containing protein 
2 OS=Homo sapiens GN=SUSD2 
PE=1 SV=1 - [SUSD2_HUMAN] 
O00560 14.43 3 2 298 32.4 7.53 300.83 Syntenin-1 OS=Homo sapiens 
GN=SDCBP PE=1 SV=1 - 
[SDCB1_HUMAN] 
P10599 12.38 1 1 105 11.7 4.92 85.98 Thioredoxin OS=Homo sapiens 
GN=TXN PE=1 SV=3 - 
[THIO_HUMAN] 
P05543 6.75 3 3 415 46.3 6.30 120.75 Thyroxine-binding globulin 
OS=Homo sapiens 
GN=SERPINA7 PE=1 SV=2 - 
[THBG_HUMAN] 
P02766 48.30 5 5 147 15.9 5.76 247.35 Transthyretin OS=Homo sapiens 
GN=TTR PE=1 SV=1 - 
[TTHY_HUMAN] 
P60174 10.44 2 2 249 26.7 6.90 80.80 Triosephosphate isomerase 
OS=Homo sapiens GN=TPI1 
PE=1 SV=2 - [TPIS_HUMAN] 
O14773 9.77 4 3 563 61.2 6.48 242.71 Tripeptidyl-peptidase 1 
OS=Homo sapiens GN=TPP1 
PE=1 SV=2 - [TPP1_HUMAN] 
P30530 2.01 1 1 894 98.3 5.43 72.45 Tyrosine-protein kinase receptor 
UFO OS=Homo sapiens GN=AXL 
PE=1 SV=3 - [UFO_HUMAN] 
Q9H1C7 10.31 1 1 97 10.6 4.32 59.23 UPF0467 protein C5orf32 
OS=Homo sapiens GN=C5orf32 
PE=2 SV=1 - [CE032_HUMAN] 
Q6UX73 3.23 1 1 402 45.4 6.19 72.46 UPF0764 protein C16orf89 
OS=Homo sapiens GN=C16orf89 
PE=2 SV=2 - [CP089_HUMAN] 
P00749 4.87 2 2 431 48.5 8.41 134.85 Urokinase-type plasminogen 
activator OS=Homo sapiens 
GN=PLAU PE=1 SV=2 - 
[UROK_HUMAN] 
P07911 34.84 84 17 640 69.7 5.24 4820.87 Uromodulin OS=Homo sapiens 
GN=UMOD PE=1 SV=1 - 
[UROM_HUMAN] 
Q9NP79 6.51 1 1 307 33.9 6.29 66.83 Vacuolar protein sorting-
associated protein VTA1 homolog 
OS=Homo sapiens GN=VTA1 
PE=1 SV=1 - [VTA1_HUMAN] 
Q6EMK4 10.10 4 4 673 71.7 7.39 242.73 Vasorin OS=Homo sapiens 
GN=VASN PE=1 SV=1 - 
[VASN_HUMAN] 
Q12907 18.54 4 4 356 40.2 6.95 331.12 Vesicular integral-membrane 
protein VIP36 OS=Homo sapiens 
GN=LMAN2 PE=1 SV=1 - 
[LMAN2_HUMAN] 
P22891 13.50 4 4 400 44.7 5.97 184.28 Vitamin K-dependent protein Z 
OS=Homo sapiens GN=PROZ 
PE=1 SV=2 - [PROZ_HUMAN] 
Q7Z5L0 54.95 8 6 202 21.5 5.07 371.00 Vitelline membrane outer layer 
protein 1 homolog OS=Homo 
sapiens GN=VMO1 PE=1 SV=1 - 
[VMO1_HUMAN] 
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P04004 10.25 3 3 478 54.3 5.80 177.86 Vitronectin OS=Homo sapiens 
GN=VTN PE=1 SV=1 - 
[VTNC_HUMAN] 
Q14508 11.29 2 1 124 13.0 4.84 103.89 WAP four-disulfide core domain 
protein 2 OS=Homo sapiens 
GN=WFDC2 PE=1 SV=2 - 
[WFDC2_HUMAN] 
O43895 4.45 2 2 674 75.6 6.04 97.58 Xaa-Pro aminopeptidase 2 
OS=Homo sapiens GN=XPNPEP2 
PE=1 SV=3 - [XPP2_HUMAN] 
P25311 32.21 8 8 298 34.2 6.05 412.05 Zinc-alpha-2-glycoprotein 
OS=Homo sapiens GN=AZGP1 
PE=1 SV=2 - [ZA2G_HUMAN] 
Q96DA0 30.77 5 5 208 22.7 7.39 270.94 Zymogen granule protein 16 
homolog B OS=Homo sapiens 
GN=ZG16B PE=1 SV=3 - 
[ZG16B_HUMAN] 
 
Supplementary table S2.3: Identification of proteins in (P18+P200) CHAPS SN200 sample 
2. Accession of the protein, sequence coverage, PSM (Match between a fragmentation mass 
spectrum and peptide), number of peptides found, number of amino acids in the protein, 
molecular weight, calculated PI and mascot score along with the description of the protein are 
indicated in the table. 
Accession Coverage % # 
PSMs 
# 
Peptides 
# 
AAs 
MW 
[kDa
] 
calc. 
pI 
Score Description 
P63104 4.90 1 1 245 27.7 4.79 59.74 14-3-3 protein zeta/delta 
OS=Homo sapiens GN=YWHAZ 
PE=1 SV=1 - [1433Z_HUMAN] 
Q13510 30.13 13 9 395 44.6 7.62 679.07 Acid ceramidase OS=Homo 
sapiens GN=ASAH1 PE=1 SV=5 - 
[ASAH1_HUMAN] 
Q92485 2.64 1 1 455 50.8 5.64 68.27 Acid sphingomyelinase-like 
phosphodiesterase 3b OS=Homo 
sapiens GN=SMPDL3B PE=2 
SV=2 - [ASM3B_HUMAN] 
P60709 9.60 3 3 375 41.7 5.48 189.11 Actin, cytoplasmic 1 OS=Homo 
sapiens GN=ACTB PE=1 SV=1 - 
[ACTB_HUMAN] 
P02763 32.34 6 5 201 23.5 5.02 242.57 Alpha-1-acid glycoprotein 1 
OS=Homo sapiens GN=ORM1 
PE=1 SV=1 - [A1AG1_HUMAN] 
P19652 12.94 2 2 201 23.6 5.11 92.87 Alpha-1-acid glycoprotein 2 
OS=Homo sapiens GN=ORM2 
PE=1 SV=2 - [A1AG2_HUMAN] 
P01011 13.71 4 4 423 47.6 5.52 279.42 Alpha-1-antichymotrypsin 
OS=Homo sapiens 
GN=SERPINA3 PE=1 SV=2 - 
[AACT_HUMAN] 
P01009 33.73 17 12 418 46.7 5.59 877.80 Alpha-1-antitrypsin OS=Homo 
sapiens GN=SERPINA1 PE=1 
SV=3 - [A1AT_HUMAN] 
P04217 9.90 4 4 495 54.2 5.87 186.68 Alpha-1B-glycoprotein OS=Homo 
sapiens GN=A1BG PE=1 SV=3 - 
[A1BG_HUMAN] 
P02765 16.62 5 5 367 39.3 5.72 335.80 Alpha-2-HS-glycoprotein 
OS=Homo sapiens GN=AHSG 
PE=1 SV=1 - [FETUA_HUMAN] 
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P12814 1.12 1 1 892 103.
0 
5.41 80.88 Alpha-actinin-1 OS=Homo 
sapiens GN=ACTN1 PE=1 SV=2 - 
[ACTN1_HUMAN] 
P04745 10.37 4 4 511 57.7 6.93 336.72 Alpha-amylase 1 OS=Homo 
sapiens GN=AMY1A PE=1 SV=2 - 
[AMY1_HUMAN] 
P19961 10.37 4 4 511 57.7 7.09 337.82 Alpha-amylase 2B OS=Homo 
sapiens GN=AMY2B PE=1 SV=1 - 
[AMY2B_HUMAN] 
P06733 8.53 2 2 434 47.1 7.39 181.18 Alpha-enolase OS=Homo sapiens 
GN=ENO1 PE=1 SV=2 - 
[ENOA_HUMAN] 
P54802 23.15 12 11 743 82.1 6.54 578.03 Alpha-N-acetylglucosaminidase 
OS=Homo sapiens GN=NAGLU 
PE=1 SV=1 - [ANAG_HUMAN] 
P15144 27.92 31 20 967 109.
5 
5.48 1761.40 Aminopeptidase N OS=Homo 
sapiens GN=ANPEP PE=1 SV=4 - 
[AMPN_HUMAN] 
P01019 10.52 4 3 485 53.1 6.32 177.07 Angiotensinogen OS=Homo 
sapiens GN=AGT PE=1 SV=1 - 
[ANGT_HUMAN] 
P04083 3.76 1 1 346 38.7 7.02 70.05 Annexin A1 OS=Homo sapiens 
GN=ANXA1 PE=1 SV=2 - 
[ANXA1_HUMAN] 
P08758 34.38 7 7 320 35.9 5.05 321.92 Annexin A5 OS=Homo sapiens 
GN=ANXA5 PE=1 SV=2 - 
[ANXA5_HUMAN] 
P02647 15.73 3 3 267 30.8 5.76 220.49 Apolipoprotein A-I OS=Homo 
sapiens GN=APOA1 PE=1 SV=1 - 
[APOA1_HUMAN] 
P02652 20.00 1 1 100 11.2 6.62 70.43 Apolipoprotein A-II OS=Homo 
sapiens GN=APOA2 PE=1 SV=1 - 
[APOA2_HUMAN] 
P05090 24.34 16 6 189 21.3 5.15 840.55 Apolipoprotein D OS=Homo 
sapiens GN=APOD PE=1 SV=1 - 
[APOD_HUMAN] 
P02649 27.13 8 7 317 36.1 5.73 493.24 Apolipoprotein E OS=Homo 
sapiens GN=APOE PE=1 SV=1 - 
[APOE_HUMAN] 
P15289 8.09 2 2 507 53.6 6.07 146.85 Arylsulfatase A OS=Homo 
sapiens GN=ARSA PE=1 SV=3 - 
[ARSA_HUMAN] 
O75882 8.68 10 10 1429 158.
4 
7.31 517.68 Attractin OS=Homo sapiens 
GN=ATRN PE=1 SV=2 - 
[ATRN_HUMAN] 
P98160 1.48 4 4 4391 468.
5 
6.51 261.62 Basement membrane-specific 
heparan sulfate proteoglycan 
core protein OS=Homo sapiens 
GN=HSPG2 PE=1 SV=3 - 
[PGBM_HUMAN] 
P02749 9.28 2 2 345 38.3 7.97 108.24 Beta-2-glycoprotein 1 OS=Homo 
sapiens GN=APOH PE=1 SV=3 - 
[APOH_HUMAN] 
P61769 8.40 1 1 119 13.7 6.52 69.68 Beta-2-microglobulin OS=Homo 
sapiens GN=B2M PE=1 SV=1 - 
[B2MG_HUMAN] 
P16278 5.02 3 3 677 76.0 6.57 196.01 Beta-galactosidase OS=Homo 
sapiens GN=GLB1 PE=1 SV=2 - 
[BGAL_HUMAN] 
P06865 2.08 1 1 529 60.7 5.16 72.45 Beta-hexosaminidase subunit 
alpha OS=Homo sapiens 
GN=HEXA PE=1 SV=1 - 
[HEXA_HUMAN] 
P43251 7.92 3 3 543 61.1 6.25 161.44 Biotinidase OS=Homo sapiens 
GN=BTD PE=1 SV=2 - 
[BTD_HUMAN] 
Q5VW32 3.89 1 1 411 46.4 7.65 65.53 BRO1 domain-containing protein 
BROX OS=Homo sapiens 
GN=BROX PE=1 SV=1 - 
[BROX_HUMAN] 
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P12830 5.44 3 3 882 97.4 4.73 157.63 Cadherin-1 OS=Homo sapiens 
GN=CDH1 PE=1 SV=3 - 
[CADH1_HUMAN] 
P19022 6.18 3 3 906 99.7 4.81 177.43 Cadherin-2 OS=Homo sapiens 
GN=CDH2 PE=1 SV=4 - 
[CADH2_HUMAN] 
Q9BYE9 2.06 2 2 1310 141.
5 
4.50 122.44 Cadherin-related family member 
2 OS=Homo sapiens GN=CDHR2 
PE=1 SV=2 - [CDHR2_HUMAN] 
P14384 4.06 2 2 443 50.5 7.36 91.85 Carboxypeptidase M OS=Homo 
sapiens GN=CPM PE=1 SV=2 - 
[CBPM_HUMAN] 
P22792 17.98 9 7 545 60.6 5.99 464.82 Carboxypeptidase N subunit 2 
OS=Homo sapiens GN=CPN2 
PE=1 SV=2 - [CPN2_HUMAN] 
P07858 5.31 1 1 339 37.8 6.30 88.55 Cathepsin B OS=Homo sapiens 
GN=CTSB PE=1 SV=3 - 
[CATB_HUMAN] 
P07339 21.84 6 6 412 44.5 6.54 345.17 Cathepsin D OS=Homo sapiens 
GN=CTSD PE=1 SV=1 - 
[CATD_HUMAN] 
Q8N6Q3 3.43 1 1 437 46.3 6.29 58.93 CD177 antigen OS=Homo 
sapiens GN=CD177 PE=1 SV=2 - 
[CD177_HUMAN] 
Q9Y5K6 2.19 1 1 639 71.4 6.40 111.79 CD2-associated protein 
OS=Homo sapiens GN=CD2AP 
PE=1 SV=1 - [CD2AP_HUMAN] 
P16070 2.96 3 2 742 81.5 5.33 122.18 CD44 antigen OS=Homo sapiens 
GN=CD44 PE=1 SV=2 - 
[CD44_HUMAN] 
P13987 25.00 5 4 128 14.2 6.48 232.29 CD59 glycoprotein OS=Homo 
sapiens GN=CD59 PE=1 SV=1 - 
[CD59_HUMAN] 
P08962 4.20 1 1 238 25.6 7.81 82.96 CD63 antigen OS=Homo sapiens 
GN=CD63 PE=1 SV=2 - 
[CD63_HUMAN] 
P21926 10.96 1 1 228 25.4 7.15 65.01 CD9 antigen OS=Homo sapiens 
GN=CD9 PE=1 SV=4 - 
[CD9_HUMAN] 
P11597 3.04 1 1 493 54.7 6.09 59.48 Cholesteryl ester transfer protein 
OS=Homo sapiens GN=CETP 
PE=1 SV=2 - [CETP_HUMAN] 
P10909 23.61 10 8 449 52.5 6.27 519.59 Clusterin OS=Homo sapiens 
GN=CLU PE=1 SV=1 - 
[CLUS_HUMAN] 
Q6UXG3 4.82 1 1 332 36.0 5.92 97.17 CMRF35-like molecule 9 
OS=Homo sapiens GN=CD300LG 
PE=1 SV=2 - [CLM9_HUMAN] 
P12109 7.20 6 5 1028 108.
5 
5.43 231.90 Collagen alpha-1(VI) chain 
OS=Homo sapiens GN=COL6A1 
PE=1 SV=3 - [CO6A1_HUMAN] 
P39059 0.94 1 1 1388 141.
6 
5.00 104.31 Collagen alpha-1(XV) chain 
OS=Homo sapiens GN=COL15A1 
PE=1 SV=2 - [COFA1_HUMAN] 
P12111 2.64 8 6 3177 343.
5 
6.68 426.02 Collagen alpha-3(VI) chain 
OS=Homo sapiens GN=COL6A3 
PE=1 SV=4 - [CO6A3_HUMAN] 
P01024 0.96 1 1 1663 187.
0 
6.40 94.26 Complement C3 OS=Homo 
sapiens GN=C3 PE=1 SV=2 - 
[CO3_HUMAN] 
P0C0L4 0.86 1 1 1744 192.
7 
7.08 94.14 Complement C4-A OS=Homo 
sapiens GN=C4A PE=1 SV=1 - 
[CO4A_HUMAN] 
P08174 2.10 1 1 381 41.4 7.59 93.84 Complement decay-accelerating 
factor OS=Homo sapiens 
GN=CD55 PE=1 SV=4 - 
[DAF_HUMAN] 
P05156 4.97 2 2 583 65.7 7.50 110.32 Complement factor I OS=Homo 
sapiens GN=CFI PE=1 SV=1 - 
[CFAI_HUMAN] 
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P08185 8.89 3 3 405 45.1 6.04 121.20 Corticosteroid-binding globulin 
OS=Homo sapiens 
GN=SERPINA6 PE=1 SV=1 - 
[CBG_HUMAN] 
O60494 11.40 26 26 3623 398.
4 
5.35 1386.85 Cubilin OS=Homo sapiens 
GN=CUBN PE=1 SV=4 - 
[CUBN_HUMAN] 
P01040 30.61 2 2 98 11.0 5.50 122.24 Cystatin-A OS=Homo sapiens 
GN=CSTA PE=1 SV=1 - 
[CYTA_HUMAN] 
P01034 7.53 1 1 146 15.8 8.75 85.99 Cystatin-C OS=Homo sapiens 
GN=CST3 PE=1 SV=1 - 
[CYTC_HUMAN] 
Q15828 50.34 5 5 149 16.5 8.09 217.97 Cystatin-M OS=Homo sapiens 
GN=CST6 PE=1 SV=1 - 
[CYTM_HUMAN] 
P24855 7.80 2 2 282 31.4 4.91 131.31 Deoxyribonuclease-1 OS=Homo 
sapiens GN=DNASE1 PE=1 SV=1 
- [DNAS1_HUMAN] 
P81605 12.73 1 1 110 11.3 6.54 89.46 Dermcidin OS=Homo sapiens 
GN=DCD PE=1 SV=2 - 
[DCD_HUMAN] 
P15924 1.32 4 3 2871 331.
6 
6.81 256.24 Desmoplakin OS=Homo sapiens 
GN=DSP PE=1 SV=3 - 
[DESP_HUMAN] 
P16444 43.07 16 13 411 45.6 6.15 791.26 Dipeptidase 1 OS=Homo sapiens 
GN=DPEP1 PE=1 SV=3 - 
[DPEP1_HUMAN] 
P53634 11.23 4 4 463 51.8 6.99 233.92 Dipeptidyl peptidase 1 OS=Homo 
sapiens GN=CTSC PE=1 SV=1 - 
[CATC_HUMAN] 
Q9UHL4 2.44 1 1 492 54.3 6.32 84.87 Dipeptidyl peptidase 2 OS=Homo 
sapiens GN=DPP7 PE=1 SV=3 - 
[DPP2_HUMAN] 
P27487 2.48 2 2 766 88.2 6.04 210.81 Dipeptidyl peptidase 4 OS=Homo 
sapiens GN=DPP4 PE=1 SV=2 - 
[DPP4_HUMAN] 
Q12805 28.60 12 10 493 54.6 5.07 548.10 EGF-containing fibulin-like 
extracellular matrix protein 1 
OS=Homo sapiens GN=EFEMP1 
PE=1 SV=2 - [FBLN3_HUMAN] 
Q9HCU0 1.85 1 1 757 80.8 5.35 127.02 Endosialin OS=Homo sapiens 
GN=CD248 PE=1 SV=1 - 
[CD248_HUMAN] 
Q9UNN8 12.61 2 2 238 26.7 7.18 124.53 Endothelial protein C receptor 
OS=Homo sapiens GN=PROCR 
PE=1 SV=1 - [EPCR_HUMAN] 
P61916 10.60 1 1 151 16.6 7.65 69.34 Epididymal secretory protein E1 
OS=Homo sapiens GN=NPC2 
PE=1 SV=1 - [NPC2_HUMAN] 
P02751 5.74 9 9 2386 262.
5 
5.71 491.06 Fibronectin OS=Homo sapiens 
GN=FN1 PE=1 SV=4 - 
[FINC_HUMAN] 
Q9UBX5 10.04 5 4 448 50.1 4.73 218.41 Fibulin-5 OS=Homo sapiens 
GN=FBLN5 PE=1 SV=1 - 
[FBLN5_HUMAN] 
Q5D862 0.46 1 1 2391 247.
9 
8.31 63.33 Filaggrin-2 OS=Homo sapiens 
GN=FLG2 PE=1 SV=1 - 
[FILA2_HUMAN] 
P15328 4.28 1 1 257 29.8 7.97 64.95 Folate receptor alpha OS=Homo 
sapiens GN=FOLR1 PE=1 SV=3 - 
[FOLR1_HUMAN] 
P09467 5.03 1 1 338 36.8 6.99 66.39 Fructose-1,6-bisphosphatase 1 
OS=Homo sapiens GN=FBP1 
PE=1 SV=4 - [F16P1_HUMAN] 
Q08380 28.38 16 11 585 65.3 5.27 947.38 Galectin-3-binding protein 
OS=Homo sapiens 
GN=LGALS3BP PE=1 SV=1 - 
[LG3BP_HUMAN] 
Q92820 8.18 2 2 318 35.9 7.11 134.49 Gamma-glutamyl hydrolase 
OS=Homo sapiens GN=GGH 
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PE=1 SV=2 - [GGH_HUMAN] 
P19440 12.83 6 5 569 61.4 7.12 342.53 Gamma-glutamyltranspeptidase 1 
OS=Homo sapiens GN=GGT1 
PE=1 SV=2 - [GGT1_HUMAN] 
P17900 15.54 2 2 193 20.8 5.31 97.81 Ganglioside GM2 activator 
OS=Homo sapiens GN=GM2A 
PE=1 SV=4 - [SAP3_HUMAN] 
P06396 7.67 4 4 782 85.6 6.28 269.39 Gelsolin OS=Homo sapiens 
GN=GSN PE=1 SV=1 - 
[GELS_HUMAN] 
Q16769 14.40 3 3 361 40.9 6.61 161.96 Glutaminyl-peptide 
cyclotransferase OS=Homo 
sapiens GN=QPCT PE=1 SV=1 - 
[QPCT_HUMAN] 
P09211 16.67 2 2 210 23.3 5.64 118.20 Glutathione S-transferase P 
OS=Homo sapiens GN=GSTP1 
PE=1 SV=2 - [GSTP1_HUMAN] 
P51654 2.59 2 1 580 65.5 6.37 191.49 Glypican-3 OS=Homo sapiens 
GN=GPC3 PE=1 SV=1 - 
[GPC3_HUMAN] 
Q8NBJ4 2.49 1 1 401 45.3 4.97 60.96 Golgi membrane protein 1 
OS=Homo sapiens GN=GOLM1 
PE=1 SV=1 - [GOLM1_HUMAN] 
P28799 2.53 2 1 593 63.5 6.83 143.36 Granulins OS=Homo sapiens 
GN=GRN PE=1 SV=2 - 
[GRN_HUMAN] 
Q8NHV1 2.00 1 1 300 34.5 6.46 67.91 GTPase IMAP family member 7 
OS=Homo sapiens GN=GIMAP7 
PE=2 SV=1 - [GIMA7_HUMAN] 
P00738 11.08 5 4 406 45.2 6.58 261.27 Haptoglobin OS=Homo sapiens 
GN=HP PE=1 SV=1 - 
[HPT_HUMAN] 
P11142 2.17 1 1 646 70.9 5.52 59.46 Heat shock cognate 71 kDa 
protein OS=Homo sapiens 
GN=HSPA8 PE=1 SV=1 - 
[HSP7C_HUMAN] 
Q96RW7 0.44 2 2 5635 613.
0 
6.49 116.06 Hemicentin-1 OS=Homo sapiens 
GN=HMCN1 PE=1 SV=2 - 
[HMCN1_HUMAN] 
P02790 14.72 5 4 462 51.6 7.02 239.97 Hemopexin OS=Homo sapiens 
GN=HPX PE=1 SV=2 - 
[HEMO_HUMAN] 
P37235 6.22 1 1 193 22.3 5.35 81.02 Hippocalcin-like protein 1 
OS=Homo sapiens GN=HPCAL1 
PE=1 SV=3 - [HPCL1_HUMAN] 
Q86YZ3 2.35 2 2 2850 282.
2 
10.0
4 
159.14 Hornerin OS=Homo sapiens 
GN=HRNR PE=1 SV=2 - 
[HORN_HUMAN] 
Q12794 19.08 4 4 435 48.3 6.77 175.75 Hyaluronidase-1 OS=Homo 
sapiens GN=HYAL1 PE=1 SV=2 - 
[HYAL1_HUMAN] 
O75144 8.61 2 2 302 33.3 5.31 123.06 ICOS ligand OS=Homo sapiens 
GN=ICOSLG PE=1 SV=2 - 
[ICOSL_HUMAN] 
P01876 9.07 3 3 353 37.6 6.51 218.37 Ig alpha-1 chain C region 
OS=Homo sapiens GN=IGHA1 
PE=1 SV=2 - [IGHA1_HUMAN] 
P01877 9.41 3 3 340 36.5 6.10 167.35 Ig alpha-2 chain C region 
OS=Homo sapiens GN=IGHA2 
PE=1 SV=3 - [IGHA2_HUMAN] 
P01857 14.85 3 3 330 36.1 8.19 157.85 Ig gamma-1 chain C region 
OS=Homo sapiens GN=IGHG1 
PE=1 SV=1 - [IGHG1_HUMAN] 
P01861 14.98 3 3 327 35.9 7.36 153.39 Ig gamma-4 chain C region 
OS=Homo sapiens GN=IGHG4 
PE=1 SV=1 - [IGHG4_HUMAN] 
P01777 15.97 1 1 119 12.8 8.50 94.72 Ig heavy chain V-III region TEI 
OS=Homo sapiens PE=1 SV=1 - 
[HV316_HUMAN] 
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P01765 16.52 1 1 115 12.3 9.13 80.98 Ig heavy chain V-III region TIL 
OS=Homo sapiens PE=1 SV=1 - 
[HV304_HUMAN] 
P01834 80.19 7 6 106 11.6 5.87 386.88 Ig kappa chain C region 
OS=Homo sapiens GN=IGKC 
PE=1 SV=1 - [IGKC_HUMAN] 
P01593 31.48 2 2 108 12.0 5.99 102.61 Ig kappa chain V-I region AG 
OS=Homo sapiens PE=1 SV=1 - 
[KV101_HUMAN] 
P01617 32.74 2 2 113 12.3 6.00 119.05 Ig kappa chain V-II region TEW 
OS=Homo sapiens PE=1 SV=1 - 
[KV204_HUMAN] 
P01620 39.45 3 3 109 11.8 8.48 151.14 Ig kappa chain V-III region SIE 
OS=Homo sapiens PE=1 SV=1 - 
[KV302_HUMAN] 
P04434 7.76 1 1 116 12.7 5.94 65.50 Ig kappa chain V-III region VH 
(Fragment) OS=Homo sapiens 
PE=4 SV=1 - [KV310_HUMAN] 
P01625 23.68 3 2 114 12.6 7.93 124.44 Ig kappa chain V-IV region Len 
OS=Homo sapiens PE=1 SV=2 - 
[KV402_HUMAN] 
P0CG05 47.17 4 3 106 11.3 7.24 190.30 Ig lambda-2 chain C regions 
OS=Homo sapiens GN=IGLC2 
PE=1 SV=1 - [LAC2_HUMAN] 
P01591 7.55 1 1 159 18.1 5.24 120.62 Immunoglobulin J chain 
OS=Homo sapiens GN=IGJ PE=1 
SV=4 - [IGJ_HUMAN] 
P18065 3.69 1 1 325 34.8 7.50 63.26 Insulin-like growth factor-binding 
protein 2 OS=Homo sapiens 
GN=IGFBP2 PE=1 SV=2 - 
[IBP2_HUMAN] 
Q16270 17.02 3 3 282 29.1 7.90 167.76 Insulin-like growth factor-binding 
protein 7 OS=Homo sapiens 
GN=IGFBP7 PE=1 SV=1 - 
[IBP7_HUMAN] 
Q14624 6.88 5 4 930 103.
3 
6.98 253.53 Inter-alpha-trypsin inhibitor 
heavy chain H4 OS=Homo 
sapiens GN=ITIH4 PE=1 SV=4 - 
[ITIH4_HUMAN] 
P53990 2.20 1 1 364 39.7 5.35 80.70 IST1 homolog OS=Homo sapiens 
GN=KIAA0174 PE=1 SV=1 - 
[IST1_HUMAN] 
P06870 16.03 3 3 262 28.9 4.83 182.31 Kallikrein-1 OS=Homo sapiens 
GN=KLK1 PE=1 SV=2 - 
[KLK1_HUMAN] 
P13645 50.86 38 23 584 58.8 5.21 1956.71 Keratin, type I cytoskeletal 10 
OS=Homo sapiens GN=KRT10 
PE=1 SV=6 - [K1C10_HUMAN] 
P13646 5.02 2 2 458 49.6 4.96 158.12 Keratin, type I cytoskeletal 13 
OS=Homo sapiens GN=KRT13 
PE=1 SV=4 - [K1C13_HUMAN] 
P02533 33.69 13 12 472 51.5 5.16 680.04 Keratin, type I cytoskeletal 14 
OS=Homo sapiens GN=KRT14 
PE=1 SV=4 - [K1C14_HUMAN] 
P08779 38.27 17 16 473 51.2 5.05 769.78 Keratin, type I cytoskeletal 16 
OS=Homo sapiens GN=KRT16 
PE=1 SV=4 - [K1C16_HUMAN] 
Q04695 16.44 6 6 432 48.1 5.02 364.57 Keratin, type I cytoskeletal 17 
OS=Homo sapiens GN=KRT17 
PE=1 SV=2 - [K1C17_HUMAN] 
P35527 54.90 27 21 623 62.0 5.24 1631.29 Keratin, type I cytoskeletal 9 
OS=Homo sapiens GN=KRT9 
PE=1 SV=3 - [K1C9_HUMAN] 
P04264 46.27 39 26 644 66.0 8.12 1899.51 Keratin, type II cytoskeletal 1 
OS=Homo sapiens GN=KRT1 
PE=1 SV=6 - [K2C1_HUMAN] 
P35908 46.48 26 24 639 65.4 8.00 1556.88 Keratin, type II cytoskeletal 2 
epidermal OS=Homo sapiens 
GN=KRT2 PE=1 SV=2 - 
[K22E_HUMAN] 
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P12035 6.20 5 4 629 64.5 6.48 282.40 Keratin, type II cytoskeletal 3 
OS=Homo sapiens GN=KRT3 
PE=1 SV=2 - [K2C3_HUMAN] 
P19013 3.75 3 2 534 57.2 6.61 132.19 Keratin, type II cytoskeletal 4 
OS=Homo sapiens GN=KRT4 
PE=1 SV=4 - [K2C4_HUMAN] 
P13647 29.15 18 17 590 62.3 7.74 794.02 Keratin, type II cytoskeletal 5 
OS=Homo sapiens GN=KRT5 
PE=1 SV=3 - [K2C5_HUMAN] 
P02538 30.67 19 18 564 60.0 8.00 850.05 Keratin, type II cytoskeletal 6A 
OS=Homo sapiens GN=KRT6A 
PE=1 SV=3 - [K2C6A_HUMAN] 
P04259 27.84 19 17 564 60.0 8.00 844.08 Keratin, type II cytoskeletal 6B 
OS=Homo sapiens GN=KRT6B 
PE=1 SV=5 - [K2C6B_HUMAN] 
P48668 30.67 19 18 564 60.0 8.00 843.15 Keratin, type II cytoskeletal 6C 
OS=Homo sapiens GN=KRT6C 
PE=1 SV=3 - [K2C6C_HUMAN] 
Q8N1N4 3.85 2 2 520 56.8 6.02 100.64 Keratin, type II cytoskeletal 78 
OS=Homo sapiens GN=KRT78 
PE=1 SV=2 - [K2C78_HUMAN] 
P01042 18.32 12 10 644 71.9 6.81 670.29 Kininogen-1 OS=Homo sapiens 
GN=KNG1 PE=1 SV=2 - 
[KNG1_HUMAN] 
Q9H756 3.51 1 1 370 42.3 5.12 66.66 Leucine-rich repeat-containing 
protein 19 OS=Homo sapiens 
GN=LRRC19 PE=2 SV=1 - 
[LRC19_HUMAN] 
Q6GTX8 4.53 1 1 287 31.4 5.63 97.51 Leukocyte-associated 
immunoglobulin-like receptor 1 
OS=Homo sapiens GN=LAIR1 
PE=1 SV=1 - [LAIR1_HUMAN] 
P05451 6.02 1 1 166 18.7 5.94 64.64 Lithostathine-1-alpha OS=Homo 
sapiens GN=REG1A PE=1 SV=3 - 
[REG1A_HUMAN] 
P00338 4.52 1 1 332 36.7 8.27 106.81 L-lactate dehydrogenase A chain 
OS=Homo sapiens GN=LDHA 
PE=1 SV=2 - [LDHA_HUMAN] 
P07195 3.29 2 1 334 36.6 6.05 136.07 L-lactate dehydrogenase B chain 
OS=Homo sapiens GN=LDHB 
PE=1 SV=2 - [LDHB_HUMAN] 
P98164 6.51 25 23 4655 521.
6 
5.08 1213.09 Low-density lipoprotein receptor-
related protein 2 OS=Homo 
sapiens GN=LRP2 PE=1 SV=3 - 
[LRP2_HUMAN] 
P11117 11.11 4 4 423 48.3 6.74 230.34 Lysosomal acid phosphatase 
OS=Homo sapiens GN=ACP2 
PE=1 SV=3 - [PPAL_HUMAN] 
P10253 18.49 17 12 952 105.
3 
5.99 788.99 Lysosomal alpha-glucosidase 
OS=Homo sapiens GN=GAA 
PE=1 SV=3 - [LYAG_HUMAN] 
P10619 5.63 2 2 480 54.4 6.61 234.31 Lysosomal protective protein 
OS=Homo sapiens GN=CTSA 
PE=1 SV=2 - [PPGB_HUMAN] 
P42785 7.06 3 3 496 55.8 7.21 117.18 Lysosomal Pro-X 
carboxypeptidase OS=Homo 
sapiens GN=PRCP PE=1 SV=1 - 
[PCP_HUMAN] 
P11279 3.84 1 1 417 44.9 8.75 100.31 Lysosome-associated membrane 
glycoprotein 1 OS=Homo sapiens 
GN=LAMP1 PE=1 SV=3 - 
[LAMP1_HUMAN] 
P13473 9.27 3 3 410 44.9 5.63 166.00 Lysosome-associated membrane 
glycoprotein 2 OS=Homo sapiens 
GN=LAMP2 PE=1 SV=2 - 
[LAMP2_HUMAN] 
P09603 5.78 2 2 554 60.1 5.29 112.68 Macrophage colony-stimulating 
factor 1 OS=Homo sapiens 
GN=CSF1 PE=1 SV=1 - 
[CSF1_HUMAN] 
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P40925 7.78 2 2 334 36.4 7.36 126.16 Malate dehydrogenase, 
cytoplasmic OS=Homo sapiens 
GN=MDH1 PE=1 SV=4 - 
[MDHC_HUMAN] 
O43451 6.41 7 7 1857 209.
7 
5.50 596.95 Maltase-glucoamylase, intestinal 
OS=Homo sapiens GN=MGAM 
PE=1 SV=5 - [MGA_HUMAN] 
O00187 5.39 3 3 686 75.7 5.77 131.45 Mannan-binding lectin serine 
protease 2 OS=Homo sapiens 
GN=MASP2 PE=1 SV=3 - 
[MASP2_HUMAN] 
P33908 1.84 1 1 653 72.9 6.47 58.32 Mannosyl-oligosaccharide 1,2-
alpha-mannosidase IA OS=Homo 
sapiens GN=MAN1A1 PE=1 SV=3 
- [MA1A1_HUMAN] 
P26038 1.56 1 1 577 67.8 6.40 61.39 Moesin OS=Homo sapiens 
GN=MSN PE=1 SV=3 - 
[MOES_HUMAN] 
P15941 3.11 3 3 1255 122.
0 
7.47 129.17 Mucin-1 OS=Homo sapiens 
GN=MUC1 PE=1 SV=3 - 
[MUC1_HUMAN] 
Q9H8L6 5.27 5 3 949 104.
3 
5.86 293.31 Multimerin-2 OS=Homo sapiens 
GN=MMRN2 PE=1 SV=2 - 
[MMRN2_HUMAN] 
Q9UNW1 8.83 3 3 487 55.0 7.81 157.16 Multiple inositol polyphosphate 
phosphatase 1 OS=Homo sapiens 
GN=MINPP1 PE=1 SV=1 - 
[MINP1_HUMAN] 
P34059 7.66 2 2 522 58.0 6.74 109.55 N-acetylgalactosamine-6-
sulfatase OS=Homo sapiens 
GN=GALNS PE=1 SV=1 - 
[GALNS_HUMAN] 
P15586 3.26 2 2 552 62.0 8.31 112.45 N-acetylglucosamine-6-sulfatase 
OS=Homo sapiens GN=GNS 
PE=1 SV=3 - [GNS_HUMAN] 
O96009 13.33 5 4 420 45.4 6.61 246.37 Napsin-A OS=Homo sapiens 
GN=NAPSA PE=1 SV=1 - 
[NAPSA_HUMAN] 
P08473 15.73 8 8 750 85.5 5.73 503.40 Neprilysin OS=Homo sapiens 
GN=MME PE=1 SV=2 - 
[NEP_HUMAN] 
Q99574 2.44 1 1 410 46.4 4.91 79.31 Neuroserpin OS=Homo sapiens 
GN=SERPINI1 PE=1 SV=1 - 
[NEUS_HUMAN] 
P59665 9.57 1 1 94 10.2 6.99 98.17 Neutrophil defensin 1 OS=Homo 
sapiens GN=DEFA1 PE=1 SV=1 - 
[DEF1_HUMAN] 
P10153 10.56 2 1 161 18.3 8.73 167.89 Non-secretory ribonuclease 
OS=Homo sapiens GN=RNASE2 
PE=1 SV=2 - [RNAS2_HUMAN] 
P61970 29.13 2 2 127 14.5 5.38 112.01 Nuclear transport factor 2 
OS=Homo sapiens GN=NUTF2 
PE=1 SV=1 - [NTF2_HUMAN] 
P50897 9.15 2 2 306 34.2 6.52 102.00 Palmitoyl-protein thioesterase 1 
OS=Homo sapiens GN=PPT1 
PE=1 SV=1 - [PPT1_HUMAN] 
P04746 10.37 4 4 511 57.7 7.05 330.28 Pancreatic alpha-amylase 
OS=Homo sapiens GN=AMY2A 
PE=1 SV=2 - [AMYP_HUMAN] 
O95497 10.33 4 4 513 57.0 5.55 197.26 Pantetheinase OS=Homo sapiens 
GN=VNN1 PE=1 SV=2 - 
[VNN1_HUMAN] 
Q9UBV8 3.87 1 1 284 30.4 6.54 115.32 Peflin OS=Homo sapiens 
GN=PEF1 PE=1 SV=1 - 
[PEF1_HUMAN] 
O75594 39.29 6 4 196 21.7 8.59 338.88 Peptidoglycan recognition protein 
1 OS=Homo sapiens 
GN=PGLYRP1 PE=1 SV=1 - 
[PGRP1_HUMAN] 
P30041 11.61 2 2 224 25.0 6.38 99.97 Peroxiredoxin-6 OS=Homo 
sapiens GN=PRDX6 PE=1 SV=3 - 
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[PRDX6_HUMAN] 
P04180 3.18 1 1 440 49.5 6.11 80.92 Phosphatidylcholine-sterol 
acyltransferase OS=Homo 
sapiens GN=LCAT PE=1 SV=1 - 
[LCAT_HUMAN] 
P30086 18.18 2 2 187 21.0 7.53 143.21 Phosphatidylethanolamine-
binding protein 1 OS=Homo 
sapiens GN=PEBP1 PE=1 SV=3 - 
[PEBP1_HUMAN] 
Q96FE7 5.70 1 1 263 28.2 5.01 96.38 Phosphoinositide-3-kinase-
interacting protein 1 OS=Homo 
sapiens GN=PIK3IP1 PE=1 SV=2 
- [P3IP1_HUMAN] 
P05155 15.40 10 6 500 55.1 6.55 434.63 Plasma protease C1 inhibitor 
OS=Homo sapiens 
GN=SERPING1 PE=1 SV=2 - 
[IC1_HUMAN] 
P05154 19.21 9 7 406 45.7 9.26 440.96 Plasma serine protease inhibitor 
OS=Homo sapiens 
GN=SERPINA5 PE=1 SV=2 - 
[IPSP_HUMAN] 
P13796 3.83 2 2 627 70.2 5.33 91.37 Plastin-2 OS=Homo sapiens 
GN=LCP1 PE=1 SV=5 - 
[PLSL_HUMAN] 
P01833 29.45 16 15 764 83.2 5.74 881.01 Polymeric immunoglobulin 
receptor OS=Homo sapiens 
GN=PIGR PE=1 SV=4 - 
[PIGR_HUMAN] 
P0CG48 21.02 1 1 685 77.0 7.66 124.57 Polyubiquitin-C OS=Homo 
sapiens GN=UBC PE=1 SV=1 - 
[UBC_HUMAN] 
P07602 11.64 8 5 524 58.1 5.17 331.77 Proactivator polypeptide 
OS=Homo sapiens GN=PSAP 
PE=1 SV=2 - [SAP_HUMAN] 
Q9H3G5 2.52 1 1 476 54.1 5.62 71.60 Probable serine carboxypeptidase 
CPVL OS=Homo sapiens 
GN=CPVL PE=1 SV=2 - 
[CPVL_HUMAN] 
P01133 20.30 19 17 1207 133.
9 
5.85 1093.64 Pro-epidermal growth factor 
OS=Homo sapiens GN=EGF 
PE=1 SV=2 - [EGF_HUMAN] 
Q8WUM4 3.23 2 2 868 96.0 6.52 136.52 Programmed cell death 6-
interacting protein OS=Homo 
sapiens GN=PDCD6IP PE=1 
SV=1 - [PDC6I_HUMAN] 
O75340 26.18 3 3 191 21.9 5.40 147.99 Programmed cell death protein 6 
OS=Homo sapiens GN=PDCD6 
PE=1 SV=1 - [PDCD6_HUMAN] 
P12273 22.60 4 3 146 16.6 8.05 252.60 Prolactin-inducible protein 
OS=Homo sapiens GN=PIP PE=1 
SV=1 - [PIP_HUMAN] 
P41222 24.74 7 4 190 21.0 7.80 348.74 Prostaglandin-H2 D-isomerase 
OS=Homo sapiens GN=PTGDS 
PE=1 SV=1 - [PTGDS_HUMAN] 
Q16651 11.66 3 3 343 36.4 5.85 103.73 Prostasin OS=Homo sapiens 
GN=PRSS8 PE=1 SV=1 - 
[PRSS8_HUMAN] 
O43653 21.95 2 2 123 12.9 5.29 154.17 Prostate stem cell antigen 
OS=Homo sapiens GN=PSCA 
PE=1 SV=1 - [PSCA_HUMAN] 
P15309 20.47 6 6 386 44.5 6.24 299.53 Prostatic acid phosphatase 
OS=Homo sapiens GN=ACPP 
PE=1 SV=3 - [PPAP_HUMAN] 
Q06323 4.82 1 1 249 28.7 6.02 72.70 Proteasome activator complex 
subunit 1 OS=Homo sapiens 
GN=PSME1 PE=1 SV=1 - 
[PSME1_HUMAN] 
P02760 43.18 22 12 352 39.0 6.25 1147.02 Protein AMBP OS=Homo sapiens 
GN=AMBP PE=1 SV=1 - 
[AMBP_HUMAN] 
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P80370 2.09 1 1 383 41.3 5.67 63.89 Protein delta homolog 1 
OS=Homo sapiens GN=DLK1 
PE=1 SV=3 - [DLK1_HUMAN] 
P31949 15.24 1 1 105 11.7 7.12 90.24 Protein S100-A11 OS=Homo 
sapiens GN=S100A11 PE=1 
SV=2 - [S10AB_HUMAN] 
Q96FQ6 10.68 1 1 103 11.8 6.79 66.20 Protein S100-A16 OS=Homo 
sapiens GN=S100A16 PE=1 
SV=1 - [S10AG_HUMAN] 
P06703 8.89 1 1 90 10.2 5.48 84.12 Protein S100-A6 OS=Homo 
sapiens GN=S100A6 PE=1 SV=1 
- [S10A6_HUMAN] 
P31151 10.89 1 1 101 11.5 6.77 60.94 Protein S100-A7 OS=Homo 
sapiens GN=S100A7 PE=1 SV=4 
- [S10A7_HUMAN] 
P05109 11.83 1 1 93 10.8 7.03 91.60 Protein S100-A8 OS=Homo 
sapiens GN=S100A8 PE=1 SV=1 
- [S10A8_HUMAN] 
P06702 56.14 6 5 114 13.2 6.13 270.52 Protein S100-A9 OS=Homo 
sapiens GN=S100A9 PE=1 SV=1 
- [S10A9_HUMAN] 
P25815 13.68 1 1 95 10.4 4.88 74.10 Protein S100-P OS=Homo 
sapiens GN=S100P PE=1 SV=2 - 
[S100P_HUMAN] 
P00734 11.09 7 5 622 70.0 5.90 343.90 Prothrombin OS=Homo sapiens 
GN=F2 PE=1 SV=2 - 
[THRB_HUMAN] 
Q12913 0.90 1 1 1337 145.
9 
5.58 59.90 Receptor-type tyrosine-protein 
phosphatase eta OS=Homo 
sapiens GN=PTPRJ PE=1 SV=3 - 
[PTPRJ_HUMAN] 
Q13332 1.23 2 2 1948 217.
0 
6.51 73.14 Receptor-type tyrosine-protein 
phosphatase S OS=Homo sapiens 
GN=PTPRS PE=1 SV=2 - 
[PTPRS_HUMAN] 
O75787 2.57 1 1 350 39.0 6.10 84.90 Renin receptor OS=Homo sapiens 
GN=ATP6AP2 PE=1 SV=2 - 
[RENR_HUMAN] 
Q9HD89 24.07 2 2 108 11.4 6.86 108.16 Resistin OS=Homo sapiens 
GN=RETN PE=2 SV=1 - 
[RETN_HUMAN] 
Q9HB40 7.96 4 3 452 50.8 5.81 226.38 Retinoid-inducible serine 
carboxypeptidase OS=Homo 
sapiens GN=SCPEP1 PE=1 SV=1 
- [RISC_HUMAN] 
P02753 11.44 1 1 201 23.0 6.07 68.77 Retinol-binding protein 4 
OS=Homo sapiens GN=RBP4 
PE=1 SV=3 - [RET4_HUMAN] 
P07998 43.59 3 3 156 17.6 8.79 145.18 Ribonuclease pancreatic 
OS=Homo sapiens GN=RNASE1 
PE=1 SV=4 - [RNAS1_HUMAN] 
Q8WVN6 14.52 3 2 248 27.0 7.43 206.16 Secreted and transmembrane 
protein 1 OS=Homo sapiens 
GN=SECTM1 PE=1 SV=2 - 
[SCTM1_HUMAN] 
P55000 24.27 1 1 103 11.2 5.33 83.12 Secreted Ly-6/uPAR-related 
protein 1 OS=Homo sapiens 
GN=SLURP1 PE=1 SV=2 - 
[SLUR1_HUMAN] 
Q86SR0 45.36 2 2 97 10.2 6.62 121.44 Secreted Ly-6/uPAR-related 
protein 2 OS=Homo sapiens 
GN=SLURP2 PE=2 SV=1 - 
[SLUR2_HUMAN] 
P04279 7.36 2 2 462 52.1 9.29 99.57 Semenogelin-1 OS=Homo 
sapiens GN=SEMG1 PE=1 SV=2 - 
[SEMG1_HUMAN] 
P02787 5.73 3 3 698 77.0 7.12 206.86 Serotransferrin OS=Homo 
sapiens GN=TF PE=1 SV=2 - 
[TRFE_HUMAN] 
P02768 62.40 53 33 609 69.3 6.28 2536.79 Serum albumin OS=Homo 
sapiens GN=ALB PE=1 SV=2 - 
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[ALBU_HUMAN] 
Q9HAT2 5.16 2 2 523 58.3 7.33 116.86 Sialate O-acetylesterase 
OS=Homo sapiens GN=SIAE 
PE=1 SV=1 - [SIAE_HUMAN] 
Q99519 3.37 1 1 415 45.4 5.88 72.82 Sialidase-1 OS=Homo sapiens 
GN=NEU1 PE=1 SV=1 - 
[NEUR1_HUMAN] 
P30626 9.09 2 2 198 21.7 5.59 104.80 Sorcin OS=Homo sapiens 
GN=SRI PE=1 SV=1 - 
[SORCN_HUMAN] 
Q9UGT4 8.39 3 3 822 90.1 6.28 140.38 Sushi domain-containing protein 
2 OS=Homo sapiens GN=SUSD2 
PE=1 SV=1 - [SUSD2_HUMAN] 
O60635 5.39 1 1 241 26.3 5.25 70.21 Tetraspanin-1 OS=Homo sapiens 
GN=TSPAN1 PE=1 SV=2 - 
[TSN1_HUMAN] 
P10599 20.95 2 2 105 11.7 4.92 124.20 Thioredoxin OS=Homo sapiens 
GN=TXN PE=1 SV=3 - 
[THIO_HUMAN] 
P07204 3.48 1 1 575 60.3 4.92 77.65 Thrombomodulin OS=Homo 
sapiens GN=THBD PE=1 SV=2 - 
[TRBM_HUMAN] 
P04216 18.01 2 2 161 17.9 8.73 136.44 Thy-1 membrane glycoprotein 
OS=Homo sapiens GN=THY1 
PE=1 SV=2 - [THY1_HUMAN] 
P05543 6.02 2 2 415 46.3 6.30 113.65 Thyroxine-binding globulin 
OS=Homo sapiens 
GN=SERPINA7 PE=1 SV=2 - 
[THBG_HUMAN] 
P20062 3.75 1 1 427 47.5 7.01 89.75 Transcobalamin-2 OS=Homo 
sapiens GN=TCN2 PE=1 SV=3 - 
[TCO2_HUMAN] 
P02766 47.62 4 4 147 15.9 5.76 178.78 Transthyretin OS=Homo sapiens 
GN=TTR PE=1 SV=1 - 
[TTHY_HUMAN] 
O14773 10.48 3 3 563 61.2 6.48 136.25 Tripeptidyl-peptidase 1 
OS=Homo sapiens GN=TPP1 
PE=1 SV=2 - [TPP1_HUMAN] 
Q969Z4 2.56 2 2 430 46.1 8.35 127.20 Tumor necrosis factor receptor 
superfamily member 19L 
OS=Homo sapiens GN=RELT 
PE=1 SV=1 - [TR19L_HUMAN] 
P30530 3.36 2 2 894 98.3 5.43 112.99 Tyrosine-protein kinase receptor 
UFO OS=Homo sapiens GN=AXL 
PE=1 SV=3 - [UFO_HUMAN] 
Q6UX73 11.69 3 3 402 45.4 6.19 113.58 UPF0764 protein C16orf89 
OS=Homo sapiens GN=C16orf89 
PE=2 SV=2 - [CP089_HUMAN] 
P07911 30.16 27 14 640 69.7 5.24 1573.47 Uromodulin OS=Homo sapiens 
GN=UMOD PE=1 SV=1 - 
[UROM_HUMAN] 
P11684 12.09 2 2 91 10.0 5.06 100.09 Uteroglobin OS=Homo sapiens 
GN=SCGB1A1 PE=1 SV=1 - 
[UTER_HUMAN] 
Q9NP79 6.51 1 1 307 33.9 6.29 78.64 Vacuolar protein sorting-
associated protein VTA1 homolog 
OS=Homo sapiens GN=VTA1 
PE=1 SV=1 - [VTA1_HUMAN] 
Q6EMK4 7.88 5 4 673 71.7 7.39 299.15 Vasorin OS=Homo sapiens 
GN=VASN PE=1 SV=1 - 
[VASN_HUMAN] 
Q12907 5.90 2 2 356 40.2 6.95 102.94 Vesicular integral-membrane 
protein VIP36 OS=Homo sapiens 
GN=LMAN2 PE=1 SV=1 - 
[LMAN2_HUMAN] 
P22891 11.25 3 3 400 44.7 5.97 233.11 Vitamin K-dependent protein Z 
OS=Homo sapiens GN=PROZ 
PE=1 SV=2 - [PROZ_HUMAN] 
Q7Z5L0 32.67 4 4 202 21.5 5.07 231.32 Vitelline membrane outer layer 
protein 1 homolog OS=Homo 
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sapiens GN=VMO1 PE=1 SV=1 - 
[VMO1_HUMAN] 
P04004 10.88 4 4 478 54.3 5.80 192.37 Vitronectin OS=Homo sapiens 
GN=VTN PE=1 SV=1 - 
[VTNC_HUMAN] 
Q14508 38.71 4 3 124 13.0 4.84 239.68 WAP four-disulfide core domain 
protein 2 OS=Homo sapiens 
GN=WFDC2 PE=1 SV=2 - 
[WFDC2_HUMAN] 
O43895 19.58 9 9 674 75.6 6.04 592.18 Xaa-Pro aminopeptidase 2 
OS=Homo sapiens GN=XPNPEP2 
PE=1 SV=3 - [XPP2_HUMAN] 
P25311 19.13 5 5 298 34.2 6.05 225.11 Zinc-alpha-2-glycoprotein 
OS=Homo sapiens GN=AZGP1 
PE=1 SV=2 - [ZA2G_HUMAN] 
Q96DA0 25.96 4 4 208 22.7 7.39 271.33 Zymogen granule protein 16 
homolog B OS=Homo sapiens 
GN=ZG16B PE=1 SV=3 - 
[ZG16B_HUMAN] 
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Chapter 3 
Proteomic analysis of urinary 
membrane vesicles isolated by a 
modified differential 
centrifugation method 
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3.1 Introduction 
Building on the previous chapter, it was considered that after defining a method for 
enrichment of urinary membrane vesicles and removal of soluble protein contaminants, the 
obvious next step is the proteomic characterization of the vesicles enriched. Exosomes and 
other types of vesicles present in urine are an important source of potentially valuable 
biomarkers and a thorough knowledge of their proteome is an absolute requirement. There 
was one previous study with large-scale proteomic profiling of the exosomes/membrane 
vesicles isolated from urine using the differential centrifugation method and removal of 
soluble contaminants like THP using DTT treatment followed by a second centrifugation 
(Gonzales et al., 2009). Based on this approach Gonzalez et al., (2009) were able to identify 
1,132 proteins altogether unambiguously, including 14 phosphoproteins. Another very recent 
study published has expanded the proteome coverage of urinary exosomes/membrane 
vesicles with up to 3,280 proteins identified (Wang et al., 2011). This study compared two 
methods of protein digestion one being trifluoroethanol solution phase digestion and the other 
being ‘in-gel’ digestion. It was concluded that both the digestion protocols were not 
susbtantially different from each other in terms of proteins identified. Furthermore, a new 
generation of high efficiency ion-trap instrumentation (LTQ velos, Thermo Fisher Scientific, 
USA) was compared to the older LTQ. It was found that Velos performed better than LTQ in 
increasing proteome coverage. With our method which is efficient in removing high 
contaminant proteins from the exosomes/membrane vesicles, it is hoped that more low 
abundance proteins are identified increasing the proteome coverage of these vesicles from 
urine. However, we did not take a multidimensional separation approach for resolving 
peptides. This would mean a lesser number of identifications compared to some of the other 
studies. However, here, we want to develop an approach which can be applied to a large 
number of samples such as encountered in a clinical setting. A multi-dimensional approach 
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applied to a large number of samples would not work. Our approach has a significantly 
reduced number of steps and it can be expanded in future to include quantitative analysis of 
the membrane vesicular proteome. Here we report the proteomic characterisation of the high-
speed pellet (exosomal fraction, P200,000g) and low speed pellet (urine sediment and 
possibly large size membrane vesicles, P18,000g) prepared using an enrichment protocol 
established in our lab, as discussed in the previous chapter. The high speed pellet proteomic 
identifications are compared to most of the studies reported in the literature and low speed 
pellet identification (due to the lack of proteomic studies on large membrane vesicles which 
pellet down at low speed) is compared between the two methods of enrichment (DTT and 
CHAPS treatment of P18,000g). 
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3.2 Material and methods 
3.2.1 Isolation of CHAPS detergent resistant nano vesicles 
A schematic representation of the methodology used to isolate vesicles is shown in Figure 
3.1. The detailed method used for isolation of membrane vesicles is reported in methods 
section of Chapter 2 (Section 2.2.2). 
 
Figure 3.1: Workflow for isolation of nano vesicles. The samples highlighted in blue were 
high speed pellets (P200,000g) selected for proteomic analysis using mass spectrometry and 
samples highlighted in orange were low speed pellet (P18,000g) selected for proteomic 
analysis. a: Dialysis and concentration, b: DTT/CHAPS treatment, x: DTT/CHAPS. 
3.2.2 LC_MS/MS analysis and Data Analysis 
This was performed as described in methods section of Chapter 2 (Sections 2.2.5 and 2.2.6). 
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3.2.3 Bioinformatic analysis 
Bioinformatic analysis was performed using IPA software (Ingenuity systems, Mountain 
View, CA). Guest trial access to IPA was obtained. All the Tables were made manually and 
gene ontology figures were created in the MS Excel program. David bioinformatic resources 
6.7 (Huang, Sherman & Lempicki, 2009a; Huang, Sherman & Lempicki, 2009b) and 
Blast2Go software (Conesa et al., 2005) were also used for bioinformatic analysis as 
indicated in sections of this chapter (section 3.3.1 and sub-sections therein). 
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3.3 Results  
The workflow used for enrichment of exosomes/microveicles is shown in Figure 3.1 and the 
fractions selected for proteomic analysis using Orbitrap LTQ are highlighted. There are 
mainly two types of vesicles enriched one being in high-speed pellet (Blue in Figure 3.1) and 
other in low speed pellet (Orange in Figure 3.1). High speed pellet contains smaller vesicles 
(exosomes/ectosomes) and low speed pellet most likely consist of bigger sized vesicles 
(membrane vesicles). Although some small vesicles may be trapped in THP polymers and 
pellet down at low speed but, as discussed in the previous chapter, CHAPS or DTT treatment 
helps reduce this problem of interference.  
3.3.1 Large-scale proteomic analysis of the high speed pellet 
We were able to identify 437 proteins unambiguously in the high speed pellet. The proteins 
identified are listed in Supplementary Table S3.1.  
3.3.1.1 Comparison with other exosome/microvesicle and urine proteomics studies 
There have been a few proteomic studies characterising urinary exosomes (Gonzales et al., 
2009) (Wang et al., 2011) and exosome like vesicles (Hogan et al., 2009) for their protein 
content. We compare, here, proteomic identifications of our analysis with that of these studies 
as well as with the largest proteomic study on whole urine (Marimuthu et al., 2011). This 
comparison validates the identification of proteins in our analysis. We also compare our 
identifications with the the largest database of human exosomal proteins purified from any 
source (Exocarta) (Mathivanan et al., 2012).  
Figure 3.2 compares our proteomic identifications (P200,000g) with Pistikun et al., (Pisitkun, 
Shen & Knepper, 2004) and Gonzalez et al., (Gonzales et al., 2009) (both studies have been 
combined here non-redundantly and given the name Knepper), Hogan et al., (Hogan et al., 
2009), and Marimuthu et al., (Marimuthu et al., 2011) The first two studies (combined as 
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Knepper) are on urinary exosomes isolated using the differential centrifugation protocol. The 
second study (Hogan) is on urinary ‘exosome-like’ vesicles which were fractionated further 
by a sucrose density gradient using differential centrifugation-derived exosomal pellets as the 
starting material and segregated based on the prevalence of three biomakers among the 
fractions (aquaporin-2, polycystin-1, and podocin). The last one (Marimuthu) is a large-scale 
proteomic study on whole urine. 
 
Figure 3.2: Comparison of various urinary exosomes (Knepper) (Gonzales et al., 2009; 
Pisitkun, Shen & Knepper, 2004) and ‘exosome-like’ vesicles (Hogan) (Hogan et al., 2009) 
and whole urine (Marimuthu) (Marimuthu et al., 2011) with our protein list. To enable 
comparison the various identifiers reported in the studies (Entrez Id, uniprot accessions, gene 
name, Uniprot Id) were converted to unigene identifiers using a batch retrieval service of 
Uniprot (http://www.uniprot.org/). 
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Hundred and sixty one proteins are common to all four studies while different numbers come 
up when comparing the two studies, as can be seen in Figure 3.2,. Hogan and Knepper are 
studies of urinary exosomes and ‘exosome-like’ vesicles and, when compared with our study, 
135 proteins (~30%) in our study are new. Out of these 135, 103 have been identified in urine 
previously (Marimuthu) while 32 are reported here for the first time in urine. 
Very recently another study has been published on urinary exosomes which has identified 
3,280 proteins confidently (Wang et al., 2011). Comparison of our protein list to this study is 
shown in Figure 3.3. 
 
Figure 3.3: Venn diagram comparing our protein list to Wang et al., (Wang et al., 2011), 
which is the largest study on urinary exosomes to date.  
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The protein list in our study and Wang et al., (Wang et al., 2011) was directly compared as 
both had Uniprot accession as identifiers so no conversion to other gene identifiers was 
needed. 83 proteins (19%) were unique to our study. 
When our protein list was compared to Exocarta (Mathivanan et al., 2012), which is the 
largest database for exosomal proteins from any cell type or body fluid, 86 proteins (~20%) 
were found to be unique to our study.  
 
Figure 3.4: Comparison between our protein list and that of Exocarta (Mathivanan et al., 
2012). Our protein list was converted to Entrez Id identifiers to enable comparison to 
Exocarta protein list (Exocarta provides Entrez Ids as identifiers of proteins). 
The proteins which are novel in term of urinary membrane vesicles association are shown in 
Table 3.1. 
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Table 3.1: Presents the proteins which have not previously been shown to be part of any type 
of urinary membrane vesicles, including exosomes. 
Gene Name UniGene SwissProt (name) SwissProt 
(acc) 
TUBB4 Hs.110837  TBB4_HUMAN 
RIB2_HUMAN  
P04350 
P04844  
APOB Hs.120759  AGTR2_HUMAN  P50052  
KRT17 Hs.2785      
THOC7 Hs.288151      
LDHAL6B Hs.307052  LDH6B_HUMAN  Q9BYZ2  
DEFB1 Hs.32949  BD01_HUMAN  P60022  
FCN3 Hs.333383  P4HA2_HUMAN 
FCN3_HUMAN  
O15460 
O75636  
SERPINB12 Hs.348541  SPB12_HUMAN  Q96P63  
CFH Hs.363396  CFAH_HUMAN  P08603  
C8B Hs.391835  CO8B_HUMAN  P07358  
CNDP1 Hs.400613  CNDP1_HUMAN  Q96KN2  
ITIH1 Hs.420257  ITIH1_HUMAN  P19827  
KRT6A Hs.433845  K2C6A_HUMAN 
K2C6C_HUMAN  
P02538 
P48666  
HIST1H2BK Hs.437275  H2B1C_HUMAN 
H2B1K_HUMAN  
P62807 
O60814  
PTGDS Hs.446429      
HLA-C Hs.449621  1C07_HUMAN  P10321  
IFITM2 Hs.458414  IFM2_HUMAN  Q01629  
C1QC Hs.467753      
IGHG1 Hs.510635  IGHD_HUMAN  P01880  
GCNT2 Hs.519884  GCNT2_HUMAN  Q06430  
UBC Hs.520348      
ORM2 Hs.522356  A1AG2_HUMAN  P19652  
MUC5B Hs.523395  MUC5B_HUMAN  Q9HC84  
CEL Hs.533258  CEL_HUMAN  P19835  
C4A Hs.534847      
PSMAL Hs.645352  PSMAL_HUMAN  Q9HBA9  
AMY2A Hs.654437  AMYP_HUMAN  P04746  
PRSS3 Hs.654513      
KRT13 Hs.654550  K1C13_HUMAN  P13646  
KRT15 Hs.654570  K1C15_HUMAN  P19012  
KRT4 Hs.654610  K2C4_HUMAN  P19013  
KRT16 Hs.655160  K1C16_HUMAN  P08779  
LRG1 Hs.655559  A2GL_HUMAN  P02750  
KRT72 Hs.662013      
TUBA4B Hs.664469      
HIST1H2BK Hs.689116  H2B1C_HUMAN 
H2B1K_HUMAN  
P62807 
O60814  
CFB Hs.69771  CFAB_HUMAN  P00751  
 Hs.708950      
 Hs.719954      
 Hs.720022      
 Hs.724927      
C7 Hs.78065  CO7_HUMAN  P10643  
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C1QB Hs.8986      
 
Mucin 5B (MUC5B) was shown not to be expressed in normal kidney and renal cell 
carcinoma by histochemistry and northern blot analysis. This becomes the first report 
suggesting that MUC5B might be expressed in kidney by at least some of the cell types. To 
the best of our knowledge MUC5B has not been reported to part of exosomes either (source: 
Exocarta). 
3.3.1.2 Disease associations 
Identified proteins were classified using DAVID Bioinformatics Resources 6.7, National 
Institute of Allergy and Infectious Diseases (NIAID), NIH (Huang, Sherman & Lempicki, 
2009a; Huang, Sherman & Lempicki, 2009b). These 437 proteins mapped to 412 unique 
DAVID Ids and various types of analysis were performed on these proteins using DAVID. 
Out of these 412, 166 proteins are related to human diseases on the basis of their presence in 
OMIM database (Online Mendelian Inheritance in Man, a database of human genes and 
genetic disorders, http://www.ncbi.nlm.nih.gov/omim). These proteins are listed in 
supplemntary Table S3.2. The presence of these proteins suggests that urinary exosomes and 
other membrane vesicles are a rich source of biomarkers and can be applied for clinical 
biomarker analysis. Moreover, our identifications also contain 66 proteins whose gene have 
been found to contain genetic associations with cardiovascular diseases (Supplementary 
Table S3.3) and 23 proteins with genetic association to various renal diseases (Supplementary 
Table S3.4). 
3.3.1.3 Sequence features 
Total proteins identified were run on DAVID Bioinformatics Resources 6.7 for enrichment 
analysis for various sequence features. There were 192 different categories for various 
sequence features including, but not limited to, types of glycosylation, signal peptide, 
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mutagenesis sites, protein variants and many types of repeats. Some of the major ones are 
listed in Table 3.2. 
Table 3.2: Lists the major sequence features found in proteins identified in the high speed 
pellet (P200,000xg). 
Term Count % of 
total 
signal peptide 214 51.94175 
disulfide bond 165 40.04854 
glycosylation site:N-linked (GlcNAc...) 222 53.8835 
glycosylation site:O-linked (GalNAc...) 22 5.339806 
glycosylation site:N-linked (GlcNAc...) (complex) 5 1.213592 
glycosylation site:C-linked (Man) 7 1.699029 
glycosylation site:N-linked (Glc) (glycation) 7 1.699029 
sequence variant 306 74.27184 
mutagenesis site 80 19.41748 
 
Two hundred and fourteen proteins, corresponding to 48.9% of the total proteins identified 
were classified as having signal peptides. Signal peptide is found in proteins which are 
known to be secreted. Forty % of proteins were shown to employ disulfide bonds to generate 
tertiary structure. Fifty three % proteins were found to be N-glycosylated while only 5.3 % 
were reported to be O-glycosylated. This is expected as N-linked glycosylation is much more 
common compared to O-linked glycosylation. Among the O-glycosylated proteins, inter-
alpha (globulin) inhibitor H4 is known to be involved in susceptibility to 
hypercholesterolemia. Among the N-glycosylated proteins, 5 proteins were found to possess 
complex type N-glycans. These proteins were alpha-1-microglobulin/bikunin precursor, 
angiotensin I converting enzyme 1, carboxyl ester lipase and inter-alpha (globulin) inhibitors 
H1 and H2. Another 7 proteins were found which are known to be glycated including 
albumin, CD59, complement factor B, apoliporpoteins A-I and E and haemoglobin alpha and 
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beta chains. 309 proteins were found to have sequence variants and 80 proteins had one or 
more mutagenesis sites. 
3.3.1.4 Gene ontology/annotations 
IPA software (Ingenuity systems, USA) was used for annotating the protein list and graph 
representations were generated manually using Microsoft (MS) Excel program. Figure 3.5 
presents the major categories of proteins annotated using IPA in cellular component analysis. 
This classifies the protein list into sub-categories according to their localization in cell. As 
can be seen in figure 3.5, 36% of proteins belong to extracellular space category. 
Extracellular proteins if associated to the vesicle surface should be removed by DTT/CHAPS 
treatment and accordingly some extracellular proteins were found in CHAPS and DTT 
SN200,000 (Figure 2.7, Chapter 2). However, extracellular proteins which are endocytosed 
by the cells might be released with exosomes entrapped in the lumen. Such proteins would be 
found in the P200,000g regardless of CHAPS/DTT treatment. Thirty eight % proteins are 
cytoplasmic and 23% belong to plasma membrane category. Only 2 % proteins were found to 
be nuclear while 1% proteins were annotated as unknown. When the list of proteins was 
annotated according to the molecular function of proteins (Figure 3.6), 45% of proteins were 
found to be enzymes. Twenty one % and 18% were found to be peptidases and transporters, 
respectively. Four % transmembrane receptors were present while transcription/translation 
regulators and phosphatases were 3% each. Two % each of G-protein coupled-receptors, 
kinases and growth factors were also found. 
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Figure 3.5: Annotation of our protein list using IPA software according to the cellular 
component to which they belong. 
 
 
Cytoplasm 
38% 
Extracellular Space 
36% 
Nucleus 
2% 
Plasma Membrane 
23% 
Unknown 
1% 
Gene Ontology: Cellular component 
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Figure 3.6: Annotation of our protein list using IPA software according to their molecular 
function. 
Our protein list was annotated according to biological processes, in which these proteins are 
involved, using Blast2GO software (Conesa et al., 2005) and ‘cut-off’ value was kept high 
(70 proteins) so only major biological processes are enriched (Figure 3.7). 
Enzyme 
45% 
G-protein coupled 
receptor 
2% 
Growth factor 
2% 
Kinase 
2% 
Peptidase 
21% 
Phosphatase 
3% 
Transcription/translati
on regulator 
3% 
Transmembrane 
receptor 
4% 
Transporter 
18% 
Gene Ontology: Molecular function 
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Figure 3.7: Annotation of our protein list using Blast2Go software (Conesa et al., 2005) 
according to the biological processes in which they are involved. 
As can be seen in Figure 3.7, the most number of proteins present in our list are the 
regulatory proteins regulating cellular processes (135 proteins) with 86 proteins involved in 
positive regulation of biological processes and 80 being the negative regulators of biological 
processes. Another significant biological process is the immune function with 89 proteins 
involved in immune responses being present and 72 proteins involved in defence responses. 
Cellular homeostasis is another important category as 78 proteins involved in response to 
wounding are also present. Seventy two proteins involved in proteolysis also demonstrate the 
importance of these vesicles in homeostasis. One hundred and seven transporters and 87 
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signalling proteins are present suggesting these vesicles have the complete machinery to 
impart functionality to their target cells. 
Blast2go takes protein sequences in FASTA format as its input and there is no option of 
retrieving proteins which are classified into a particular category. For this reason, all the 
identified proteins in the high-speed pellet (437), which mapped to 412 DAVID Id, were 
annotated again using DAVID Bioinformatics Resources 6.7 into three categories: 1. 
Molecular function, 2. Biological process, and 3. Cellular components. Major classes falling 
in these categories were retrieved in the form of gene lists to discuss more about them. Some 
of the lists which seem interesting cast further light on importance of these vesicles are 
presented here. 
Exosomes are released into urine when multivesicular body (MVB) fuse to the apical plasma 
membrane of cells lining the urinary drainage system. Therefore, identification of endosomal 
protein would suggest MVB origin of the vesicles we have identified. DAVID annotation was 
performed on our protein list and proteins belonging to endosomes were retrieved (Table 
3.3). Class E vacuolar protein-sorting (VPS) proteins and some associated proteins were 
found in addition to tumor susceptibility gene 101 (Tsg101) and CD63 which are exosomal 
markers. Cubilin and megalin which are involved in endocytosis of proteins and cofactors 
into the endosomal system and they would be expected in exosomes as well. 
Table 3.3: Proteins identified in our list which according to DAVID annotation belong to 
endosomes.  
ID Gene Name 
Q6UXG3 CD300 molecule-like family member g 
P08962 CD63 molecule 
Q9H223 EH-domain containing 4 
Q9NP79 Vps20-associated 1 homolog (S. cerevisiae) 
P12821 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 
192 
 
P07355 annexin A2 pseudogene 3; annexin A2; annexin A2 pseudogene 1 
P04114 apolipoprotein B (including Ag (x) antigen) 
P15289 arylsulfatase A 
Q7LBR1 chromatin modifying protein 1B 
O43633 chromatin modifying protein 2A 
Q9H444 chromatin modifying protein 4B 
O60494 cubilin (intrinsic factor-cobalamin receptor) 
P02649 hypothetical LOC100129500; apolipoprotein E 
P98164 low density lipoprotein-related protein 2 
P11279 lysosomal-associated membrane protein 1 
P13473 lysosomal-associated membrane protein 2 
P02787 Transferring 
Q99816 tumor susceptibility gene 101 
Q9UN37 vacuolar protein sorting 4 homolog A (S. cerevisiae) 
O75351 vacuolar protein sorting 4 homolog B (S. cerevisiae) 
 
Exosomes are thought to be derived from the apical part of plasma membrane in kidney. The 
DAVID annotation classified some proteins as belonging to the apical part. They are 
presented in Table 3.4. These proteins found in the exosomal pellet would agree with the 
theory that exosomes are released from the apical part of the plasma membrane in urinary 
tract. 
Table 3.4: Proteins annotated to be from apical part of the plasma membrane. 
ID Gene Name 
P05026 ATPase, Na+/K+ transporting, beta 1 polypeptide 
Q9UBD6 Rh family, C glycoprotein 
P14550 aldo-keto reductase family 1, member A1 (aldehyde reductase) 
P08133 annexin A6 
P29972 aquaporin 1 (Colton blood group) 
P43251 Biotinidase 
P00918 carbonic anhydrase II 
P07858 cathepsin B 
P60953 cell division cycle 42 (GTP binding protein, 25kDa); cell division cycle 42 pseudogene 2 
O60494 cubilin (intrinsic factor-cobalamin receptor) 
P27487 dipeptidyl-peptidase 4 
P02751 fibronectin 1 
Q07075 glutamyl aminopeptidase (aminopeptidase A) 
P15311 hypothetical protein LOC100129652; ezrin 
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P98164 low density lipoprotein-related protein 2 
P26038 Moesin 
P15941 mucin 1, cell surface associated 
P27105 phosphatidylethanolamine binding protein 1 
O43490 prominin 1 
P35241 Radixin 
P55017 solute carrier family 12 (sodium/chloride transporters), member 3 
Q13621 solute carrier family 12 (sodium/potassium/chloride transporters), member 1 
P07911 Uromodulin 
  
Although some proteins from the basolateral part of the plasma membrane were also found 
(Table 3.5).  
Table 3.5: Proteins annotated by DAVID to be part of basolateral membrane. 
ID Gene Name 
P08183 ATP-binding cassette, sub-family B (MDR/TAP), member 1 
P05026 ATPase, Na+/K+ transporting, beta 1 polypeptide 
Q9UBD6 Rh family, C glycoprotein 
P31151 S100 calcium binding protein A7 
P15291 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1 
P12814 actinin, alpha 1 
P04083 annexin A1 
P29972 aquaporin 1 (Colton blood group) 
P00918 carbonic anhydrase II 
P15924 Desmoplakin 
P26038 Moesin 
O00159 myosin IC 
O00560 syndecan binding protein (syntenin) 
P02787 Transferring 
 
The expression of these proteins (Table 3.5) is not restricted to basolateral part so the theory 
of apical generation of exosomes cannot be excluded. For example, Aquaporin 1 is also found 
on the apical side of the plasma membrane (Source: Uniprot). 
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Some proteins of the brush border membrane of proximal tubuli were found in our 
identifications (Table 3.6) suggesting that most if not all parts of the urinary drainage system 
release these vesicles. 
Table 3.6: Proteins annotated to brush border/microvillus by DAVID. 
ID Gene Name 
P15291 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1 
O60494 cubilin (intrinsic factor-cobalamin receptor) 
Q7Z4W1 dicarbonyl/L-xylulose reductase 
Q07075 glutamyl aminopeptidase (aminopeptidase A) 
P98164 low density lipoprotein-related protein 2 
O00159 myosin IC 
O43490 prominin 1 
P31639 solute carrier family 5 (sodium/glucose cotransporter), member 2 
P35241 Radixin 
P26038 Moesin 
P00918 carbonic anhydrase II 
P15311 hypothetical protein LOC100129652; ezrin 
 
The whole membrane attack complex subunits of complement system were found in our 
identifications. This raises questions about constitutive secretion over stimulus-mediated 
secretion. 
Table 3.7: Proteins annotated to be complement components by DAVID. 
ID Gene Name 
P10909 Clusterin 
P02746 complement component 1, q subcomponent, B chain 
P02747 complement component 1, q subcomponent, C chain 
Q9NZP8 complement component 1, r subcomponent-like 
P04003 complement component 4 binding protein, alpha 
P0C0L4 complement component 4A (Rodgers blood group) 
P0C0L5 complement component 4B (Chido blood group) 
P01031 complement component 5 
P10643 complement component 7 
P07357 complement component 8, alpha polypeptide 
P07358 complement component 8, beta polypeptide 
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P02748 complement component 9 
P00751 complement factor B 
P08603 complement factor H 
P05156 complement factor I 
Q15485 ficolin (collagen/fibrinogen domain containing lectin) 2 (hucolin) 
O75636 ficolin (collagen/fibrinogen domain containing) 3 (Hakata antigen) 
P04264 keratin 1 
O00187 mannan-binding lectin serine peptidase 2 
P05155 serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 
P01024 similar to Complement C3 precursor; complement component 3; hypothetical protein LOC100133511 
 
Another interesting feature of our protein list was some proteins which bind unfolded 
proteins. In other words these proteins act as chaperones aiding protein folding and also 
acting in the clearance of misfolded proteins. These proteins are presented in Table 3.8. 
HSP70 variants and HSP90 are present as well as cyclophilin A, B and C.  
Table 3.8: Unfolded protein binding proteins annotated by DAVID. 
ID Gene Name 
P02743 amyloid P component, serum 
P08107 heat shock 70kDa protein 1A; heat shock 70kDa protein 1B 
P54652 heat shock 70kDa protein 2 
P11142 heat shock 70kDa protein 8 
P08238 heat shock protein 90kDa alpha (cytosolic), class B member 1 
P23284 peptidylprolyl isomerase B (cyclophilin B) 
P45877 peptidylprolyl isomerase C (cyclophilin C) 
P62937 similar to TRIMCyp; peptidylprolyl isomerase A (cyclophilin A); peptidylprolyl isomerase A 
(cyclophilin A)-like 3 
P68371 tubulin, beta 2C 
 
Another important class of proteins were identified in our high speed pellet as having GTPase 
activity. These include many of the G-proteins, RAS oncogene family members and 
translation elongation factor 1. 
 
 
196 
 
Table 3.9: Proteins annotated as having GTPase activity by DAVID 
ID Gene Name 
Q9H223 EH-domain containing 4 
P63092 GNAS complex locus 
P61224 RAP1B, member of RAS oncogene family 
P60953 cell division cycle 42 (GTP binding protein, 25kDa); cell division cycle 42 pseudogene 2 
P68104 eukaryotic translation elongation factor 1 alpha-like 7; eukaryotic translation elongation factor 1 alpha-like 
3; similar to eukaryotic translation elongation factor 1 alpha 1; eukaryotic translation elongation factor 1 
alpha 1 
P29992 guanine nucleotide binding protein (G protein), alpha 11 (Gq class) 
P63096 guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 
P62873 guanine nucleotide binding protein (G protein), beta polypeptide 1 
P62879 guanine nucleotide binding protein (G protein), beta polypeptide 2 
P50148 guanine nucleotide binding protein (G protein), q polypeptide 
P61586 ras homolog gene family, member A 
Q9BQE3 tubulin, alpha 1c 
P68366 tubulin, alpha 4a 
Q9H853 tubulin, alpha 4b (pseudogene) 
P68371 tubulin, beta 2C 
P04350 tubulin, beta 4 
 
3.3.1.5 Comparison of High speed pellet with HDL and LDL particles 
Lipoprotein particles, particularly the high-density lipoproteins (HDL), share some 
biophysical characteristics with urinary exosomes. For example, HDL have a density of 
1.063-1.125 g/mL although its diameter ranges from 7-12nm (Gordon et al., 2010), which is 
smaller than exosomes. HDL particles have been identified in urine previously (Gomo, 
Henderson & Myrick, 1988). Owing to a similar density, HDL might sediment with 
exosomes when exosomes are prepared from urine using ultracentrifugation. LDL and VLDL 
would be expected to remain in solution due to their lower densities, although the presence of 
dense LDL particles cannot be ruled out. Proteomic studies on HDL particles have to deal 
with the possibility of contamination of lipoprotein preparations with soluble abundant 
proteins. For this reason, one recent HDL proteomics study was selected in which size 
exclusion chromatography and affinity chromatography were used to purify HDLs which 
197 
 
were subsequently analysed by MS for their proteomic content (“the HDL proteome”) 
(Gordon et al., 2010). Lipid binding proteins identified in this study were compared to our 
protein list (Figure 3.8). 
 
Figure 3.8: Comparison of HDL-associated proteins (Gordon et al., 2010) with proteins of 
high speed pellet (P200,000g). 
Out of the 12 proteins which were converted to 13 Unigene identifications for comparison, 
apolipoprotein C1 (APOC1), apolipoprotein L1 (APOL1), apolipoprotein A2 (APOA2) and 
serum amyloid A (SAA) were not found in our study. In the Figure 5 proteins are shown but 
only four were absent. This was due to the conversion of proteins to different identification 
Ids for comparison. All other proteins were present in our protein list. APOA1, APOA4, 
APOE, complement C3, PON1, complement C4-B and cholesteryl ester transfer protein 
(CETP), which have been identified previously to be HDL-associated proteins (Vaisar et al., 
2007) are also present in our protein list. The presence of full length APO B-100 was 
suggested by the peptides identified in our analysis (Figure 3.9) which also suggests the 
presence of LDL. 
198 
 
EEEMLENVSLVCPKDATRFKHLRKYTYNYEAESSSGVPGTADSRSATRINCKVELEVPQLCSFILKTSQCTLKEVYGFNPEGKALLKKTKNSEEFAAAMSRYELKLAI
PEGKQVFLYPEKDEPTYILNIKRGIISALLVPPETEEAKQVLFLDTVYGNCSTHFTVKTRKGNVATEISTERDLGQCDRFKPIRTGISPLALIKGMTRPLSTLISSSQSCQ
YTLDAKRKHVAEAICKEQHLFLPFSYKNKYGMVAQVTQTLKLEDTPKINSRFFGEGTKKMGLAFESTKSTSPPKQAEAVLKTLQELKKLTISEQNIQRANLFNKLVT
ELRGLSDEAVTSLLPQLIEVSSPITLQALVQCGQPQCSTHILQWLKRVHANPLLIDVVTYLVALIPEPSAQQLREIFNMARDQRSRATLYALSHAVNNYHKTNPTGT
QELLDIANYLMEQIQDDCTGDEDYTYLILRVIGNMGQTMEQLTPELKSSILKCVQSTKPSLMIQKAAIQALRKMEPKDKDQEVLLQTFLDDASPGDKRLAAYLML
MRSPSQADINKIVQILPWEQNEQVKNFVASHIANILNSEELDIQDLKKLVKEALKESQLPTVMDFRKFSRNYQLYKSVSLPSLDPASAKIEGNLIFDPNNYLPKESM
LKTTLTAFGFASADLIEIGLEGKGFEPTLEALFGKQGFFPDSVNKALYWVNGQVPDGVSKVLVDHFGYTKDDKHEQDMVNGIMLSVEKLIKDLKSKEVPEARAYL
RILGEELGFASLHDLQLLGKLLLMGARTLQGIPQMIGEVIRKGSKNDFFLHYIFMENAFELPTGAGLQLQISSSGVIAPGAKAGVKLEVANMQAELVAKPSVSVEFV
TNMGIIIPDFARSGVQMNTNFFHESGLEAHVALKAGKLKFIIPSPKRPVKLLSGGNTLHLVSTTKTEVIPPLIENRQSWSVCKQVFPGLNYCTSGAYSNASSTDSASY
YPLTGDTRLELELRPTGEIEQYSVSATYELQREDRALVDTLKFVTQAEGAKQTEATMTFKYNRQSMTLSSEVQIPDFDVDLGTILRVNDESTEGKTSYRLTLDIQNK
KITEVALMGHLSCDTKEERKIKGVISIPRLQAEARSEILAHWSPAKLLLQMDSSATAYGSTVSKRVAWHYDEEKIEFEWNTGTNVDTKKMTSNFPVDLSDYPKSLH
MYANRLLDHRVPQTDMTFRHVGSKLIVAMSSWLQKASGSLPYTQTLQDHLNSLKEFNLQNMGLPDFHIPENLFLKSDGRVKYTLNKNSLKIEIPLPFGGKSSRDL
KMLETVRTPALHFKSVGFHLPSREFQVPTFTIPKLYQLQVPLLGVLDLSTNVYSNLYNWSASYSGGNTSTDHFSLRARYHMKADSVVDLLSYNVQGSGETTYDHK
NTFTLSYDGSLRHKFLDSNIKFSHVEKLGNNPVSKGLLIFDASSSWGPQMSASVHLDSKKKQHLFVKEVKIDGQFRVSSFYAKGTYGLSCQRDPNTGRLNGESNLR
FNSSYLQGTNQITGRYEDGTLSLTSTSDLQSGIIKNTASLKYENYELTLKSDTNGKYKNFATSNKMDMTFSKQNALLRSEYQADYESLRFFSLLSGSLNSHGLELNAD
ILGTDKINSGAHKATLRIGQDGISTSATTNLKCSLLVLENELNAELGLSGASMKLTTNGRFREHNAKFSLDGKAALTELSLGSAYQAMILGVDSKNIFNFKVSQEGLK
LSNDMMGSYAEMKFDHTNSLNIAGLSLDFSSKLDNIYSSDKFYKQTVNLQLQPYSLVTTLNSDLKYNALDLTNNGKLRLEPLKLHVAGNLKGAYQNNEIKHIYAISS
AALSASYKADTVAKVQGVEFSHRLNTDIAGLASAIDMSTNYNSDSLHFSNVFRSVMAPFTMTIDAHTNGNGKLALWGEHTGQLYSKFLLKAEPLAFTFSHDYKG
STSHHLVSRKSISAALEHKVSALLTPAEQTGTWKLKTQFNNNEYSQDLDAYNTKDKIGVELTGRTLADLTLLDSPIKVPLLLSEPINIIDALEMRDAVEKPQEFTIVAF
VKYDKNQDVHSINLPFFETLQEYFERNRQTIIVVLENVQRNLKHINIDQFVRKYRAALGKLPQQANDYLNSFNWERQVSHAKEKLTALTKKYRITENDIQIALDDA
KINFNEKLSQLQTYMIQFDQYIKDSYDLHDLKIAIANIIDEIIEKLKSLDEHYHIRVNLVKTIHDLHLFIENIDFNKSGSSTASWIQNVDTKYQIRIQIQEKLQQLKRHIQ
NIDIQHLAGKLKQHIEAIDVRVLLDQLGTTISFERINDILEHVKHFVINLIGDFEVAEKINAFRAKVHELIERYEVDQQIQVLMDKLVELAHQYKLKETIQKLSNVLQQ
VKIKDYFEKLVGFIDDAVKKLNELSFKTFIEDVNKFLDMLIKKLKSFDYHQFVDETNDKIREVTQRLNGEIQALELPQKAEALKLFLEETKATVAVYLESLQDTKITLIIN
WLQEALSSASLAHMKAKFRETLEDTRDRMYQMDIQQELQRYLSLVGQVYSTLVTYISDWWTLAAKNLTDFAEQYSIQDWAKRMKALVEQGFTVPEIKTILGTM
PAFEVSLQALQKATFQTPDFIVPLTDLRIPSVQINFKDLKNIKIPSRFSTPEFTILNTFHIPSFTIDFVEMKVKIIRTIDQMLNSELQWPVPDIYLRDLKVEDIPLARITLP
DFRLPEIAIPEFIIPTLNLNDFQVPDLHIPEFQLPHISHTIEVPTFGKLYSILKIQSPLFTLDANADIGNGTTSANEAGIAASITAKGESKLEVLNFDFQANAQLSNPKINP
LALKESVKFSSKYLRTEHGSEMLFFGNAIEGKSNTVASLHTEKNTLELSNGVIVKINNQLTLDSNTKYFHKLNIPKLDFSSQADLRNEIKTLLKAGHIAWTSSGKGSW
KWACPRFSDEGTHESQISFTIEGPLTSFGLSNKINSKHLRVNQNLVYESGSLNFSKLEIQSQVDSQHVGHSVLTAKGMALFGEGKAEFTGRHDAHLNGKVIGTLKN
SLFFSAQPFEITASTNNEGNLKVRFPLRLTGKIDFLNNYALFLSPSAQQASWQVSARFNQYKYNQNFSAGNNENIMEAHVGINGEANLDFLNIPLTIPEMRLPYTII
TTPPLKDFSLWEKTGLKEFLKTTKQSFDLSVKAQYKKNKHRHSITNPLAVLCEFISQSIKSFDRHFEKNRNNALDFVTKSYNETKIKFDKYKAEKSHDELPRTFQIPGY
TVPVVNVEVSPFTIEMSAFGYVFPKAVSMPSFSILGSDVRVPSYTLILPSLELPVLHVPRNLKLSLPDFKELCTISHIFIPAMGNITYDFSFKSSVITLNTNAELFNQSDI
VAHLLSSSSSVIDALQYKLEGTTRLTRKRGLKLATALSLSNKFVEGSHNSTVSLTTKNMEVSVATTTKAQIPILRMNFKQELNGNTKSKPTVSSSMEFKYDFNSSML
YSTAKGAVDHKLSLESLTSYFSIESSTKGDVKGSVLSREYSGTIASEANTYLNSKSTRSSVKLQGTSKIDDIWNLEVKENFAGEATLQRIYSLWEHSTKNHLQLEGLFF
TNGEHTSKATLELSPWQMSALVQVHASQPSSFHDFPDLGQEVALNANTKNQKIRWKNEVRIHSGSFQSQVELSNDQEKAHLDIAGSLEGHLRFLKNIILPVYDKS
LWDFLKLDVTTSIGRRQHLRVSTAFVYTKNPNGYSFSIPVKVLADKFIIPGLKLNDLNSVLVMPTFHVPFTDLQVPSCKLDFREIQIYKKLRTSSFALNLPTLPEVKFPE
VDVLTKYSQPEDSLIPFFEITVPESQLTVSQFTLPKSVSDGIAALDLNAVANKIADFELPTIIVPEQTIEIPSIKFSVPAGIVIPSFQALTARFEVDSPVYNATWSASLKNK
ADYVETVLDSTCSSTVQFLEYELNVLGTHKIEDGTLASKTKGTFAHRDFSAEYEEDGKYEGLQEWEGKAHLNIKSPAFTDLHLRYQKDKKGISTSAASPAVGTVGM
DMDEDDDFSKWNFYYSPQSSPDKKLTIFKTELRVRESDEETQIKVNWEEEAASGLLTSLKDNVPKATGVLYDYVNKYHWEHTGLTLREVSSKLRRNLQNNAEWV
YQGAIRQIDDIDVRFQKAASGTTGTYQEWKDKAQNLYQELLTQEGQASFQGLKDNVFDGLVRVTQEFHMKVKHLIDSLIDFLNFPRFQFPGKPGIYTREELCTM
FIREVGTVLSQVYSKVHNGSEILFSYFQDLVITLPFELRKHKLIDVISMYRELLKDLSKEAQEVFKAIQSLKTTEVLRNLQDLLQFIFQLIEDNIKQLKEMKFTYLINYIQD
EINTIFSDYIPYVFKLLKENLCLNLHKFNEFIQNELQEASQELQQIHQYIMALREEYFDPSIVGWTVKYYELEEKIVSLIKNLLVALKDFHSEYIVSASNFTSQLSSQVEQ
FLHRNIQEYLSILTDPDGKGKEKIAELSATAQEIIKSQAIATKKIISDYHQQFRYKLQDFSDQLSDYYEKFIAESKRLIDLSIQNYHTFLIYITELLKKLQSTTVMNPYMKL
APGELTIILSEAEDASLLSFMQGYMKHATKTAKDALSSVQESQVAQQARGWVTDGFSSLKDYWSTVKDKFSEFWDLDPEVRPTSAVAA 
Figure 3.9: Sequence of full length APO B-100. Amino acids highlighted in green are the 
peptides identified in our study and red amino acids are lipid binding amino acids. 
3.3.2 Low speed pellet proteomic analysis 
Proteins pelleting down at low speed (18,000g) after DTT or CHAPS treatment were also 
identified. It is known from previous studies that some populations of exosomes pellet down 
at low speed pellet owing to their entrapment by THP polymers. However, DTT treatment 
releases these vesicles which then pellet down at high speed (P200,000g) (Fernandez-Llama 
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et al., 2010). Therefore, DTT-treated P18,000g, theoretically, would be expected to have only 
larger vesicles. Seventy five proteins were identified in DTT and CHAPS-treated P18,000g 
(pelleted again after treatment fo the crude pellet P18DTT/CHAPSP18). A complete non-
redundant list of proteins identified in low speed pellet (P18,000g) is presented in 
Supplementary Table S3.5. DTT treatment is the method suggested by some previous studies 
while CHAPS treatment was established by us (Chapter 2). When these two methods were 
compared to each other in terms of protein identifications, our method (CHAPS) yielded 
more proteins while most (66%) of the proteins identified in DTT method were common to 
our method. 
 
Figure 3.10: DTT versus CHAPS treatment in terms of protein identification for low speed 
pellet (18,000g). 
Sixty six % of DTT-treated pellet proteins are common to CHAPS pellet while only 38% of 
CHAPS are common to DTT method (Figure 3.10). This suggests that CHAPS is not only 
better in terms of removing contamination of soluble proteins but this also enriches for 
proteins not otherwise identified in the pellet when it is treated with DTT. 
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Proteins identified in P18,000, after treatment with either DTT or CHAPS separately (DTT 
and CHAPS treated P18,000g; P18DP18 and P18CP18), were combined together non-
redundantly and compared to P200,000g (Figure 3.11). 
 
Figure 3.11: Comparison of total proteins of low speed pellet (P18DTT and P18CHAPS 
combined) with High speed pellet (P200,000g). 
Eighty five % proteins in P18,000g are common to P200,000g as can be seen in Figure 3.11. 
Out of 23 proteins unique to the low speed pellet (P18,000g), 14 have been previously 
identified in a large-scale proteomic study of urinary exosomes (Wang et al., 2011).  
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3.4 Discussion 
Proteomic analyses of the high and low speed pellets were carried out and a large number of 
proteins were identified. Out of the 437 proteins identified in the high-speed pellet 
(P200,000g or exosomal fraction), 86 proteins have never been described in urinary 
exosomes. Exocarta is the largest database of exosomal proteins from any source 
(Mathivanan et al., 2012) and 83 proteins identified in our study are new and not reported in 
Exocarta. However, as compared to the largest proteomics study on whole urine (Marimuthu 
et al., 2011) most of our proteins have been identified in urine except the 32 proteins which 
are new to our study. Thirty nine proteins are, for the first time, shown to be part of urinary 
membrane vesicles and they have not been reported previously in urinary exosomes and 
‘exosome-like’ vesicles study.  
One hundred and sixty-six proteins have been found in the OMIM database associated with 
various diseases with 66 proteins having genetic associations to cardiovascular diseases and 
23 with genetic associations to renal diseases. This highlights the potential importance of 
these vesicles in clinical practise. Two hundred and twenty two proteins in our list were 
found to be N-glycosylated, as annotated by DAVID bioinformatics resources 6.7, and 22 
were O-glycosylated. Glycosylation patterns of proteins are important variables in disease 
processes which most likely reflect the respective pathology in the form of aberrant or altered 
glycosylation. Interestingly, membrane vesicles have a distinct glycan signature which is 
different from the parent cells secreting them (Escrevente et al., 2011). These membrane 
vesicles originate from specialised microdomains of the plasma membrane of the cell 
suggesting that glycosylation plays a part in sorting these proteins to such microdomains. As 
an example, special processing of prion protein is involved in targeting it to membrane 
vesicles and only a certain glycoform is preferentially secreted as part of membrane vesicles 
(Vella et al., 2007) over other forms. This further suggests a role for glycosylation in sorting 
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different proteins to specific membrane vesicle groups. Additionally, 7 proteins including 
albumin and haemoglobin alpha and beta chains which are known to be glycated are present 
in our high-speed pellet protein list. Advanced glycation end (AGE) products are known to be 
formed characteristically in diabetes and diabetic nephropathy. They seem to act as stimuli to 
induce production of extracellular matrix and inhibit its degradation. Furthermore, AGE 
modification of matrix proteins disrupts matrix-matrix and matrix-cell interactions leading to 
a profibrotic state (Silbiger et al., 1993; Krishnamurti et al., 1997; Mott et al., 1997; Raabe et 
al., 1998). It remains to be established if these proteins are secreted in their glycated forms in 
membrane vesicles or not. If glycated forms can be found in membrane vesicles it could work 
as a diagnostic modality to determine concentration of glycated proteins in association with 
progression of various diseases. Twenty two proteins were annotated as O-glycosylated in 
our high-speed pellet protein list. It has been reported that metabolic flux through the 
hexosamine biosynthetic pathway is increased in the presence of high circulating glucose 
levels as in diabetes. Furthermore, it induces the expression of genes necessary for 
development of diabetic nephropathy and O-glycosylation was found to be necessary for the 
expression of these genes (Goldberg et al., 2006). Twenty proteins were annotated to be part 
of endosomes in our high-speed pellet protein list. Class E vacuolar protein-sorting (VPS) 
proteins are involved in MVB biogenesis and Tsg101 and CD63 help sort proteins to MVB. 
This provides evidence that high speed pellets contain mostly vesicles originating in MVB 
which are also known as urinary exosomes. It is believed that exosomes are secreted 
following the fusion of MVB to the apical part of plasma membranes in the urinary drainage 
system (Pisitkun, Shen & Knepper; 2004). Twenty three proteins, which are markers of apical 
part of the plasma membrane, were found in our study confirming this hypothesis. However, 
14 proteins were also annotated to be part of basolateral aspect of the membrane while many 
of these proteins like ATPase Na+/K+ transporting, beta1 polypeptide and Rh family C 
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glycoprotein are common to the apical part as well. The expression of these proteins, 
annotated as basolateral proteins, is not strictly basolateral and typically strict basolateral 
makrer proteins like gp58 and E-cadherin (Manninen et al., 2005) were not found in our 
protein list. Therefore, our results support the hypothesis about generation of exosomes from 
the the apical part of the plasma membrane. 
HDL particles have been identified in urine previously (Gomo, Henderson & Myrick, 1988) 
and they share some biophysical characteristics with exosomes like a similar density range. 
The traditional method of exosome isolation uses ultracentrifugation and membrane vesicles, 
like exosomes, pellet down depending on their density and mass. Therefore, it is not 
unexpected if this method also pellets down HDL particles along with membrane vesicles. A 
number of HDL-associated proteins are present in our identifications but some like APOC1, 
APOL1, APOA2 and SAA are absent as well. However, a point to remember is that CHAPS, 
which is used in our enrichment protocol, has been reported to solubilise HDL and release 
apolipoproteins at roughly 10mM final concentration along with other detergents like cholate 
(Shiflett et al., 2005). We have used 1% (w/v) CHAPS which is roughly equivalent to 16mM 
suggesting that HDL, if present, may be solubilised to release apolipoproteins. Identification 
of these apolipoproteins in our high speed pellet would then mean that either these proteins 
are secreted as part of membrane vesicles, or, upon their release from HDL, they bind to 
exosome or other membrane vesicles. Alternatively, CHAPS, without the presence of other 
detergents, may not have any solubilisation effect on HDL and thus these particles would be 
present in our nano vesicle fraction. The presence of dense LDL particle can also not be ruled 
out as peptides covering the full length of APO B-100 are present in our identifications. 
Exosomes are thought to be secreted constitutively from various cells as part of routine 
cellular transport processes, whereas ectosomes are mostly released upon receipt of a 
stimulus such as complement attack (Morgan, Dankert & Esser, 1987). Complement attack 
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leads to the formation of a membrane attack complex (MAC) on the cell surface which, if not 
disposed of, can lead to cell death (Mayer 1961). Cells dispose of MAC by either releasing 
ectosomes consisiting of MAC (Morgan, Dankert & Esser, 1987) or by internalising MAC 
into MVBs and then secreting it as part of exosomes, as shown in glomerular epithelial cells 
in kidney (Kerjaschki et al., 1989). Our protein list in the high-speed pellet (P200,000g) 
contains all subunits of MAC and it can only be speculated as to whether it is exosomes or 
ectosomes which delivered them to urine. However, HDL has also been found previously to 
be associated with MAC (Choimiura et al., 1993) and presence of HDL in our vesicle 
fraction carrying MAC cannot be ruled out. 
Our protein list also consisted of a number of proteins having chaperone activity which bind 
to unfolded proteins including Hsp70, 90 and clycophilin A, B and C. This suggests that 
target cells taking up exosomes (and these chaperones with them), would be better equipped 
to deal with stress induced by unfolded proteins although it remains to be determined in 
detail. Moreover, cyclophilin A is known to be packaged in HIV-1 virion (Gitti et al., 1996) 
and it has been suggested that HIV-1 uses the same machinery as membrane vesicles for 
budding (Krishnamoorthy et al., 2009). 
The low speed pellet (P18,000g) of urine has never been subjected to proteomic analysis 
before. For the first time we have processed the pellet using two methods described in 
Chapter one namely, DTT and CHAPS treatment. It was clear that CHAPS treatment helped 
us to identify more proteins in the low speed pellet compared to DTT treatment (130 as 
compared to 75 proteins identified). This is possibly due to the more efficient removal of 
interference of the highly abundant protein THP. However, when we combined the proteins 
recovered with these two methods and compared it to the high-speed pellet (P200,000g) only 
23 proteins were found to be unique to the low speed pellet. Out of these 23, 14 have been 
previously identified in the high speed pellet (P200,000g) (Wang et al., 2011). This suggests 
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that due to either THP entrapment of membrane vesicles (Fernandez-Llama et al., 2010) or 
other physicochemical factors, a population of exosomes, and other vesicles of low density, 
pellet down at low speed (P18,000g). Therefore, complete recovery of all the vesciles, 
present in urine with sizes similar to exosomes, at high-speed pellet (P200,000g) was 
obtained even following both treatment methods (DTT and CHAPS), although it can 
definitely be improved using these two methods. 
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Supplementary table S3.1: Complete non-redundant list of proteins identified in the high 
speed pellet (P200,000g). Uniprot accession and gene names are given. 
UNIPROT_AC
CESSION 
Gene name 
P07339 cathepsin D 
P19440 gamma-glutamyltransferase light chain 3; gamma-glutamyltransferase 4 pseudogene; gamma-
glutamyltransferase 2; gamma-glutamyltransferase 1; gamma-glutamyltransferase light chain 5 pseudogene 
P63104 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide 
P04279 semenogelin I 
O00560 syndecan binding protein (syntenin) 
Q9NR99 matrix-remodelling associated 5 
P15941 mucin 1, cell surface associated 
Q14624 inter-alpha (globulin) inhibitor H4 (plasma Kallikrein-sensitive glycoprotein) 
P33908 mannosidase, alpha, class 1A, member 1 
P02766 Transthyretin 
Q9H6S3 EPS8-like 2 
P01011 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 
P50148 guanine nucleotide binding protein (G protein), q polypeptide 
P05546 serpin peptidase inhibitor, clade D (heparin cofactor), member 1 
O14773 tripeptidyl peptidase I 
Q9H444 chromatin modifying protein 4B 
O00391 quiescin Q6 sulfhydryl oxidase 1 
Q9NQ84 G protein-coupled receptor, family C, group 5, member C 
Q92896 golgi apparatus protein 1 
Q9Y287 integral membrane protein 2B 
Q8TCD5 5', 3'-nucleotidase, cytosolic 
Q99816 tumor susceptibility gene 101 
Q8IV08 phospholipase D family, member 3 
P05543 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 7 
Q8WWI5 solute carrier family 44, member 1 
Q9UBD6 Rh family, C glycoprotein 
P31949 S100 calcium binding protein A11; S100 calcium binding protein A11 pseudogene 
P08582 antigen p97 (melanoma associated) identified by monoclonal antibodies 133.2 and 96.5 
P69905 hemoglobin, alpha 2; hemoglobin, alpha 1 
P62937 similar to TRIMCyp; peptidylprolyl isomerase A (cyclophilin A); peptidylprolyl isomerase A (cyclophilin A)-like 3 
Q9HAT2 sialic acid acetylesterase 
Q96DG6 carboxymethylenebutenolidase homolog (Pseudomonas) 
P02675 fibrinogen beta chain 
Q6V0I7 FAT tumor suppressor homolog 4 (Drosophila) 
P53990 similar to CG10103; KIAA0174 
Q03154 aminoacylase 1 
P13987 CD59 molecule, complement regulatory protein 
P34896 serine hydroxymethyltransferase 1 (soluble) 
Q96KP4 CNDP dipeptidase 2 (metallopeptidase M20 family) 
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P19827 inter-alpha (globulin) inhibitor H1 
Q9UI12 ATPase, H+ transporting, lysosomal 50/57kDa, V1 subunit H 
Q5D862 filaggrin family member 2 
Q13510 N-acylsphingosine amidohydrolase (acid ceramidase) 1 
P68371 tubulin, beta 2C 
P22732 solute carrier family 2 (facilitated glucose/fructose transporter), member 5 
P01008 serpin peptidase inhibitor, clade C (antithrombin), member 1 
P30039 phenazine biosynthesis-like protein domain containing 
P07998 ribonuclease, RNase A family, 1 (pancreatic) 
P29622 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4 
O00159 myosin IC 
Q12913 protein tyrosine phosphatase, receptor type, J 
O43866 CD5 molecule-like 
O15162 phospholipid scramblase 1 
P01024 similar to Complement C3 precursor; complement component 3; hypothetical protein LOC100133511 
P35030 protease, serine, 3 
Q00610 clathrin, heavy chain (Hc) 
P61224 RAP1B, member of RAS oncogene family 
Q9Y644 RFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase 
P29508 serpin peptidase inhibitor, clade B (ovalbumin), member 3 
P29992 guanine nucleotide binding protein (G protein), alpha 11 (Gq class) 
Q9UHL4 dipeptidyl-peptidase 7 
Q12805 EGF-containing fibulin-like extracellular matrix protein 1 
P11597 cholesteryl ester transfer protein, plasma 
Q9H3G5 carboxypeptidase, vitellogenic-like 
P98160 heparan sulfate proteoglycan 2 
Q96IU4 abhydrolase domain containing 14B 
P10253 glucosidase, alpha; acid 
P41222 prostaglandin D2 synthase, hematopoietic; prostaglandin D2 synthase 21kDa (brain) 
Q12907 lectin, mannose-binding 2 
P21810 Biglycan 
P25815 S100 calcium binding protein P 
P07858 cathepsin B 
P12277 creatine kinase, brain 
Q7LBR1 chromatin modifying protein 1B 
P01861 immunoglobulin heavy constant gamma 4 (G4m marker) 
P10909 Clusterin 
P50395 GDP dissociation inhibitor 2 
P20073 annexin A7 
P08183 ATP-binding cassette, sub-family B (MDR/TAP), member 1 
P31946 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta polypeptide 
P10153 ribonuclease, RNase A family, 2 (liver, eosinophil-derived neurotoxin) 
P01857 immunoglobulin heavy constant gamma 1 (G1m marker); immunoglobulin heavy constant mu; 
immunoglobulin heavy variable 3-7; immunoglobulin heavy constant gamma 3 (G3m marker); 
immunoglobulin heavy variable 3-11 (gene/pseudogene); immunoglobulin heavy variable 4-31; 
immunoglobulin heavy locus 
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P01871 immunoglobulin heavy constant gamma 1 (G1m marker); immunoglobulin heavy constant mu; 
immunoglobulin heavy variable 3-7; immunoglobulin heavy constant gamma 3 (G3m marker); 
immunoglobulin heavy variable 3-11 (gene/pseudogene); immunoglobulin heavy variable 4-31; 
immunoglobulin heavy locus 
P01860 immunoglobulin heavy constant gamma 1 (G1m marker); immunoglobulin heavy constant mu; 
immunoglobulin heavy variable 3-7; immunoglobulin heavy constant gamma 3 (G3m marker); 
immunoglobulin heavy variable 3-11 (gene/pseudogene); immunoglobulin heavy variable 4-31; 
immunoglobulin heavy locus 
P51654 glypican 3 
O96009 napsin A aspartic peptidase 
P12109 collagen, type VI, alpha 1 
P17174 glutamic-oxaloacetic transaminase 1, soluble (aspartate aminotransferase 1) 
P09525 annexin A4 
P08236 glucuronidase, beta 
P01133 epidermal growth factor (beta-urogastrone) 
P19801 amiloride binding protein 1 (amine oxidase (copper-containing)) 
P12035 keratin 3 
P02748 complement component 9 
P49721 proteasome (prosome, macropain) subunit, beta type, 2 
P05026 ATPase, Na+/K+ transporting, beta 1 polypeptide 
P15311 hypothetical protein LOC100129652; ezrin 
P15924 Desmoplakin 
P68104 eukaryotic translation elongation factor 1 alpha-like 7; eukaryotic translation elongation factor 1 alpha-like 3; 
similar to eukaryotic translation elongation factor 1 alpha 1; eukaryotic translation elongation factor 1 alpha 1 
P11279 lysosomal-associated membrane protein 1 
P35527 keratin 9 
P02765 alpha-2-HS-glycoprotein 
Q5SZK8 FRAS1 related extracellular matrix protein 2 
Q7Z7M0 multiple EGF-like-domains 8 
P04406 glyceraldehyde-3-phosphate dehydrogenase-like 6; hypothetical protein LOC100133042; glyceraldehyde-3-
phosphate dehydrogenase 
P36955 serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1 
P05154 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 
Q99519 sialidase 1 (lysosomal sialidase) 
O75636 ficolin (collagen/fibrinogen domain containing) 3 (Hakata antigen) 
Q8WW52 family with sequence similarity 151, member A 
Q86YZ3 Hornerin 
P05109 S100 calcium binding protein A8 
P30041 peroxiredoxin 6 
P15289 arylsulfatase A 
Q9HBJ8 transmembrane protein 27 
P23526 Adenosylhomocysteinase 
P14618 similar to Pyruvate kinase, isozymes M1/M2 (Pyruvate kinase muscle isozyme) (Cytosolic thyroid hormone-
binding protein) (CTHBP) (THBP1); pyruvate kinase, muscle 
P63261 actin, gamma 1 
P01042 kininogen 1 
P01764 immunoglobulin heavy variable 3-23; immunoglobulin heavy variable group 
P04196 histidine-rich glycoprotein 
P16278 galactosidase, beta 1 
O75340 aryl-hydrocarbon receptor repressor; programmed cell death 6 
212 
 
Q9C0H2 tweety homolog 3 (Drosophila) 
Q8N0V5 glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group) 
P09467 fructose-1,6-bisphosphatase 1 
P21266 glutathione S-transferase mu 3 (brain) 
Q53GD3 solute carrier family 44, member 4 
P68871 hemoglobin, beta 
O95865 dimethylarginine dimethylaminohydrolase 2 
P60022 defensin, beta 1 
P01593 similar to hCG1642538 
P00966 argininosuccinate synthetase 1 
P08962 CD63 molecule 
P00751 complement factor B 
P12273 prolactin-induced protein 
P61626 lysozyme (renal amyloidosis) 
P04746 amylase, alpha 2A (pancreatic) 
P01023 alpha-2-macroglobulin 
P23284 peptidylprolyl isomerase B (cyclophilin B) 
P39059 collagen, type XV, alpha 1 
P24855 deoxyribonuclease I 
Q6EMK4 Vasorin 
P11117 acid phosphatase 2, lysosomal 
Q9Y6W3 calpain 7 
P34059 galactosamine (N-acetyl)-6-sulfate sulfatase 
P19835 carboxyl ester lipase (bile salt-stimulated lipase) 
Q9Y6R7 Fc fragment of IgG binding protein; similar to IgGFc-binding protein precursor (FcgammaBP) (Fcgamma-
binding protein antigen) 
P02753 retinol binding protein 4, plasma 
Q7Z4W1 dicarbonyl/L-xylulose reductase 
P60033 CD81 molecule 
Q08380 lectin, galactoside-binding, soluble, 3 binding protein 
P08603 complement factor H 
Q7Z794 keratin 77 
Q9H1C7 chromosome 5 open reading frame 32 
P35858 insulin-like growth factor binding protein, acid labile subunit 
P01876 immunoglobulin heavy constant alpha 1 
P02649 hypothetical LOC100129500; apolipoprotein E 
Q04695 keratin 17; keratin 17 pseudogene 3 
P02774 group-specific component (vitamin D binding protein) 
P14384 carboxypeptidase M 
O60814 histone cluster 1, H2bk 
P04350 tubulin, beta 4 
O95336 6-phosphogluconolactonase 
P01880 immunoglobulin heavy constant delta 
P12821 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 
P00747 Plasminogen 
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P02746 complement component 1, q subcomponent, B chain 
Q6UXG3 CD300 molecule-like family member g 
P00450 ceruloplasmin (ferroxidase) 
P06280 galactosidase, alpha 
Q96FQ6 S100 calcium binding protein A16 
Q9H853 tubulin, alpha 4b (pseudogene) 
P00558 phosphoglycerate kinase 1 
P15309 acid phosphatase, prostate 
P35908 keratin 2 
O00322 uroplakin 1A 
P00918 carbonic anhydrase II 
P04264 keratin 1 
P02533 keratin 14 
Q8IWA5 solute carrier family 44, member 2 
P08294 superoxide dismutase 3, extracellular 
P02788 Lactotransferrin 
P62805 histone cluster 1, H4l; histone cluster 1, H4k; histone cluster 4, H4; histone cluster 1, H4h; histone cluster 1, 
H4j; histone cluster 1, H4i; histone cluster 1, H4d; histone cluster 1, H4c; histone cluster 1, H4f; histone 
cluster 1, H4e; histone cluster 1, H4b; histone cluster 1, H4a; histone cluster 2, H4a; histone cluster 2, H4b 
P60709 actin, beta 
Q8N271 prominin 2 
P48061 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 
P05156 complement factor I 
P02751 fibronectin 1 
P08238 heat shock protein 90kDa alpha (cytosolic), class B member 1 
P06396 gelsolin (amyloidosis, Finnish type) 
P54802 N-acetylglucosaminidase, alpha- 
P00749 plasminogen activator, urokinase 
Q5VW32 chromosome 1 open reading frame 58 
Q99835 smoothened homolog (Drosophila) 
P60953 cell division cycle 42 (GTP binding protein, 25kDa); cell division cycle 42 pseudogene 2 
Q9NS93 transmembrane 7 superfamily member 3 
Q86UD1 OAF homolog (Drosophila) 
Q6UX06 olfactomedin 4 
Q6UX73 chromosome 16 open reading frame 89 
P01031 complement component 5 
P19823 inter-alpha (globulin) inhibitor H2 
P05155 serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 
P55083 microfibrillar-associated protein 4 
P42785 prolylcarboxypeptidase (angiotensinase C) 
O75882 Attractin 
P62879 guanine nucleotide binding protein (G protein), beta polypeptide 2 
P02749 apolipoprotein H (beta-2-glycoprotein I) 
Q9NP79 Vps20-associated 1 homolog (S. cerevisiae) 
P05090 apolipoprotein D 
P22352 glutathione peroxidase 3 (plasma) 
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P00734 coagulation factor II (thrombin) 
P04217 alpha-1-B glycoprotein 
P19652 orosomucoid 2 
P02760 alpha-1-microglobulin/bikunin precursor 
P29972 aquaporin 1 (Colton blood group) 
P02679 fibrinogen gamma chain 
P08195 solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 
P01009 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 
P08185 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 6 
P50995 annexin A11 
P03951 coagulation factor XI 
P06312 immunoglobulin kappa variable 4-1 
P08133 annexin A6 
P51884 Lumican 
Q9Y646 plasma glutamate carboxypeptidase 
P15291 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1 
Q99988 growth differentiation factor 15 
P08779 keratin 16; keratin type 16-like 
Q12794 hyaluronoglucosaminidase 1 
O75594 peptidoglycan recognition protein 1 
P07357 complement component 8, alpha polypeptide 
P08697 serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 2 
P07996 thrombospondin 1 
P07195 lactate dehydrogenase B 
Q93088 betaine-homocysteine methyltransferase 
Q9BQE3 tubulin, alpha 1c 
O43895 X-prolyl aminopeptidase (aminopeptidase P) 2, membrane-bound 
P01877 immunoglobulin heavy constant alpha 2 (A2m marker) 
P35241 Radixin 
O75787 ATPase, H+ transporting, lysosomal accessory protein 2 
P06870 kallikrein 1 
P11142 heat shock 70kDa protein 8 
P10599 Thioredoxin 
P21399 aconitase 1, soluble 
O75351 vacuolar protein sorting 4 homolog B (S. cerevisiae) 
P55017 solute carrier family 12 (sodium/chloride transporters), member 3 
P04083 annexin A1 
Q9HC84 mucin 5B, oligomeric mucus/gel-forming 
Q96FN5 kinesin family member 12 
P02763 orosomucoid 1 
P16444 dipeptidase 1 (renal) 
P13647 keratin 5 
P53634 cathepsin C 
O75955 flotillin 1 
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P02750 leucine-rich alpha-2-glycoprotein 1 
Q86T13 C-type lectin domain family 14, member A 
P68366 tubulin, alpha 4a 
P07355 annexin A2 pseudogene 3; annexin A2; annexin A2 pseudogene 1 
P02743 amyloid P component, serum 
Q96RW7 hemicentin 1 
P04003 complement component 4 binding protein, alpha 
P22891 protein Z, vitamin K-dependent plasma glycoprotein 
Q92673 sortilin-related receptor, L(DLR class) A repeats-containing 
P00738 haptoglobin-related protein; haptoglobin 
Q14393 similar to growth arrest-specific 6; growth arrest-specific 6 
P14923 junction plakoglobin 
P02790 Hemopexin 
P27487 dipeptidyl-peptidase 4 
P0C0L4 complement component 4A (Rodgers blood group) 
Q14CN4 keratin 72 
Q3LXA3 dihydroxyacetone kinase 2 homolog (S. cerevisiae) 
P62258 similar to 14-3-3 protein epsilon (14-3-3E) (Mitochondrial import stimulation factor L subunit) (MSF L); 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide 
Q9BYF1 angiotensin I converting enzyme (peptidyl-dipeptidase A) 2 
O43653 prostate stem cell antigen 
P09211 glutathione S-transferase pi 1 
P61970 nuclear transport factor 2 
P27105 Stomatin 
P01591 immunoglobulin J polypeptide, linker protein for immunoglobulin alpha and mu polypeptides 
Q9UBV8 penta-EF-hand domain containing 1 
Q8WVN6 secreted and transmembrane 1 
P31639 solute carrier family 5 (sodium/glucose cotransporter), member 2 
Q9UN37 vacuolar protein sorting 4 homolog A (S. cerevisiae) 
P61026 RAB10, member RAS oncogene family 
P06744 glucose phosphate isomerise 
P06733 enolase 1, (alpha) 
Q92820 gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase) 
P12429 annexin A3 
Q02383 semenogelin II 
P0C0L5 complement component 4B (Chido blood group) 
P10643 complement component 7 
P02792 similar to ferritin, light polypeptide; ferritin, light polypeptide 
P01034 cystatin C 
P12814 actinin, alpha 1 
Q02413 desmoglein 1 
P06727 apolipoprotein A-IV 
P12111 collagen, type VI, alpha 3 
Q14314 fibrinogen-like 2 
Q14019 coactosin-like 1 (Dictyostelium) 
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P01833 polymeric immunoglobulin receptor 
P08758 annexin A5 
Q15485 ficolin (collagen/fibrinogen domain containing lectin) 2 (hucolin) 
O43451 maltase-glucoamylase (alpha-glucosidase) 
Q14108 scavenger receptor class B, member 2 
P04114 apolipoprotein B (including Ag(x) antigen) 
Q6W4X9 mucin 6, oligomeric mucus/gel-forming 
O00187 mannan-binding lectin serine peptidase 2 
Q8TF66 leucine rich repeat containing 15 
P02747 complement component 1, q subcomponent, C chain 
P06702 S100 calcium binding protein A9 
P18428 lipopolysaccharide binding protein 
Q7Z5L0 vitelline membrane outer layer 1 homolog (chicken) 
P07358 complement component 8, beta polypeptide 
P21926 CD9 molecule 
O60637 tetraspanin 3 
P54652 heat shock 70kDa protein 2 
P04004 Vitronectin 
P08107 heat shock 70kDa protein 1A; heat shock 70kDa protein 1B 
P21796 voltage-dependent anion channel 1; similar to voltage-dependent anion channel 1 
P14550 aldo-keto reductase family 1, member A1 (aldehyde reductase) 
P10619 cathepsin A 
Q7RTS7 keratin 74 
O43490 prominin 1 
P09543 2',3'-cyclic nucleotide 3' phosphodiesterase 
P40925 malate dehydrogenase 1, NAD (soluble) 
O60494 cubilin (intrinsic factor-cobalamin receptor) 
Q9UGT4 sushi domain containing 2 
Q8NFJ5 G protein-coupled receptor, family C, group 5, member A 
P81605 Dermcidin 
P05164 Myeloperoxidase 
Q8N1N4 keratin 78 
P31944 caspase 14, apoptosis-related cysteine peptidase 
Q96SA4 serine incorporator 2 
P04066 fucosidase, alpha-L- 1, tissue 
P22792 carboxypeptidase N, polypeptide 2 
P02671 fibrinogen alpha chain 
Q07075 glutamyl aminopeptidase (aminopeptidase A) 
P19961 amylase, alpha 2B (pancreatic) 
O43633 chromatin modifying protein 2A 
P13164 interferon induced transmembrane protein 1 (9-27) 
Q96DA0 zymogen granule protein 16 homolog B (rat) 
Q495M3 solute carrier family 36 (proton/amino acid symporter), member 2 
Q96KN2 carnosine dipeptidase 1 (metallopeptidase M20 family) 
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P02768 Albumin 
P01859 immunoglobulin heavy constant gamma 2 (G2m marker) 
Q9HB40 serine carboxypeptidase 1 
Q8WUM4 programmed cell death 6 interacting protein 
P07911 Uromodulin 
P15144 alanyl (membrane) aminopeptidase 
Q16706 mannosidase, alpha, class 2A, member 1 
P01834 similar to hCG26659; immunoglobulin kappa constant; similar to Ig kappa chain V-I region HK102 precursor 
P19971 thymidine phosphorylase 
Q9H223 EH-domain containing 4 
Q16769 glutaminyl-peptide cyclotransferase 
P07288 kallikrein-related peptidase 3 
Q9HBA9 folate hydrolase 1B 
P45877 peptidylprolyl isomerase C (cyclophilin C) 
P13646 keratin 13 
P02647 apolipoprotein A-I 
P13473 lysosomal-associated membrane protein 2 
Q9Y2S2 crystallin, lambda 1 
P25787 proteasome (prosome, macropain) subunit, alpha type, 2 
Q9UKU6 thyrotropin-releasing hormone degrading enzyme 
P59665 defensin, alpha 1 
P16152 carbonyl reductase 1 
Q9UIQ6 leucyl/cystinyl aminopeptidase 
P08571 CD14 molecule 
P19012 keratin 15 
P43251 Biotinidase 
P01019 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 
P52209 phosphogluconate dehydrogenase 
P60174 TPI1 pseudogene; triosephosphate isomerase 1 
P00338 lactate dehydrogenase A 
P61586 ras homolog gene family, member A 
P63092 GNAS complex locus 
P02538 keratin 6A 
P53801 pituitary tumor-transforming 1 interacting protein 
P27169 paraoxonase 1 
P54793 arylsulfatase F 
P31151 S100 calcium binding protein A7 
Q6I9Y2 THO complex 7 homolog (Drosophila) 
P63096 guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 
Q16270 insulin-like growth factor binding protein 7 
P51688 N-sulfoglucosamine sulfohydrolase 
P14543 nidogen 1 
P08473 membrane metallo-endopeptidase 
P01617 hypothetical LOC440786 
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P04745 amylase, alpha 1A (salivary); amylase, alpha 1B (salivary); amylase, alpha 1C (salivary) 
P27105 phosphatidylethanolamine binding protein 1 
P13645 keratin 10 
Q6UWR7 ectonucleotide pyrophosphatase/phosphodiesterase 6 
P62873 guanine nucleotide binding protein (G protein), beta polypeptide 1 
O00182 lectin, galactoside-binding, soluble, 9 
P26038 Moesin 
P49221 transglutaminase 4 (prostate) 
P17050 N-acetylgalactosaminidase, alpha- 
Q9BRK3 matrix-remodelling associated 8 
P05062 aldolase B, fructose-bisphosphate 
Q9HD89 Resistin 
Q96P63 serpin peptidase inhibitor, clade B (ovalbumin), member 12 
P08263 glutathione S-transferase alpha 1 
P19013 keratin 4 
P02787 Transferring 
P04259 keratin 6B 
Q9NZP8 complement component 1, r subcomponent-like 
Q8WZ75 roundabout homolog 4, magic roundabout (Drosophila) 
P02794 ferritin, heavy polypeptide 1; ferritin, heavy polypeptide-like 16; similar to ferritin, heavy polypeptide 1; 
ferritin, heavy polypeptide-like 3 pseudogene 
Q9H8L6 multimerin 2 
P25311 alpha-2-glycoprotein 1, zinc-binding pseudogene 1; alpha-2-glycoprotein 1, zinc-binding 
Q9UKU9 angiopoietin-like 2 
Q13621 solute carrier family 12 (sodium/potassium/chloride transporters), member 1 
Q9BYZ2 lactate dehydrogenase A-like 6B 
O00468 Agrin 
P98164 low density lipoprotein-related protein 2 
P01768 Ig heavy chain V-III region CAM 
P0CG04 Ig lambda-1 chain C regions 
P04220 Ig mu heavy chain disease protein 
P01613 Ig kappa chain V-I region Ni 
P01770 Ig heavy chain V-III region NIE 
P01779 Ig heavy chain V-III region TUR 
P01621 Ig kappa chain V-III region NG9 (Fragment) 
P04208 Ig lambda chain V-I region WAH 
P01769 Ig heavy chain V-III region GA 
P01620 Ig kappa chain V-III region SIE 
P01598 Ig kappa chain V-I region EU 
P01714 Ig lambda chain V-III region SH 
P0CG05 Ig lambda-2 chain C regions 
P80748 Ig lambda chain V-III region LOI 
P01777 Ig heavy chain V-III region TEI 
P01766 Ig heavy chain V-III region BRO 
P0CG48 Polyubiquitin-C 
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P01762 Ig heavy chain V-III region TRO 
P01765 Ig heavy chain V-III region TIL 
P04207 Ig kappa chain V-III region CLL (Rheumatoid factor) 
P01781 Ig heavy chain V-III region GAL 
P01619 Ig kappa chain V-III region B6 
P01616 Ig kappa chain V-II region MIL 
P01625 Ig kappa chain V-IV region Len 
 
Supplementary table S3.2: The following genes were annotated and classified as being 
related to human diseases as evidenced by their OMIM IDs mapped using DAVID 
Bioinformatics Resources 6.7, National Institute of Allergy and Infectious Diseases (NIAID), 
NIH. Uniprot Id, gene name and OMIM disease names are given in the table. 
ID Gene Name OMIM_DISEASE 
P08183 ATP-binding cassette, sub-family B (MDR/TAP), 
member 1 
Colchicine resistance,Inflammatory bowel disease 13, 
susceptibility to, 
O75787 ATPase, H+ transporting, lysosomal accessory 
protein 2 
Mental retardation, X-linked, with epilepsy, 
P05026 ATPase, Na+/K+ transporting, beta 1 
polypeptide 
Blood pressure regulation QTL, 
P13987 CD59 molecule, complement regulatory protein CD59 deficiency, 
Q12805 EGF-containing fibulin-like extracellular matrix 
protein 1 
Doyne honeycomb degeneration of retina,Genome-wide 
association analysis identifies 20 loci that influence adult 
height,Many sequence variants affecting diversity of adult 
human height, 
Q5SZK8 FRAS1 related extracellular matrix protein 2 Fraser syndrome, 
P63092 GNAS complex locus Acromegaly,McCune-Albright syndrome,Osseous heteroplasia, 
progressive,Pituitary ACTH secreting adenoma,Pituitary ACTH 
secreting adenoma, somatic,Pituitary ACTH secreting 
adenoma, somatic 219090,Prolonged bleeding time, 
brachydactyly and mental 
retardation,Pseudohypoparathyroidism 
Ia,Pseudohypoparathyroidism Ib,Pseudohypoparathyroidism, 
type Ia,Pseudohypoparathyroidism, type 
Ib,Pseudopseudohypoparathyroidism,Somatotrophinoma, 
P17050 N-acetylgalactosaminidase, alpha- Kanzaki disease,Schindler disease, type I,Schindler disease, 
type III, 
P54802 N-acetylglucosaminidase, alpha- mucopolysaccharidosis type IIIB,Sanfilippo syndrome, type B, 
Q13510 N-acylsphingosine amidohydrolase (acid 
ceramidase) 1 
Farber lipogranulomatosis, 
P51688 N-sulfoglucosamine sulfohydrolase Sanfilippo syndrome, type A, 
P60174 TPI1 pseudogene; triosephosphate isomerase 1 Hemolytic anemia due to triosephosphate isomerase 
deficiency, 
P15291 UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 1 
Congenital disorder of glycosylation, type IId, 
O43895 X-prolyl aminopeptidase (aminopeptidase P) 2, 
membrane-bound 
Angioedema induced by ACE inhibitors, susceptibility to, 
P60709 actin, beta Dystonia, juvenile-onset, 
P63261 actin, gamma 1 Deafness, autosomal dominant 20/26, 
P23526 Adenosylhomocysteinase Hypermethioninemia with deficiency of S-
adenosylhomocysteine hydrolase, 
P02768 Albumin Analbuminemia,Dysalbuminemic 
hyperthyroxinemia,Dysalbuminemic hyperzincemia, 
P05062 aldolase B, fructose-bisphosphate Fructose intolerance, 
P01023 alpha-2-macroglobulin Alzheimer disease, susceptibility to,Emphysema due to alpha-
2-macroglobulin deficiency, 
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Q03154 aminoacylase 1 Aminoacylase 1 deficiency, 
P02743 amyloid P component, serum ?Amyloidosis, secondary, susceptibility to, 
P12821 angiotensin I converting enzyme (peptidyl-
dipeptidase A) 1 
Alzheimer disease, susceptibility to,Angiotensin I-converting 
enzyme, benign serum increase,Diabetic nephropathy, 
susceptibility to,Microvascular complications of diabetes 
3,Myocardial infarction, susceptibility to,Renal tubular 
dysgenesis,SARS, progression of, 
P01019 angiotensinogen (serpin peptidase inhibitor, 
clade A, member 8) 
Hypertension, essential, susceptibility to,Preeclampsia, 
susceptibility to,Renal tubular dysgenesis, 
P02647 apolipoprotein A-I A null mutation in human APOC3 confers a favorable plasma 
lipid profile and apparent cardioprotection,Amyloidosis, 3 or 
more types,ApoA-I and apoC-III deficiency, 
combined,Common variants at 30 loci contribute to polygenic 
dyslipidemia,Corneal clouding, autosomal recessive,Genome-
wide association study identifies genes for biomarkers of 
cardiovascular disease: serum urate and 
dyslipidemia,Genome-wide scan identifies variation in MLXIPL 
associated with plasma triglycerides,Hypertriglyceridemia, 
one form,Hypoalphalipoproteinemia,Loci influencing lipid 
levels and coronary heart disease risk in 16 European 
population cohorts,Newly identified loci that influence lipid 
concentrations and risk of coronary artery disease,Six new 
loci associated with blood low-density lipoprotein cholesterol, 
high-density lipoprotein cholesterol or triglycerides in 
humans, 
P06727 apolipoprotein A-IV A null mutation in human APOC3 confers a favorable plasma 
lipid profile and apparent cardioprotection,Common variants 
at 30 loci contribute to polygenic dyslipidemia,Loci influencing 
lipid levels and coronary heart disease risk in 16 European 
population cohorts,Newly identified loci that influence lipid 
concentrations and risk of coronary artery disease,Six new 
loci associated with blood low-density lipoprotein cholesterol, 
high-density lipoprotein cholesterol or triglycerides in 
humans, 
P04114 apolipoprotein B (including Ag(x) antigen) Common variants at 30 loci contribute to polygenic 
dyslipidemia,Genome-wide association analysis of metabolic 
traits in a birth cohort from a founder 
population,Hypercholesterolemia, due to ligand-defective apo 
B,Hypobetalipoproteinemia,Hypobetalipoproteinemia, 
normotriglyceridemic,LDL-cholesterol concentrations: a 
genome-wide association study,Loci influencing lipid levels 
and coronary heart disease risk in 16 European population 
cohorts,Newly identified loci that influence lipid 
concentrations and risk of coronary artery disease,Six new 
loci associated with blood low-density lipoprotein cholesterol, 
high-density lipoprotein cholesterol or triglycerides in 
humans, 
P02749 apolipoprotein H (beta-2-glycoprotein I) Apolipoprotein H deficiency, 
P29972 aquaporin 1 (Colton blood group) Aquaporin-1 deficiency,Blood group, Colton, 
P00966 argininosuccinate synthetase 1 Citrullinemia, 
P15289 arylsulfatase A Metachromatic leukodystrophy, 
P43251 Biotinidase Biotinidase deficiency, 
P00918 carbonic anhydrase II Osteopetrosis, autosomal recessive 3, with renal tubular 
acidosis,Renal tubular acidosis-osteopetrosis syndrome, 
P19835 carboxyl ester lipase (bile salt-stimulated lipase) Maturity-onset diabetes of the young, type VIII, 
Q9H3G5 carboxypeptidase, vitellogenic-like Genome-wide association with diabetes-related traits in the 
Framingham Heart Study, 
P10619 cathepsin A Galactosialidosis, 
P53634 cathepsin C Haim-Munk syndrome,Papillon-Lefevre 
syndrome,Periodontitis, juvenile, 
P07339 cathepsin D Ceroid lipofuscinosis, neuronal, 10, 
P00450 ceruloplasmin (ferroxidase) Cerebellar ataxia,Hemosiderosis, systemic, due to 
aceruloplasminemia,Hypoceruloplasminemia, hereditary, 
P48061 chemokine (C-X-C motif) ligand 12 (stromal cell-
derived factor 1) 
AIDS, resistance to,Genomewide association analysis of 
coronary artery disease, 
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P11597 cholesteryl ester transfer protein, plasma CETP deficiency,Common genetic variation near MC4R is 
associated with waist circumference and insulin 
resistance,Common variants at 30 loci contribute to polygenic 
dyslipidemia,Genome-wide association analysis of metabolic 
traits in a birth cohort from a founder population,High density 
lipoprotein cholesterol level QTL 
10,Hyperalphalipoproteinemia,Loci influencing lipid levels and 
coronary heart disease risk in 16 European population 
cohorts,Longevity, exceptional,Newly identified loci that 
influence lipid concentrations and risk of coronary artery 
disease,Six new loci associated with blood low-density 
lipoprotein cholesterol, high-density lipoprotein cholesterol or 
triglycerides in humans, 
Q9H444 chromatin modifying protein 4B Cataract, posterior polar, 3,Cataract, posterior polar-3, 
P00734 coagulation factor II (thrombin) Dysprothrombinemia,Hyperprothrombinemia,Hypoprothrombi
nemia, 
P03951 coagulation factor XI Factor XI deficiency, autosomal dominant,Factor XI 
deficiency, autosomal recessive, 
P12109 collagen, type VI, alpha 1 Bethlem myopathy,Ossification of the posterior longitudinal 
spinal ligaments,Ullrich congenital muscular dystrophy, 
P12111 collagen, type VI, alpha 3 Bethlem myopathy,Ullrich congenital muscular dystrophy, 
P02746 complement component 1, q subcomponent, B 
chain 
C1q deficiency, type B, 
P02747 complement component 1, q subcomponent, C 
chain 
C1q deficiency, type C, 
P0C0L4 complement component 4A (Rodgers blood 
group) 
Blood group, Rodgers,C4 deficiency,Systemic lupus 
erythematosus, susceptibility to or protection against, 
P0C0L5 complement component 4B (Chido blood group) C4 deficiency, 
P01031 complement component 5 C5 deficiency,Liver fibrosis, susceptibility to, 
P10643 complement component 7 C7 deficiency, 
P07357 complement component 8, alpha polypeptide C8 deficiency, type I, 
P07358 complement component 8, beta polypeptide C8 deficiency, type II, 
P02748 complement component 9 C9 deficiency,C9 deficiency with dermatomyositis, 
P00751 complement factor B Macular degeneration, age-related, reduced risk of, 
P08603 complement factor H Basal laminar drusen,Complement factor H 
deficiency,Complement factor H polymorphism in age-related 
macular degeneration,Factor H and factor H-like 1,Hemolytic-
uremic syndrome,Macular degeneration, age-related, 
4,Membranoproliferative glomerulonephritis with CFH 
deficiency,Myocardial infarction, susceptibility to, 
P05156 complement factor I C3b inactivator deficiency,Complement factor I deficiency, 
O60494 cubilin (intrinsic factor-cobalamin receptor) Megaloblastic anemia-1, Finnish type, 
P01034 cystatin C A genome-wide association for kidney function and 
endocrine-related traits in the NHLBI's Framingham Heart 
Study,Cerebral amyloid angiopathy,Macular degeneration, 
age-related, 11, 
P24855 deoxyribonuclease I Systemic lupus erythematosus, susceptibility to, 
P81605 Dermcidin Meta-analysis of genome-wide association data and large-
scale replication identifies additional susceptibility loci for type 
2 diabetes, 
Q02413 desmoglein 1 Keratosis palmoplantaris striata I, 
P15924 Desmoplakin Arrhythmogenic right ventricular dysplasia 8,Dilated 
cardiomyopathy with woolly hair and 
keratoderma,Epidermolysis bullosa, lethal 
acantholytic,Keratosis palmoplantaris striata II,Skin fragility-
woolly hair syndrome, 
P06733 enolase 1, (alpha) Enolase deficiency, 
P01133 epidermal growth factor (beta-urogastrone) Hypomagnesemia 4, renal, 
P02794 ferritin, heavy polypeptide 1; ferritin, heavy 
polypeptide-like 16; similar to ferritin, heavy 
polypeptide 1; ferritin, heavy polypeptide-like 3 
pseudogene 
Iron overload, autosomal dominant, 
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P02671 fibrinogen alpha chain Afibrinogenemia, congenital,Amyloidosis, hereditary 
renal,Dysfibrinogenemia, alpha type, causing bleeding 
diathesis,Dysfibrinogenemia, alpha type, causing recurrent 
thrombosis, 
P02675 fibrinogen beta chain Afibrinogenemia, congenital,Dysfibrinogenemia, beta 
type,Thrombophilia, dysfibrinogenemic, 
P02679 fibrinogen gamma chain Dysfibrinogenemia, gamma type,Hypofibrinogenemia, gamma 
type,Thrombophilia, dysfibrinogenemic, 
P02751 fibronectin 1 Glomerulopathy with fibronectin deposits 2,Glomerulopathy, 
fibronectin, 
P09467 fructose-1,6-bisphosphatase 1 Fructose-1,6-bidphosphatase deficiency,Fructose-
bisphosphatase deficiency, 
P04066 fucosidase, alpha-L- 1, tissue Fucosidosis, 
P34059 galactosamine (N-acetyl)-6-sulfate sulfatase Mucopolysaccharidosis IVA, 
P06280 galactosidase, alpha Fabry disease,Fabry disease, cardiac variant, 
P16278 galactosidase, beta 1 GM1-gangliosidosis,GM1-gangliosidosis, type I,GM1-
gangliosidosis, type II,GM1-gangliosidosis, type III,Morquio 
syndrome B,Mucopolysaccharidosis IVB, 
P19440 gamma-glutamyltransferase light chain 3; 
gamma-glutamyltransferase 4 pseudogene; 
gamma-glutamyltransferase 2; gamma-
glutamyltransferase 1; gamma-
glutamyltransferase light chain 5 pseudogene 
A Genome-Wide Association Study Identifies Protein 
Quantitative Trait Loci (pQTLs),Gamma-glutamyltransferase, 
familial high serum,Glutathionuria,Population-based genome-
wide association studies reveal six loci influencing plasma 
levels of liver enzymes, 
P06396 gelsolin (amyloidosis, Finnish type) Amyloidosis, Finnish type, 
Q8N0V5 glucosaminyl (N-acetyl) transferase 2, I-
branching enzyme (I blood group) 
Adult i phenotype with congenital cataract,Adult i phenotype 
without cataract,Blood group, Ii,Juvenile congenital cataract, 
P06744 glucose phosphate isomerise Hemolytic anemia due to glucosephosphate isomerase 
deficiency,Hydrops fetalis, one form, 
P10253 glucosidase, alpha; acid Glycogen storage disease II, 
P08236 glucuronidase, beta Mucopolysaccharidosis VII, 
Q07075 glutamyl aminopeptidase (aminopeptidase A) Variants conferring risk of atrial fibrillation on chromosome 
4q25, 
P51654 glypican 3 Simpson-Golabi-Behmel syndrome, type 1,Wilms tumor, 
somatic, 
Q92896 golgi apparatus protein 1 A pilot genome-wide association study of early-onset breast 
cancer, 
P02774 group-specific component (vitamin D binding 
protein) 
Graves disease, susceptibility to, 3, 
P50148 guanine nucleotide binding protein (G protein), q 
polypeptide 
Bleeding diathesis due to GNAQ deficiency, 
P00738 haptoglobin-related protein; haptoglobin Anhaptoglobinemia,Hypohaptoglobinemia, 
Q96RW7 hemicentin 1 Macular degeneration, age-related, 1, 
P69905 hemoglobin, alpha 2; hemoglobin, alpha 1 Erythremias, alpha-,Erythrocytosis,Heinz body anemia,Heinz 
body anemias, alpha-,Hemoglobin H disease,Hypochromic 
microcytic anemia,Methemoglobinemias, alpha-,Thalassemia, 
alpha-,Thalassemias, alpha-, 
P68871 hemoglobin, beta A QTL influencing F cell production maps to a gene encoding 
a zinc-finger protein on chromosome 2p15,Erythremias, beta-
,Genome-wide association study shows BCL11A associated 
with persistent fetal hemoglobin and amelioration of the 
phenotype of beta-thalassemia,Heinz body anemias, beta-
,Hereditary persistence of fetal hemoglobin,HPFH, deletion 
type,Methemoglobinemias, beta-,Sickle cell 
anemia,Thalassemia-beta, dominant inclusion-
body,Thalassemias, beta-, 
P98160 heparan sulfate proteoglycan 2 Dyssegmental dysplasia, Silverman-Handmaker 
type,Schwartz-Jampel syndrome, type 1, 
P04196 histidine-rich glycoprotein ?Thrombophilia due to elevated HRG,Thrombophilia due to 
HRG deficiency, 
Q12794 hyaluronoglucosaminidase 1 Mucopolysaccharidosis type IX, 
P02649 hypothetical LOC100129500; apolipoprotein E A genome-wide association study for late-onset al.,zheimer's 
disease using DNA pooling,A high-density whole-genome 
association study reveals that APOE is the major susceptibility 
gene for sporadic late-onset al.,zheimer's disease,Alzheimer 
disease-2,Candidate single-nucleotide polymorphisms from a 
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genomewide association study of Alzheimer disease,Common 
SNPs in HMGCR in Micronesians and Whites Associated With 
LDL-Cholesterol Levels Affect Alternative Splicing of 
Exon13,Common variants at 30 loci contribute to polygenic 
dyslipidemia,Hyperlipoproteinemia, type III,Lipoprotein 
glomerulopathy,Loci influencing lipid levels and coronary 
heart disease risk in 16 European population cohorts,Loci 
Related to Metabolic-Syndrome Pathways Including LEPR, 
HNF1A, IL6R, and GCKR Associate with Plasma C-Reactive 
Protein: The Women's Genome Health Study,Macular 
degeneration, age-related,Myocardial infarction 
susceptibility,Newly identified loci that influence lipid 
concentrations and risk of coronary artery 
disease,Polymorphisms of the HNF1A Gene Encoding 
Hepatocyte Nuclear Factor-1 Alpha are Associated with C-
Reactive Protein,Sea-blue histiocyte disease,Six new loci 
associated with blood low-density lipoprotein cholesterol, 
high-density lipoprotein cholesterol or triglycerides in 
humans,Sorl1 as an Alzheimer's disease predisposition gene?, 
P01857, 
P01871, 
P01860 
immunoglobulin heavy constant gamma 1 (G1m 
marker); immunoglobulin heavy constant mu; 
immunoglobulin heavy variable 3-7; 
immunoglobulin heavy constant gamma 3 (G3m 
marker); immunoglobulin heavy variable 3-11 
(gene/pseudogene); immunoglobulin heavy 
variable 4-31; immunoglobulin heavy locus 
Agammaglobulinemia, 
P01859 immunoglobulin heavy constant gamma 2 (G2m 
marker) 
IgG2 deficiency, selective, 
P35858 insulin-like growth factor binding protein, acid 
labile subunit 
Acid-labile subunit, deficiency of, 
Q9Y287 integral membrane protein 2B Dementia, familial British,Dementia, familial Danish, 
Q14624 inter-alpha (globulin) inhibitor H4 (plasma 
Kallikrein-sensitive glycoprotein) 
Hypercholesterolemia, susceptibility to, 
P14923 junction plakoglobin Arrhythmogenic right ventricular dysplasia, familial, 12,Naxos 
disease, 
P06870 kallikrein 1 Kallikrein, decreased urinary activity of, 
P07288 kallikrein-related peptidase 3 Multiple newly identified loci associated with prostate cancer 
susceptibility, 
P04264 keratin 1 Cyclic ichthyosis with epidermolytic 
hyperkeratosis,Epidermolytic hyperkeratosis,Ichthyosis histrix, 
Curth-Macklin type,Keratosis palmoplantaria striata,Keratosis 
palmoplantaris striata III,Unna-Thost disease, 
nonepidermolytic, 
P13645 keratin 10 Epidermolytic hyperkeratosis,Ichthyosis, cyclic, with 
epidermolytic hyperkeratosis,Keratosis palmaris et 
plantaris,Nevus, epidermal, epidermolytic hyperkeratotic type, 
P13646 keratin 13 White sponge nevus, 
P02533 keratin 14 Dermatopathia pigmentosa reticularis,Epidermolysis bullosa 
simplex, Dowling-Meara type,Epidermolysis bullosa simplex, 
Koebner type,Epidermolysis bullosa simplex, Koebner, 
Dowling-Meara, and Weber-Cockayne types, 131900, 
131760,Epidermolysis bullosa simplex, 
recessive,Epidermolysis bullosa simplex, Weber-Cockayne 
type,Naegeli-Franceschetti-Jadassohn syndrome, 
P08779 keratin 16; keratin type 16-like Pachyonychia congenita, Jadassohn-Lewandowsky 
type,Palmoplantar keratoderma, 
nonepidermolytic,Palmoplantar verrucous nevus, unilateral, 
Q04695 keratin 17; keratin 17 pseudogene 3 Pachyonychia congenita, Jackson-Lawler type,Steatocystoma 
multiplex, 
P35908 keratin 2 Ichthyosis bullosa of Siemens, 
P12035 keratin 3 Meesmann corneal dystrophy, 
P19013 keratin 4 White sponge nevus, 
P13647 keratin 5 Dowling-Degos disease,Epidermolysis bullosa simplex with 
migratory circinate erythema,Epidermolysis bullosa simplex 
with mottled pigmentation,Epidermolysis bullosa simplex, 
Dowling-Meara type,Epidermolysis bullosa simplex, Koebner 
type,Epidermolysis bullosa simplex, Koebner, Dowling-Meara, 
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and Weber-Cockayne types, 131900, 131760,Epidermolysis 
bullosa simplex, Weber-Cockayne type, 
P02538 keratin 6A Pachyonychia congenita, Jadassohn-Lewandowsky type, 
P04259 keratin 6B Pachyonychia congenita, Jackson-Lawler type, 
P35527 keratin 9 Epidermolytic palmoplantar keratoderma, 
P01042 kininogen 1 Fitzgerald factor deficiency,High molecular weight kininogen 
deficiency,High-molecular-weight kininogen 
deficiency,Kininogen deficiency, 
P00338 lactate dehydrogenase A Exertional myoglobinuria due to deficiency of LDH-A, 
P07195 lactate dehydrogenase B Lactate dehydrogenase-B deficiency, 
P98164 low density lipoprotein-related protein 2 Donnai-Barrow syndrome, 
P13473 lysosomal-associated membrane protein 2 Glycogen storage disease IIb, 
P61626 lysozyme (renal amyloidosis) Amyloidosis, renal,Genomic association analysis suggests 
chromosome 12 locus influencing antihypertensive response 
to thiazide diuretic,Many sequence variants affecting diversity 
of adult human height, 
O00187 mannan-binding lectin serine peptidase 2 MASP2 deficiency, 
P08473 membrane metallo-endopeptidase Membranous glomerulonephritis, antenatal,Neutral 
endopeptidase deficiency, 
P05164 Myeloperoxidase Alzheimer disease, susceptibility to,Lung cancer, protection 
against, in smokers,Myeloperoxidase deficiency, 
P27169 paraoxonase 1 Coronary artery disease, susceptibility to,Coronary artery 
spasm, susceptibility to,Genome-wide association scan 
identifies candidate polymorphisms associated with 
differential response to anti-TNF treatment in Rheumatoid 
Arthritis,Organophosphate poisoning, sensitivity to, 
P00558 phosphoglycerate kinase 1 Myoglobinuria/hemolysis due to PGK 
deficiency,Phosphoglycerate kinase 1 deficiency, 
P00747 Plasminogen Conjunctivitis, ligneous,Plasminogen deficiency, types I and 
II,Plasminogen Tochigi disease,Thrombophilia, 
dysplasminogenemic, 
P00749 plasminogen activator, urokinase Alzheimer disease, late-onset, susceptibility to, 
P01833 polymeric immunoglobulin receptor IgA nephropathy, susceptibility to, 
O43490 prominin 1 Cone-rod dystrophy 12,Macular dystrophy 2, Bull's 
eye,Macular dystrophy, retinal, 2,Retinal degeneration, 
autosomal recessive, prominin-related,Retinitis pigmentosa-
41,Stargardt disease 4, 
P22891 protein Z, vitamin K-dependent plasma 
glycoprotein 
Genome-wide association and linkage analyses of hemostatic 
factors and hematological phenotypes in the Framingham 
Heart Study, 
Q12913 protein tyrosine phosphatase, receptor type, J Colon cancer, somatic, 
P35241 Radixin Deafness, autosomal recessive, 24, 
Q9HD89 Resistin Diabetes mellitus, noninsulin-dependent, susceptibility 
to,Hypertension, insulin resistance-related, susceptibility to, 
P02753 retinol binding protein 4, plasma Retinol binding protein, deficiency of, 
Q14108 scavenger receptor class B, member 2 Action myoclonus-renal failure syndrome, 
P01009 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 1 
Emphysema,Emphysema-cirrhosis,Hemorrhagic diathesis due 
to 'antithrombin' Pittsburgh,Hemorrhagic diathesis due to 
`antithrombin' Pittsburgh,Pulmonary disease, chronic 
obstructive, susceptibility to, 
P01011 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 3 
Alpha-1-antichymotrypsin deficiency,Cerebrovascular disease, 
occlusive, 
P05154 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 5 
Protein C inhibitor deficiency, 
P08185 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 6 
Corticosteroid-binding globulin deficiency,Transcortin 
deficiency, 
P05543 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 7 
Thyroxine-binding globulin deficiency, 
P01008 serpin peptidase inhibitor, clade C 
(antithrombin), member 1 
Antithrombin III deficiency, 
P05546 serpin peptidase inhibitor, clade D (heparin 
cofactor), member 1 
Thrombophilia due to heparin cofactor II deficiency, 
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P08697 serpin peptidase inhibitor, clade F (alpha-2 
antiplasmin, pigment epithelium derived factor), 
member 2 
Plasmin inhibitor deficiency, 
P05155 serpin peptidase inhibitor, clade G (C1 inhibitor), 
member 1 
Angioedema, hereditary,Angioedema, hereditary, types I and 
II,Complement component 4, partial deficiency of, 
Q99519 sialidase 1 (lysosomal sialidase) Sialidosis, type I,Sialidosis, type II, 
P62258 similar to 14-3-3 protein epsilon (14-3-3E) 
(Mitochondrial import stimulation factor L 
subunit) (MSF L); tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase 
activation protein, epsilon polypeptide 
Miller-Dieker lissencephaly, 
P53990 similar to CG10103; KIAA0174 Conduct disorder and ADHD: Evaluation of conduct problems 
as a categorical and quantitative trait in the international 
multicentre ADHD genetics study, 
P01024 similar to Complement C3 precursor; 
complement component 3; hypothetical protein 
LOC100133511 
C3 deficiency,Macular degeneration, age-related, 9, 
P02792 similar to ferritin, light polypeptide; ferritin, light 
polypeptide 
Basal ganglia disease, adult-onset,Hyperferritinemia-cataract 
syndrome, 
P01834 similar to hCG26659; immunoglobulin kappa 
constant; similar to Ig kappa chain V-I region 
HK102 precursor 
Kappa light chain deficiency, 
Q99835 smoothened homolog (Drosophila) Basal cell carcinoma, somatic, 
P55017 solute carrier family 12 (sodium/chloride 
transporters), member 3 
Gitelman syndrome, 
Q13621 solute carrier family 12 
(sodium/potassium/chloride transporters), 
member 1 
Bartter syndrome, type 1, 
P31639 solute carrier family 5 (sodium/glucose 
cotransporter), member 2 
Renal glucosuria, 
Q92673 sortilin-related receptor, L(DLR class) A repeats-
containing 
Alzheimer disease, pathogenesis, association with, 
P08294 superoxide dismutase 3, extracellular Superoxide dismutase, elevated extracellular, 
P19971 thymidine phosphorylase Mitochondrial neurogastrointestinal encephalomyopathy 
syndrome, 
P02787 Transferring Atransferrinemia,Iron deficiency anemia, susceptibility 
to,Variants in TF and HFE explain approximately 40% of 
genetic variation in serum-transferrin levels, 
P02766 Transthyretin Amyloid neuropathy, familial, several allelic types,Amyloid 
polyneuropathy, several types,Amyloidosis, senile 
systemic,Carpal tunnel syndrome, 
familial,Dystransthyretinemic hyperthyroxinemia, 
O14773 tripeptidyl peptidase I Ceroid-lipofuscinosis, neuronal 2, classic late infantile, 
P68366 tubulin, alpha 4a Many sequence variants affecting diversity of adult human 
height, 
Q99816 tumor susceptibility gene 101 Breast cancer, 
P63104 tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta 
polypeptide 
Conduct disorder and ADHD: Evaluation of conduct problems 
as a categorical and quantitative trait in the international 
multicentre ADHD genetics study, 
P07911 Uromodulin Glomerulocystic kidney disease with hyperuricemia and 
isosthenuria,Hyperuricemic nephropathy, familial 
juvenile,Medullary cystic kidney disease 2,Medullary cystic 
kidney disease 2 (autosomal dominant), 
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Supplementary table S3.3: The following genes were annotated and classified as having 
genetic association to cardiovascular diseases using DAVID Bioinformatics resources 6.7, 
National Institute of Allergy and Infectious Diseases (NIAID), NIH. Uniprot Ids and gene 
names are given. 
ID Gene Name 
P09543 2',3'-cyclic nucleotide 3' phosphodiesterase 
P08183 ATP-binding cassette, sub-family B (MDR/TAP), member 1 
P08571 CD14 molecule 
P63092 GNAS complex locus 
O43895 X-prolyl aminopeptidase (aminopeptidase P) 2, membrane-bound 
P23526 Adenosylhomocysteinase 
P02765 alpha-2-HS-glycoprotein 
P01023 alpha-2-macroglobulin 
P12821 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 
Q9BYF1 angiotensin I converting enzyme (peptidyl-dipeptidase A) 2 
P01019 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 
P08758 annexin A5 
P02647 apolipoprotein A-I 
P06727 apolipoprotein A-IV 
P04114 apolipoprotein B (including Ag(x) antigen) 
P02749 apolipoprotein H (beta-2-glycoprotein I) 
Q93088 betaine-homocysteine methyltransferase 
Q96KN2 carnosine dipeptidase 1 (metallopeptidase M20 family) 
P53634 cathepsin C 
P48061 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 
P11597 cholesteryl ester transfer protein, plasma 
P10909 Clusterin 
P00734 coagulation factor II (thrombin) 
P03951 coagulation factor XI 
P0C0L4 complement component 4A (Rodgers blood group) 
P0C0L5 complement component 4B (Chido blood group) 
P08603 complement factor H 
P01034 cystatin C 
P24855 deoxyribonuclease I 
O95865 dimethylarginine dimethylaminohydrolase 2 
P01133 epidermal growth factor (beta-urogastrone) 
P02671 fibrinogen alpha chain 
P02675 fibrinogen beta chain 
P02679 fibrinogen gamma chain 
P02751 fibronectin 1 
P06280 galactosidase, alpha 
Q16769 glutaminyl-peptide cyclotransferase 
P08263 glutathione S-transferase alpha 1 
P09211 glutathione S-transferase pi 1 
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P22352 glutathione peroxidase 3 (plasma) 
P00738 haptoglobin-related protein; haptoglobin 
P08107 heat shock 70kDa protein 1A; heat shock 70kDa protein 1B 
P68871 hemoglobin, beta 
P98160 heparan sulfate proteoglycan 2 
P02649 hypothetical LOC100129500; apolipoprotein E 
P06870 kallikrein 1 
P18428 lipopolysaccharide binding protein 
P05164 Myeloperoxidase 
P27169 paraoxonase 1 
P00747 Plasminogen 
P00749 plasminogen activator, urokinase 
P41222 prostaglandin D2 synthase, hematopoietic; prostaglandin D2 synthase 21kDa (brain) 
P22891 protein Z, vitamin K-dependent plasma glycoprotein 
Q9HD89 Resistin 
P34896 serine hydroxymethyltransferase 1 (soluble) 
P01009 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 
P01011 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 
P01008 serpin peptidase inhibitor, clade C (antithrombin), member 1 
Q14393 similar to growth arrest-specific 6; growth arrest-specific 6 
P55017 solute carrier family 12 (sodium/chloride transporters), member 3 
Q13621 solute carrier family 12 (sodium/potassium/chloride transporters), member 1 
P08294 superoxide dismutase 3, extracellular 
P07996 thrombospondin 1 
P02787 Transferring 
P02766 Transthyretin 
P07911 Uromodulin 
 
Supplementary table S3.4: The following genes were annotated and classified as having 
genetic association to renal diseases using DAVID Bioinformatics resources 6.7, National 
Institute of Allergy and Infectious Diseases (NIAID), NIH. Uniprot Ids and gene names are 
given. 
ID Gene Name 
P08183 ATP-binding cassette, sub-family B (MDR/TAP), member 1 
P08571 CD14 molecule 
P12821 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 
Q9BYF1 angiotensin I converting enzyme (peptidyl-dipeptidase A) 2 
P01019 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 
P04114 apolipoprotein B (including Ag(x) antigen) 
Q96KN2 carnosine dipeptidase 1 (metallopeptidase M20 family) 
P11597 cholesteryl ester transfer protein, plasma 
P08603 complement factor H 
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P02675 fibrinogen beta chain 
P00738 haptoglobin-related protein; haptoglobin 
P08107 heat shock 70kDa protein 1A; heat shock 70kDa protein 1B 
P11142 heat shock 70kDa protein 8 
P02649 hypothetical LOC100129500; apolipoprotein E 
P01042 kininogen 1 
P02788 Lactotransferrin 
P05164 Myeloperoxidase 
P27169 paraoxonase 1 
P01833 polymeric immunoglobulin receptor 
P01009 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 
Q99519 sialidase 1 (lysosomal sialidase) 
P55017 solute carrier family 12 (sodium/chloride transporters), member 3 
P08294 superoxide dismutase 3, extracellular 
 
Supplementary table S3.5: Complete non-redundant list of proteins identified in the low 
speed pellet (P18,000g) using both DTT and CHAPS treatment methods. Uniprot accessions 
and gene names are given. 
UNIPROT_ACCESSION Gene name 
Q6UX06 olfactomedin 4 
P63104 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide 
O76031 ClpX caseinolytic peptidase X homolog (E. coli) 
P04114 apolipoprotein B (including Ag(x) antigen) 
P04279 semenogelin I 
P05109 S100 calcium binding protein A8 
Q86YZ3 Hornerin 
O00560 syndecan binding protein (syntenin) 
P23526 Adenosylhomocysteinase 
O95837 guanine nucleotide binding protein (G protein), alpha 14 
P02747 complement component 1, q subcomponent, C chain 
P06702 S100 calcium binding protein A9 
P15941 mucin 1, cell surface associated 
P63261 actin, gamma 1 
P01042 kininogen 1 
Q14624 inter-alpha (globulin) inhibitor H4 (plasma Kallikrein-sensitive glycoprotein) 
P62879 guanine nucleotide binding protein (G protein), beta polypeptide 2 
P53675 clathrin, heavy chain-like 1 
P13929 enolase 3 (beta, muscle) 
P04196 histidine-rich glycoprotein 
P05090 apolipoprotein D 
P01011 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 
P00734 coagulation factor II (thrombin) 
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Q7Z5L0 vitelline membrane outer layer 1 homolog (chicken) 
P16278 galactosidase, beta 1 
Q9C0H2 tweety homolog 3 (Drosophila) 
P02760 alpha-1-microglobulin/bikunin precursor 
P50148 guanine nucleotide binding protein (G protein), q polypeptide 
P29972 aquaporin 1 (Colton blood group) 
P02652 apolipoprotein A-II 
P02679 fibrinogen gamma chain 
P04004 Vitronectin 
P36543 ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E1 
P01009 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 
P21796 voltage-dependent anion channel 1; similar to voltage-dependent anion channel 1 
P50995 annexin A11 
P11678 eosinophil peroxidise 
P08133 annexin A6 
P21266 glutathione S-transferase mu 3 (brain) 
O43490 prominin 1 
Q53GD3 solute carrier family 44, member 4 
P68871 hemoglobin, beta 
Q8N2U0 chromosome 17 open reading frame 61 
Q9HCY8 S100 calcium binding protein A14 
P31949 S100 calcium binding protein A11; S100 calcium binding protein A11 pseudogene 
O00299 chloride intracellular channel 1 
P08779 keratin 16; keratin type 16-like 
P01593 similar to hCG1642538 
P62937 similar to TRIMCyp; peptidylprolyl isomerase A (cyclophilin A); peptidylprolyl isomerase A 
(cyclophilin A)-like 3 
O75594 peptidoglycan recognition protein 1 
Q9NSB4 keratin 82 
P07195 lactate dehydrogenase B 
Q8N474 secreted frizzled-related protein 1 
P02768 Albumin 
Q9HB40 serine carboxypeptidase 1 
Q9BQE3 tubulin, alpha 1c 
Q8WUM4 programmed cell death 6 interacting protein 
P07911 Uromodulin 
O43895 X-prolyl aminopeptidase (aminopeptidase P) 2, membrane-bound 
P15144 alanyl (membrane) aminopeptidase 
P01834 similar to hCG26659; immunoglobulin kappa constant; similar to Ig kappa chain V-I region 
HK102 precursor 
P35241 Radixin 
P13987 CD59 molecule, complement regulatory protein 
P39059 collagen, type XV, alpha 1 
Q6EMK4 Vasorin 
P55017 solute carrier family 12 (sodium/chloride transporters), member 3 
P04083 annexin A1 
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P13646 keratin 13 
Q5D862 filaggrin family member 2 
Q9Y277 voltage-dependent anion channel 3 
Q13510 N-acylsphingosine amidohydrolase (acid ceramidase) 1 
P16444 dipeptidase 1 (renal) 
P13647 keratin 5 
P02647 apolipoprotein A-I 
O00159 myosin IC 
P07355 annexin A2 pseudogene 3; annexin A2; annexin A2 pseudogene 1 
Q14390 gamma-glutamyltransferase light chain 2 
P02743 amyloid P component, serum 
Q08380 lectin, galactoside-binding, soluble, 3 binding protein 
P04003 complement component 4 binding protein, alpha 
Q7Z794 keratin 77 
Q9H1C7 chromosome 5 open reading frame 32 
P01024 similar to Complement C3 precursor; complement component 3; hypothetical protein 
LOC100133511 
P19012 keratin 15 
P01876 immunoglobulin heavy constant alpha 1 
P02649 hypothetical LOC100129500; apolipoprotein E 
P00338 lactate dehydrogenase A 
P08727 keratin 19 
P02538 keratin 6A 
P36873 protein phosphatase 1, catalytic subunit, gamma isoform 
O60814 histone cluster 1, H2bk 
P04350 tubulin, beta 4 
O60635 tetraspanin 1 
P54793 arylsulfatase F 
Q9Y512 sorting and assembly machinery component 50 homolog (S. cerevisiae) 
O43653 prostate stem cell antigen 
P09211 glutathione S-transferase pi 1 
P01591 immunoglobulin J polypeptide, linker protein for immunoglobulin alpha and mu polypeptides 
P12277 creatine kinase, brain 
Q96FQ6 S100 calcium binding protein A16 
P08473 membrane metallo-endopeptidase 
Q8WVN6 secreted and transmembrane 1 
Q9H853 tubulin, alpha 4b (pseudogene) 
P10909 Clusterin 
P00558 phosphoglycerate kinase 1 
P15309 acid phosphatase, prostate 
P13645 keratin 10 
P20073 annexin A7 
P10153 ribonuclease, RNase A family, 2 (liver, eosinophil-derived neurotoxin) 
Q6UWR7 ectonucleotide pyrophosphatase/phosphodiesterase 6 
P31946 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta polypeptide 
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P61026 RAB10, member RAS oncogene family 
P01857 immunoglobulin heavy constant gamma 1 (G1m marker); immunoglobulin heavy constant 
mu; immunoglobulin heavy variable 3-7; immunoglobulin heavy constant gamma 3 (G3m 
marker); immunoglobulin heavy variable 3-11 (gene/pseudogene); immunoglobulin heavy 
variable 4-31; immunoglobulin heavy locus 
P62873 guanine nucleotide binding protein (G protein), beta polypeptide 1 
P35908 keratin 2 
P26038 Moesin 
O96009 napsin A aspartic peptidase 
P12109 collagen, type VI, alpha 1 
P09525 annexin A4 
Q92820 gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase) 
P01133 epidermal growth factor (beta-urogastrone) 
Q02383 semenogelin II 
P00918 carbonic anhydrase II 
P00748 coagulation factor XII (Hageman factor) 
P12035 keratin 3 
P04264 keratin 1 
Q9HD89 Resistin 
P02533 keratin 14 
P02788 Lactotransferrin 
P15924 Desmoplakin 
P15311 hypothetical protein LOC100129652; ezrin 
P60709 actin, beta 
P48061 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 
P02751 fibronectin 1 
P35527 keratin 9 
P02787 Transferring 
P19013 keratin 4 
Q6ZVX7 non-specific cytotoxic cell receptor protein 1 homolog (zebrafish) 
P06727 apolipoprotein A-IV 
P04259 keratin 6B 
P54802 N-acetylglucosaminidase, alpha- 
P04406 glyceraldehyde-3-phosphate dehydrogenase-like 6; hypothetical protein LOC100133042; 
glyceraldehyde-3-phosphate dehydrogenase 
P00749 plasminogen activator, urokinase 
P01833 polymeric immunoglobulin receptor 
P08758 annexin A5 
P05154 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 
Q12931 TNF receptor-associated protein 1 
P60953 cell division cycle 42 (GTP binding protein, 25kDa); cell division cycle 42 pseudogene 2 
Q13621 solute carrier family 12 (sodium/potassium/chloride transporters), member 1 
A6NIZ1 Ras-related protein Rap-1b-like protein 
A6NGU5 Putative gamma-glutamyltranspeptidase 3 
P01620 Ig kappa chain V-III region SIE 
P0CG04 Ig lambda-1 chain C regions 
P0CG05 Ig lambda-2 chain C regions 
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P04220 Ig mu heavy chain disease protein (BOT) 
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Chapter 4 
A Lipid affinity-based novel method 
for isolation of urinary membrane 
vesicles and their subsequent 
characterization 
 
 
 
 
 
 
 
 
234 
 
4.1 Introduction 
Human urine contains various types of vesicles including exosomes (40-100nm) (Pisitkun, 
Shen & Knepper 2004) and bigger vesicles (66-187nm) which reportedly contain polycystin-
1, aquaporin-2 and podocin (Hogan et al., 2009) as well as podocalyxin-positive 125nm 
membrane particles (Hara et al., 2010). These vesicles can potentially provide information 
about the pathophysiological state of the entire urinary tract. The traditional method for 
urinary exosome isolation was the differential centrifugation where a low speed 
centrifugation (17,000g) was adopted to remove whole cells, tubular casts and membrane 
fragments. This is followed by ultracentrifugation (200,000g) to pellet down urinary 
exosomes and other similar sized vesicles (Pisitkun, Shen & Knepper, 2004). However, the 
problem associated with this method is contamination of the 200,000g pellet with soluble or 
aggregated high-abundance proteins like Tamm-Horsfall glycoprotein (THP) and albumin. It 
was found that, entrapped in THP polymers, exosomes were also precipitating with low speed 
pellet (P17,000g) (Fernandez-Llama et al., 2010). To remove contamination of aggregated 
proteins one solution has been proposed which includes treatment of low speed (P17,000g) 
and high speed pellets (P200,000g) with DTT followed by a second centrifugation at low and 
high speed as above. This procedure increases the exosomal yield but it creates a new 
problem as THP is now present in high amounts in the high speed pellet. This may interfere 
with the further analysis of exosomal pellet by masking low abundance proteins. Moreover, 
the random re-oxidation subsequent to DTT treatment would result in multiple proteins losing 
their activity (See Chapter 2). If an activity-based analysis is the ultimate aim of the 
membrane vesicle isolation, this loss in activity would render it unsuccessful. 
Another method which can be employed for vesicle isolation is sucrose density gradient 
centrifugation which has been used mainly to isolate exosomes from immune cells and cell 
culture but also on urinary exosome separations (Welton et al., 2010; Keller et al., 2011). The 
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sucrose density gradient ultracentrifugation method is more sensitive and yields the purest 
form of exosomes with minimal contamination with high abundance proteins. It is recognised 
that both these ultracentrifugation-based methods are very labour intensive and require 
extensive instrumentation and long processing times making them unsuitable for clinical 
settings. The fact that these isolation methods are labour intensive involving manual 
techniques makes them impractical when a large number of samples have to be handled. 
Alternatives have been proposed including the use of a nanomembrane concentrator (pore 
size 13nm and MWCO 100kDa) to enrich for the exosomal fraction from urine (Cheruvanky 
et al., 2007). Advantages of the method are the short processing time and the use of 
inexpensive instrumentation like a table-top centrifuge. The 100 kDa ‘cut-off’ would mean 
that high molecular weight proteins and protein complexes not part of exosomes would be 
enriched as well and would interfere with further analysis masking low abundance proteins in 
exosomes. Many proteins, like THP and albumin, remain in polymeric forms (Atmeh, 
Shabsoug 1997; Fernandez-Llama et al., 2010) that would be enriched with exosomes as 
well. It was already shown that nanomembrane ultrafiltration enriched soluble proteins, like 
albumin and α-1-antitrypsin in large amounts along with exosomes, when applied on 
nephrotic urine (Rood et al., 2010) which limited the detection of microvesicular proteins. 
This study also used an alternative method which showed that loading crude 
ultracentrifugation pellet onto a size exclusion chromatography columns yielded three 
fractions (HMW, LMW and >10kDa). The high molecular weight fraction (HMW) showed 
the presence of exosomal markers while the low molecular weight (LMW) fraction had only 
high abundance proteins (Rood et al., 2010). The LMW fraction was present only in 
nephrotic urine and absent in normal urine suggesting that large amounts of high abundance 
proteins interfere with the isolation and subsequent analysis of exosomes in nephrotic urine. 
Another method has been proposed involving the commercial reagent ExoQuick-TC (System 
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biosciences, Mountain view, CA) (Alvarez et al., 2012). This method is simple and easy to 
perform and involves precipitatation of the exosomes from minimally processed urine. 
However, it was found in the study that this reagent also precipitates the THP with the 
exosomal fraction making it no different from other methods. 
Taken together, most of the methods used in various studies are either labour intensive, 
require sophisticated instrumentation or they result in high abundance protein contamination 
in the vesicular fraction. Most of the methods mentioned above rely on biophysical 
parameters to separate membrane vesicles from urine which are shared by some of the 
contaminants as well. Therefore, there is need and scope for development of membrane 
vesicle isolation methods from the urine which are simple, robust and can be applied to a 
large number of samples without the need for additional sophisticated instrumentation. We 
hypothesized that a method based on affinity or biomolecular recognition should lead to a 
higher purity vesicle-containing fraction. The obvious choice for affinity, namely using 
immuno-affinity chromatography requires antibodies which are often expensive and, due to 
sensitivity to harsh elution conditions, their re-use is problematic if not completely 
impossible. Here we have developed a lipid affinity-based method for isolation of urinary 
microvesicles. Based on available information we have selected five peptides which bind to 
various lipids (phosphatidylserine, phosphatidylcholine, cholesterol, galactosylceramide and 
sphingomyelin) and immobilized synthetic biotinylated peptides on streptavidin agarose 
which was applied to ‘cell-free’ urine to enrich for microvesicles from urine. 
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4.2 Material and methods 
Urine collection has been described in chapter 2. 
4.2.1 Peptide-affinity chromatography 
Peptides were appropriately designed and thereafter obtained from Genscript USA Inc, NJ. 
Five peptides were selected based on their physicochemical properties (Table 4.1). Three of 
them showed strong affinity to phosphatidylserine (PS), cholesterol (CL) and sphingomyelin 
(SM) while two others bind phosphatidylcholine (PC). Two peptides binding PC were 
inserted in a single sequence separated by three glycine residues. This would be expected to 
increase avidity of the resulting peptides having two binding sites for PC. 
Table 4.1: List of all five peptides employed in the study. Amino acids in red denote glycine 
which was employed as a spacer to reduce steric hindrance because of the proximity of the 
peptide with the agarose beads. N-terminal glycine was biotinylated for capturing the peptide 
on streptavidin-agarose which was subsequently employed for affinity chromatography to 
isolate membrane vesicles from urine. 
Peptide Sequence Lipid binder Comments Reference 
P1 Biotin-
GGGGGFNFRLKAGQKIRFG 
 
Phosphatidylserine 
(PS) 
Naturally Found 
in PS-
decarboxylase, 
protein kinase C 
 (Igarashi 
et al., 
1995) 
P2 Biotin-GGGGGKRESGGGFREL 
 
Phoshpatidylcholine Synthetic 
peptides; Can 
bind HDL 
 (Navab et 
al., 2005) 
P3 Biotin-
GGGGATVLNYYVWRDNS 
 
Cholesterol Naturally found 
in Peripheral-
type 
benzodiazepine 
receptor 
 (Li et al., 
2001) 
P4 Biotin-
GGGGKQHTVTTTTKGENFTE
TDVKMMER 
 
Galactosylceramide, 
sphingomyelin 
Naturally found 
in Prion protein, 
can potentially 
bind Lipid rafts 
 (Mahfoud 
et al., 
2002) 
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Four or five glycines were added at the N-terminal and the first glycine in all the peptides 
was biotinylated. This biotin was used for immobilising the peptides on streptavidin-agarose 
(Genscript). 1mL of streptavidin-agarose resin was mixed with 3mg of the respective 
peptides (P1 and P2 dissolved in water while P3 and P4 dissolved in DMSO) diluted in 
phosphate buffer saline (PBS, pH 7.4) and left on a rotating mixer overnight. On the 
following day the resin was washed with PBS to remove non-bound peptide. The P200,000g 
fraction obtained from the traditional ultracentrifugation method was incubated with P1-
agarose overnight. The next day, after washing with 10mM phosphate buffer (20 column 
volumes) the bound vesicles were eluted with 100mM glycine buffer (pH 2.4). For affinity 
chromatography on whole urine, 50mL urine (SN2000g) was concentrated to 2mL using a 
Vivaspin (MWCO 5 or 300kDa, Sartorius, Goettingen). This reduction in volume was 
performed to reduce urine to manageable volumes without reaching high ionic strength or 
changing pH which would happen if dialysis and vacuum concentration was used. This 2mL 
volume was diluted to 4mL with 20mM phosphate buffer without salt and incubated with 
peptide-agarose on rotation overnight at 4°C. The non-bound fraction from peptide-agarose 
was collected the following day and resin was washed with phosphate buffer (20 column 
volumes). For elution 100mM glycine buffer (pH 2.4) was incubated with resin for 2 hours at 
+4
oC while rotating. The eluate was dialysed in a membrane with 3.5 kDa ‘cut-off’ against 
water and concentrated in a speed vac concentrator. This concentrated eluate was used for 
SDS-PAGE and WB, as described in Chapter 2. It was found that reproducible results were 
obtained for these peptide columns up to 15-20 intermittent runs. 
Reduction, alkylation, trypsin digestion and mass spectrometric analysis were performed as 
described in Chapter 3.  
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4.3 Results  
4.3.1 Selection of peptides 
A number of studies have reported the typical lipid composition of exosomes derived from 
various sources. Interestingly, the phospholipid composition of the reticulocyte-derived 
exosomes is quite similar to the plasma memebrane of the cell (Vidal et al., 1989). 
Phosphatidylcholine (PC) is the major phospholipid followed by phosphatidylethanolamine 
(PE) and then phosphatidylserine (PS) and phosphatidylinositol (PI) while sphingomyelin 
(SM) is similar to combined PS+PI. In case of mast cell and dendritic cell-derived exosomes, 
SM is enriched in exosomes compared to parent cell (Laulagnier et al., 2004). Cholesterol 
(CL) is much more enriched in MHC II-bearing exosomes from B lymphocytes compared to 
the parent cell (Wubbolts et al., 2003) while in case of exosomes from erythrocytes and mast 
cells CL amount is highly similar to parent cell plasma membrane (Vidal et al., 1989; 
Laulagnier et al., 2004).  
Here, we sought to develop a lipid affinity-based method for isolation of urinary membrane 
vesicles from whole urine. Notably, our approach appears theoretically important as short 
peptides displaying binding to any of the above-mentioned lipids would be suitable for the 
task to isolate vesicles. For this purpose, we did a thorough literature search for short peptides 
and their binding properties to various lipids and five peptides with high affinity to various 
lipids were selected. The peptides selected are presented in Table 4.1. 
4.3.2 Peptide affinity chromatography 
Five peptides which bind various lipids (Table 4.1) were selected and 4-5 glycines were 
added to their N-terminal domain as a spacer to reduce steric hindrance resulting from 
proximity to the bead attached. These peptides with N-terminal glycine biotinylated allowing 
immobilisation to streptavidin-agarose, were obtained by peptide synthesis as supplied 
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commercially. To confirm if this approach using a lipid-binding peptide will work to isolate 
membrane vesicles, we first incubated P200,000g with P1-agarose and eluted the bound 
fraction.  
4.3.3 PS binding peptide binding to exosomal pellet from urine and MS analysis 
A small fraction of exosomes and the majority of ectosomes expose phosphatidylserine on 
their surface. Therefore, a crude pellet of exosomes (P200) was applied to P1-agarose to 
isolate only this fraction. This fraction was reduced, alkylated and trypsin digested and all 
proteins identified using LC-MS/MS. This served as positive control that this peptide (P1) 
actually is able to bind to membrane vesicles. 
A complete list of the proteins identified in P1-peptide enriched fraction of P200,000g is 
given in Appendix 4.A. A total of 295 proteins were identified unambiguously. These 
proteins were compared to previously published datasets of urinary exosomes and ‘exosome-
like’ vesicles. A comparison of P1-peptide-enriched proteins with two previous urine 
exosomal studies combined together (Pistikun et al.,. and Gonzalez et al., combined as 
Knepper) (Pisitkun, Shen & Knepper, 2004, Gonzales et al., 2009) and one study on urinary 
‘exosome-like’ vesicles (Hogan et al.,) (Hogan et al., 2009) is shown in Figure 4.1. 
241 
 
 
Figure 4.1: Comparison of P1-peptide enriched vesicle proteins with urinary exosomes (two 
studies combined as Knepper) (Pisitkun, Shen & Knepper, 2004) (Gonzales et al., 2009) and 
exosome-like vesicles (Hogan) (Hogan et al., 2009). For comparison, all the identifiers were 
converted to Unigene identifiers. 
Eighty-five proteins (28% of our identifications) were found to be shared among all three 
studies while other than these, P1-peptide-enriched proteins are more in common with 
urinary exosomes (Knepper, 63% of P1 identifications common with this set) than with 
‘exosome-like’ vesicles (Hogan, 31% of P1 proteins common with Hogan). However, very 
recently a study was published which has identified the highest number of proteins in urinary 
exosomes (3,280 proteins) to date (Wang et al., 2011). This study has used the same isolation 
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protocol for urinary exosomes as that of previous studies (Pisitkun, Shen & Knepper, 2004, 
Gonzales et al., 2009). Figure 4.2 shows the comparison of our protein list to the proteins 
they identified.  
 Figure 4.2: Comparison of P1-peptide-enriched vesicles with that of the largest protein 
identification study of urinary exosomes (Wang et al.,) (Wang et al., 2011). Gene identifiers 
were converted to Unigene for comparison. 
As can be seen in Figure 4.2, most of the proteins (93%) identified in our study are common 
to that of the largest previous study of urinary exosomes. This suggests that what we have 
enriched as vesicles is in common to the traditional protocol (ultracentrifugation-based 
isolation) used for urinary exosomes. It is to be noted that the differential centrifugation 
method will isolate a heterogenous mixture of different types of vesicles present in urine. 
Another study has previously been published which used complement receptor-1 (CR-1) 
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antibodies to enrich membrane vesicles from the urine of various patients having different 
types of kidney diseases (Lescuyer et al., 2008). CR-1 is an ectosomal marker which is 
known to be expressed by the glomerular visceral epithelial cells, podocytes, in the kidney 
(Pascual et al., 1994). When anti-CR-1 antibody-mediated enrichment of vesicles was used, 
76 proteins from different patient samples were identified. To establish whether this is a 
different population of vesicles than our P1-peptide-enriched vesicles (other urinary exosome 
studies), we compared these proteins with that of largest urinary exosome proteome study and 
our protein list (Figure 4.3). 
 
Figure 4.3: Comparison of anti-CR-1 immunopurified vesicles (Lescuyer et al., 2008) 
proteome with that of largest urinary exosome proteome (Wang et al.,) (Wang et al., 2011), 
our protein list (P1 peptide) and whole proteome identifications from Chapter 3 (CP200). 
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It can be seen in Figure 4.3 that all the proteins from CR-1 study, bar 9, have been identified 
in urinary exosome previously and a large proportion (60%) were found in our study (P1-
peptide) as well. Another 30% were identified in the whole proteome study reported in 
Chapter 3.  
Our protein list was annotated using IPA software (Redwood city, CA) and Blast2Go 
software (Conesa et al., 2005) and graphics were generated for cellular component-based, 
molecular function and biological process-based categories. Figure 4.4 shows the annotation 
of our protein list according to the cellular component group. 
 
Figure 4.4: Annotation of our protein list according to the cellular component to which they 
belong, using IPA software. For comparison, the total proteome list from Chapter 3 is also 
shown (CP200). 
Thirty-two% proteins belong to extracellular space while 37% were identified as cytosolic 
proteins. There are a large proportion of membrane proteins with 26% proteins belonging to 
membrane fraction. Only 1% proteins belong to nucleus. It can be seen in the Figure that by 
comparison all categories are similarly represented in total proteome of P200,000g  from 
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Chapter 3. This suggests that what we have enriched using P1-peptides are similar to vesicles 
present in P200,000g isolated using differential centrifugation. The annotation of the protein 
list according to molecular function is shown in Figure 4.5. 
 
Figure 4.5: Annotation of our protein list according to their molecular functions using 
Blast2Go. 
Forty-two percent proteins were annotated as ‘other’, which is comparable to those found in 
total proteome from chapter 3. Enzymes comprise 25 % of the proteins while peptidases and 
transporters make 11 % each. One % each of growth factors, G-protein coupled receptors, 
kinases and ion channels were found. Two % each of transmembrane receptor, 
transcription/translation regulators and phosphatases were found as well. Again, all the 
categories are similarly represented. The G-protein coupled receptor (GPCRC5C) was found 
in both the CP200 from Chapter 3 and P1-peptide-enriched vesicles here. However, 
smoothened, frizzled family receptor and frizzled family receptor 4 were unique to CP200 
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and P1-peptide, respectively. Similarly, in kinases, phosphoglycerate kinase 1 was common 
to both datasets. However, creatine kinase (brain) and phosphofrucokinase (liver) were 
unique to CP200 and P1-peptide, respectively. 
Figure 4.6 shows the annotation of our protein list using Blast2Go software (Conesa et al., 
2005) according to biological processes in which they are involved. Seventy transport 
proteins were identified in our list followed by 64 proteins involved in regulation of 
biological quality and 62 involved in cellular component organization. Forty-two proteins are 
involved in the defense response while 61 proteins take part in immune response. 
 
Figure 4.6: Annotation of our protein list according to biological processes in which these 
proteins are involved using Blast2Go software (Conesa et al., 2005). 
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Forty-six proteins involved in proteolysis while 40 and 42 proteins involved in positive and 
negative regulation of cellular processes respectively were found in our list. Notably, 41 
proteins involved in signalling pathways and 48 proteins involved in signal transmission were 
also identified. 
4.3.4 Isolation of membrane vesicles from minimally processed urine 
After confirming that our peptide-agarose matrix is able to bind membrane vesicles as 
evidenced by proteins identified in the elution of P1-agarose from P200,000g, all four 
peptide-agarose columns were applied to purify membrane vesicles from whole urine cleared 
of cells (Supernatant 2000xg). Phosphate buffer (10mM, pH 7.2) was chosen as binding 
buffer and concentrated urine (50mL was reduced to 2mL by Vivaspin MWCO 300kDa; 
5kDa filter also works fine) was incubated with peptide-agarose overnight at rotation at +4
o
C. 
After washing with binding buffer, elution was performed with reduced pH (100mM glycine, 
pH 2.4). The flow chart of the whole method is shown in Figure 4.7. 
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Figure 4.7: The workflow for peptide-affinity chromatography. 
The same chromatography was performed on all four peptides separately. In another 
experiment, the non-bound fraction of P1-agarose was applied to P2-agarose to recover 
vesicles which are left in the urine. The obtained elution was dialysed to remove glycine and 
SDS-PAGE was performed after reducing the volume by speed vacuum centrifugation.  
Figure 4.8 shows the SDS-PAGE of elution of all four peptides and P2 elution of P1 non-
bound. 
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Figure 4.8: Shows the silver stained SDS-PAGE of elutions of all four peptide-agarose 
columns (P1-P4) in non-reducing conditions. P2-P1 means that non-bound of P1 was applied 
to P2-agarose. P200 is the crude exosomal fraction obtained using the traditional differential 
centrifugation method (Pisitkun, Shen & Knepper, 2004). P1-P4 her means the vesicles 
eluted from these peptides were loaded onto the gel.  
It can be seen in Figure 4.8 that all four peptides enrich proteins which resemble a complex 
pattern from low to high molecular weight suggesting presence of membrane vesicles. Whole 
urine also has proteins in the same range as these peptide elution fraction but THP and 
albumin are more abundant in the urine and break the pattern of multiple proteins present in 
similar intensity. This is not the case here suggesting peptide-eluted fraction is a sub-fraction 
of urine. Approximately, the same amount of protein (3µg by the Bradford assay) was loaded 
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onto every lane. It can be clearly seen that in the crude exosomal fraction, obtained by 
traditional differential centrifugation method, the major proteins are Tamm-Horsfall 
glycoprotein (THP) at ~80kDa and albumin at ~65kDa. All other proteins are not clearly 
resolved and are present in low amounts. This is not the case with all four peptide-agarose 
elutions which show a complex pattern with least interference of THP and albumin. P2-P1 
shows two bands above 250kDa which are not present in other peptide elutions even in P2-
agarose elutions when applied to whole urine. Apart from this the, major pattern of proteins is 
similar in all four peptide elutions although difference can be found such as presence of 
several proteins which can be seen to be less or more enriched among four peptides. 
4.3.4.1 Western blotting with exosomal markers and abundant proteins 
All four peptide-agarose elutions were immunoblotted for exosomal marker CD63 (Figures 
4.9). CD63 (Figure 4.9) is present as 48kDa band in P1, P2 and P2-P1 elutions in high 
intensity band while less intense in P3 and P4. This 48kDa band appears to be enriched in 
peptide-agarose elutions compared to P200 (crude exosomal fraction).  
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Figure 4.9: Western blot of all four peptide-agarose elutions using anti-CD63 antibodies in 
reducing conditions. P200 is the crude vesicular pellet obtained from urine using differential 
centrifugation method. P1 to P4 are elution fractions of peptide-agaroses when urine to 
applied to these peptide columns. P2-P1 means that non-bound fraction of P1-peptide-agarose 
was applied to P2 peptide-agarose and bound fraction of P2 was eluted. 
There is another band at 65kDa which is most intense in P1 compared to P200 while less so 
in other peptide elutions. P1 and P2-P1 elutions have a band at 100kDa while another band at 
75kDa is present in all elutions of P1 and P2 but not in P3 and P4. Looking at the overall 
pattern, P1 is similar to P2 and P3 is similar to P4. P2-P1 although a bit similar to P1 and P2, 
seems to be different from all other peptides. CD63 is a tetraspanin protein which is 
considered as a marker of exosomal membrane vesicles. The pattern found here for CD63 has 
some similarity with DTT, and CHAPS-treated P200,000g and P18,000g as reported in 
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Chapter 2 (Figure 2.4, Panel  A). However, multiple low molecular weight bands are present 
here which were not visible in those fractions. In comparison with crude pellet P18,000g 
(Figure 2.4, Chapter 2) the band at 50 and 25 kDa  is common however the band at ~65kDa 
found here in P1 and P2 peptide is not present in crude P18,000g.  
Using the traditional method of isolation of membrane vesicles, a high interference of THP 
and albumin is observed in the exosomal fraction. We immuno-blotted all peptide eluates and 
non-bound fractions for THP and all eluates for albumin and observed the efficiency of 
peptide-affinity chromatography in enriching vesicles without interference by these proteins.  
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Figure 4.10: Western blot of peptide-agarose non-bound and elution using anti-THP 
antibodies. P200 is the crude vesicular pellet obtained from urine using differential 
centrifugation method. P1 to P4 are elution fractions of peptide-agaroses when urine to 
applied to these peptide columns. P2-P1 means that non-bound fraction of P1-peptide-agarose 
was applied to P2 peptide-agarose and bound fraction of P2 was eluted. 
The non-bound fraction of peptide-agarose chromatography has significant amount of THP, 
as can be seen in Figure 4.10. However, in eluates, THP is present in negligible amounts 
when compared to crude P200 (exosomal fraction) obtained by traditional centrifugation 
although very small fragments (~12kDa) can be seen in all peptide elutions. P2 elution has 
more THP compared to P1 and P3 elutions but when P1 non-bound is applied to P2 THP is 
absent in the elution fraction. Peptide 4 elution also has almost undetectable levels of THP. 
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Figure 4.11 shows that full length albumin (~66kDa) is present in large amounts in crude 
exosomal pellets obtained by the traditional centrifugation method. Higher order aggregates 
of albumin and smaller fragments are also present in significant amounts in this pellet. 
However, all the peptide elutions are essentially free of fragments and aggregates of albumin 
while full-length albumin (whole protein ~66kDa) is present in a trace amount. Once again a 
similar pattern to THP is observed here with slightly more albumin (although non-significant 
amounts) being present in the P2 elution and when non-bound of P1 is applied to P2-agarose 
the eluate of P2 becomes free of it. 
 
Figure 4.11: All peptide-agarose elutions were immunoblotted for albumin using a 
monoclonal anti-albumin antibody. P200 is the crude vesicular pellet obtained from urine 
using differential centrifugation method. P1 to P4 are elution fractions of peptide-agaroses 
when urine to applied to these peptide columns. P2-P1 means that non-bound fraction of P1-
peptide-agarose was applied to P2 peptide-agarose and bound fraction of P2 was eluted. 
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Finally, to validate that the isolation of membrane vesicles is due to the lipid binding ability 
of the peptide and not due to the non-specific adsorption to stationary phase matrix, the whole 
procedure was repeated on streptavidin-agarose alone without the immobilised peptides. 
Figure 4.12 shows the SDS-PAGE of our negative control and the P1 peptide-agarose eluate. 
 
Figure 4.12: Silver stained SDS-PAGE of negative control (Streptavidin agarose) and P1-
peptide eluate. N: streptavidin agarose (without any peptide immobilised) and P1: P1 peptide 
agarose. 
There are three proteins which are common to the negative control and to P1-peptide agarose, 
as can be seen in Figure 4.12,. One is approximately 80kDa which could be THP and the 
other two being 60kDa and 12kDa proteins. These three proteins might be becoming enriched 
with elution non-specifically owing to their interaction with the stationary phase matrix or 
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streptavidin. The overall pattern of P1-peptide agarose is similar to one shown in Figure 4.8. 
To exclude binding of these peptides to any exosomal or membrane vesicle proteins, we 
probed the P200,000g, P18,000g and SN200,000g with these peptides by western blotting 
using a previously published protocol (Melrose, Ghosh & Patel, 1995). No bands were 
observed suggesting these peptides are enriching vesicles through lipid affinity only.  
4.3.4.2 Transmission electron microscopy (TEM) of vesicles isolated from minimally 
processed urine using P1 and P2 
Peptide P3 and P4 had lower levels of CD63. Therefore, they were excluded from further 
analysis. Elutions from P1 and P2 were further analysed by TEM to assess the morphology 
and size of the vesicles enriched. Figure 4.13 shows the representative vesicles enriched by 
peptide P1. 
 
Figure 4.13: TEM analyses of vesicles enriched by PS binding peptide (P1). The scale bar in 
both the panels of figures is 500nm and direct magnification in panel A is 6000x while in 
panel B, it is 5000x. The bars shown below the picture are 500nm. 
The figure 4.14 shows the representative TEM picture of vesicles enriched by PC binding 
peptide (P2). 
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Figure 4.14: TEM analyses of vesicles enriched by PC binding peptide (P2). The scale bar 
shown below the picture in is 2000nm and direct magnification is 2500x. 
Multiple pictures were obtained for both the peptides and size of all the vesicles calculated 
using ImageJ software. A graph was created for size distribution of vesicles enriched by both 
the peptides (Figure 4.15). 
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Figure 4.15: Size distribution of vesicles enriched by both the peptides (P1 and P2). X-axis is 
the size of vesicles in nanometers (nm) and Y-axis is the percent vesicles in any given size 
range. 
The majority of the vesicles in the both the peptides were from 200-550nm (72% for P1 and 
77% for P2) while lesser number of vesicles were found in 550-700nm range (18% for P1 
and 11% for P2). There were approximately 10% of vesicles which were bigger than 700 and 
lesser than 1µm for both the peptides. This clearly shows that, although P1 can bind to 
vesicles in the exosomal fraction (section 4.3.3), both the peptides (P1 and P2) when applied 
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to minimally processed whole urine, enrich vesicles (200-1000nm) which have been given 
the name microvesicles or microparticles in the literature. The published procedure for 
vesicle counting from TEM pictures employs 20 image fields (Fernandez-Llama et al., 2010). 
We have captured 7 fields for P1 peptide and 5 fields for P2 peptides. Therefore the size 
distribution presented in figure 4.15 has a limitation for extrapolation to the whole sample. 
This size distribution is crude and only provides a rough idea about the percentage of vesicles 
having a given size.  
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4.4 Discussion 
A novel method to enrich membrane vesicles from urine was developed. Five peptides were 
designed based on the published literature, which show binding to PS, PC, CL and SM. Three 
of these peptides are naturally present in various proteins which bind the cognate lipids listed 
in Table1, while two peptides (KRES and FREL) are synthetic which have been shown to 
bind to PC (Navab et al., 2005). These 2 PC binding peptides were joined together in a single 
sequence separated by 3 glycine residues while 5 glycines were used to separate them from 
the agarose bead. All of the other three peptides were similarly inserted in a sequence. 
phosphate buffer saline (PBS pH 7.4) was initially chosen as binding buffer because lipid-
binding proteins (parent proteins of these peptides) bind the respective lipids intracellularly 
(pH 7.2) and the synthetic peptides has been shown to bind to PC at this pH (Navab et al., 
2005). However, urine has THP which precipitates at 150mM salt concentration (Kobayashi 
& Fukuoka, 2001), and therefore, NaCl was removed from the buffer. Finally only 10mM 
phosphate buffer (pH 7.2) was used as the binding buffer. Urine was centrifuged at 2000xg 
and the pellet containing cells was discarded because shed or dead cells present in urine 
would bind to these lipid-binding columns.  
The traditional method of urinary exosome isolation was differential centrifugation (Pisitkun, 
Shen & Knepper, 2004; Gonzales et al., 2009; Wang et al., 2011). However, this method 
enriches for soluble proteins like THP and albumin in large quantities which are known to 
interfere with the subsequent analysis of vesicles and mask low abundance proteins. THP also 
causes a lot of membrane vesicles to pellet down at low speed by entrapping them in its fibers 
(Fernandez-Llama et al., 2010). DTT treatment has been proposed to resolve this problem 
and it does increase the yield but causes a lot of THP to precipitate with the high speed 
exosomal fraction (P200,000g) instead of low speed (P18,000g) (Fernandez-Llama et al., 
2010). Other methods like density-gradient ultracentrifugation have less interference from 
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soluble protein but they are labour-intensive and not suitable for clinical applications. Our 
method, as shown in the results section, does not enrich for soluble proteins like THP and 
albumin while enriching CD63, which is a membrane vesicle marker. CD63, a tetraspanin, is 
traditionally an exosomal marker (exosomes are 40-100nm in size) but, as can be seen in the 
TEM picture of P1 and P2 peptide elution, only vesicles bigger than 200nm are present. 
These results question the specificity of CD63 as a stringent exosomal marker. CD63 has 
been shown to float in high density regions (1.26-1.29 g/ml) of a sucrose gradient. Although 
density floatation has not been determined for larger microvesicles or microparticles, a 
density of 1.26-1.29g/mL would be expected for vesicles much larger than exosomes. In 
another study, CD63 was detected in bigger microvesicles (100-1000nm) secreted by 
platelets although it was more enriched in exosomes. This evidence from other studies, as 
well as our study, present a picture in which CD63, although enriched in exosomal fractions 
from various sources, is also present on bigger microvesicles. 
Only a fraction of exosomes, and most of the ectosomes and microvesicles (100-1000nm), 
are expected to expose PS while all vesicles would be expected to expose PC. We have 
fractionated the traditional high speed pellet (200,000g) known to isolate exosomes using a 
PS binding peptide. In the PS-exposing fraction of exosomal pellet enriched by P1-peptide 
agarose, CD63, CD82 and CD9 were identified but TSG101 and alix, which reflect the 
endosomal origin of the exosomes, were absent. CD133 or prominin-1, which is a marker of 
membrane particles (Marzesco et al., 2005), was also identified in our PS-binding peptide-
enriched fraction. Recently it was shown that hematopoietic stem cells release CD133-
positive vesicles upon differentiation and CD63 inside the cell co-localises with CD133 
(Bauer et al., 2011). Therefore, distinct populations of membrane vesicles are all present in 
the high speed pellet from the traditional centrifugation method. This leads us to suggest that 
the high speed pellet generated using the traditional differential centrifugation method is a 
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heterogeneous mixture of different types of vesicles derived from different pathways of 
trafficking in cells. This view is also supported by our finding that, PS exposing vesicles, 
from the high speed pellet, have the majority of the proteins common to the largest urinary 
exosomes proteomic study (Wang et al., 2011). The relevance of PS exposure only on a small 
fraction of exosomes is not clear; therefore a method to fractionate and purify only the PS-
exposing exosomes from other populations of exosomes will help future functional studies on 
these vesicles. Moreover, MFG-E8 or lactadherin was identified to be present in crude as well 
as CHAPS and DTT-treated P18,000g and P200,000g pellets (Figure 2.4 Panel C, Chapter 2). 
This protein can bind integrins present on exosomes (Taylor et al., 1997) as well as PS which 
might be present on surface of different types of vesicles. This protein could potentially 
cross-link various populations of vesicles and cause them to pellet down at a given 
centrifugal force (e.g. 18,000g or 200,000g). 
The vivaspin filtration column was used in our protocol because it can reduce the volume of 
urine to a manageable volume and maintain the same ionic strength at the same time. 
Therefore vivaspin-concentrated samples will be free of high ionic strength (typically seen in 
other concentration methods such as vacuum concentration) which might interfere with 
peptide vesicle binding. When P1 and P2 peptides are employed to isolate membrane vesicles 
from minimally processed whole urine, these peptides enrich mostly bigger vesicles (200-
1000nm). However, P1 peptide can bind to exosomal fractions enriching a sub-population of 
exosomes (Section 4.3.3) or ‘exosome-like’ vesicles. There could be two reasons for this 
discrepancy:  
1. Microvesicles (100-1000nm) expose a greater amount of PS on their surface and, 
therefore, smaller vesicles are not enriched which expose only small amounts of PS. 
This was shown to be true in case for platelet microvesicles and exosomes where only 
18% of exosomes expose PS on their surface while most microvesicles expose PS.  
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2. There are a much higher number of microvesicles present in urine and small sub-
populations of exosomes exposing PS lose out in competition with microvesicles for 
binding to P1 peptide resin. Although crude information about numbers of smaller 
exosome and ‘exosome-like’ vesicles has been reported (Fernandez-Llama et al., 
2010), there is no data about numbers of bigger microvesicles in urine. Therefore, no 
comparisons can be made and this remains only a hypothesis. 
There is no data for PC exposure on membrane vesicles in the literature and we propose the 
above same two arguments for explaining the lack of presence of smaller exosomes and 
‘exosome-like’ vesicles in P2 elution fractions. Bigger microvesicles (100-1000nm) having 
procoagulant activity in the urine of rabbits has been described (Wiggins et al., 1987). These 
vesicles are thought to bud from glomerular epithelial cells and are also visible in the 
proximal tubular lumen. The procoagulant activity was ‘tissue factor/Factor VII-like’ which 
was associated with microvesicles (100-1000nm). No report of such vesicles exists in human 
urine samples therefore we are the first to show the presence of microvesicles in urine which 
expose PS on their surface and might contain procoagulant activity. 
This method is very simple and can be performed in any laboratory without the need for 
expensive instrumentation or trained professionals. In the future, an automated method for 
membrane vesicles isolation from urine using these peptides bound to stationary phase can be 
envisaged. Moreover, most of the proteins identified in urinary vesicles from patients of 
various types of nephropathies (CR-1) are common with our study (60% overlap between 
both the studies) and this suggests the clinical utility of our method of isolation of membrane 
vesicles. 
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Supplementary table S4.1: Total proteins identified in the membrane vesicles enriched from 
P200,000g using P1-Peptide agarose. Uniprot accessions, sequence coverage, PSM, peptides 
found, number of amino acid in the proteins, molecular weight, calculated PI, mascot score 
and description of the proteins is given. 
Accession Coverage 
% 
# PSMs # 
Peptides 
# 
AAs 
MW 
[kDa] 
calc. 
pI 
Score Description 
P62258 12.16 2 2 255 29.2 4.74 135.78 14-3-3 protein epsilon OS=Homo 
sapiens GN=YWHAE PE=1 SV=1 - 
[1433E_HUMAN] 
P63104 4.90 1 1 245 27.7 4.79 64.56 14-3-3 protein zeta/delta OS=Homo 
sapiens GN=YWHAZ PE=1 SV=1 - 
[1433Z_HUMAN] 
Q9BUT1 4.90 1 1 245 26.7 7.65 82.20 3-hydroxybutyrate dehydrogenase 
type 2 OS=Homo sapiens GN=BDH2 
PE=1 SV=2 - [BDH2_HUMAN] 
Q8TCD5 8.96 1 1 201 23.4 6.64 80.01 5'(3')-deoxyribonucleotidase, 
cytosolic type OS=Homo sapiens 
GN=NT5C PE=1 SV=2 - 
[NT5C_HUMAN] 
P17858 1.92 1 1 780 85.0 7.50 65.71 6-phosphofructokinase, liver type 
OS=Homo sapiens GN=PFKL PE=1 
SV=6 - [K6PL_HUMAN] 
Q96IU4 16.19 3 3 210 22.3 6.40 108.53 Abhydrolase domain-containing 
protein 14B OS=Homo sapiens 
GN=ABHD14B PE=1 SV=1 - 
[ABHEB_HUMAN] 
Q13510 25.57 12 7 395 44.6 7.62 474.76 Acid ceramidase OS=Homo sapiens 
GN=ASAH1 PE=1 SV=5 - 
[ASAH1_HUMAN] 
P60709 17.87 6 5 375 41.7 5.48 325.20 Actin, cytoplasmic 1 OS=Homo 
sapiens GN=ACTB PE=1 SV=1 - 
[ACTB_HUMAN] 
P23526 6.71 3 3 432 47.7 6.34 122.91 Adenosylhomocysteinase OS=Homo 
sapiens GN=AHCY PE=1 SV=4 - 
[SAHH_HUMAN] 
Q06278 1.20 1 1 1338 147.8 7.17 66.61 Aldehyde oxidase OS=Homo sapiens 
GN=AOX1 PE=2 SV=2 - 
[ADO_HUMAN] 
P01011 19.86 6 6 423 47.6 5.52 343.23 Alpha-1-antichymotrypsin OS=Homo 
sapiens GN=SERPINA3 PE=1 SV=2 - 
[AACT_HUMAN] 
P01009 33.25 15 11 418 46.7 5.59 702.93 Alpha-1-antitrypsin OS=Homo 
sapiens GN=SERPINA1 PE=1 SV=3 - 
[A1AT_HUMAN] 
P08697 15.27 5 5 491 54.5 6.29 209.54 Alpha-2-antiplasmin OS=Homo 
sapiens GN=SERPINF2 PE=1 SV=3 - 
[A2AP_HUMAN] 
P02765 3.81 1 1 367 39.3 5.72 60.41 Alpha-2-HS-glycoprotein OS=Homo 
sapiens GN=AHSG PE=1 SV=1 - 
[FETUA_HUMAN] 
P04745 20.16 6 6 511 57.7 6.93 301.99 Alpha-amylase 1 OS=Homo sapiens 
GN=AMY1A PE=1 SV=2 - 
[AMY1_HUMAN] 
P19961 16.05 6 6 511 57.7 7.09 321.43 Alpha-amylase 2B OS=Homo sapiens 
GN=AMY2B PE=1 SV=1 - 
[AMY2B_HUMAN] 
P06733 8.53 2 2 434 47.1 7.39 131.52 Alpha-enolase OS=Homo sapiens 
GN=ENO1 PE=1 SV=2 - 
[ENOA_HUMAN] 
P06280 6.76 2 2 429 48.7 5.60 138.47 Alpha-galactosidase A OS=Homo 
sapiens GN=GLA PE=1 SV=1 - 
[AGAL_HUMAN] 
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P17050 6.57 2 2 411 46.5 5.19 105.96 Alpha-N-acetylgalactosaminidase 
OS=Homo sapiens GN=NAGA PE=1 
SV=2 - [NAGAB_HUMAN] 
P54802 23.69 14 12 743 82.1 6.54 686.14 Alpha-N-acetylglucosaminidase 
OS=Homo sapiens GN=NAGLU PE=1 
SV=1 - [ANAG_HUMAN] 
P19801 3.73 2 2 751 85.3 7.09 92.58 Amiloride-sensitive amine oxidase 
[copper-containing] OS=Homo 
sapiens GN=ABP1 PE=1 SV=4 - 
[ABP1_HUMAN] 
P15144 28.23 24 18 967 109.5 5.48 1093.36 Aminopeptidase N OS=Homo sapiens 
GN=ANPEP PE=1 SV=4 - 
[AMPN_HUMAN] 
Q9UBD6 2.71 1 1 479 53.1 6.39 76.92 Ammonium transporter Rh type C 
OS=Homo sapiens GN=RHCG PE=1 
SV=1 - [RHCG_HUMAN] 
Q9UKU9 5.88 3 3 493 57.1 7.53 118.68 Angiopoietin-related protein 2 
OS=Homo sapiens GN=ANGPTL2 
PE=2 SV=1 - [ANGL2_HUMAN] 
P12821 1.07 1 1 1306 149.6 6.39 71.25 Angiotensin-converting enzyme 
OS=Homo sapiens GN=ACE PE=1 
SV=1 - [ACE_HUMAN] 
P50995 5.35 2 2 505 54.4 7.65 120.56 Annexin A11 OS=Homo sapiens 
GN=ANXA11 PE=1 SV=1 - 
[ANX11_HUMAN] 
P01008 13.58 4 4 464 52.6 6.71 200.24 Antithrombin-III OS=Homo sapiens 
GN=SERPINC1 PE=1 SV=1 - 
[ANT3_HUMAN] 
P05090 38.10 16 10 189 21.3 5.15 548.73 Apolipoprotein D OS=Homo sapiens 
GN=APOD PE=1 SV=1 - 
[APOD_HUMAN] 
P02649 21.14 6 5 317 36.1 5.73 319.65 Apolipoprotein E OS=Homo sapiens 
GN=APOE PE=1 SV=1 - 
[APOE_HUMAN] 
P29972 5.58 1 1 269 28.5 7.42 110.95 Aquaporin-1 OS=Homo sapiens 
GN=AQP1 PE=1 SV=3 - 
[AQP1_HUMAN] 
P00966 10.19 3 3 412 46.5 8.02 165.18 Argininosuccinate synthase 
OS=Homo sapiens GN=ASS1 PE=1 
SV=2 - [ASSY_HUMAN] 
P15289 3.35 1 1 507 53.6 6.07 88.12 Arylsulfatase A OS=Homo sapiens 
GN=ARSA PE=1 SV=3 - 
[ARSA_HUMAN] 
P25705 2.35 1 1 553 59.7 9.13 60.23 ATP synthase subunit alpha, 
mitochondrial OS=Homo sapiens 
GN=ATP5A1 PE=1 SV=1 - 
[ATPA_HUMAN] 
P06576 2.46 1 1 529 56.5 5.40 88.64 ATP synthase subunit beta, 
mitochondrial OS=Homo sapiens 
GN=ATP5B PE=1 SV=3 - 
[ATPB_HUMAN] 
O75882 7.35 9 8 1429 158.4 7.31 385.18 Attractin OS=Homo sapiens 
GN=ATRN PE=1 SV=2 - 
[ATRN_HUMAN] 
P98160 1.62 5 5 4391 468.5 6.51 227.69 Basement membrane-specific 
heparan sulfate proteoglycan core 
protein OS=Homo sapiens 
GN=HSPG2 PE=1 SV=3 - 
[PGBM_HUMAN] 
P15291 5.03 1 1 398 43.9 8.65 96.50 Beta-1,4-galactosyltransferase 1 
OS=Homo sapiens GN=B4GALT1 
PE=1 SV=5 - [B4GT1_HUMAN] 
P16278 24.08 15 14 677 76.0 6.57 595.22 Beta-galactosidase OS=Homo sapiens 
GN=GLB1 PE=1 SV=2 - 
[BGAL_HUMAN] 
P08236 4.30 2 2 651 74.7 7.02 104.80 Beta-glucuronidase OS=Homo 
sapiens GN=GUSB PE=1 SV=2 - 
[BGLR_HUMAN] 
P06865 5.86 2 2 529 60.7 5.16 115.60 Beta-hexosaminidase subunit alpha 
OS=Homo sapiens GN=HEXA PE=1 
SV=1 - [HEXA_HUMAN] 
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P07686 1.80 1 1 556 63.1 6.76 62.70 Beta-hexosaminidase subunit beta 
OS=Homo sapiens GN=HEXB PE=1 
SV=3 - [HEXB_HUMAN] 
Q93088 19.95 6 6 406 45.0 7.03 332.85 Betaine--homocysteine S-
methyltransferase 1 OS=Homo 
sapiens GN=BHMT PE=1 SV=2 - 
[BHMT1_HUMAN] 
O00462 1.48 1 1 879 100.8 5.52 79.44 Beta-mannosidase OS=Homo sapiens 
GN=MANBA PE=1 SV=3 - 
[MANBA_HUMAN] 
P52848 0.79 1 1 882 100.8 7.97 62.44 Bifunctional heparan sulfate N-
deacetylase/N-sulfotransferase 1 
OS=Homo sapiens GN=NDST1 PE=1 
SV=1 - [NDST1_HUMAN] 
P21810 2.99 1 1 368 41.6 7.52 68.04 Biglycan OS=Homo sapiens GN=BGN 
PE=1 SV=2 - [PGS1_HUMAN] 
Q5VW32 6.33 2 2 411 46.4 7.65 98.65 BRO1 domain-containing protein 
BROX OS=Homo sapiens GN=BROX 
PE=1 SV=1 - [BROX_HUMAN] 
P12830 2.61 3 2 882 97.4 4.73 133.91 Cadherin-1 OS=Homo sapiens 
GN=CDH1 PE=1 SV=3 - 
[CADH1_HUMAN] 
Q9BYE9 6.49 6 6 1310 141.5 4.50 251.84 Cadherin-related family member 2 
OS=Homo sapiens GN=CDHR2 PE=1 
SV=2 - [CDHR2_HUMAN] 
Q9HBB8 4.50 2 2 845 88.2 4.93 86.73 Cadherin-related family member 5 
OS=Homo sapiens GN=CDHR5 PE=1 
SV=3 - [CDHR5_HUMAN] 
P00918 6.15 1 1 260 29.2 7.40 69.24 Carbonic anhydrase 2 OS=Homo 
sapiens GN=CA2 PE=1 SV=2 - 
[CAH2_HUMAN] 
P22792 8.81 4 3 545 60.6 5.99 201.13 Carboxypeptidase N subunit 2 
OS=Homo sapiens GN=CPN2 PE=1 
SV=2 - [CPN2_HUMAN] 
P07858 12.68 4 3 339 37.8 6.30 222.70 Cathepsin B OS=Homo sapiens 
GN=CTSB PE=1 SV=3 - 
[CATB_HUMAN] 
P07339 5.10 2 2 412 44.5 6.54 115.82 Cathepsin D OS=Homo sapiens 
GN=CTSD PE=1 SV=1 - 
[CATD_HUMAN] 
P09668 12.54 3 2 335 37.4 8.07 195.04 Cathepsin H OS=Homo sapiens 
GN=CTSH PE=1 SV=4 - 
[CATH_HUMAN] 
P11717 3.17 5 5 2491 274.1 5.91 167.49 Cation-independent mannose-6-
phosphate receptor OS=Homo 
sapiens GN=IGF2R PE=1 SV=2 - 
[MPRI_HUMAN] 
P13987 15.63 3 2 128 14.2 6.48 154.26 CD59 glycoprotein OS=Homo sapiens 
GN=CD59 PE=1 SV=1 - 
[CD59_HUMAN] 
P08962 7.56 4 3 238 25.6 7.81 153.86 CD63 antigen OS=Homo sapiens 
GN=CD63 PE=1 SV=2 - 
[CD63_HUMAN] 
P27701 3.75 1 1 267 29.6 5.24 61.76 CD82 antigen OS=Homo sapiens 
GN=CD82 PE=1 SV=1 - 
[CD82_HUMAN] 
P21926 15.35 2 2 228 25.4 7.15 138.54 CD9 antigen OS=Homo sapiens 
GN=CD9 PE=1 SV=4 - 
[CD9_HUMAN] 
P00450 27.98 20 18 1065 122.1 5.72 809.80 Ceruloplasmin OS=Homo sapiens 
GN=CP PE=1 SV=1 - 
[CERU_HUMAN] 
P11597 25.15 11 11 493 54.7 6.09 406.75 Cholesteryl ester transfer protein 
OS=Homo sapiens GN=CETP PE=1 
SV=2 - [CETP_HUMAN] 
Q8WWI5 6.09 3 3 657 73.3 8.60 98.54 Choline transporter-like protein 1 
OS=Homo sapiens GN=SLC44A1 
PE=1 SV=1 - [CTL1_HUMAN] 
Q8IWA5 14.02 7 7 706 80.1 8.62 270.76 Choline transporter-like protein 2 
OS=Homo sapiens GN=SLC44A2 
PE=1 SV=2 - [CTL2_HUMAN] 
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Q53GD3 7.61 10 6 710 79.2 8.59 361.93 Choline transporter-like protein 4 
OS=Homo sapiens GN=SLC44A4 
PE=2 SV=1 - [CTL4_HUMAN] 
P10909 26.95 13 10 449 52.5 6.27 565.78 Clusterin OS=Homo sapiens GN=CLU 
PE=1 SV=1 - [CLUS_HUMAN] 
P12109 5.06 3 3 1028 108.5 5.43 141.93 Collagen alpha-1(VI) chain OS=Homo 
sapiens GN=COL6A1 PE=1 SV=3 - 
[CO6A1_HUMAN] 
P39059 1.95 2 2 1388 141.6 5.00 99.58 Collagen alpha-1(XV) chain 
OS=Homo sapiens GN=COL15A1 
PE=1 SV=2 - [COFA1_HUMAN] 
Q9HBJ8 5.86 1 1 222 25.2 5.63 58.38 Collectrin OS=Homo sapiens 
GN=TMEM27 PE=1 SV=1 - 
[TMM27_HUMAN] 
Q9NZP8 6.37 4 2 487 53.5 7.20 191.48 Complement C1r subcomponent-like 
protein OS=Homo sapiens GN=C1RL 
PE=1 SV=2 - [C1RL_HUMAN] 
P01024 12.69 17 16 1663 187.0 6.40 765.93 Complement C3 OS=Homo sapiens 
GN=C3 PE=1 SV=2 - [CO3_HUMAN] 
P0C0L4 5.85 5 5 1744 192.7 7.08 248.32 Complement C4-A OS=Homo sapiens 
GN=C4A PE=1 SV=1 - 
[CO4A_HUMAN] 
P02748 3.94 2 2 559 63.1 5.59 81.66 Complement component C9 
OS=Homo sapiens GN=C9 PE=1 
SV=2 - [CO9_HUMAN] 
Q2VPA4 2.11 1 1 569 62.7 7.23 59.58 Complement component receptor 1-
like protein OS=Homo sapiens 
GN=CR1L PE=1 SV=3 - 
[CR1L_HUMAN] 
P08603 1.06 1 1 1231 139.0 6.61 75.96 Complement factor H OS=Homo 
sapiens GN=CFH PE=1 SV=4 - 
[CFAH_HUMAN] 
Q12860 1.87 2 2 1018 113.2 5.90 74.32 Contactin-1 OS=Homo sapiens 
GN=CNTN1 PE=1 SV=1 - 
[CNTN1_HUMAN] 
O60494 22.77 77 55 3623 398.4 5.35 3521.98 Cubilin OS=Homo sapiens GN=CUBN 
PE=1 SV=4 - [CUBN_HUMAN] 
P01034 10.96 1 1 146 15.8 8.75 91.29 Cystatin-C OS=Homo sapiens 
GN=CST3 PE=1 SV=1 - 
[CYTC_HUMAN] 
Q96KP4 7.37 2 2 475 52.8 5.97 131.04 Cytosolic non-specific dipeptidase 
OS=Homo sapiens GN=CNDP2 PE=1 
SV=2 - [CNDP2_HUMAN] 
P24855 6.74 2 2 282 31.4 4.91 105.13 Deoxyribonuclease-1 OS=Homo 
sapiens GN=DNASE1 PE=1 SV=1 - 
[DNAS1_HUMAN] 
P81605 22.73 2 2 110 11.3 6.54 118.08 Dermcidin OS=Homo sapiens 
GN=DCD PE=1 SV=2 - 
[DCD_HUMAN] 
P15924 0.91 2 2 2871 331.6 6.81 121.81 Desmoplakin OS=Homo sapiens 
GN=DSP PE=1 SV=3 - 
[DESP_HUMAN] 
P16444 19.95 6 5 411 45.6 6.15 272.09 Dipeptidase 1 OS=Homo sapiens 
GN=DPEP1 PE=1 SV=3 - 
[DPEP1_HUMAN] 
P53634 24.19 10 8 463 51.8 6.99 360.09 Dipeptidyl peptidase 1 OS=Homo 
sapiens GN=CTSC PE=1 SV=1 - 
[CATC_HUMAN] 
Q9UHL4 17.48 9 6 492 54.3 6.32 387.29 Dipeptidyl peptidase 2 OS=Homo 
sapiens GN=DPP7 PE=1 SV=3 - 
[DPP2_HUMAN] 
P27487 12.01 8 8 766 88.2 6.04 392.73 Dipeptidyl peptidase 4 OS=Homo 
sapiens GN=DPP4 PE=1 SV=2 - 
[DPP4_HUMAN] 
Q12805 27.99 12 9 493 54.6 5.07 549.25 EGF-containing fibulin-like 
extracellular matrix protein 1 
OS=Homo sapiens GN=EFEMP1 
PE=1 SV=2 - [FBLN3_HUMAN] 
P68104 8.87 2 2 462 50.1 9.01 89.82 Elongation factor 1-alpha 1 
OS=Homo sapiens GN=EEF1A1 PE=1 
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SV=1 - [EF1A1_HUMAN] 
Q9Y2E5 3.77 3 3 1009 113.9 7.24 150.15 Epididymis-specific alpha-
mannosidase OS=Homo sapiens 
GN=MAN2B2 PE=1 SV=4 - 
[MA2B2_HUMAN] 
P33947 10.38 2 2 212 24.4 8.72 112.87 ER lumen protein retaining receptor 2 
OS=Homo sapiens GN=KDELR2 PE=1 
SV=1 - [ERD22_HUMAN] 
P56537 7.35 1 1 245 26.6 4.68 70.15 Eukaryotic translation initiation factor 
6 OS=Homo sapiens GN=EIF6 PE=1 
SV=1 - [IF6_HUMAN] 
P43005 3.44 1 1 524 57.1 5.71 77.44 Excitatory amino acid transporter 3 
OS=Homo sapiens GN=SLC1A1 PE=1 
SV=2 - [EAA3_HUMAN] 
P15311 2.90 1 1 586 69.4 6.27 88.81 Ezrin OS=Homo sapiens GN=EZR 
PE=1 SV=4 - [EZRI_HUMAN] 
P35555 0.45 1 1 2871 312.1 4.93 64.99 Fibrillin-1 OS=Homo sapiens 
GN=FBN1 PE=1 SV=2 - 
[FBN1_HUMAN] 
P02671 12.70 12 6 866 94.9 6.01 558.20 Fibrinogen alpha chain OS=Homo 
sapiens GN=FGA PE=1 SV=2 - 
[FIBA_HUMAN] 
Q14314 12.30 5 4 439 50.2 7.39 264.28 Fibroleukin OS=Homo sapiens 
GN=FGL2 PE=1 SV=1 - 
[FGL2_HUMAN] 
P02751 12.57 19 17 2386 262.5 5.71 843.15 Fibronectin OS=Homo sapiens 
GN=FN1 PE=1 SV=4 - 
[FINC_HUMAN] 
P23142 7.54 5 5 703 77.2 5.22 207.01 Fibulin-1 OS=Homo sapiens 
GN=FBLN1 PE=1 SV=4 - 
[FBLN1_HUMAN] 
Q5D862 2.55 2 2 2391 247.9 8.31 75.61 Filaggrin-2 OS=Homo sapiens 
GN=FLG2 PE=1 SV=1 - 
[FILA2_HUMAN] 
P15328 7.39 2 2 257 29.8 7.97 89.55 Folate receptor alpha OS=Homo 
sapiens GN=FOLR1 PE=1 SV=3 - 
[FOLR1_HUMAN] 
Q5SZK8 2.02 5 5 3169 350.9 5.03 167.96 FRAS1-related extracellular matrix 
protein 2 OS=Homo sapiens 
GN=FREM2 PE=1 SV=2 - 
[FREM2_HUMAN] 
Q9ULV1 2.98 1 1 537 59.8 7.27 71.30 Frizzled-4 OS=Homo sapiens 
GN=FZD4 PE=1 SV=2 - 
[FZD4_HUMAN] 
P05062 5.49 2 2 364 39.4 7.87 76.62 Fructose-bisphosphate aldolase B 
OS=Homo sapiens GN=ALDOB PE=1 
SV=2 - [ALDOB_HUMAN] 
P54803 2.19 1 1 685 77.0 6.64 85.96 Galactocerebrosidase OS=Homo 
sapiens GN=GALC PE=1 SV=2 - 
[GALC_HUMAN] 
Q08380 30.94 20 13 585 65.3 5.27 1039.17 Galectin-3-binding protein OS=Homo 
sapiens GN=LGALS3BP PE=1 SV=1 - 
[LG3BP_HUMAN] 
O00182 4.51 1 1 355 39.5 9.17 88.46 Galectin-9 OS=Homo sapiens 
GN=LGALS9 PE=1 SV=2 - 
[LEG9_HUMAN] 
Q92820 20.13 6 5 318 35.9 7.11 242.07 Gamma-glutamyl hydrolase 
OS=Homo sapiens GN=GGH PE=1 
SV=2 - [GGH_HUMAN] 
P19440 4.75 2 2 569 61.4 7.12 120.62 Gamma-glutamyltranspeptidase 1 
OS=Homo sapiens GN=GGT1 PE=1 
SV=2 - [GGT1_HUMAN] 
P13284 4.21 1 1 261 29.1 4.98 83.20 Gamma-interferon-inducible 
lysosomal thiol reductase OS=Homo 
sapiens GN=IFI30 PE=1 SV=2 - 
[GILT_HUMAN] 
P17900 15.54 2 2 193 20.8 5.31 86.43 Ganglioside GM2 activator OS=Homo 
sapiens GN=GM2A PE=1 SV=4 - 
[SAP3_HUMAN] 
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P07093 7.54 2 2 398 44.0 9.29 79.58 Glia-derived nexin OS=Homo sapiens 
GN=SERPINE2 PE=1 SV=1 - 
[GDN_HUMAN] 
P06744 3.05 1 1 558 63.1 8.32 63.37 Glucose-6-phosphate isomerase 
OS=Homo sapiens GN=GPI PE=1 
SV=4 - [G6PI_HUMAN] 
Q16769 11.08 3 3 361 40.9 6.61 135.96 Glutaminyl-peptide cyclotransferase 
OS=Homo sapiens GN=QPCT PE=1 
SV=1 - [QPCT_HUMAN] 
Q07075 5.75 4 3 957 109.2 5.47 206.36 Glutamyl aminopeptidase OS=Homo 
sapiens GN=ENPEP PE=1 SV=3 - 
[AMPE_HUMAN] 
P21266 25.78 5 5 225 26.5 5.54 276.42 Glutathione S-transferase Mu 3 
OS=Homo sapiens GN=GSTM3 PE=1 
SV=3 - [GSTM3_HUMAN] 
P04406 33.43 8 7 335 36.0 8.46 336.18 Glyceraldehyde-3-phosphate 
dehydrogenase OS=Homo sapiens 
GN=GAPDH PE=1 SV=3 - 
[G3P_HUMAN] 
P51654 5.17 2 2 580 65.5 6.37 128.15 Glypican-3 OS=Homo sapiens 
GN=GPC3 PE=1 SV=1 - 
[GPC3_HUMAN] 
Q92896 1.44 2 2 1179 134.5 6.90 93.01 Golgi apparatus protein 1 OS=Homo 
sapiens GN=GLG1 PE=1 SV=2 - 
[GSLG1_HUMAN] 
Q8NBJ4 5.74 2 2 401 45.3 4.97 108.52 Golgi membrane protein 1 OS=Homo 
sapiens GN=GOLM1 PE=1 SV=1 - 
[GOLM1_HUMAN] 
Q9NQ84 18.82 6 5 441 48.2 8.43 303.35 G-protein coupled receptor family C 
group 5 member C OS=Homo 
sapiens GN=GPRC5C PE=1 SV=2 - 
[GPC5C_HUMAN] 
P63096 6.21 2 2 354 40.3 5.97 78.40 Guanine nucleotide-binding protein 
G(i) subunit alpha-1 OS=Homo 
sapiens GN=GNAI1 PE=1 SV=2 - 
[GNAI1_HUMAN] 
Q9UBI6 15.28 1 1 72 8.0 8.97 73.78 Guanine nucleotide-binding protein 
G(I)/G(S)/G(O) subunit gamma-12 
OS=Homo sapiens GN=GNG12 PE=1 
SV=3 - [GBG12_HUMAN] 
P62873 11.47 3 3 340 37.4 6.00 140.70 Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-1 
OS=Homo sapiens GN=GNB1 PE=1 
SV=3 - [GBB1_HUMAN] 
P62879 11.47 3 3 340 37.3 6.00 159.26 Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-2 
OS=Homo sapiens GN=GNB2 PE=1 
SV=3 - [GBB2_HUMAN] 
P54652 2.50 1 1 639 70.0 5.74 75.89 Heat shock-related 70 kDa protein 2 
OS=Homo sapiens GN=HSPA2 PE=1 
SV=1 - [HSP72_HUMAN] 
P69905 10.56 1 1 142 15.2 8.68 70.76 Hemoglobin subunit alpha OS=Homo 
sapiens GN=HBA1 PE=1 SV=2 - 
[HBA_HUMAN] 
P68871 53.74 7 6 147 16.0 7.28 276.73 Hemoglobin subunit beta OS=Homo 
sapiens GN=HBB PE=1 SV=2 - 
[HBB_HUMAN] 
Q93099 2.25 1 1 445 49.9 6.96 62.23 Homogentisate 1,2-dioxygenase 
OS=Homo sapiens GN=HGD PE=1 
SV=2 - [HGD_HUMAN] 
Q86YZ3 9.23 6 6 2850 282.2 10.0
4 
284.89 Hornerin OS=Homo sapiens 
GN=HRNR PE=1 SV=2 - 
[HORN_HUMAN] 
P01876 37.68 17 12 353 37.6 6.51 687.77 Ig alpha-1 chain C region OS=Homo 
sapiens GN=IGHA1 PE=1 SV=2 - 
[IGHA1_HUMAN] 
P01877 29.12 11 8 340 36.5 6.10 431.51 Ig alpha-2 chain C region OS=Homo 
sapiens GN=IGHA2 PE=1 SV=3 - 
[IGHA2_HUMAN] 
P01857 28.79 6 6 330 36.1 8.19 249.68 Ig gamma-1 chain C region 
OS=Homo sapiens GN=IGHG1 PE=1 
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SV=1 - [IGHG1_HUMAN] 
P01859 7.98 2 2 326 35.9 7.59 176.29 Ig gamma-2 chain C region 
OS=Homo sapiens GN=IGHG2 PE=1 
SV=2 - [IGHG2_HUMAN] 
P01742 10.26 4 1 117 12.5 6.57 113.67 Ig heavy chain V-I region EU 
OS=Homo sapiens PE=1 SV=1 - 
[HV101_HUMAN] 
P01743 22.22 2 2 117 12.9 8.92 90.03 Ig heavy chain V-I region HG3 
OS=Homo sapiens PE=4 SV=1 - 
[HV102_HUMAN] 
P06331 10.96 1 1 146 16.2 8.28 80.27 Ig heavy chain V-II region ARH-77 
OS=Homo sapiens PE=4 SV=1 - 
[HV209_HUMAN] 
P01766 25.00 4 2 120 13.2 6.57 213.66 Ig heavy chain V-III region BRO 
OS=Homo sapiens PE=1 SV=1 - 
[HV305_HUMAN] 
P01781 18.97 2 2 116 12.7 8.48 110.43 Ig heavy chain V-III region GAL 
OS=Homo sapiens PE=1 SV=1 - 
[HV320_HUMAN] 
P01771 9.09 1 1 121 13.6 9.36 67.49 Ig heavy chain V-III region HIL 
OS=Homo sapiens PE=1 SV=1 - 
[HV310_HUMAN] 
P01765 26.09 3 2 115 12.3 9.13 171.68 Ig heavy chain V-III region TIL 
OS=Homo sapiens PE=1 SV=1 - 
[HV304_HUMAN] 
P01762 15.57 3 1 122 13.5 9.72 142.18 Ig heavy chain V-III region TRO 
OS=Homo sapiens PE=1 SV=1 - 
[HV301_HUMAN] 
P01779 26.72 2 2 116 12.4 9.73 121.71 Ig heavy chain V-III region TUR 
OS=Homo sapiens PE=1 SV=1 - 
[HV318_HUMAN] 
P01764 18.80 3 2 117 12.6 8.28 164.88 Ig heavy chain V-III region VH26 
OS=Homo sapiens PE=1 SV=1 - 
[HV303_HUMAN] 
P01834 80.19 13 6 106 11.6 5.87 685.01 Ig kappa chain C region OS=Homo 
sapiens GN=IGKC PE=1 SV=1 - 
[IGKC_HUMAN] 
P01593 31.48 4 2 108 12.0 5.99 218.14 Ig kappa chain V-I region AG 
OS=Homo sapiens PE=1 SV=1 - 
[KV101_HUMAN] 
P01596 16.82 1 1 107 11.7 9.41 102.63 Ig kappa chain V-I region CAR 
OS=Homo sapiens PE=1 SV=1 - 
[KV104_HUMAN] 
P01597 16.67 12 1 108 11.7 9.36 186.48 Ig kappa chain V-I region DEE 
OS=Homo sapiens PE=1 SV=1 - 
[KV105_HUMAN] 
P01613 30.36 2 2 112 12.2 5.36 108.29 Ig kappa chain V-I region Ni 
OS=Homo sapiens PE=1 SV=1 - 
[KV121_HUMAN] 
P01611 16.67 1 1 108 11.6 7.28 77.26 Ig kappa chain V-I region Wes 
OS=Homo sapiens PE=1 SV=1 - 
[KV119_HUMAN] 
P01616 11.61 1 1 112 12.0 9.29 86.34 Ig kappa chain V-II region MIL 
OS=Homo sapiens PE=1 SV=1 - 
[KV203_HUMAN] 
P01617 21.24 1 1 113 12.3 6.00 117.46 Ig kappa chain V-II region TEW 
OS=Homo sapiens PE=1 SV=1 - 
[KV204_HUMAN] 
P01620 31.19 2 2 109 11.8 8.48 119.81 Ig kappa chain V-III region SIE 
OS=Homo sapiens PE=1 SV=1 - 
[KV302_HUMAN] 
P06312 29.75 3 3 121 13.4 5.25 96.97 Ig kappa chain V-IV region 
(Fragment) OS=Homo sapiens 
GN=IGKV4-1 PE=4 SV=1 - 
[KV401_HUMAN] 
P01625 36.84 4 3 114 12.6 7.93 148.67 Ig kappa chain V-IV region Len 
OS=Homo sapiens PE=1 SV=2 - 
[KV402_HUMAN] 
P04208 11.93 1 1 109 11.7 6.54 109.57 Ig lambda chain V-I region WAH 
OS=Homo sapiens PE=1 SV=1 - 
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[LV106_HUMAN] 
P80748 21.62 2 2 111 11.9 5.08 114.11 Ig lambda chain V-III region LOI 
OS=Homo sapiens PE=1 SV=1 - 
[LV302_HUMAN] 
P01714 25.00 2 2 108 11.4 6.52 116.26 Ig lambda chain V-III region SH 
OS=Homo sapiens PE=1 SV=1 - 
[LV301_HUMAN] 
P0CG04 77.36 10 6 106 11.3 7.87 493.61 Ig lambda-1 chain C regions 
OS=Homo sapiens GN=IGLC1 PE=1 
SV=1 - [LAC1_HUMAN] 
P0CG05 75.47 10 6 106 11.3 7.24 514.52 Ig lambda-2 chain C regions 
OS=Homo sapiens GN=IGLC2 PE=1 
SV=1 - [LAC2_HUMAN] 
P01871 9.29 3 3 452 49.3 6.77 162.54 Ig mu chain C region OS=Homo 
sapiens GN=IGHM PE=1 SV=3 - 
[IGHM_HUMAN] 
Q9Y6R7 7.25 14 11 5405 571.6 5.34 607.42 IgGFc-binding protein OS=Homo 
sapiens GN=FCGBP PE=1 SV=3 - 
[FCGBP_HUMAN] 
P01591 16.98 2 2 159 18.1 5.24 103.02 Immunoglobulin J chain OS=Homo 
sapiens GN=IGJ PE=1 SV=4 - 
[IGJ_HUMAN] 
Q969P0 1.63 1 1 613 65.0 8.00 65.85 Immunoglobulin superfamily member 
8 OS=Homo sapiens GN=IGSF8 
PE=1 SV=1 - [IGSF8_HUMAN] 
P18065 3.69 1 1 325 34.8 7.50 68.44 Insulin-like growth factor-binding 
protein 2 OS=Homo sapiens 
GN=IGFBP2 PE=1 SV=2 - 
[IBP2_HUMAN] 
Q16270 15.25 3 3 282 29.1 7.90 129.74 Insulin-like growth factor-binding 
protein 7 OS=Homo sapiens 
GN=IGFBP7 PE=1 SV=1 - 
[IBP7_HUMAN] 
P35858 2.64 1 1 605 66.0 6.79 79.36 Insulin-like growth factor-binding 
protein complex acid labile subunit 
OS=Homo sapiens GN=IGFALS PE=1 
SV=1 - [ALS_HUMAN] 
Q9Y287 7.89 2 2 266 30.3 5.14 99.50 Integral membrane protein 2B 
OS=Homo sapiens GN=ITM2B PE=1 
SV=1 - [ITM2B_HUMAN] 
Q14624 13.76 8 8 930 103.3 6.98 332.69 Inter-alpha-trypsin inhibitor heavy 
chain H4 OS=Homo sapiens 
GN=ITIH4 PE=1 SV=4 - 
[ITIH4_HUMAN] 
P53990 11.54 5 5 364 39.7 5.35 184.03 IST1 homolog OS=Homo sapiens 
GN=KIAA0174 PE=1 SV=1 - 
[IST1_HUMAN] 
P06870 18.32 4 3 262 28.9 4.83 192.89 Kallikrein-1 OS=Homo sapiens 
GN=KLK1 PE=1 SV=2 - 
[KLK1_HUMAN] 
P29622 21.08 7 7 427 48.5 7.75 265.06 Kallistatin OS=Homo sapiens 
GN=SERPINA4 PE=1 SV=3 - 
[KAIN_HUMAN] 
P13645 50.68 45 23 584 58.8 5.21 2028.78 Keratin, type I cytoskeletal 10 
OS=Homo sapiens GN=KRT10 PE=1 
SV=6 - [K1C10_HUMAN] 
P13646 10.92 6 5 458 49.6 4.96 261.83 Keratin, type I cytoskeletal 13 
OS=Homo sapiens GN=KRT13 PE=1 
SV=4 - [K1C13_HUMAN] 
P02533 48.73 18 18 472 51.5 5.16 808.54 Keratin, type I cytoskeletal 14 
OS=Homo sapiens GN=KRT14 PE=1 
SV=4 - [K1C14_HUMAN] 
P19012 10.53 5 5 456 49.2 4.77 266.13 Keratin, type I cytoskeletal 15 
OS=Homo sapiens GN=KRT15 PE=1 
SV=2 - [K1C15_HUMAN] 
P08779 39.96 17 15 473 51.2 5.05 722.80 Keratin, type I cytoskeletal 16 
OS=Homo sapiens GN=KRT16 PE=1 
SV=4 - [K1C16_HUMAN] 
P35527 63.24 40 25 623 62.0 5.24 1805.64 Keratin, type I cytoskeletal 9 
OS=Homo sapiens GN=KRT9 PE=1 
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SV=3 - [K1C9_HUMAN] 
P04264 51.09 48 30 644 66.0 8.12 1995.10 Keratin, type II cytoskeletal 1 
OS=Homo sapiens GN=KRT1 PE=1 
SV=6 - [K2C1_HUMAN] 
Q7Z794 3.82 3 2 576 61.7 5.85 113.44 Keratin, type II cytoskeletal 1b 
OS=Homo sapiens GN=KRT77 PE=1 
SV=2 - [K2C1B_HUMAN] 
P35908 61.97 33 29 639 65.4 8.00 1621.97 Keratin, type II cytoskeletal 2 
epidermal OS=Homo sapiens 
GN=KRT2 PE=1 SV=2 - 
[K22E_HUMAN] 
P12035 6.36 4 4 629 64.5 6.48 203.80 Keratin, type II cytoskeletal 3 
OS=Homo sapiens GN=KRT3 PE=1 
SV=2 - [K2C3_HUMAN] 
P19013 3.75 3 2 534 57.2 6.61 114.19 Keratin, type II cytoskeletal 4 
OS=Homo sapiens GN=KRT4 PE=1 
SV=4 - [K2C4_HUMAN] 
P13647 28.47 19 16 590 62.3 7.74 735.76 Keratin, type II cytoskeletal 5 
OS=Homo sapiens GN=KRT5 PE=1 
SV=3 - [K2C5_HUMAN] 
P02538 32.27 20 17 564 60.0 8.00 731.15 Keratin, type II cytoskeletal 6A 
OS=Homo sapiens GN=KRT6A PE=1 
SV=3 - [K2C6A_HUMAN] 
P04259 27.48 19 15 564 60.0 8.00 677.45 Keratin, type II cytoskeletal 6B 
OS=Homo sapiens GN=KRT6B PE=1 
SV=5 - [K2C6B_HUMAN] 
Q14CN4 4.11 3 2 511 55.8 6.89 139.87 Keratin, type II cytoskeletal 72 
OS=Homo sapiens GN=KRT72 PE=1 
SV=2 - [K2C72_HUMAN] 
Q7RTS7 3.97 3 3 529 57.8 7.71 127.60 Keratin, type II cytoskeletal 74 
OS=Homo sapiens GN=KRT74 PE=1 
SV=2 - [K2C74_HUMAN] 
P01042 18.79 12 9 644 71.9 6.81 537.37 Kininogen-1 OS=Homo sapiens 
GN=KNG1 PE=1 SV=2 - 
[KNG1_HUMAN] 
Q9Y2S2 13.79 3 3 319 35.4 6.18 144.67 Lambda-crystallin homolog OS=Homo 
sapiens GN=CRYL1 PE=1 SV=3 - 
[CRYL1_HUMAN] 
P18428 19.75 9 7 481 53.3 6.70 378.83 Lipopolysaccharide-binding protein 
OS=Homo sapiens GN=LBP PE=1 
SV=3 - [LBP_HUMAN] 
P00338 18.37 6 5 332 36.7 8.27 275.52 L-lactate dehydrogenase A chain 
OS=Homo sapiens GN=LDHA PE=1 
SV=2 - [LDHA_HUMAN] 
P07195 26.65 8 6 334 36.6 6.05 335.02 L-lactate dehydrogenase B chain 
OS=Homo sapiens GN=LDHB PE=1 
SV=2 - [LDHB_HUMAN] 
P98164 27.78 132 86 4655 521.6 5.08 5205.16 Low-density lipoprotein receptor-
related protein 2 OS=Homo sapiens 
GN=LRP2 PE=1 SV=3 - 
[LRP2_HUMAN] 
P11117 7.09 3 3 423 48.3 6.74 130.41 Lysosomal acid phosphatase 
OS=Homo sapiens GN=ACP2 PE=1 
SV=3 - [PPAL_HUMAN] 
P10253 7.46 6 6 952 105.3 5.99 264.77 Lysosomal alpha-glucosidase 
OS=Homo sapiens GN=GAA PE=1 
SV=3 - [LYAG_HUMAN] 
P10619 5.63 2 2 480 54.4 6.61 138.23 Lysosomal protective protein 
OS=Homo sapiens GN=CTSA PE=1 
SV=2 - [PPGB_HUMAN] 
P42785 1.81 1 1 496 55.8 7.21 78.21 Lysosomal Pro-X carboxypeptidase 
OS=Homo sapiens GN=PRCP PE=1 
SV=1 - [PCP_HUMAN] 
P11279 6.47 2 2 417 44.9 8.75 128.58 Lysosome-associated membrane 
glycoprotein 1 OS=Homo sapiens 
GN=LAMP1 PE=1 SV=3 - 
[LAMP1_HUMAN] 
P13473 6.34 2 2 410 44.9 5.63 125.07 Lysosome-associated membrane 
glycoprotein 2 OS=Homo sapiens 
GN=LAMP2 PE=1 SV=2 - 
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[LAMP2_HUMAN] 
P61626 8.11 1 1 148 16.5 9.16 65.16 Lysozyme C OS=Homo sapiens 
GN=LYZ PE=1 SV=1 - 
[LYSC_HUMAN] 
P14174 7.83 1 1 115 12.5 7.88 58.96 Macrophage migration inhibitory 
factor OS=Homo sapiens GN=MIF 
PE=1 SV=4 - [MIF_HUMAN] 
O43451 3.88 4 4 1857 209.7 5.50 226.10 Maltase-glucoamylase, intestinal 
OS=Homo sapiens GN=MGAM PE=1 
SV=5 - [MGA_HUMAN] 
O00187 7.73 6 4 686 75.7 5.77 319.05 Mannan-binding lectin serine 
protease 2 OS=Homo sapiens 
GN=MASP2 PE=1 SV=3 - 
[MASP2_HUMAN] 
P33908 19.45 14 9 653 72.9 6.47 636.82 Mannosyl-oligosaccharide 1,2-alpha-
mannosidase IA OS=Homo sapiens 
GN=MAN1A1 PE=1 SV=3 - 
[MA1A1_HUMAN] 
Q9NR34 2.86 1 1 630 70.9 7.46 120.17 Mannosyl-oligosaccharide 1,2-alpha-
mannosidase IC OS=Homo sapiens 
GN=MAN1C1 PE=1 SV=1 - 
[MA1C1_HUMAN] 
P02795 19.67 1 1 61 6.0 7.83 71.21 Metallothionein-2 OS=Homo sapiens 
GN=MT2A PE=1 SV=1 - 
[MT2_HUMAN] 
P08571 4.80 1 1 375 40.1 6.23 58.33 Monocyte differentiation antigen 
CD14 OS=Homo sapiens GN=CD14 
PE=1 SV=2 - [CD14_HUMAN] 
P15941 2.23 2 2 1255 122.0 7.47 84.01 Mucin-1 OS=Homo sapiens 
GN=MUC1 PE=1 SV=3 - 
[MUC1_HUMAN] 
Q9HC84 3.58 5 5 5703 590.1 6.67 193.26 Mucin-5B OS=Homo sapiens 
GN=MUC5B PE=1 SV=2 - 
[MUC5B_HUMAN] 
Q9H8L6 5.27 3 3 949 104.3 5.86 235.00 Multimerin-2 OS=Homo sapiens 
GN=MMRN2 PE=1 SV=2 - 
[MMRN2_HUMAN] 
Q7Z7M0 5.69 11 10 2845 302.9 6.87 443.30 Multiple epidermal growth factor-like 
domains protein 8 OS=Homo sapiens 
GN=MEGF8 PE=1 SV=2 - 
[MEGF8_HUMAN] 
O95865 7.37 1 1 285 29.6 6.01 74.60 N(G),N(G)-dimethylarginine 
dimethylaminohydrolase 2 OS=Homo 
sapiens GN=DDAH2 PE=1 SV=1 - 
[DDAH2_HUMAN] 
O96009 16.90 4 4 420 45.4 6.61 209.00 Napsin-A OS=Homo sapiens 
GN=NAPSA PE=1 SV=1 - 
[NAPSA_HUMAN] 
P08473 20.40 11 11 750 85.5 5.73 628.52 Neprilysin OS=Homo sapiens 
GN=MME PE=1 SV=2 - 
[NEP_HUMAN] 
P59665 19.15 2 2 94 10.2 6.99 88.97 Neutrophil defensin 1 OS=Homo 
sapiens GN=DEFA1 PE=1 SV=1 - 
[DEF1_HUMAN] 
Q5JS37 3.46 1 1 347 38.3 6.43 66.13 NHL repeat-containing protein 3 
OS=Homo sapiens GN=NHLRC3 
PE=2 SV=1 - [NHLC3_HUMAN] 
P14543 1.68 1 1 1247 136.3 5.29 95.14 Nidogen-1 OS=Homo sapiens 
GN=NID1 PE=1 SV=3 - 
[NID1_HUMAN] 
P61970 29.13 2 2 127 14.5 5.38 155.79 Nuclear transport factor 2 OS=Homo 
sapiens GN=NUTF2 PE=1 SV=1 - 
[NTF2_HUMAN] 
Q6UX06 16.27 6 6 510 57.2 5.69 281.54 Olfactomedin-4 OS=Homo sapiens 
GN=OLFM4 PE=1 SV=1 - 
[OLFM4_HUMAN] 
P78380 12.82 2 2 273 30.9 7.28 119.08 Oxidized low-density lipoprotein 
receptor 1 OS=Homo sapiens 
GN=OLR1 PE=1 SV=1 - 
[OLR1_HUMAN] 
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P00558 4.08 1 1 417 44.6 8.10 76.65 Phosphoglycerate kinase 1 OS=Homo 
sapiens GN=PGK1 PE=1 SV=3 - 
[PGK1_HUMAN] 
O15162 6.29 1 1 318 35.0 4.94 68.00 Phospholipid scramblase 1 OS=Homo 
sapiens GN=PLSCR1 PE=1 SV=1 - 
[PLS1_HUMAN] 
Q9BTY2 3.21 1 1 467 54.0 6.25 65.49 Plasma alpha-L-fucosidase OS=Homo 
sapiens GN=FUCA2 PE=1 SV=2 - 
[FUCO2_HUMAN] 
P05155 17.20 7 7 500 55.1 6.55 431.29 Plasma protease C1 inhibitor 
OS=Homo sapiens GN=SERPING1 
PE=1 SV=2 - [IC1_HUMAN] 
P05154 42.12 28 15 406 45.7 9.26 1070.79 Plasma serine protease inhibitor 
OS=Homo sapiens GN=SERPINA5 
PE=1 SV=2 - [IPSP_HUMAN] 
P00747 3.83 1 1 810 90.5 7.24 92.68 Plasminogen OS=Homo sapiens 
GN=PLG PE=1 SV=2 - 
[PLMN_HUMAN] 
P01833 29.97 23 17 764 83.2 5.74 1007.64 Polymeric immunoglobulin receptor 
OS=Homo sapiens GN=PIGR PE=1 
SV=4 - [PIGR_HUMAN] 
P0CG48 23.65 2 2 685 77.0 7.66 117.31 Polyubiquitin-C OS=Homo sapiens 
GN=UBC PE=1 SV=1 - 
[UBC_HUMAN] 
Q9UHG3 3.96 2 2 505 56.6 6.18 104.25 Prenylcysteine oxidase 1 OS=Homo 
sapiens GN=PCYOX1 PE=1 SV=3 - 
[PCYOX_HUMAN] 
P07602 10.31 7 4 524 58.1 5.17 219.10 Proactivator polypeptide OS=Homo 
sapiens GN=PSAP PE=1 SV=2 - 
[SAP_HUMAN] 
Q9H3G5 24.16 11 9 476 54.1 5.62 421.42 Probable serine carboxypeptidase 
CPVL OS=Homo sapiens GN=CPVL 
PE=1 SV=2 - [CPVL_HUMAN] 
P01133 41.92 66 35 1207 133.9 5.85 2644.30 Pro-epidermal growth factor 
OS=Homo sapiens GN=EGF PE=1 
SV=2 - [EGF_HUMAN] 
Q8WUM4 5.65 4 4 868 96.0 6.52 159.24 Programmed cell death 6-interacting 
protein OS=Homo sapiens 
GN=PDCD6IP PE=1 SV=1 - 
[PDC6I_HUMAN] 
P12273 18.49 2 2 146 16.6 8.05 102.59 Prolactin-inducible protein OS=Homo 
sapiens GN=PIP PE=1 SV=1 - 
[PIP_HUMAN] 
O43490 11.45 8 7 865 97.1 7.27 345.73 Prominin-1 OS=Homo sapiens 
GN=PROM1 PE=1 SV=1 - 
[PROM1_HUMAN] 
Q14914 3.04 1 1 329 35.8 8.29 59.44 Prostaglandin reductase 1 OS=Homo 
sapiens GN=PTGR1 PE=1 SV=2 - 
[PTGR1_HUMAN] 
P41222 36.32 5 4 190 21.0 7.80 265.73 Prostaglandin-H2 D-isomerase 
OS=Homo sapiens GN=PTGDS PE=1 
SV=1 - [PTGDS_HUMAN] 
O43653 23.58 3 3 123 12.9 5.29 170.58 Prostate stem cell antigen OS=Homo 
sapiens GN=PSCA PE=1 SV=1 - 
[PSCA_HUMAN] 
P15309 2.59 1 1 386 44.5 6.24 73.09 Prostatic acid phosphatase OS=Homo 
sapiens GN=ACPP PE=1 SV=3 - 
[PPAP_HUMAN] 
P02760 40.06 17 10 352 39.0 6.25 736.61 Protein AMBP OS=Homo sapiens 
GN=AMBP PE=1 SV=1 - 
[AMBP_HUMAN] 
P31151 21.78 2 2 101 11.5 6.77 71.62 Protein S100-A7 OS=Homo sapiens 
GN=S100A7 PE=1 SV=4 - 
[S10A7_HUMAN] 
P06702 11.40 2 1 114 13.2 6.13 159.64 Protein S100-A9 OS=Homo sapiens 
GN=S100A9 PE=1 SV=1 - 
[S10A9_HUMAN] 
Q9C0H2 9.94 6 3 523 57.5 5.39 291.27 Protein tweety homolog 3 OS=Homo 
sapiens GN=TTYH3 PE=1 SV=3 - 
[TTYH3_HUMAN] 
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P00734 4.34 2 2 622 70.0 5.90 119.25 Prothrombin OS=Homo sapiens 
GN=F2 PE=1 SV=2 - [THRB_HUMAN] 
Q6V0I7 2.21 9 8 4981 542.4 4.94 407.50 Protocadherin Fat 4 OS=Homo 
sapiens GN=FAT4 PE=2 SV=2 - 
[FAT4_HUMAN] 
Q9UN70 1.61 1 1 934 101.0 5.21 79.15 Protocadherin gamma-C3 OS=Homo 
sapiens GN=PCDHGC3 PE=1 SV=1 - 
[PCDGK_HUMAN] 
Q495M3 5.80 2 2 483 53.2 8.12 101.50 Proton-coupled amino acid 
transporter 2 OS=Homo sapiens 
GN=SLC36A2 PE=2 SV=1 - 
[S36A2_HUMAN] 
P00491 3.46 1 1 289 32.1 6.95 63.37 Purine nucleoside phosphorylase 
OS=Homo sapiens GN=PNP PE=1 
SV=2 - [PNPH_HUMAN] 
Q8NHP8 5.09 2 2 589 65.4 6.80 73.61 Putative phospholipase B-like 2 
OS=Homo sapiens GN=PLBD2 PE=1 
SV=2 - [PLBL2_HUMAN] 
Q9H853 5.81 2 1 241 27.5 7.83 91.42 Putative tubulin-like protein alpha-4B 
OS=Homo sapiens GN=TUBA4B 
PE=5 SV=2 - [TBA4B_HUMAN] 
P61026 16.50 3 3 200 22.5 8.38 94.69 Ras-related protein Rab-10 
OS=Homo sapiens GN=RAB10 PE=1 
SV=1 - [RAB10_HUMAN] 
A6NIZ1 8.15 1 1 184 20.9 5.48 82.14 Ras-related protein Rap-1b-like 
protein OS=Homo sapiens PE=2 
SV=1 - [RP1BL_HUMAN] 
Q12913 2.32 2 2 1337 145.9 5.58 127.14 Receptor-type tyrosine-protein 
phosphatase eta OS=Homo sapiens 
GN=PTPRJ PE=1 SV=3 - 
[PTPRJ_HUMAN] 
Q9HD89 51.85 8 4 108 11.4 6.86 376.55 Resistin OS=Homo sapiens GN=RETN 
PE=2 SV=1 - [RETN_HUMAN] 
Q9HB40 5.53 5 2 452 50.8 5.81 323.19 Retinoid-inducible serine 
carboxypeptidase OS=Homo sapiens 
GN=SCPEP1 PE=1 SV=1 - 
[RISC_HUMAN] 
P02753 20.40 2 2 201 23.0 6.07 164.73 Retinol-binding protein 4 OS=Homo 
sapiens GN=RBP4 PE=1 SV=3 - 
[RET4_HUMAN] 
Q8WVN6 14.52 4 2 248 27.0 7.43 325.97 Secreted and transmembrane protein 
1 OS=Homo sapiens GN=SECTM1 
PE=1 SV=2 - [SCTM1_HUMAN] 
Q13591 1.02 1 1 1074 120.5 7.21 63.70 Semaphorin-5A OS=Homo sapiens 
GN=SEMA5A PE=1 SV=3 - 
[SEM5A_HUMAN] 
P34896 2.28 1 1 483 53.0 7.71 60.55 Serine hydroxymethyltransferase, 
cytosolic OS=Homo sapiens 
GN=SHMT1 PE=1 SV=1 - 
[GLYC_HUMAN] 
Q96SA4 8.55 2 2 456 50.8 6.19 93.68 Serine incorporator 2 OS=Homo 
sapiens GN=SERINC2 PE=2 SV=2 - 
[SERC2_HUMAN] 
P02787 37.97 34 17 698 77.0 7.12 1585.18 Serotransferrin OS=Homo sapiens 
GN=TF PE=1 SV=2 - [TRFE_HUMAN] 
Q96P63 4.20 1 1 405 46.2 5.53 77.37 Serpin B12 OS=Homo sapiens 
GN=SERPINB12 PE=1 SV=1 - 
[SPB12_HUMAN] 
P29508 12.56 4 4 390 44.5 6.81 135.85 Serpin B3 OS=Homo sapiens 
GN=SERPINB3 PE=1 SV=2 - 
[SPB3_HUMAN] 
P02768 50.08 48 26 609 69.3 6.28 1979.24 Serum albumin OS=Homo sapiens 
GN=ALB PE=1 SV=2 - 
[ALBU_HUMAN] 
Q9HAT2 2.29 1 1 523 58.3 7.33 85.37 Sialate O-acetylesterase OS=Homo 
sapiens GN=SIAE PE=1 SV=1 - 
[SIAE_HUMAN] 
P31639 2.23 1 1 672 72.8 7.47 62.08 Sodium/glucose cotransporter 2 
OS=Homo sapiens GN=SLC5A2 PE=1 
SV=1 - [SC5A2_HUMAN] 
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Q13621 4.09 3 3 1099 121.4 7.39 130.61 Solute carrier family 12 member 1 
OS=Homo sapiens GN=SLC12A1 
PE=1 SV=2 - [S12A1_HUMAN] 
P22732 5.39 3 3 501 54.9 6.04 140.45 Solute carrier family 2, facilitated 
glucose transporter member 5 
OS=Homo sapiens GN=SLC2A5 PE=1 
SV=1 - [GTR5_HUMAN] 
Q4U2R8 2.13 1 1 563 61.8 8.76 74.41 Solute carrier family 22 member 6 
OS=Homo sapiens GN=SLC22A6 
PE=1 SV=1 - [S22A6_HUMAN] 
Q14515 3.16 1 1 664 75.2 4.81 85.54 SPARC-like protein 1 OS=Homo 
sapiens GN=SPARCL1 PE=1 SV=2 - 
[SPRL1_HUMAN] 
P17405 1.75 1 1 629 69.7 7.28 69.10 Sphingomyelin phosphodiesterase 
OS=Homo sapiens GN=SMPD1 PE=1 
SV=4 - [ASM_HUMAN] 
P52823 9.31 2 2 247 27.6 7.99 111.17 Stanniocalcin-1 OS=Homo sapiens 
GN=STC1 PE=1 SV=1 - 
[STC1_HUMAN] 
Q9UGT4 3.04 2 2 822 90.1 6.28 131.08 Sushi domain-containing protein 2 
OS=Homo sapiens GN=SUSD2 PE=1 
SV=1 - [SUSD2_HUMAN] 
O00560 17.79 4 3 298 32.4 7.53 219.36 Syntenin-1 OS=Homo sapiens 
GN=SDCBP PE=1 SV=1 - 
[SDCB1_HUMAN] 
Q8TB96 2.29 1 1 612 68.1 5.39 64.06 T-cell immunomodulatory protein 
OS=Homo sapiens GN=ITFG1 PE=1 
SV=1 - [TIP_HUMAN] 
O60635 5.39 2 1 241 26.3 5.25 78.20 Tetraspanin-1 OS=Homo sapiens 
GN=TSPAN1 PE=1 SV=2 - 
[TSN1_HUMAN] 
O43657 5.31 1 1 245 27.5 8.10 95.09 Tetraspanin-6 OS=Homo sapiens 
GN=TSPAN6 PE=1 SV=1 - 
[TSN6_HUMAN] 
P07996 0.94 1 1 1170 129.3 4.94 101.45 Thrombospondin-1 OS=Homo 
sapiens GN=THBS1 PE=1 SV=2 - 
[TSP1_HUMAN] 
Q9UKU6 14.06 12 12 1024 116.9 6.99 464.27 Thyrotropin-releasing hormone-
degrading ectoenzyme OS=Homo 
sapiens GN=TRHDE PE=2 SV=1 - 
[TRHDE_HUMAN] 
P05543 15.66 5 5 415 46.3 6.30 289.98 Thyroxine-binding globulin OS=Homo 
sapiens GN=SERPINA7 PE=1 SV=2 - 
[THBG_HUMAN] 
P61586 13.47 3 2 193 21.8 6.10 204.58 Transforming protein RhoA 
OS=Homo sapiens GN=RHOA PE=1 
SV=1 - [RHOA_HUMAN] 
Q14956 3.15 1 1 572 63.9 6.64 71.63 Transmembrane glycoprotein NMB 
OS=Homo sapiens GN=GPNMB PE=1 
SV=2 - [GPNMB_HUMAN] 
O43280 1.89 1 1 583 66.5 5.68 60.93 Trehalase OS=Homo sapiens 
GN=TREH PE=1 SV=2 - 
[TREA_HUMAN] 
O14773 14.21 4 4 563 61.2 6.48 246.57 Tripeptidyl-peptidase 1 OS=Homo 
sapiens GN=TPP1 PE=1 SV=2 - 
[TPP1_HUMAN] 
Q9H1C7 10.31 1 1 97 10.6 4.32 67.31 UPF0467 protein C5orf32 OS=Homo 
sapiens GN=C5orf32 PE=2 SV=1 - 
[CE032_HUMAN] 
P00749 16.94 7 7 431 48.5 8.41 315.08 Urokinase-type plasminogen activator 
OS=Homo sapiens GN=PLAU PE=1 
SV=2 - [UROK_HUMAN] 
P07911 30.47 21 14 640 69.7 5.24 964.49 Uromodulin OS=Homo sapiens 
GN=UMOD PE=1 SV=1 - 
[UROM_HUMAN] 
Q6EMK4 12.33 6 5 673 71.7 7.39 257.62 Vasorin OS=Homo sapiens GN=VASN 
PE=1 SV=1 - [VASN_HUMAN] 
Q12907 19.66 5 5 356 40.2 6.95 258.74 Vesicular integral-membrane protein 
VIP36 OS=Homo sapiens GN=LMAN2 
PE=1 SV=1 - [LMAN2_HUMAN] 
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P22891 8.25 2 2 400 44.7 5.97 79.33 Vitamin K-dependent protein Z 
OS=Homo sapiens GN=PROZ PE=1 
SV=2 - [PROZ_HUMAN] 
P04004 10.67 3 3 478 54.3 5.80 118.49 Vitronectin OS=Homo sapiens 
GN=VTN PE=1 SV=1 - 
[VTNC_HUMAN] 
P21796 23.67 5 5 283 30.8 8.54 214.46 Voltage-dependent anion-selective 
channel protein 1 OS=Homo sapiens 
GN=VDAC1 PE=1 SV=2 - 
[VDAC1_HUMAN] 
P38606 2.92 1 1 617 68.3 5.52 96.78 V-type proton ATPase catalytic 
subunit A OS=Homo sapiens 
GN=ATP6V1A PE=1 SV=2 - 
[VATA_HUMAN] 
Q9UI12 3.31 1 1 483 55.8 6.48 70.12 V-type proton ATPase subunit H 
OS=Homo sapiens GN=ATP6V1H 
PE=1 SV=1 - [VATH_HUMAN] 
O43895 13.20 6 6 674 75.6 6.04 241.89 Xaa-Pro aminopeptidase 2 OS=Homo 
sapiens GN=XPNPEP2 PE=1 SV=3 - 
[XPP2_HUMAN] 
Q96DA0 25.96 4 4 208 22.7 7.39 223.46 Zymogen granule protein 16 homolog 
B OS=Homo sapiens GN=ZG16B 
PE=1 SV=3 - [ZG16B_HUMAN] 
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CHAPTER 5 
Glycoproteomics of urinary  
membrane vesicles and novel 
method for enrichment of 
membrane vesicles from minimally 
processed urine 
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5.1 Introduction 
The urinary proteome may serve as a rich source of biomarkers for uro-genital and systemic 
diseases which have been reviewed previously (Pisitkun, Johnstone & Knepper, 2006). 
Notably, urine collection is a non-invasive procedure which makes it an ideal source for 
biomarker discovery. Due to their complex structure and functions, the analysis of glycans of 
cellular glycoproteins and glycolipids is rapidly emerging as an important aspect of novel 
biomarkers either directly from tissue/cellular samples or as analyzed from body fluids 
(Nilsson et al., 2009; Halim et al., 2012). However, up to now, there have been only a few 
large-scale studies on urine glycoproteome analysis (Adachi et al., 2006; Wang et al., 2006). 
For this purpose, the membrane vesicles, including exosomes as secreted by many cell types 
along the uro genital tract are attractive sources of glycoanalytics. Notably, the exosomes 
display functions like antigen-presentation, cell to cell communication and immuno-
modulation (Nieuwland & Sturk, 2010). These are specialised compartment of cells and not 
only do they mirror the physiological state of cells secreting them but also provide 
information about the environment into which they are secreted; i.e., immunosuppressive and 
pro-angiogenic environment of cancer may be mediated in part by exosomes (Nieuwland & 
Sturk, 2010).  
Exosomes and other types of membrane vesicles have been discovered in urine and known to 
be secreted by epithelial cells lining the genitourinary system (Pisitkun, Shen & Knepper, 
2004). Glycosylation is an important modality of post-translational modification which plays 
many roles including but not limited to cell adhesion, cell to cell communication, immune 
response etc (Bhatia & Mukhopadhyay, 1999). Glycosylation has also been shown to be very 
important for targeting of proteins to various compartments inside the cells. Glycans (the 
complex carbohydrate chains linked to proteins or lipids) present on glycoproteins are 
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important in sorting these proteins to membrane microdomains and have been shown to 
influence their intracellular trafficking (Huet et al., 2003). Interestingly, it has been recently 
found that membrane vesicles may have a glycan signature which is distinct from the parent 
cell itself, suggesting that they originate from specialised membrane microdomains. This 
implies a role of glycosylation in membrane vesicle protein sorting (Batista et al., 2011; 
Escrevente et al., 2011). For example, HIV-1 particles were found to have a glycome 
common to membrane vesicles which was cell-specific implying that virus hijacks the 
machinery of infected cells and uses it to infect other cells (Krishnamoorthy et al., 2009).   
Exosome uptake in various cell types was shown to occur through clathrin-mediated 
endocytosis, phagocytosis and macropinocytosis (Hao et al., 2007; Barres et al., 2010). The 
uptake of exosomes, particularly by dendritic cells and macrophages, was shown to be 
inhibited by mannose, N-acetylglucosamine and lactose, respectively. An important mediator 
of this uptake turned out to be a C-type lectin in dendritic cells and galectin-5 in macrophages 
(Hao et al., 2007; Barres et al., 2010). All this points towards a system, in which, the 
exosomal glycosylation pattern is maintained as a specific feature of the cells or sub-cellular 
organelles secreting them. Consequently, the tagged exosomes appear fitted for a specific 
target cell uptake pathway and distinct downstream functions. Taken together, these finding 
suggest that better understanding of surface glycosylation patterns as well as the whole 
glycoproteome of exosome may help define the biology of exosome uptake by target cells 
e.g.  the pathways involved. Glycoproteome of urinary membrane vesicles, therefore, will 
provide information about both the functional state of constituent proteins and also highlight 
the special signatures of proteins which are specifically targeted to membrane vesicles. On 
the other hand it appears that lectins provide useful tools for glycan profiling from complex 
samples and have been applied in many assay and array formats for dynamic glycan profiling 
(Pilcibello, Slawek & Mahal, 2007; Hsu & Mahal, 2006).  
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Here we have devised a fluorophore-linked lectin assay (FLLA) for glycan profiling of 
purified membrane vesicles and other fractions from urine obtained using the traditional 
differential centrifugation method. Eighteen lectins, falling into 7 broad classes based on their 
nominal glycan binding specificities, were chosen for this study. All these lectins were 
further used for verification in lectin blots of membrane vesicles and other urinary fractions 
to reveal consitituent glycoproteins bearing the respective nominal glycans. Based on the 
analysis of these results we were able to use lectin affinity chromatography, to enrich urinary 
membrane vesicles directly from whole urine. This is a novel application area of lectins 
which is simple and avoids the use of specialised techniques like ultracentrifugation and 
setting up density gradients. Furthermore, to gain functional information about classes of 
proteins sorted to distinct membrane vesicle classes and to broaden the membrane vesicle 
glycoproteome coverage, we also perfomed multiple lectin-affinity chromatography (LAC) 
using 9 different lectins from 7 different nominal specificity classes of lectins on membrane 
vesicle extracts and proceeded to subsequent identification of these proteins. To complement 
the LAC method, hydrazide chemistry was also applied to P18,000g and P200,000g pellets to 
enrich and subsequently identify the glycoproteins. Two hundred and eighty-two proteins in 
total were identified and classified according to their sub-cellular localization and functions.   
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5.2 Material and methods 
5.2.1 Preparation of nano vesicle and other fractions of urine 
Vesicle preparation has been described in detail in methods section of Chapter 2. A schematic 
representation of the methodology used to isolated vesicles is shown in Figure 5.1.  
P200,000g is a heterogeneous mixture of different types of vesicles and the method 
developed in Chapter 2 using CHAPS treatment might select for specific populations of 
vesicles. DTT and CHAPS treatment methods are complementary which is also evident by 
the large overlap between DTT and CHAPS SN200,000g (76%, Chapter 2). However, 
activity of proteins is better preserved in the CHAPS treatment method (Figure 2.5, chapter 
2). But here, the aim is not to perform activity based proteomics therefore any of these two 
methods can be used. We have used DTT-treated pellet (P18DTTP18 and P200DTTP200) for 
lectin affinity chromatography and crude pellet (P18,000g and P200,000g) for FLLA and 
hydrazide  enrichment. 
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Figure 5.1: Schematic of vesicle purification from urine. Box highlighted in blue were used 
for lectin affinity chromatography. P18,000g, P200,000g crude and SN200,000g (Purple box) 
were used for FLLA and hydrazide enrichment. 
5.2.2 THP Purification 
THP was purified as described in methods section of Chapter 2.  
5.2.3 Protein quantification, SDS-PAGE and Western Blotting 
It was carried out as described in methods section of Chapter 2 (Musante et al., 2012). 
5.2.4 Fluorophore-linked lectin assay (FLLA) 
Microtitre plate wells were coated overnight with 100µl/well of 100µg/mL different urine 
fractions at +37°C. All the subsequent steps were carried out at room temperature. Wells 
DTT 
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were washed with PBS (pH 7.4) five times between each step. Wells were blocked with 
odyssey blocking buffer (LI-COR biosciences, Lincoln, NE) (diluted 1:1 with PBS) for 1 
hour on agitation at room temperature. Biotinylated lectins (Vector laboratories, Burlingame, 
CA) were applied (100µl of 1:2000 dilutions from stocks of 2mg/mL) to the wells and 
incubated for 1 hour on agitation. Streptavidin conjugated to IRDye-800 (100µl of 1:5000 
dilutions of company stock) was added to the wells and incubated on agitation for 1 hour. 
Finally wells were washed five times with PBS (pH 7.4) and image was acquired on Odyssey 
Infrared Laser Scanner (LI-COR Biosciences, Lincoln, NE) in 800nm channel at highest 
intensity. Intensities of fluorescence of wells were calculated using the Odyssey V3.0 
software and imported into a text file. For the control (streptavidin fractions control) triplicate 
measurements were taken in which biotinylated lectins were substituted with PBS while rest 
of the procedure remained same. To be more stringent, additional controls were taken; (1) 
empty wells were blocked and lectin and streptavidin were added subsequently as per the 
protocol described (lectin blocking control) (2) only streptavidin was added to blocked wells 
(streptavidin blocking control). Streptavidin fraction control was subtracted from the final 
intensity of different fractions and streptavidin blocking control was subtracted from the 
lectin blocking control. This gave the values of lectin non-specific adsorption on blocking 
and lectin specific binding to different urine fractions. Finally lectin non-specific adsorption 
was subtracted from different fraction intensity to get specific lectin binding to different 
fractions. 
5.2.5 Lectin blotting 
SDS-PAGE was carried out as described in Chapter 2. Proteins were transferred to a 
nitrocellulose membrane using iBlot (Invitrogen, Life technologies, NY). Membranes were 
blocked for 1 hour at RT with the Odyssey blocking buffer solution (LI-COR Biosciences). 
All incubation steps with biotinylated lectins (1:2000, 1 hour) were performed in a 1:1 (v/v) 
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mixture of Odyssey blocking buffer and PBS with 0.1 % (v/v) Tween 20 (PBST). Blots were 
washed with PBST 6 times 10 minutes each. Finally streptavidin conjugated to IRDye-800 
was prepared (1:5000) and incubated with blots for 1 hour and subsequently blots were 
washed 5 times with PBST and once with PBS. Images were acquired with Odyssey Infrared 
Laser Scanner (LI-COR Biosciences). 
5.2.6 Hydrazide chemistry for enriching surface and other glycoproteins of P18,000g 
and P200,000g 
A hydrazide chemistry-based approach was used to enrich glycoproteins from P18,000g and 
P200,000g (Crude pellets) as described previously (McDonald et al., 2009). Briefly, 
P18,000g and P200,000g was suspended in 50mM Tris buffer, pH 7.4 and incubated with 
10mM sodium metaperiodate for 1 hour at room temperature on rotation. Immediately after, 
the mixture was incubated with hydrazide resin (Sigma, St. Louis, MO) overnight at room 
temperature on rotation. Non-bound material was removed by washing with Tris buffer (pH 
7.4). Here, the membrane vesicles in these two pellets were bound to the resin through 
surface glycoproteins. The resin was incubated with 1% (w/v) beta-octyl glucoside to lyse the 
vesicles. Non-bound material recovered was re-oxidised with 10mM sodium metaperiodate 
and incubated with hydrazide resin as described. These two resins thus generated will have 
surface glycoproteins bound to the resin in one and all other glycoproteins bound to the other. 
Then both resins were processed simultaneously. The resin was washed with 8M urea in Tris 
buffer (TU buffer, pH 7.4) to remove the non-bound material. The resins were then incubated 
with 50mM DTT in 50mM Tris buffer (pH7.4) for one hour at 37°C. DTT was removed by 
washing with TU buffer and resin was incubated with 65mM iodoacetamide in dark for 30 
minutes. The resin was then washed with TU buffer and 1.5M NaCl in Tris buffer (pH 7.4) 
three alternate times to remove all the non-glycoproteins from the resin. The immobilised 
proteins were digested ‘on-column’ with 40ng/µL of sequencing grade trypsin (Promega, 
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Madison, WI) overnight at 37°C. The tryptic peptides were recovered the next day and 
enriched by Sep-Pak solid phase extraction columns (Waters, Milford, MA) as described in 
methods sections of Chapter 2. These enriched peptides were analysed by LC-MS/MS as 
described ahead. 
5.2.7 Lectin affinity chromatography 
Eight biotinylated lectins (Con-A, LCA, UEA, SNA, MAL-II, PHA-E, WGA, RCA120 and 
Jacalin, from Vector laboratories; refer to Table 5.1 for full names of these lectins) were 
immobilised on streptavidin agarose. Lectins (500µg each in PBS) were incubated with the 
agarose slurry overnight at +4°C on rotation. Next day the non-bound lectins were removed 
by washing with PBS. RCA120 already coupled to agarose was bought commercially (Vector 
laboratories). Six hundred microgram of P200,000g and P18,000g (DTT treated, see blue 
boxes in Figure 5.1) extract (prepared in 1% beta-octyl glucoside) was diluted in HEPES 
buffered-saline (100mM HEPES + .15M NaCl) to a 2mL final volume and incubated 
overnight with lectin-agarose at +4°C on rotation. For Con-A, 50mM tris buffer with .5M 
NaCl was used as a binding buffer. Some of these lectins (Con-A, LCA, PHA-E) require 
calcium and manganese ions for their binding ability to glycoproteins and 1mM of these 
divalent cations were added to the binding buffer of respective lectins. These cations were not 
used in FLLA and lectin blotting because phosphate in PBS might precipitate with calcium as 
calcium phosphate. Next day, the non-bound fraction was collected and lectin-agarose was 
incubated with respective elution buffers for 2 hours at +4°C on rotation and elution was 
recovered. Elution buffers were made by adding inhibiting/eluting sugars to binding buffers: 
200mM galactose + 200mM lactose for RCA120, 200mM α-methyl mannoside + 200mM α-
methyl glucoside for Con-A and LCA, 800mM galactose for Jacalin, 100mM L-fucose for 
UEA and 200mM lactose for MAL-II. SNA-agarose-bound proteins were eluted by 500mM 
lactose in binding buffer followed by 500mM lactose in 100mM acetic acid. PHA-E-bound 
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proteins were eluted by 100mM acetic acid. WGA-bound glycoproteins were eluted with 
500mM N-acetylglucosamine. All the eluates were dialysed against water for further 
processing required for MS analysis.   
5.2.8 Jacalin affinity chromatography for isoltion of membrane vesicles from minimally 
processed urine. 
Five hundred microgram of biotinylated Jacalin was incubated with 1mL of streptavidin-
agarose (SIGMA) overnight in PBS buffer on rotation. Non-bound material was removed the 
next day and newly generated Jacalin agarose was incubated with 4mL (50mL of SN2000g 
concentrated to 2mL with Vivaspin ‘cut-off’ 5 or 300 kDa (Sartorius) and diluted to 4mL 
with either 200mM HEPES buffer saline {HBS, 2X} or only 20mM phosphate buffer, pH 
7.4) concentrated urine. After overnight incubation at +4°C on rotation, the non-bound 
fraction was removed and the Jacalin-agarose was washed with 20 column volumes (20mL) 
of 1X HEPES buffer saline or 10mM phosphate buffer. The bound fraction was eluted by 
incubating the resin with 800mM galactose in HBS or phosphate buffer for 2 hours. 
5.2.9 MS analysis of proteins and database searching 
Sample preparation for MS analysis was carried out as described in Chapter 3. Nano LC–
MS/MS analysis was carried out using an Ultimate 3000 nanoLC system (Dionex, Sunnyvale, 
CA) coupled to a hybrid linear ion trap/Orbitrap mass spectrometer (LTQ Orbitrap XL; 
Thermo Fisher Scientific, Somerset, NJ). Five microlitres of digest were loaded onto a C18 
trap column (C18 PepMap, 300μm ID × 5mm, 5μm particle size, 100Å pore size; Dionex) 
and desalted for 10 min using a flow rate of 25μL/min in 0.1% TFA. The trap column was 
then switched online with the analytical column (PepMap C18, 75μm ID × 250mm, 3μm 
particle and 100Å pore size; (Dionex)) and peptides were eluted with the following binary 
gradients of solvent A and B: 0–25% solvent B in 120min and 25–50% solvent B in a further 
60min, where solvent A consisted of 2% acetonitrile (ACN) and 0.1% (v/v) formic acid in 
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water and solvent B consisted of 80% (v/v in water) ACN and 0.08% (v/v in water) formic 
acid. Column flow rate was set to 350nL/min. 
Data were acquired with Xcalibur software, version 2.0.7 (Thermo Fisher Scientific). The 
mass spectrometer was operated in data-dependent mode and externally calibrated. Survey 
MS scans were acquired in the Orbitrap in the 400–1800 m/z range with the resolution set to 
a value of 60,000 at m/z 400. Lock mass was set at 445.120025u (protonated (Si (CH3)2O)6). 
Up to seven of the most intense ions (1+, 2+ and 3+) per scan were CID fragmented in the 
linear ion trap. A dynamic exclusion window was applied within 40s. All tandem mass 
spectra were collected using normalised collision energy of 35%, an isolation window of 3 
m/z, and one microscan. 
Proteins were identified using BioWorks 3.2 from Thermo Fisher Scientific using the HUPO 
criteria with XC scores of 1.8, 2.2, 3.75 for single, double and triple charged ions. A peptide 
probability score of 0.05 was also used. The database used was Human UniProt-SwissProt 
downloaded January 2012. Carboxymethylation of cysteine was set as fixed and oxidation of 
methionine as a variable modification. Two missed cleavages were allowed. The mass 
tolerance for precursor ions was 20ppm and the mass tolerance for fragment ions was 0.5Da. 
For some sample’s spectra, that was searched using Mascot the protein score ‘cut-off’ was 
kept at 40. 
5.2.10 Transmission electron microscopy 
TEM was performed as described in the methods section of Chapter 2 (Musante et al., 2012). 
5.2.11 Bioinformatic analysis 
Bioinformatic analysis was performed as described in Chapter 3. Additionally I2D 
(http://ophid.utoronto.ca/ophidv2.201/ppi.jsp) and iRefWeb (Turner et al., 2010) databases 
were used to search for protein-protein interactions of proteins present in the dataset. SOSUI 
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(Hirokawa, Boon-Chieng & Mitaku, 1998) was used for classification of proteins according 
to the presence of transmembrane domains. 
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5.3 Results 
5.3.1 Glycan profile of urinary membrane vesicles surface and other fraction of urine 
FLLA was performed on isolated nano vesicle fraction (P200,000g), low speed pellet 
(P18,000g), ‘nano vesicle-free’ urine (SN 200,000g) and purified Tamm-Horsfall 
glycoprotein (THP). FLLA was performed with crude fractions because we wanted to 
develop a method with least number of steps and the ultimate aim is to develop a method 
which can be performed rapidly on minimally-processed urine. A list of all the lectins used in 
this study in different techniques can be found in Table 5.1. These lectins were specifically 
chosen because they cover the widest range of glycan binding specificities. Therefore, they 
are suited to profile the surface glycans of membrane vesicles.  
Table 5.1: Lectins used in FLLA and their binding specificities along with their source 
organisms. Binding of lectin to various fractions of urine in FLLA is given (Please refer to 
Figure 5.2). 
Abbreviations Origin Nominal sugar binding 
specificity (Gabius & Gabius, 
1997;  Liener, Sharon & 
Goldstein, 1986; Debray et al., 
1981)  
P18 P200 SN200 THP 
LCA/LcH Lens culinaris Fucα1-6GlcNAc ; α-Man ; α-Glc - - - - 
PSA Pisum sativum Fucα1-6GlcNAc ; α-Man  - + - - 
UEA-I Ulex europeus Fucα1-2LacNAc ; α-Fuc - - - - 
SNA Sambucus nigra Siaα2-6Gal ; GalNAc +++ +++ - + 
MAL/ MAA I Maakia 
amurensis 
Galβ1-4GlcNAc ++ + - + 
MAL II   Siaα2-3Gal - - - - 
RCA
120
 Ricinus communis Lac ; LacNAc +++ ++++++ +++ + 
PHA (L) Phaseolus 
vulgaris 
Tetraantennary complex 
oligosaccharides 
++ ++ - + 
PHA (E) Phaseolus 
vulgaris 
NA2 ; bisecting GlcNAc ++ ++++ - ++ 
ConA Canavalia 
ensiformis 
α-Man branched and terminal; 
terminal GlcNAc 
+++ +++ + + 
WGA Triticum vulgaris  (GlcNAc)n ; multivalent Sia ; β-
GlcNAc, GalNAc 
++ ++ - + 
succ WGA  GlcNAc - - - - 
PNA Arachis hypogeal Galβ1-3GalNAcα-Thr/Ser (T) ; 
terminal Galβ-OR 
- - - - 
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JAC/ Jacalin Artocarpus 
integrifolia 
Galβ1-3GalNAcα-Thr/Ser (T) ; 
GalNAcα-Thr/Ser (Tn) 
+++ +++ + - 
GSL-I/ GSI Griffonia 
smplicifolia 
α-GalNAc ; GalNAcα-Thr/Ser 
(Tn) ; α –Gal 
+ - - + 
DBA Dolichos biflorus GalNAc α -Thr/Ser (Tn) ; 
GalNAc α 1-3GalNAc 
++ + - + 
SBA Glycine max Terminal GalNAc (especially 
GalNAc α 1-3Gal) 
+ + - - 
SJA Sophora japonica β-GalNac ; β-Gal - - - - 
 
THP is the most abundant protein in normal human urine. As THP is present in all fractions 
of urine (Figure 2.3 from Chapter 2) and consists of a wide variety of glycans (Wu et al., 
2008) which make up 30% of total mass, we included THP in our FLLA study as a positive 
control. The same concentration of all the fractions was used in the study. The membrane 
vesicle fraction (P200,000g) consists of many different proteins (and potentially 
glycoproteins) in addition to THP (Panel A Figure 2.3 in Chapter 2) so FLLA signal in 
membrane vesicle fractions cannot be directly correlated and concluded to be because of 
THP. P18,000g as judged by SDS-PAGE (Panel A Figure 2.3 in Chapter 2) consisting more 
amount of THP, so any lectin binding to low speed pellet more than the purified THP fraction 
was considered to be due to other constituents. Multiple stringent process controls were also 
taken other than the normal background control as described in the methods section. Surface 
glycan profile of urinary membrane vesicles can be seen in Figure 5.2. 
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Figure 5.2: Fluorophore linked lectin assay (FLLA) was employed on membrane vesicles 
and other urine fractions. Fluorescence signal with standard deviation (based on triplicate 
measurements) is provided in the Figure. For every lectin, the bars from left to right are 
P200,000g, P18,000g, SN200,000g and purified THP which are also indicated by colour code 
in the legends on the right side of the figure. 
Moreover, to confirm that signal generated from FLLA was due to the lectin-glycan 
interaction, four lectins were selected and the same procedure was repeated with the 
difference that inhibiting sugars of the respective lectins were added to the lectin solution. No 
significant signal above background was expected from this assay and results confirmed the 
specificity of the lectin binding (Figure 5.3).  
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Figure 5.3: FLLA signal with P200,000g in presence and absence of inhibiting sugars (Con-
A: 200 mM α-methyl mannoside, SNA: 500 mM lactose, JAC: 500 mM galactose, WGA: 
500 mM N-acetylglucosamine) to demonstrate specificity of lectin binding to sugars in 
various fractions. 
Some of the lectins having highest signal in the nano vesicle fraction representing surface 
glycan profile are indicated in Table 5.1. Briefly, tetrantennary complex oligosaccharides 
(PHA-L), bisecting GlcNAc complex structures (PHA-E), Sia α 2-6Gal ; GalNAc (SNA), Lac 
; LacNAc (RCA120), α-Man branched and terminal; terminal GlcNAc (Con-A), (GlcNAc)n ; 
multivalent Sia ; β-GlcNAc, GalNAc (WGA), Gal β 1-3GalNAca-Thr/Ser (T) ; GalNAca-
Thr/Ser (Tn) (JAC), GalNAcaThr/Ser (Tn) ; GalNAca1-3GalNAc (DBA) were enriched in 
the nano vesicles fraction. On the other hand, MAL-II, GSA, SWGA, SBA and PNA bound 
to much lesser degree to this fraction while SJA and UEA did not show any binding.  
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5.3.2 Lectin blotting 
All the 18 lectins used in FLLA were also used in lectin blotting to reveal more information 
about constituent proteins of all these fractions. Only some of the lectins showing major 
binding to either membrane vesicle fraction (P200,000g) or P18,000g or SN 200,000g are 
shown in Figure 4. Lectin blotting results (Figure 5.4) are categorized according to the 
binding specificities of lectins.  
 
Figure 5.4: Lectin blloting using 14 lectins is shown. Lectins with shared binding specificity 
are grouped together horizontally except for MAL-II and SNA which are grouped together 
vertically. M: molecular weight markers; 1: P18,000g; 2: P200,000g; 3: SN 200,000g; 4: 
Purified THP. 
As THP is present in all of the fractions and it is recognised by most lectins, any band of 
~80kDa is considered to be due to THP. Notably, this is only an assumption and lectin 
blotting alone does not provide any proof for it and there may be more than one protein 
present in the same band. From top left, first panel comprising two lectins (PHA-E, PHA-L) 
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will display glycoproteins with tetrantennary complex oligosaccharides (PHA-L) and 
bisecting GlcNAc complex structures (PHA-E). PHA-E binding proteins in P200,000g are 
mainly present as a smear from 60kDa to 120kDa while in P18,000g the main band is that of 
THP (which can be compared to purified THP; Lane 4). In P18,000g, apart from THP, one 
weak band at 150kDa can be easily seen while in SN200,000g bands of 28, 40 and 60 kDa 
can be found apart from a usual band at molecular weight corresponding to THP. In blot of 
PHA-L there is a clear band of THP in P200,000g and equally intense band of 70kDa of 
unknown identity. In P18,000g there is no other band than that of THP while, in SN200,000g, 
bands of 20, 35 and 60kDa can be seen. This result can be compared to FLLA signal 
(Figure5.2) where intense signal in P200,000g can be seen for PHA-E and PHA-L while less 
so in P18,000g. No signal in FLLA is present for SN200,000 for PHA-L which is similar in 
lectin blotting. However, there are some bands present in lectin blot of SN200,000g of PHA-
E while signal in FLLA for this fraction is absent (PHA-E in Fiigure 5.2). This can be 
explained if these proteins seen in lectin blot are present in the vesicle lumen and not on 
surface.  
The second panel of three lectins (JAC, MAL-I and RCA120) show nominal specificity to 
galactose bearing structures although their binding specificities can be markedly different. All 
the precise binding specificity of lectins used in this study can be compared in Table 5.1. 
Jacalin showed binding to three proteins between 100kDa and 160kDa and three proteins 
between 50kDa and 75 kDa in P200,000g while in P18,000g showed a smear between 15kDa 
and 37kDa. In SN200,000g many bands were visible between 28 to 40kDa, one major band at 
55kDa and a smear between 75 to 200kDa while there was no binding with THP (lane 4). 
Signal in FLLA for Jacalin is similar to lectin blotting for purified THP (No signal in both the 
techniques). P18,000g and P200,000, show good signal in FLLA for Jacalin while less so in 
lectin blotting. The converse is true for SN200,000g which shows some bands in lectin 
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blotting while FLLA signal is very low. MAL-I mainly showed two bands of 70kDa and 
80kDa in P200,000g which can be directly compared to bands seen in PHA-L. In the 
SN200,000g, the usual THP band can be seen apart from the two very weak bands of 40kDa 
and 22 kDa. In the case of RCA
120
 with nominal glycan specificity to terminal galactose and 
N-acetylgalactosamine (similar to JAC), there is a huge smear of signal from 37kDa to 
250kDa and above in both P200,000g and SN200,000g suggesting that majority of 
glycoproteins in urine in this range have this type of glycosylation. This is directly 
comparable with FLLA signal for RCA
120
. In P18,000g many bands between 10kDa and 
20kDa were visible apart from 2 bands at approximately 37kDa, one at 70kDa and one band 
at 150 kDa.  
SJA and SBA binds to terminal N-acetylgalactosamine and galactose with the difference 
being that SJA prefers β-anomers. SJA showed a smear in P200,000g from very low 
molecular weight to ~80kDa where the band of THP was visible while some bands in the 
smear could be seen at 10, 20 and 35 kDa. In SN200,000g, one band at 20kDa, one at 37kDa 
and one at 65kDa and three bands below 15kDa could be seen. In SBA blots one band at 18 
and one at 35 kDa could be seen in P200,000g while in SN200,000g three bands at 20, 37 and 
50kDa could be seen. SBA and SJA did not have good signal in FLLA for any of the 
fractions which can be compared to lectin blots where signal is not intense, although present.   
Con-A, LCA and PSA have been grouped together due to their shared nominal binding 
specificity to α-linked mannose although Con-A additionally recognises terminal and 
branched α-linked mannose and N-acetyl glucosamine residues while LCA and PSA also 
recognise fucose α1-6N-acetylglucosamine moieties and only LCA recognises α-linked 
glucose. In LCA P18,000g there is mainly the band of THP while one weak band at 50kDa 
can also be seen. In P200,000g bands at 160, 100, 60 and 37 kDa can also be seen while in 
SN200,000g many bands from between 25kDa to 250kDa are observed. In the case of Con-A 
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in all the fractions (P18,000g, P200,000g and SN200,000g) there was a smear from low to 
high molecular weight with many visible bands suggesting a number of proteins having α-
mannose type of glycosylation which was expected.  
In the PSA blot, bands of 37, 60, 80 and 100 could be seen in P200,000g while in P18000g 
THP was the major band recognised apart from a weak and at 37kDa. In SN200,000g bands 
of proteins with mol wt 25, 37, 45, 50 and 72 could be seen with considerable intensity. Con-
A had good signal in FLLA for P18,000g and P200,000g fraction (which is comparable in 
lectin blots), less so for pure THP (similar in blotting comapred to P18,000g  and P200,000g 
fractions) and poor signal for SN200,000g (same in lectin blot). In case of PSA, the best 
signal in FLLA was for P200,000g while other fractions did not have good signal. Multiple 
bands in P200,000g can be seen in the lectin blot for PSA. However signal intensity is better 
for P18,000g and pure THP which is  in contrast with FLLA signal for these fractions.  
LCA had no signal in FLLA in any of the fractions if we consider the standard deviation. 
However, in lectin blotting SN200,000g fraction has a  lot of signal. This discrepancy in 
FLLA and lectin blotting signals for PSA and LCA can be partly explained by the fact that 
FLLA would show only surface glycan signal while lectin blotting can show all proteins 
regardless of their location inside or outside of the vesicles. WGA mainly binds glycan 
structures ending in single or multiple N-acetylglucosamine and even binds multivalent sialic 
acid residues. In P200,000g there was a smear from 35 to 75kDa and, apart from the distinct 
THP-specific band, there was a visible band at 120 kDa. There was not appreciable binding 
in P18,000g pellet apart from THP band while in SN200,000g there were multiple bands at 
28, 40, 50, 55, 60 kDa and one band at 170kDa. In FLLA, WGA had similar signal in 
P18,000g and P200,000g while the half of that signal was for pure THP. However, in lectin 
blotting, WGA signal for P18,000g (THP band) and pure THP was  visibly more than 
P200,000g which is in contrast with FLLA. For SN200,000g the signal of WGA in FLLA 
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was absent while multiple bands can be seen in this fraction in lectin blotting. Again these 
proteins might be present in the lumen of vesicles.  
UEA1 binds to α-linked fucose residues and in P18,000g there was minute binding with THP 
while one intense band at 70kDa could be seen along with a doublet band at 37kDa, one band 
at 25kDa and an intense smear from 10kDa to 20kDa. MAL-II binds preferentially to α-2, 3 
linked sialic acid while SNA binds to α-2, 6 linked sialic acid. In MAL-II blot pattern in 
P18,000g looked quite similar to UEA1 and accordingly glycan structures with fucose and α-
2, 3 linked sialic acid have been reported (Wang et al., 1990). The same was true of 
P200,000g but it could be concluded by the differential intensity of the THP bands that this 
similarity was not due to the non-specific binding of lectins to similar targets. Moreover in 
P200,000g there was a band at 40kDa in MAL-II which seemed to be absent in UEA1 blot. 
While, the pattern in SNA blot was quite different in P200,000g and apart from a more 
intense band of THP, a smear from 37 to 70kDa could be seen. In P18,000g, 22 and 27kDa 
bands were visible along with a smear from 40 to 80kDa. The signal in FLLA for UEA1 and 
MAL-II was comparable for all fractions other than P18,000g which has considerably more 
signal in lectin blotting. We have discussed previously that this could be due to the intra-
vesicular proteins.  
In the case of SNA lectin blotting had much more signal for SN200,000g compared to FLLA 
while P18,000g and P200,000g signal was much more in FLLA. In the case of THP the 
signal in the lectin blot was much more than P18,000g while the reverse was the case in 
FLLA. Speculatively, this could be due to the fact that denaturing treatment during SDS-
PAGE could expose some glycans of THP which are otherwise hidden in native conditions of 
FLLA. 
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5.3.3 Lectin-affinity chromatography and hydrazide enrichment of glycoproteins 
from P18,000 and P200,000 extracts: glycoproteome of membrane vesicles 
5.3.3.1 Hydrazide chemistry and surface glycome of urinary exosome and ‘exosome-
like’ vesicles 
To investigate which glycoproteins are present on the surface of the urinary exosome and 
‘exosome-like’ vesicles, we employed hydrazide chemistry to enrich glycoproteins on surface 
of intact vesicles. The workflow for the technique is presented in Figure 5.12. 
 
Figure 5.5: Workflow of the hydrazide chemistry methodology used in our anlysis. Crude 
pellets (P18,000g and P200,000g) were used as starting material. 
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This approach works by oxidising the diol moiety of the glycans to aldehyde which can bind 
covalently to the hydrazide resin. Non-bound and non-specifically reacting proteins were 
removed by three alternate washes with 8M urea and 1.5 M NaCl. This would result in almost 
complete removal of protein non-specifically bound to the resin matrix as well as proteins 
being retained due to their specific interactions with glycoproteins. This approach should 
result in identification of mostly glycosylated as well as non-enzymatically glycated proteins 
(Yaylayan, 2003; Mirzaei & Regnier, 2007; Zhang et al., 2007). The surface proteins would 
be identified in the first part of the approach (Called P18S and P200S) while all other proteins 
would be identified in the second part after lysis of the vesicles and re-oxidation of the non-
bound proteins (Called P18W and P200W). Although glycoproteins which would be binding 
to the surface of these vesicles by protein—protein, protein-glycan and protein-lipid 
interactions or by adsorption would also bind to the resin upon oxidation of the intact 
vesicles. Various numbers of proteins excluding keratins were identified in different samples 
(P200S: 92 and P200W: 41; P18S: 58 and P18W: 36). All these proteins are shown in 
supplementary table S5.1 in CD-ROM provided with the thesis. Comparison of all these 
proteins is presented in Figure 5.13. 
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Figure 5.6: Comparison of proteins identified in various fractions of hydrazide chemistry 
analysis of P18 and P200. S means surface proteins (Intact vesicles used) W (Non-bound 
proteins from hydrazide resin after lysis of the vesicles).  
Only 21 proteins were unique to P18S and 3 in P18W when compared to P200 
identifications. These 24 proteins are indicated in the appendix at the end of this chapter. Out 
of these 24 proteins, 10 proteins are known to be glycosylated including 6 membrane 
proteins. These 6 membrane proteins are interesting and they are putative olfactory receptor 
51H1, olfactomedin-4, solute carrier family 12 member 1, prostaglandin H2 D-isomerase, 
semenogelin-2, phosphoinositide-3-kinase interacting protein 1 and folate receptor alpha. The 
reason why these proteins were identified only in P18,000g remains to be proven but they are 
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clearly part of the surface of membrane vesicles. Ninety two proteins were identified in the 
P200S and 41 in P200W. However, only 7 proteins were unique to P200W. Out of these 7 
proteins 3 are known glycoproteins namely angiotensinogen, serotransferrin and prostate 
specific antigen. All of these 3 are soluble secreted proteins and they probably end up in 
endosomes after endocytosis from where they can be secreted as part of membrane vesicles. 
Out of 92 proteins identified in P200S 61 proteins are annotated as known or potential 
glycoproteins (66% of the total). To establish the surface glycoproteins of the exosome and 
‘exosome-like’ vesicles we classified these 61 proteins by SOSUI (Hirokawa, Boon-Chieng 
& Mitaku, 1998) (http://bp.nuap.nagoya-u.ac.jp/sosui/sosuiG/sosuigsubmit.html) and we 
found that 35 of these proteins are membrane proteins. Uniprot annotation was also used and 
it was found that 2 additional proteins are membrane-associated other than these 35. These 
are sulfhydryl oxidase 1 and CD14 molecule. These 37 proteins (60% of known 
glycoproteins identified in P200S) constitute the urinary membrane vesicles surface glycome.  
Twenty four other proteins which are known to be glycosylated are present in P200S 
probably due to their interaction with vesicular surface or lysis of some vesicles upon freeze-
thawing. However, there could be other reasons as well. For example, Napsin A, which is 
among these 24 proteins, is known to localise to MVB membranes and process pulmonary 
surfactant protein B into mature form (Ueno et al., 2004). A number of proteins among these 
24 proteins are protease inhibitors such as alpha-2-macroglobulins, alpha-1-antichymotrypsin 
and plasma serine protease inhibitor. Plasma serine protease inhibitor is associated with 
membrane of cells and microvesicles (Nishioka et al., 1998). These reasons explain the 
presence of these proteins on surface of membrane vesicles. Other than these 24 proteins, 
thirty seven surface glycoproteins (known membrane proteins) are presented in Table 5.2. 
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Table 5.2: Presents the glycoproteins which are classified by either SOSUI and/or Uniprot as 
membrane associated or transmembrane proteins. These proteins were annotated by IPA 
(Ingenuity systems, Redwood city, CA). Uniprot accession, gene symbol Entrez gene name, 
location of the protein and type of molecule is indicated in the table. 
Uniprot 
accession 
Symbol Entrez Gene Name Location Type (s) 
P11117 ACP2 acid phosphatase 2, lysosomal Cytoplasm Phosphatise 
P15144 ANPEP alanyl (membrane) aminopeptidase Plasma 
Membrane 
Peptidase 
P02649 APOE apolipoprotein E Extracellular 
Space 
Transporter 
P01024 C3 complement component 3 Extracellular 
Space 
Peptidase 
P08571 CD14 CD14 molecule Plasma 
membrane 
transmembrane 
receptor 
P19835 CEL carboxyl ester lipase (bile salt-
stimulated lipase) 
Extracellular 
Space 
Enzyme 
Q12860 CNTN1 contactin 1 Plasma 
Membrane 
Enzyme 
Q6UVK1 CSPG4 chondroitin sulfate proteoglycan 4 Plasma 
Membrane 
Other 
O60494 CUBN cubilin (intrinsic factor-cobalamin 
receptor) 
Plasma 
Membrane 
transmembrane 
receptor 
Q53TN4 CYBRD1 cytochrome b reductase 1 Cytoplasm Enzyme 
P27487 DPP4 dipeptidyl-peptidase 4 Plasma 
Membrane 
Peptidase 
P01133 EGF epidermal growth factor Extracellular 
Space 
growth factor 
O15197 EPHB6 EPH receptor B6 Plasma 
Membrane 
Kinase 
Q9NQ84 GPRC5C G protein-coupled receptor, family C, 
group 5, member C 
Plasma 
Membrane 
G-protein 
coupled receptor 
P98160 HSPG2 heparan sulfate proteoglycan 2 Plasma 
Membrane 
Enzyme 
P01591 IGJ immunoglobulin J polypeptide, linker 
protein for immunoglobulin alpha 
and mu polypeptides 
Extracellular 
Space 
Other 
P01042 KNG1 kininogen 1 Extracellular 
Space 
Other 
Q7L985 LINGO2 leucine rich repeat and Ig domain 
containing 2 
Extracellular 
Space 
Other 
P98164 LRP2 low density lipoprotein receptor-
related protein 2 
Plasma 
Membrane 
Transporter 
P02788 LTF Lactotransferrin Extracellular 
Space 
Peptidase 
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O43451 MGAM maltase-glucoamylase (alpha-
glucosidase) 
Plasma 
Membrane 
Enzyme 
P08473 MME membrane metallo-endopeptidase Plasma 
Membrane 
Peptidase 
P15941 MUC1 mucin 1, cell surface associated Plasma 
Membrane 
transcription 
regulator 
Q9BRK3 MXRA8 matrix-remodelling associated 8 unknown Other 
P54802 NAGLU N-acetylglucosaminidase, alpha Cytoplasm Enzyme 
P01833 PIGR polymeric immunoglobulin receptor Plasma 
Membrane 
Transporter 
O00592 PODXL podocalyxin-like Plasma 
Membrane 
Kinase 
O43490 PROM1 prominin 1 Plasma 
Membrane 
Other 
P00391 QSOX1 Quiescin Q6 sulfhydryl oxidase 1 Cytoplasm Enzyme 
Q86UN3 RTN4RL2 reticulon 4 receptor-like 2 Plasma 
Membrane 
Other 
P01009 SERPINA1 serpin peptidase inhibitor, clade A 
(alpha-1 antiproteinase, antitrypsin), 
member 1 
Extracellular 
Space 
Other 
P05543 SERPINA7 serpin peptidase inhibitor, clade A 
(alpha-1 antiproteinase, antitrypsin), 
member 7 
Extracellular 
Space 
Transporter 
P55017 SLC12A3 solute carrier family 12 
(sodium/chloride transporters), 
member 3 
Plasma 
Membrane 
Transporter 
Q9UGT4 SUSD2 sushi domain containing 2 Extracellular 
Space 
Other 
P07911 UMOD Uromodulin Extracellular 
Space 
Other 
Q6EMK4 VASN Vasorin Plasma 
Membrane 
Other 
O43895 XPNPEP2 X-prolyl aminopeptidase 
(aminopeptidase P) 2, membrane-
bound 
Plasma 
Membrane 
Peptidase 
 
These 37 proteins were analysed by IPA software (Ingenuity systems, USA.) and some of the 
enriched bio-functions annotation are presented in the Table 5.3. 
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Table 5.3: Membrane glycoproteins of exosomal and exosome-like vesicles were enriched 
for some of the biological functions presented in the table. Category of functions, annotated 
function, p-Value of enrichement, molecules involved in the category and total number of 
molecules in the category is indicated in the table. 
Category Functions 
Annotation 
p-Value Molecules # 
Molecules 
Organ Morphology morphology of 
kidney 
1.68E-05 APOE,LRP2,NAGLU,PODXL,
SLC12A3,UMOD 
6 
Renal and Urological 
System Development 
and Function 
morphology of 
kidney 
1.68E-05 APOE,LRP2,NAGLU,PODXL,
SLC12A3,UMOD 
6 
Renal and Urological 
System Development 
and Function 
proliferation of 
mesangial cells 
9.76E-05 APOE,EGF,HSPG2 3 
Cellular Development proliferation of 
mesangial cells 
9.76E-05 APOE,EGF,HSPG2 3 
Cellular Growth and 
Proliferation 
proliferation of 
mesangial cells 
9.76E-05 APOE,EGF,HSPG2 3 
Organ Morphology morphology of 
kidney cells 
8.19E-04 NAGLU,PODXL 2 
Renal and Urological 
System Development 
and Function 
morphology of 
kidney cells 
8.19E-04 NAGLU,PODXL 2 
Cell Morphology morphology of 
kidney cells 
8.19E-04 NAGLU,PODXL 2 
Organ Morphology abnormal 
morphology of 
renal tubule 
2.04E-03 LRP2,SLC12A3,UMOD 3 
Renal and Urological 
System Development 
and Function 
abnormal 
morphology of 
renal tubule 
2.04E-03 LRP2,SLC12A3,UMOD 3 
Organismal Injury and 
Abnormalities 
Fibrosis 3.48E-03 EGF,UMOD 2 
Organ Morphology abnormal 
morphology of 
nephrin 
8.14E-03 LRP2,PODXL 2 
Renal and Urological 
System Development 
and Function 
abnormal 
morphology of 
nephrin 
8.14E-03 LRP2,PODXL 2 
Organ Morphology mass of kidney 9.34E-03 APOE,EGF 2 
Renal and Urological 
System Development 
and Function 
mass of kidney 9.34E-03 APOE,EGF 2 
Organ Development mass of kidney 9.34E-03 APOE,EGF 2 
Tissue Development mass of kidney 9.34E-03 APOE,EGF 2 
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Embryonic 
Development 
mass of kidney 9.34E-03 APOE,EGF 2 
Organismal 
Development 
mass of kidney 9.34E-03 APOE,EGF 2 
Cell Death and Survival apoptosis of kidney 
cells 
1.16E-02 APOE,EGF 2 
Renal and Urological 
System Development 
and Function 
kidney 
development 
1.38E-02 APOE,EGF,PODXL 3 
Organ Development kidney 
development 
1.38E-02 APOE,EGF,PODXL 3 
Tissue Development kidney 
development 
1.38E-02 APOE,EGF,PODXL 3 
Embryonic 
Development 
kidney 
development 
1.38E-02 APOE,EGF,PODXL 3 
Organismal 
Development 
kidney 
development 
1.38E-02 APOE,EGF,PODXL 3 
Cell Death and Survival cell viability 1.85E-02 EGF,UMOD 2 
Cellular Development proliferation of B-
lymphocyte 
derived cell lines 
2.38E-02 EGF,HSPG2 2 
Cellular Growth and 
Proliferation 
proliferation of B-
lymphocyte 
derived cell lines 
2.38E-02 EGF,HSPG2 2 
Hematological System 
Development and 
Function 
proliferation of B-
lymphocyte 
derived cell lines 
2.38E-02 EGF,HSPG2 2 
 
Enrichment of one network was found by IPA among these 37 membrane glycoproteins. This 
network is regulation of some of these proteins by LIM homeobox 1 (LHX1) transcription 
factor. This network is shown in Figure 5.7.  
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Figure 5.7: Presents the network enriched in membrane glycoproteins by IPA. LHX1: LIM 
homeobox 1 regulated proteins present in membrane glycoprotein identifications. Gene 
symbols have been used. The expression of all of these proteins is regulated by LHX1 
transcription factor. 
LHX1 has an important role in kidney field area specification during kidney development by 
mesoderm (Cirio et al., 2011). These regulated proteins play important roles in kidney 
development as well as maintenance. These regulated proteins including cubulin and megalin 
maintain endocytic pathways in kidney to clear the lumen of nephrons. Dipeptidylpeptidase 4 
(DPP4) and aminopeptidase N (ANPEP) control the processing of regulatory peptides in 
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tubular epithelial cells by regulating the cellular response to peptide hormones (Shipp & 
Look, 1993).  
The protocol we have used for capturing glycoproteins from P200 is very stringent. After the 
oxidised proteins bound to hydrazide resin we washed the columns thrice with alternate 8M 
urea and 1.5M NaCl. This washing should get rid of all the non-specifically adsorbing 
proteins from the column and only the bound proteins should remain which would be 
expected to either be glycsylated or non-enzymatically glycated. These 31 candidate proteins 
are indicated in the appendix at the end of this chapter. Among these proteins, there are 4 
membrane proteins; Sodium/potassium-transporting ATPase subunit alpha-1, gelsolin, 
nephrocystin-3 and stomatin. The presence of these 31 proteins in hydrazide-bound fraction 
could be explained in two ways with one being the interaction of these proteins with the 
glcosylated proteins found. We explored this option and using I2D 
(http://ophid.utoronto.ca/ophidv2.201/ppi.jsp) and iRefWeb (Turner et al., 2010) 
(http://wodaklab.org/iRefWeb/search) databases we found interacting partners of these 
candidate proteins in the glycosylated protein list. We present the network that emerged in 
Figure 5.8. 
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Figure 5.8: Interaction network was manually created between the glycosylated and non-
glycosylated proteins using data from I2D and iRefWeb (Turner et al., 2010) databases. The 
proteins in blue outlines are non-glycosylated proteins and proteins in orange outlines are 
glycosylated proteins found in hydrazide-enriched fractions. Interacting proteins are 
connected with thick black lines. 
This theory explains the presence of 6 proteins and although they are not glycosylated, they 
might be bound to the hydrazide column through their glycosylated partners. However, it is 
surprising that, even after washing the column three times alternatively with 8M urea and 
1.5M NaCl, these proteins maintained their association with their interacting partner. The 
second possibility is that amino acids in non-glycosylated proteins gets oxidised by sodium 
metaperiodate and subsequently coupled to hydrazide column. Oxidation of proteins and 
subsequent reaction with hydrazide has been previously reported (Mirzaei & Regnier, 2007). 
Moreover, in the same study the presence of cross-linked proteins upon oxidation was also 
313 
 
discovered. Cross-linked proteins and reaction of oxidised proteins with hydrazide can 
explain presence of these 31 proteins in hydrazide-bound fraction. These proteins need not be 
glycosyated to be present in this fraction. 
5.3.3.2 Lectin affinity chromatography for enrichment of glycoproteins from P200,000g 
and P18,000g 
Nine lectins were used for lectin affinity chromatography (LAC) of P18,000g and P200,000g 
extract (Table 5.4). Extract was prepared using 1% beta-octyl glucoside (because it 
solubilises lipid rafts (Garner, Smith & Hooper, 2008) and is compatible with LAC) to 
disrupt the vesicles for efficient enrichment of glycoproteins from both the pellets. Elution 
was performed on each lectin as described in methods (see elution conditions in Table 5.4). 
Most of these lectins were chosen because they showed high signal in FLLA (Figure 5.2). 
While, others like LCA, UEA and MAL-II were chosen because they recognised multiple 
proteins in the P18,000g and P200,000g in lectin blotting (Figure 5.3). 
Table 5.4: Presents nine lectins used in LAC along with their origin and specificity. 
Abbreviation Origin Nominal sugar binding specificity Elution 
conditions 
LCA/LcH Lens culinaris Fucα1-6GlcNAc ; α-Man ; α-Glc 200mM α-
methyl 
mannoside + 
200mM α-
methyl glucoside 
UEA-I Ulex europeus Fucα1-2LacNAc ; α-Fuc 100mM L-fucose 
SNA Sambucus nigra Siaα2-6Gal ; GalNAc 500mM lactose  
followed by 
500mM lactose 
in 100mM acetic 
acid 
MAL II  Maakia amurensis Siaα2-3Gal 200mM lactose 
RCA
120
 Ricinus communis Lac ; LacNAc 200mM 
galactose + 
200mM lactose 
PHA (E) Phaseolus vulgaris Bisecting GlcNAc 100mM acetic 
acid 
ConA Canavalia ensiformis α-Man branched and terminal; terminal GlcNAc 200mM α-
methyl 
mannoside + 
200mM α-
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methyl glucoside 
WGA Triticum vulgaris  (GlcNAc)n ; multivalent Sia ; β-GlcNAc, 
GalNAc 
 
JAC/ Jacalin Artocarpus 
integrifolia 
Gal β 1-3GalNAcα-Thr/Ser (T) ; GalNAcα-
Thr/Ser (Tn) 
800mM 
galactose 
 
Based on the total proteins enriched by these lectins, one tenth of the proteins in elution was 
resolved by SDS-PAGE. This reflects the proteins enriched by corresponding lectins in LAC.  
 
Figure 5.9: Silver stained SDS-PAGE (10%T) profile of proteins enriched by different 
lectins. Panel (A) (P200,000g): M. Molecular weight marker in kDa. 1. LCA 2. PHA-E 3. 
RCA 4. WGA 5. MAL-II 6. SNA 7. JAC 8. Con-A; Panel (B) (P18,000g): M. Molecular 
weight marker in kDa. 1. PHA-E 2. Con-A 3. WGA  4. RCA 5. JAC 6. SNA 7. MAL-II 8. 
LCA. 
We used fixed amount of LAC elutions to run in the gel. Although starting amount of total 
protein used for each lectin in the LAC was same, but each lectin enriched variable amount of 
proteins therefore there is discrepancy in the number and amount of proteins shown in Figure 
5.9. In LCA gel (Figure 5.9, Panel A, Lane 1) it can be seen that the major protein is THP 
(~100kDa) as is the case with RCA, WGA, SNA JAC and Con-A. In LCA, some low 
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molecular weight proteins below the THP band can be faintly seen and two proteins around 
200-250 kDa are visible as well. These proteins can also be seen in lectin blot of LCA (Figure 
5.4). In P18,000g elution of  LCA (Figure 5.9, Panel B, lane 8), multiple proteins and a 
complex pattern of proteins from low to high molecular weights can be seen. This is however 
in contrast with FLLA (Figure 5.2) and lectin blot of LCA (Figure 5.4).  
In PHA-E and MAL-II (Figure 5.9, Panel A, Lane 2 & 5) the faint band of THP can be seen 
however there are not many proteins shown in these two lectin elutions. The reason for this 
could be that amount (in µg) of proteins binding to this lectin was too low to be shown on the 
gel. Although the signal in FLLA for PHA-E was high (Figure 5.2), it could be seen in Figure 
5.4 that the number of proteins recognised by PHA-E is less compared to other lectins. The 
same is true of PHA-E elution of P18,000g (Figure 5.9, Panel B, Lane 1). MAL-II recognised 
multiple proteins in P200,000g in lectin blot (Figure 5.4) but the intensity  of signal was low. 
In P18,000g  elution  of MAL-II (Figure 5.9, Panel B, lane 7) there is a complex pattern of 
proteins across the range of molecular weight  from low to high and it is similar  to the lectin 
blot of MAL-II (Figure 5.4). However, signal in FLLA for MAL-II of P18,000g was low 
which is in contrast to lectin blot and SDS-PAGE of the elutions.  
In case of RCA120 the number of proteins seen in the elution of both P18,000g and 
P2000,000g is high (Figure 5.9, Panel A, lane  3 and Panel B, lane 4). This is comparable 
with lectin blotting (Figure 5.4) and FLLA of RCA120 (Figure 5.2) for both these fractions. 
The number of proteins in P18,000g lectin blot of RCA120 is  considerably less compared to 
elution shown here. In WGA elution  of P200,000g (Figure 5.9, Panel A, lane 4) the number 
of proteins are more compared to P18,000g (Figure 5.9, Panel B, lane 3) which shows 
negligible signal. THP is the main band in elution of WGA of P200,000g which can be 
compared to THP signal in FLLA for WGA (Figure 5.2). The signal for Jacalin in elution of 
P200,000g is mainly a band which could be THP however,  in FLLA and lectin blot of 
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Jacalin the signal for THP is absent. It could be argued that THP here is getting enriched non-
specfically. For SNA, the major band seen in elution of P2000,000 (Figure 5.9, Panel A, lane 
6) and P18,000g (Figure 5.9, Panel  B, lane 6) is THP which  could also be seen in lectin blot 
(Figure 5.4) and the signal for THP in FLLA (Figure 5.2).  
For Con-A elution of P200,000g (Figure 5.9, Panel A, lane 8)  there are a number of proteins 
from low to high molecular weight however the major protein is THP which is comparable to 
THP signal in FLLA (Figure  5.2). In P18,000g of Con-A elution (Figure 5.9, Panel B, Lane 
2) there are multiple proteins and THP is not the major protein. This is comparable to signal 
of Con-A  in the P18,000g, seen in FLLA (Figure 5.2). UEA-I elution is not shown in the 
Figure 5.9 because the amount of protein enriched was visibly small (Size of the dry pellet) 
which was processed directly to be analysed by LC-MS/MS.  
To confirm whether or not all the proteins have been eluted from the lectin columns by our 
elution buffers, we boiled 50µL beads from lectin columns with SDS-PAGE loading buffer 
for 15 minutes and loaded the released proteins on the gel.  
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Figure 5.10: Silver stained SDS-PAGE (10%) of the proteins released by beads from lectin 
affinity columns. 1. UEA-I (31, 32 kDa), 2. PHA-E (33 kDa), 3. Con-A (26,52 kDa), 4. RCA 
(27, 33, 60 kDa), 5. LCA (8, 17 kDa), 6. SNA (36, 38 kDa), 7. JAC (10, 16 kDa), 8. MAL-II 
(34, 36 kDa), 9. WGA (18 kDa), M: Molecular weight markers in kDa. 
The beads boiled in loading buffer mostly revealed the lectins and their subunits at their 
molecular weights with the exception of THP. THP was found abundantly in PHA-E, RCA, 
SNA and WGA columns while in only minor amounts in other lectins. No other major 
protein was present in the beads suggesting a majority of proteins bound to lectins had been 
eluted by the elution buffers used in our study. Elution was dialysed and concentrated using 
speed vacuum and processed by reduction, alkylation and trypsin digestions. Peptides were 
enriched using Sep-Pak solid phase extraction columns and analysed by LC-MS/MS.  
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5.3.3.3 Identification of proteins enriched by Lectin affinity chromatography 
The nine lectins were used in LAC to enrich various subpopulations of glycoproteins 
displaying diverse glycan epitopes on their surface. Multiple proteins were identified in 
elution of every lectin. Excluding keratins, varying number of proteins were identified from 
LAC of P200,000g with 35 in RCA, 53 in WGA, 78 in JAC, 68 in LCA, 58 in SNA, 66 in 
PHA-E, 59 in Con-A, 44 in MAL-II and 48 in UEA. In LAC of P18,000g varying number of 
proteins, with 10 in RCA, 45 in WGA, 13 in MAL-II, 28 in JAC, 20 in LCA, 45 in SNA, 34 
in PHA-E, 21 in Con-A and 49 in UEA were identified. All these proteins are shown in 
supplementary table S5.1 in CD-ROM provided with the thesis. Multiple proteins were 
common to many lectins. In total 172 non-redundant unique proteins were identified in 
P200,000g and 97 in P18,000g. A majority of the proteins (73% of total) identified in 
P18,000g were common to P200,000g (Figure 5.11). 
  
Figure 5.11: Comparison of the proteins identified by LAC in P200,000g and P18,000g.  
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Our objective was to identify the major glycoprotein population in the exosomal and low 
speed pellet. We did not take a serial LAC approach (Non-bound of one lectin bound to 
another one) which could yield a greater number of identifications by removing high 
abundance proteins in the first few lectin columns. But such an approach would miss out on 
giving information about type of glycan epitope present on these proteins. We have incubated 
both the pellet (600µg each) separately with each of these lectins and subsequently identified 
the bound proteins. Some proteins which are heavily glycosylated at multiple sites with 
diverse glycans would be expected to be present in high amount in each LAC fraction. By 
comparing proteins identified in 9 LAC fractions we can identify the proteins which bind to 
multiple lectins. Crude information about type of glycans present on these proteins would be 
revealed in the process. Out of 172 proteins identified in P200,000g, 64 proteins (37% of 
total) were known glycosylated proteins, as annotated by SwissProt. These 64 proteins were 
distributed in a complex manner among 9 LAC fractions. All of the 9 LAC were compared 
with each other and the results are presented in table 5.5. 
Table 5.5: All the known glycoproteins identified in P200,000 by LAC using 9 lectins are 
presented. Note that multiple proteins were bound to many different lectins. 
UNIPROT 
ACCESSION 
Gene Name Lectin binding 
O43653 
P05090 
prostate stem cell antigen, Apolipoprotein D WGA, JAC,  LCA, 
SNA, PHA-E, Con-A, 
UEA 
O75594 peptidoglycan recognition protein 1 WGA, SNA, PHA-
E,Con-A, UEA 
P00734 coagulation factor II (thrombin) MAL-II 
P00738 haptoglobin-related protein; haptoglobin WGA, LCA, SNA, 
MAL-II, UEA 
P01009 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 1 
WGA, JAC,  LCA, 
SNA, MAL-II, Con-
A, UEA 
P01011 
P0C0L4 
serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 3; Complement  component 4A (Rodgers 
blood group) 
JAC, LCA, UEA 
P01023 alpha-2-macroglobulin WGA, JAC, LCA, 
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Con-A, UEA 
P01042 kininogen 1 JAC 
P01596 
Q12907 
P04114 
P00450 
P16278 
Ig kappa chain V-I region CAR; lectin, mannose-binding 2; 
apolipoprotein B (including Ag (x) antigen); ceruloplasmin 
(ferroxidase); galactosidase, beta 1 
LCA 
P01833 polymeric immunoglobulin receptor JAC, LCA, Con-A, 
MAL-II, UEA 
P01857 
P01024 
P02787 
immunoglobulin heavy constant gamma 1; Complement 
component 3; transferring 
WGA, JAC,  LCA, 
SNA, MAL-II, PHA-
E, Con-A, UEA 
P01859 immunoglobulin heavy constant gamma 2 (G2m marker) WGA, JAC, LCA, 
SNA, PHA-E, Con-A 
P01876 immunoglobulin heavy constant alpha 1 WGA, JAC,  LCA, 
SNA, MAL-II, RCA, 
Con-A, UEA 
P02649 
Q14624 
apolipoprotein E; inter-alpha (globulin) inhibitor H4 JAC, Con-A 
P02671 fibrinogen alpha chain JAC, UEA 
P02675 
P02679 
P01871 
fibrinogen beta chain; fibrinogen gamma chain; 
immunoglobulin heavy constant gamma 1 (G1m marker) 
WGA, JAC, 
LCA,SNA, Con-A, 
MAL-II, UEA 
P02743 
P01860 
P04004 
O60494 
P01861 
amyloid P component, serum; immunoglobulin heavy constant 
gamma 1 (G1m marker); vitronectin; cubilin; immunoglobulin 
heavy constant gamma 4 (G4m marker) 
UEA 
P02760 alpha-1-microglobulin/bikunin precursor WGA, JAC, LCA 
P02768 
P07911 
albumin; uromodulin WGA, JAC,  LCA, 
SNA, MAL-II, PHA-
E, RCA, Con-A, UEA 
P02790 Hemopexin JAC, LCA, SNA, 
Con-A 
P04196 histidine-rich glycoprotein JAC, SNA 
P04745 Alpha-amylase 1 WGA, JAC, LCA, 
PHA-E, RCA, MAL-II 
P05155 serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 LCA, UEA 
P07339 cathepsin D PHA-E 
P07858 cathepsin B WGA 
P08603 
Q8N2E2 
P27487 
complement factor H; von Willebrand factor D and EGF 
domains; dipeptidyl-peptidase 4 
RCA 
P08962 
O96009 
P01763 
CD63 molecule; napsin A aspartic peptidase; Ig heavy chain V-III 
region WEA 
JAC, LCA, Con-A 
P09668 cathepsin H LCA, SNA, PHA-E, 
Con-A 
P12273 prolactin-induced protein Con-A, MAL-II 
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P25311 Zinc-alpha-2-glycoprotein WGA, JAC,  LCA, 
SNA, MAL-II, RCA, 
Con-A, PHA-E 
P41222 prostaglandin D2 synthase WGA, JAC 
P51688 N-sulfoglucosamine sulfohydrolase LCA, Con-A 
P78509 Reelin SNA 
P80188 lipocalin 2 PHA_E, RCA 
P98164 low density lipoprotein-related protein 2 JAC, LCA 
Q02413 desmoglein 1 WGA, JAC, SNA, 
PHA-E, RCA, MAL-II 
Q08380 lectin, galactoside-binding, soluble, 3 binding protein WGA, JAC, LCA, 
SNA, Con-A, UEA 
Q08554 desmocollin 1 WG, JAC, LCA, 
PHA-E 
Q12805 
P21926 
P02763 
P02751 
EGF-containing fibulin-like extracellular matrix protein 1; CD9 
molecule; orosomucoid 1; fibronectin 1 
Con-A 
Q14574 desmocollin 3 JAC, PHA-E 
Q15517 Corneodesmosin WGA, SNA, PHA-E, 
Con-A 
 
Most of the proteins supposedly bound specifically to many different lectins and these 
proteins would be expected to have multiple glycosylation sites with a diverse array of 
glycans attached to them. For example, prostate stem cell antigen (PSCA), which is a GPI 
anchored protein, has 4 predicted N-glycosylation sites and it was shown in a study that 
treatment with PNGase F resulted in only one band of PSCA at 12 kDa. However, protein not 
treated with PNGase F had three isoforms at 12, 16 and 24 kDa (Reiter et al., 1998). This 
demonstrates that as much as 40% weight of this protein can be glycan moieties. Thirty seven 
known glycoproteins were identified in P18,000g LAC with similar pattern in which some 
proteins were bound to multiple lectins. We compared this 37 known glycoproteins from 
P18,000g with 64 glycoproteins from P200,000g (Figure 5.12). 
 
322 
 
 
Figure 5.12: Compares the glycoproteins identified in P18,000g and P200,000g by LAC. 
As seen in Figure 5.12, only 5 glycoproteins were unique to P18,000g (86% proteins 
common to P200,000 glycoproteins) therefore proteins identified in P18,000g will not be 
discussed further and we will focus only on glycoproteins identified in P200,000g.  
5.3.3.2 Sialylome of urinary nano-vesicles 
Three sialic acid-binding lectins were used in LAC (WGA, SNA, MAL-II). These lectins 
have different glycan binding specificities. Although WGA can bind to sialic acid in any 
linkage, it also binds N-acetylglucosamine. However, SNA and MAL-II are linkage-specific 
and bind α2-6 and α2-3 linked sialic acids respectively. Therefore comparison of proteins 
identified by LAC using these 3 lectins can reveal the nature of sialic acid linkage on 
identified proteins. WGA binding can confirm the presence of sialic acids on proteins 
identified by SNA and MAL-II. A comparison of known glycoproteins identified in LAC of 
these three lectins is shown in Figure 5.13. 
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Figure 5.13: Venn diagram showing the comparison of the proteins identified in WGA, SNA 
and MAL-II LAC. 
As can be seen in the Figure 5.13, 10 proteins are common to the three lectins which suggests 
that these glycoproteins are not only sialylated but also contain both α2-6 and α2-3 linkages 
of sialic acid. Ten other glycoproteins are present in SNA elution (6 common with WGA and 
4 unique to SNA) which would be expected to have only α2-6 linked sialic acid. Seven 
different proteins are present in MAL-II elution (4 common with WGA and 3 unique to 
MAL-II) which would be expected to have only α2-3 linked sialic acid (See Table 5.5). We 
have also described results of glycoproteins identified by hydrazide chemistry in previous 
section. Periodate oxidation also oxidises sialic acids (Larsen et al., 2007) and the resulting 
aldehyde is coupled to hydrazide resin. Therefore we compared the 27 non-redundant 
glycoproteins identified by MAL-II and SNA to proteins identified by hydrazide chemistry 
(Figure 5.14). 
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Figure 5.14: Presents comparison of sialylated proteins (identified in LAC using SNA and 
MAL-II) with proteins identified by hydrazide chemistry. 
Thirteen of the 27 proteins (48%) were also identified by hydrazide chemistry method 
validating the results of LAC. These 27 sialylated proteins are presented in Table 5.5. 
Table 5.5: The sialylated proteins identified in our study. Lectin binding and accordingly 
type of sialic acid linkage, presence of proteins in hydrazide chemistry based enrichment and 
confirmed sialylation in another study done with human plasma and saliva (Larsen et al., 
2007) is indicated in the table. 
Uniprot 
accession 
Gene/Protein Name Lectin 
Binding 
α2-3 or 
α2-6 
linkage 
Present in 
Hydrazide 
chemistry 
identificat
ions 
Known 
sialoprotein 
in Plasma or 
saliva 
(Larsen et 
al., 2007) 
P00734 Coagulation factor II (thrombin) MAL-II α2-3  Yes Yes 
P01833 Polymeric immunoglobulin 
receptor 
MAL-II α2-3  Yes Yes 
P12273 Prolactin-induced protein MAL-II α2-3  No Yes 
P02790 Hemopexin SNA α2-6 No Yes 
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P04196 Histidine-rich glycoprotein SNA α2-6 Yes Yes 
P09668 Cathepsin H SNA α2-6 No No 
P78509 Reelin SNA α2-6 No No 
P01871 Ig mu chain C region WGA, MAL-
II  
α2-3  Yes Yes 
P02675 Fibrinogen beta chain WGA, MAL-
II  
α2-3  No Yes 
P02679 Fibrinogen gamma chain WGA, MAL-
II  
α2-3  No Yes 
P04745 Amylase, alpha 1 (salivary) WGA, MAL-
II  
α2-3  Yes Yes 
P00738 Haptoglobin WGA, MAL-
II, SNA 
Both No Yes 
P01009 Serpin peptidase inhibitor, clade 
A (alpha-1 antiproteinase, 
antitrypsin), member 1 
WGA, MAL-
II, SNA 
Both Yes No 
P01024 Complement component 3 WGA, MAL-
II, SNA 
Both Yes Yes 
P01857 Immunoglobulin heavy constant 
gamma 1 (G1m marker) 
WGA, MAL-
II, SNA 
Both No No 
P01876 Immunoglobulin heavy constant 
alpha 1 
WGA, MAL-
II, SNA 
Both Yes Yes 
P02768 Albumin WGA, MAL-
II, SNA 
Both Yes Depleted 
before 
sialylated 
protein 
enrichment 
P02787 Transferrin WGA, MAL-
II, SNA 
Both Yes Yes 
P07911 Uromodulin WGA, MAL-
II, SNA 
Both Yes No 
P25311 Zinc -alpha-2-glycoprotein  WGA, MAL-
II, SNA 
Both No Yes 
Q02413 Desmoglein 1 WGA, MAL-
II, SNA 
Both No No 
O43653 Prostate stem cell antigen WGA, SNA α2-6 No No 
O75594 Peptidoglycan recognition protein 
1 
WGA, SNA α2-6 No No 
P01859 Immunoglobulin heavy constant 
gamma 2 (G2m marker) 
WGA, SNA α2-6 No Yes 
P05090 Apolipoprotein D WGA, SNA α2-6 Yes Yes 
Q08380 Galectin-3-binding protein WGA, SNA α2-6 Yes Yes 
Q15517 Corneodesmosin WGA, SNA α2-6 No No 
 
A majority of the proteins (63%) present in the table have been previously confirmed as 
sialoproteins in human plasma and saliva (Larsen et al., 2007). 
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5.3.3.4 α1-2 and α1-6 (Core) fucosylated proteins in exosomal pellet 
Two different lectins LCA and UEA-I were used in LAC for identifying fucosylated proteins. 
While LCA recognises α1-6 linked L-fucose otherwise known as core fucosylation, UEA-I 
binds to α1-2 linked L-fucose. Con-A binds biantennary glycans and some of these will have 
core fucosylation therefore such glycans will be bound by LCA as well. Most glycans which 
have α1-2 linked fucose on the outer arm (bound by UEA-I) also contain α1-6 core 
fucosylation (a1-2, 1-6 on one protein). Therefore multiple proteins should be common 
between Con-A, LCA and UEA-I although some of them would contain only one type of 
fucosylation either α1-2 or α1-6. The comparison between proteins identified in these three 
lectins is shown in Figure 5.15. 
 
Figure 5.15: Comparison between proteins identified in Con-A, LCA and UEA-I lectin 
(Panel A) and comparison of total fucosylated proteins with hydrazide method protein 
identifications (Panel B). 
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High-mannose type glycans are not known to be a substrate for α1,6-Fucosyltransferase, 
therefore, the proteins found in Con-A common with LCA should be biantennary hybrid or 
complex. Seventeen proteins in LCA (9 unique and 8 common with Con-A) are expected to 
possess only core fucosylation and not α1-2 type (See Table 5.6). Seven proteins (6 Unique to 
UEA-I and 1 common with Con-A) should contain only α1-2 type fucosylation which is 
usually found on outer arm of the glycan. However, 19 proteins common between LCA and 
UEA-I should have both types (α1-6 and α1-2) of fucosylation. These 43 potentially 
fucosylated proteins are present in table 5.6.  
Table 5.6: Potentially fucosylated proteins in urinary membrane vesicles. Uniprot accession, 
protein name, binding to either LCA or UEA-I and comparison with Con-A identified 
proteins, potential sialic acid found on same same protein, and identification in Hydrazide 
method are indicated in the table. 
Uniprot Gene/Protein Name Lectin 
binding 
Type of glycan Found in 
Sialic acid 
binding 
Lectins 
Present in 
Hydrazide 
method 
O96009 Napsin A aspartic peptidase Con-A, 
LCA  
Biantennary, 
α1-6 Fucose 
No Yes 
P01763 Ig heavy chain V-III region WEA Con-A, 
LCA  
Biantennary, 
α1-6 Fucose 
No No 
P01859 Immunoglobulin heavy constant 
gamma 2 (G2m marker) 
Con-A, 
LCA  
Biantennary, 
α1-6 Fucose 
Yes No 
P02790 Hemopexin Con-A, 
LCA  
Biantennary, 
α1-6 Fucose 
Yes No 
P08962 CD63 molecule Con-A, 
LCA  
Biantennary, 
α1-6 Fucose 
No No 
P09668 Cathepsin H Con-A, 
LCA  
Biantennary, 
α1-6 Fucose 
Yes No 
P25311 Alpha-2-glycoprotein 1, zinc-
binding pseudogene 1; alpha-2-
glycoprotein 1, zinc-binding 
Con-A, 
LCA  
Biantennary, 
α1-6 Fucose 
Yes No 
P51688 N-sulfoglucosamine 
sulfohydrolase 
Con-A, 
LCA  
Biantennary, 
α1-6 Fucose 
No No 
O43653 Prostate stem cell antigen Con-A, 
LCA, 
UEA-I 
Biantennary, 
α1-2, α1-6 
Fucose 
Yes No 
P01009 Serpin peptidase inhibitor, clade 
A (alpha-1 antiproteinase, 
Con-A, 
LCA, 
Biantennary, 
α1-2, α1-6 
Yes Yes 
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antitrypsin), member 1 UEA-I Fucose 
P01023 Alpha-2-macroglobulin Con-A, 
LCA, 
UEA-I 
Biantennary, 
α1-2, α1-6 
Fucose 
No Yes 
P01024 complement component 3 Con-A, 
LCA, 
UEA-I 
Biantennary, 
α1-2, α1-6 
Fucose 
Yes Yes 
P01833 Polymeric immunoglobulin 
receptor 
Con-A, 
LCA, 
UEA-I 
Biantennary, 
α1-2, α1-6 
Fucose 
Yes Yes 
P01857 Ig gamma-1 chain C region Con-A, 
LCA, 
UEA-I 
Biantennary, 
α1-2, α1-6 
Fucose 
Yes No 
P01871 Ig mu chain C region Con-A, 
LCA, 
UEA-I 
Biantennary, 
α1-2, α1-6 
Fucose 
Yes Yes 
P01876 Immunoglobulin heavy constant 
alpha 1 
Con-A, 
LCA, 
UEA-I 
Biantennary, 
α1-2, α1-6 
Fucose 
Yes Yes 
P02675 Fibrinogen beta chain Con-A, 
LCA, 
UEA-I 
Biantennary, 
α1-2, α1-6 
Fucose 
Yes No 
P02679 Fibrinogen gamma chain Con-A, 
LCA, 
UEA-I 
Biantennary, 
α1-2, α1-6 
Fucose 
Yes No 
P02768 Albumin Con-A, 
LCA, 
UEA-I 
Biantennary, 
α1-2, α1-6 
Fucose 
Yes Yes 
P02787 Transferrin Con-A, 
LCA, 
UEA-I 
Biantennary, 
α1-2, α1-6 
Fucose 
Yes Yes 
P05090 Apolipoprotein D Con-A, 
LCA, 
UEA-I 
Biantennary, 
α1-2, α1-6 
Fucose 
Yes Yes 
P07911 Uromodulin Con-A, 
LCA, 
UEA-I 
Biantennary, 
α1-2, α1-6 
Fucose 
Yes Yes 
Q08380 Galectin-3 binding protein Con-A, 
LCA, 
UEA-I 
Biantennary, 
α1-2, α1-6 
Fucose 
Yes Yes 
O75594 Peptidoglycan recognition protein 
1 
Con-A, 
UEA-I 
Biantennary, 
α1-2 Fucose 
Yes No 
P00450 Ceruloplasmin (ferroxidase) LCA  α1-6 Fucose No No 
P01596 Ig kappa chain V-I region CAR LCA  α1-6 Fucose No No 
P02760 Alpha-1-microglobulin/bikunin 
precursor 
LCA  α1-6 Fucose No Yes 
P04114 Apolipoprotein B (including Ag 
(x) antigen) 
LCA  α1-6 Fucose No No 
P04745 Amylase, alpha 1 (salivary) LCA  α1-6 Fucose Yes Yes 
P16278 Galactosidase, beta 1 LCA  α1-6 Fucose No No 
P98164 low density lipoprotein-related 
protein 2 
LCA  α1-6 Fucose No Yes 
Q08554 Desmocollin 1 LCA  α1-6 Fucose No No 
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Q12907 Lectin, mannose-binding 2 LCA  α1-6 Fucose No No 
P00738 Haptoglobin LCA, 
UEA-I 
α1-2, α1-6 
Fucose 
Yes No 
P01011 Serpin peptidase inhibitor, clade 
A (alpha-1 antiproteinase, 
antitrypsin), member 3 
LCA, 
UEA-I 
α1-2, α1-6 
Fucose 
No Yes 
P05155 Serpin peptidase inhibitor, clade 
G (C1 inhibitor), member 1 
LCA, 
UEA-I 
α1-2, α1-6 
Fucose 
No Yes 
P0C0L4 Complement component 4A 
(Rodgers blood group) 
LCA, 
UEA-I 
α1-2, α1-6 
Fucose 
No No 
O60494 Cubilin (intrinsic factor-
cobalamin receptor) 
UEA-I α1-2 Fucose No Yes 
P01860 Ig gamma-3 chain C region UEA-I α1-2 Fucose No No 
P01861 Immunoglobulin heavy constant 
gamma 4 (G4m marker) 
UEA-I α1-2 Fucose No No 
P02671 Fibrinogen alpha chain UEA-I α1-2 Fucose No No 
P02743 Amyloid P component, serum UEA-I α1-2 Fucose No No 
P04004 Vitronectin UEA-I α1-2 Fucose No No 
 
Many of these proteins like transferrin, haptoglobin, immunoglobulin G and A and polymeric 
immunoglobulin receptor have been previously identified in other studies to be α1-6 core 
fucosylated (Dai et al., 2007; Muinelo-Romay et al., 2011). 
5.3.3.5 Galactose bearing, high-mannose type and Complex glycan containing 
glycoproteins 
As described in Table 5.1, Jacalin binds ‘T antigen’ mostly, on O-glycosylated proteins. 
However, another study has shown that JAC can also bind oligomannose type glycans 
(Bourne et al., 2002). This population of proteins should also bind Con-A. Therefore, 
glycoproteins identified in Jac LAC were compared to those identified in Con-A. The 
common proteins should bear oligomannose type glycans and those unique to JAC should 
contain ‘T antigen’ type of glycan. Moreover, Con-A also binds biantennary types of glycans 
and it should have some proteins common with PHA-E. RCA, on the other hand binds 
galactose in N-acetyllactosamine. Some gaalctose-bearing proteins will be bound by JAC as 
well. For these reasons we compared the proteins identified in these four lectins (JAC, PHA-
E, RCA, Con-A) and common and unique proteins are presented in Table 5.7. 
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Table 5.7: The comparison of proteins identified in JAC, PHA-E, RCA and Con-A LAC. 
Uniprot accessions, Number of proteins common and unique among different lectins, lectin 
binding and information inferred from this comparison about type of glycans present in these 
proteins are indicated in the table. 
Uniprot accessions Number 
of 
proteins 
Gene/Protein Name Lectin 
binding 
Type of glycans 
P25311 P07911 2 Zinc-alpha-2-glycoprotein; 
Uromodulin 
JAC, PHA-
E, RCA, 
Con-A 
Oligomannose, 
Galactose bearing, 
complex 
Q02413 P04745 2 Desmoglien-1; Alpha-
amylase 1 
JAC, PHA-
E, RCA 
Galactose bearing, 
Complex 
P01857 O43653 
P01024 P01859 
P05090 P02787 
6 Immunoglobulin heavy 
constant gamma 1 (G1m 
marker); Apolipoprotein D; 
Immunoglobulin heavy 
constant gamma 2 (G2m 
marker); Transferrin; 
Prostate stem cell antigen; 
Complement C3  
JAC, PHA-
E, Con-A 
Oligomannose, 
complex 
P01876 1 Ig alpha-1 chain C region JAC, RCA, 
Con-A 
Galactose bearing, 
Oligomannose 
Q08554 Q14574 2 Desmocollin-1; 
Desmocollin-3 
JAC, PHA-E Oligomannose, 
complex 
P02790 P02675 
Q08380 P02649 
P01023 Q14624 
P01833 P01009 
P02679 P08962 
P01871 O96009 
P01763 
13 Immunoglobulin heavy 
constant mu; Alpha-1-
antitrypsin; Hemopexin; 
Apolipoprotein E; Polymeric 
immunoglobulin receptor; 
Fibrinogen beta chain; Inter-
alpha inhibitor H4;Glaectin-3 
binding protein; Napsin A; 
CD63; Alpha-2 
macroglobulin; fibrinogen 
gamma chain; Ig heavy chain 
V-III region WEA 
JAC, Con-A Oligomannose 
P80188 1 Neutrophil gelatinase-
associated lipocalin 
PHA-E, 
RCA 
Galactose bearing, 
Complex 
O75594 Q15517 
P09668 
3 Peptidoglycan recognition 
protein 1; Corneodesmosin; 
Pro-cathepsin H 
PHA-E, Con-
A 
Biantennary 
complex 
P01042 P01011 
P41222 P98164 
P02671 P0C0L4 
P02760 P04196 
8 Alpha-1-antichymotrypsin; 
Kininogen 1; Fibrinogen 
alpha chain; Alpha-1-
microglobulin; Histidine rich 
glycoprotein; Complement 
component 4A; 
Prostaglandin D2 sysnthase; 
Megalin 
JAC T antigen 
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P07339 1 Cathepsin D PHA-E Complex 
P08603 Q8N2E2 
P27487 
3 Complement factor H; von 
Willebrand factor D and EGF 
domain-containing protein; 
Dipeptidyl peptidase 4 
RCA Galactose bearing 
P12273 P51688 
Q12805 P21926 
P02763 P02751 
6 Prolactin-inducible protein; 
N-sulphoglucosamine 
sulphohydrolas; EGF-
containing fibulin-like 
extracellular matrix protein 
1; CD9 antigen; Alpha-1-
acid glycoprotein 1; 
Fibronectin 
Con-A Alpha-mannose 
  
5.3.3.6 Non-glycosylation proteins identified in our analysis 
We have identified 172 proteins in LAC of P200,000g out of which 64 (37%) are 
glycosylated. Sixty-three percent (63%) of total proteins identified are non-glycosylated. In a 
previous report, 70% of proteins identified in LAC using M. amurensis lectin were found to 
be non-glycosylated (McDonald et al., 2009). In the same paper it was shown that in the 
hydrazide chemistry protocol only 30% of the total identified proteins were glycosylated. 
compared to that study we have an improved identification of glycosylated proteins (66% 
glycoproteins in hydrazide method compared to 30% in the previous study and 37% 
glycoproteins in LAC compared to 30% in the previous study). However, a large number of 
non-glycosylated proteins are still present. In the same study, the authors had identified the 
proteins non-specifically adsorbing to the stationary phase matrix. When we compared our 
identification with the non-specifically adsorbing proteins of HeLa cells we found that 
although, the two samples are completely different, 14 proteins are present in our 
identifications as well. These 14 proteins are not known to be glycosylated and must be 
getting enriched by other means such as non-specific adsorption. These proteins are annexin 
A1 and A2, actin beta and alpha2, alpha enolase 1, glyceraldehyde 3-phosphate 
dehydrogenase, phosphogluconate dehydrogenase, histones H2A type 1-A and H4, 
elongation factor 1-alpha 1, 14-3-3 protein eta, pyruvate kinase isozymes M1/M2 and 
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peroxiredoxin 1 and 2. These proteins in cellular context are very abundant proteins in HeLa 
cells. However, quantitative data on their amount in exosomes is missing. Notably six of 
these are nucleotide binding proteins. The ability of these 14 proteins, adsorbing non-
specifically to the stationary phase even when they are present in different samples, could be 
due  to their sticky nature (aggregation) or high amounts. However, a clear answer is not 
known.  
Leaving these proteins apart, there are still a number of non-glycosylated proteins (94 
proteins) which were detected in LAC. We hypothesized that a majority of these proteins 
might be interacting with the glycosylated proteins. For this purpose we screened these non-
glycosylated proteins for interactions with the glycosylated proteins identified in our sample 
using protein-protein ineteraction databases I2D and iRefWeb (Turner et al., 2010). If these 
proteins form a complex with glycosylated proteins they would be detected in the LAC as 
well. Forty seven unique interactions were found and it was revealed 34 non-glycosyated 
proteins identified in LAC of P200,000g are known interacting partners of 18 glycoproteins 
identified in LAC. These interactions are presented in Table 5.8. 
 
Table 5.8: The non-glycosylated proteins identified in LAC which interact with 
glycoproteins identified in LAC. Protein name and the source of interaction are given in the 
table. 
Non-glycosylated proteins Glycosylated interacting 
partner 
Source 
CystatinA Cathepsin B I2D 
Ig kappa chain V-II region Cum Ig Mu chain I2D 
Ig kappa chain V-III region SIE Ig alpha-1 chain C 
region 
I2D 
Ig lambda chain V-I region HA Ig alpha-1 chain C 
region 
I2D 
Ig heavy chain V-III region VH26; Ig gamma-1 chain C I2D 
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Precursor region 
Ig kappa chain C region Ig gamma-1 chain C 
region 
I2D 
Cytokeratin-14 Ig gamma-1 chain C 
region 
I2D 
Cytokeratin-6A Ig gamma-1 chain C 
region 
I2D 
Apolipoprotein A-I Ig gamma-1 chain C 
region 
I2D 
Apolipoprotein A2 Serum albumin; 
Precursor 
I2D 
Apolipoprotein C1 Serum albumin; 
Precursor 
I2D 
Cystatin-B Cathepsin D I2D 
Cytokeratin-6B Serum albumin; 
Precursor 
I2D 
Apolipoprotein A-IV Serum albumin; 
Precursor 
I2D 
Annexin A2 Cathepsin B I2D 
Cytokeratin-16 Ig gamma-1 chain C 
region 
I2D 
Cytokeratin-13 Serum albumin; 
Precursor 
I2D 
Cytokeratin-5 Serum albumin; 
Precursor 
I2D 
Glial fibrillary acidic protein Serum albumin; 
Precursor 
I2D 
Junction plakoglobin Desmoglein-1 I2D 
Desmoplakin Desmocollin-1 I2D 
Cornifin-B Prolactin-inducible 
protein 
I2D 
Trypsin-3 Alpha-1-antitrypsin I2D 
Beta-catenin Megalin I2D 
Cytokeratin-9 Ig gamma-1 chain C 
region 
I2D 
Lysozyme C Alpha-2-macroglobulin I2D 
Hemoglobin beta chain Ig Mu chain I2D 
Hemoglobin alpha chain Cathepsin D I2D 
Dermcidin Serum albumin; 
Precursor 
I2D 
Plakophilin-1 Desmoglein-1 I2D 
Trypsinogen C Serum albumin; 
Precursor 
I2D 
Apolipoprotein A2 Apolipoprotein D iRefWeb 
Apolipoprotein A2 Complement C4-A iRefWeb 
Apolipoprotein A1 Apolipoprotein B iRefWeb 
Desmoplakin Desmocollin-1 iRefWeb 
Junction plakoglobin Desmocollin-1 iRefWeb 
Ig kappa chain C region Ig gamma-1 chain C 
region 
iRefWeb 
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Cystatin-B Cathepsin D iRefWeb 
Cystatin-A Cathepsin B iRefWeb 
Cystatin-A Pro-cathepsin H iRefWeb 
Junction plakoglobin Desmoglein-1 iRefWeb 
Apolipoprotein A1 Haptoglobin iRefWeb 
Cystatin-B Pro-cathepsin H iRefWeb 
Cystatin-B Cathepsin B iRefWeb 
Haptoglobin-related protein Ig mu chain C region iRefWeb 
Junction plakoglobin Desmocollin-3 iRefWeb 
Glyceraldehyde-3-phosphate 
dehydrogenase 
Cathepsin D iRefWeb 
 
Using above two approaches, we were able to account for the presence of 44% of the total 
non-glycosylated proteins detected in LAC. The remaining proteins, we speculate, could be 
present in our identification due to either new protein-protein interactions (not previously 
documented) or non-specific adsorption to stationary phase matrix. 
5.3.3.7 Gene ontology and bioinformatic analysis of total glycoproteins identified by 
LAC and hydrazide chemistry 
Combined total proteins from LAC and hydrazide method identifications (108 unique 
glycproteins) were submitted for analysis by IPA software. Proteins were annotated for sub-
cellular location and molecular function. Four proteins were not mapped by IPA and they 
were manually classified into sub-cellular localisation and molecular functions categories. 
Sub-cellular localisation of these 108 glycoproteins is presented in Figure 5.16. For 
comparison, the total proteome of P200,000g (Presented in Chapter 3) is shown side-by-side. 
This comparison gives an idea about which categories are represented heavily in 
glycoproteins compared to total proteome.  
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Figure 5.16: Sub-cellular localisation of glycoproteins of exosome and ‘exosome-like’ 
vesicles as annotated by IPA software. 
The biggest category enriched in the membrane vesicular glycoproteins is extracellular space 
(53%) and then plasma membrane (29%) and cytoplasm (13%). Extracellular proteins and 
proteins associated to plasma membrane are over-represented in glycoproteins of membrane 
vesicles compared to full proteome. However, cytoplasmic proteins in membrane vesicles are 
heavily under-represented compared to full proteome. This could be due to the fact that 
intracellular proteins are mostly O-glycosylated which is a small fraction of total 
glycoproteome where N-glycosylation is the predominant type. Further classification of 
glycoproteins by molecular functions of the proteins is presented in Figure 5.17.  
 
38 
36 
2 
23 
1 
13 
53 
2 
29 
3 
Cytoplasm 
Extracellular Space 
Nucleus 
Plasma Membrane 
Unknown 
Gene Ontology: Cellular component 
Glycoproteins P200 CP200 Total proteome 
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Figure 5.17: The classification of glycoproteins for molecular function categories by IPA. 
The biggest category of molecular function is peptidase (26%) followed by transporters 
(17%). Transmembrane receptors make up 6% of the glycoproteins while enzymes make up 
another 15%. Compared to total proteome, peptidases (26% compared to 12 in total 
proteome) and transporter proteins (17% compared to 10% in total proteome) are heavily 
over-represented in glycoproteins. For example neutrophil gelatinase-associated lipocalin 
(NGAL) was identified only in glycoprotein study here and not in total proteome in Chapter 
3. NGAL is an iron-trafficking protein involved in apoptosis, innate immunity and renal 
development (Source: Uniprot, accession: P80188). NGAL is also an early biomarker for 
diabetic nephropathy which appears much earlier than albuminuria (Alter et al., 2012). 
However, enzymes are under-represented compared to total proteome. Further IPA analysis 
revealed a set of proteins which are involved in kidney failure and are presented in table 5.9. 
Enzyme 
G-protein coupled receptor 
Growth factor 
Kinase 
Peptidase 
Phosphatase 
Transcription/translation regulator 
Transmembrane receptor 
Transporter 
25 
1 
1 
1 
12 
2 
2 
2 
10 
15 
1 
2 
2 
26 
1 
1 
6 
17 
Gene Ontology: Molecular function 
Glycoproteins P200 CP200 total proteome 
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Table 5.9: IPA bio-functions analysis revealed a category Kidney failure. Functions 
annotation, p-Value of enrichment, molecules involved (Gene symbol) and total molecules in 
the category are indicated. 
Category Functions annotation p-Value Molecules Total 
molecules 
Kidney 
Failure  
Renal failure 1.27 E-05 AGT, ALB, C3, DPP4, F2, 
IGHG1, KNG1, LCN2, PTGDS 
9 
Kidney 
Failure  
Chronic renal failure 7.02 E-06 AGT, ALB, C3, DPP4, F2, 
KNG1 
6 
Kidney 
Failure  
Failure of kidney 1.58 E-04 AGT, C3, DNASE1, PODXL 4 
Kidney 
Failure  
End stage renal disease 2.07 E-04 AGT, ALB, C3, F2, KNG1 5 
Kidney 
Failure  
Interstitial fibrosis of 
kidney 
6.53 E-03 AGT, C3, KNG1 3 
Kidney 
Failure  
Septic acute kidney 
injury 
2.40 E-03 LCN2 1 
Kidney 
Failure  
Acute tubular necrosis 3.85 E-02 LCN2 1 
Kidney 
Failure  
End stage renal disease 
of kidney 
3.85 E-02 C3 1 
Kidney 
Failure  
Acute renal failure 4.06 E-02 ALB,LCN2 2 
Kidney 
Failure  
Ischemic acute renal 
failure 
6.34 E-02 LCN2 1 
Kidney 
Failure  
Hepatorenal syndrome 6.95 E-02 ALB  1 
 
Network generation function in the core analysis feature of the IPA generated a network 
enriched in our glycoprotein identifications. This network enriched in our analysis is involved 
in neurological diseases, cancer and gastrointestinal diseases. This network is shown in 
Figure 5.18. 
338 
 
 
Figure 5.18: Network generated by IPA analysis of exosomal and exosome-like vesicular 
glycoproteins. Gene symbol of glycoproteins have been used. Proteins in grey shapes are the 
ones found in our analysis while the ones in white shape are associated with the network but 
not found in our analysis. 
This network shows the proteins which are connected by brown dotted and solid lines are the 
ones which decrease the phosphorylation of ERK1/2. While the proteins connected by blue 
lines to the HDL are components of HDL. HDL component proteins are involed in cross-talk 
with the ERK pathway. It was previously shown that isolated biliary exosomes were able to 
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induce a decrease of phosphorylated-total ERK1/2 ratio and, subsequently, cholangiocyte 
proliferation (Masyuk et al., 2010). Therefore, this network enrichment in our dataset could 
be a platform for future studies validating these targets to establish crosstalk of given 
exosomal components with the ERK pathway in the recipient cells. 
5.3.3.8 Comparison with previous studies on exosome and exosome-like vesicles 
We compared our identifications with the previous largest proteomic study on urinary 
exosomes and exosome-like vesicles (Wang et al., 2011) (Wang). We also combined our 
identifications from Chapter 2 with Wang and then compared it to the total proteins we 
identified in glycoprotein analysis. 
 
Figure 5.19: Panel A: Comparison of proteins identified in glycoprotein analysis with 
combined identifications from our Chapter 2 and largest study on exosome and exosome-like 
vesicles (Wang et al., 2011) (Wang). Panel B: the unique proteins in glycoprotein analysis 
were compared with Exocarta (Mathivanan et al., 2012) (The biggest database of exosomal 
proteins from any source, a filter was applied and only human proteins were extracted from 
Exocarta). 
340 
 
Fifty-one proteins were not found in either our proteomic identifications from chapter 2 or in 
the Wang et. al. study. These 51 proteins were converted from Uniprot accessions to Entrez 
gene ids which mapped to 39 Ids. These 39 Ids were compared to exocarta human proteins 
which are in the form of Entrez gene ids. Twenty-seven proteins were found to be unique to 
our glycoprotein analysis, which have never been described as part of exosomes or ‘exosome-
like’ vesicles. These 27 proteins are presented in Table 5.10. 
Table 5.10: The proteins shown for the first time to be part of exosome/’exosome-like’ 
vesicles. Uniprot accessions and gene/protein names are given. 
UNIPROT 
ACCESSION 
GENE/PROTEIN NAME Known/potential 
glycosylation in 
Uniprot 
P02654 apolipoprotein C-I No 
Q9NZT1 calmodulin-like 5 No 
P09668 cathepsin H Yes 
Q9UBR2 cathepsin Z Yes 
Q15517 Corneodesmosin Yes 
P09228 cystatin SA No 
P01037 cystatin SN No 
Q6E0U4 Dermokine No 
P59894 doublecortin domain containing 1 No 
O00472 elongation factor, RNA polymerase II, 2 No 
P14136 glial fibrillary acidic protein No 
Q68CZ6 HAUS augmin-like complex, subunit 3 No 
Q96QV6 histone cluster 1, H2aa No 
B9A064 Immunoglobulin lambda-like polypeptide 5 No 
P09914 interferon-induced protein with tetratricopeptide 
repeats 1 
No 
Q3SY84 keratin 71 No 
Q6ZMR3 lactate dehydrogenase A-like 6A No 
Q7L985 leucine rich repeat and Ig domain containing 2 Yes 
Q86SR0 Ly6/neurotoxin 1 No 
O60237 protein phosphatase 1, regulatory (inhibitor) subunit 
12B 
No 
Q86SG5 S100 calcium binding protein A7A No 
Q9NQ38 serine peptidase inhibitor, Kazal type 5 No 
P22528 small proline-rich protein 1B (cornifin) No 
P35325 small proline-rich protein 2B No 
P22531 small proline-rich protein 2E No 
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O94901 unc-84 homolog A (C. elegans) No 
Q8N2E2 von Willebrand factor D and EGF domains Yes 
 
None of these 27 proteins have been described in exosome or other membrane vesicles to the 
best of our knowledge. Five proteins out of these 27 are known to be glycosylated which are 
indicated in the Table 5.10. These proteins, however, could be potential targets to identify 
their glycosylation status. 
5.3.4 Lectin affinity chromatography for isolation of nano-vesicles from urine 
If a lectin affinity-based method for enrichment of membrane vesicles from urine is 
envisaged, one has to assume the possibility of contamination with high abundance proteins 
and avoid their enrichment. Two major proteins of urine are THP and albumin and THP is 
highly glycosylated (30% of total weight are glycans) while albumin is usually not 
glycosylated. Although some glycosylated variants of albumin are known, it can be assumed 
that albumin should not be enriched in elution of lectin affinity chromatography, as the 
frequency of glycosylated variants is very low. However, glycosylated variants of human 
serum albumin such as redhill have been reported (Kragh-Hansen, Donaldson & Jensen, 
2001). Based on the FLLA (Figure 5.2) and lectin blotting results (Figure 5.4), it was decided 
that Jacalin would be used for lectin-affinity isolation of membrane vesicles as THP did not 
bind to the Jacalin and P200,000g and P18,000g bound strongly to it. Moreover, in MS 
analysis of P200,000g extract 50% of total glycoproteins identified were membrane proteins 
as annotated by SOSUI web server (Hirokawa, Boon-Chieng & Mitaku, 1998). Also, the 
signal in lectin blot and FLLA for SN200,000g was much lower. Biotinylated Jacalin was 
immobilised on streptavidin agarose and subsequently Jacalin-agarose was used for lectin 
affinity chromatography (LAC). It was found that THP was still a major protein in the elution 
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of LAC (Figure 5.20 B). To remove THP, diatomaceous earth filter (DEF) was used to filter 
urine.  
 
 
Figure 5.20: SDS-PAGE of non-bound, washing and elution profile of Jacalin affinity 
chromatography of A) Negative control, B) whole urine, C) DEF non-bound, and Western 
blot D) of DEF non-bound using anti-CD63 antibodies. M: Molecular weight marker in kDa; 
N: Negative control, chromatography performed on only streptavidin-agarose without 
immobilised-Jacalin; U: Non-bound; W: Washing; E: Elution; EP200: Pellet 200,000g of 
elution of Jacalin-agarose. 
DEF non-bound material, mostly free of THP was applied to Jacalin-agarose and eluate was 
checked for membrane vesicles/exosomal marker CD63. Eluate from Jacalin-agarose was 
centrifuged at 200,000g to pellet down any membrane vesicles if any in the elution. Whole 
eluate and P200,000g of eluate had CD63 much more enriched when compared to non-bound 
fraction. It suggests that Jacalin chromatography of DEF filtered urine can enrich membrane 
vesicles without much contamination of soluble proteins like THP. To confirm that Jacalin-
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agarose enriches membrane vesicles by specific interaction with glycans and to establish a 
negative control, streptavidin-agarose without immboilised Jacalin was used for 
chromatography with whole urine. The same protocol as Jacalin-agarose chromatography 
was followed and the eluate was run on SDS-PAGE. Negative control, when compared to the 
SDS-PAGE pattern of the Jacalin-agarose chromatography eluate (Figure 5.20, N in Panel A 
versus E of Panel B & C), demonstrates that enrichment of vesicles is specific to Jacalin 
binding to the glycans on the surface of membrane vesicles.  
However, DEF filtration is a lengthy procedure and THP can entrap membrane vesicles 
(Fernandez-Llama et al., 2010) resulting in loss of vesicles in the subsequent chromatography 
step. To avoid this shortcoming and develop a method which is simple with less number of 
steps, we tried to change the binding buffer of the Jacalin chromatography. HEPES buffer 
saline was originally used and it can be seen in LAC elution as well that THP is present in the 
elution (Figure 5.9, Panel A, lane 7). THP is known to polymerise at high ionic strength 
therefore we changed the binding buffer to 10mM phosphate buffer (pH 7.4) withoutany salt. 
Polymerisation of THP might be the reason why it was getting enriched in high amounts with 
Jacalin elution. We were able to eliminate excess THP becoming enriched with fraction 
eluted from Jacalin-agarose (Figure 5.21). 
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Figure 5.21: SDS-PAGE (Panel A) of Jacalin chromatography using phosphate buffer as the  
binding buffer without any salt. 1: Jacalin elution M: molecular weight markers in kDa. 
Western blot of Jacalin elution (Panel B) using anti-CD63 antibodies. 1: Jacalin elution M: 
molecular weight markers in kDa. Western blot of Jacalin elution (Panel C) using anti-
TSG101 antibodies. 1: Elution fraction (vesicles) from the Jacalin-agarose M: molecular 
weight markers in kDa. 
It can be seen in Figure 5.21 that THP (~100 kDa) is not a major contaminant anymore in the 
Jacalin elution (Panel A) without having any effect on CD63 enrichment (Panel B). TSG101 
(intra-vesicular exosomal marker) was also found in Jacalin elution although in very low 
amounts as the image had to be acquired at high intensity to visualise the band. This elution 
was further characterised by transmission electron microscopy (TEM) to conclusively prove 
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that it contains membrane vesicles. Moreover, TEM analysis would also reveal the size and 
morphology of vesicles enriched by Jacalin from minimally processed urine. 
 
 
Figure 5.22: TEM analysis of vesicles eluted from Jacalin-agarose. Some representative 
pictures are presented here. Size of the scale bar and direct magnification is given on top of 
each panel. 
Figure 5.22 panel A shows mainly vesicles which are 50-70 nm while panel B shows bigger 
vesicles which are 378 and 389nm. Panel C shows a 126nm vesicle while panel D shows a 
639nm vesicle. We acquired multiple TEM images and size of the vesicles was calculated by 
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ImageJ software. We present a size distribution of vesicles present in 16 representative 
vesicles pictures. 
 
Figure 5.23: Presents the size-distribution of vesicles found in vesicle eluted from Jacalin-
agarose. 16 images were analysed by ImageJ software and size of all the vesicles were 
calculated. X-axis is the size of vesicles in nm and Y-axis is % vesicles in a given size range. 
We mostly found vesicles from 50 to 550 nm size but vesicles bigger than 550 were few. It 
can be said that Jacalin enriched vesicles are mixtures of exosomes and bigger microvesicles. 
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5.4 Discussion 
The purpose of our study was to use robust and exhaustively described methods for novel 
characterization of urinary vesicles for their glycoconjugates profile. Additionally this 
information was used to devise a new method to rapidly isolate urinary membrane vesicles. 
FLLA results showed that urinary membrane vesicles (P200,000g) are enriched in multiple 
glycan epitopes including complex N-linked glycans (PHA-E, PHA-L), high mannose 
structures (Con-A, PSA), Sia α 2-6Gal ; GalNAc and multivalent Sia (SNA, WGA), LacNAc 
(RCA120), GalNAcα-Thr/Ser (Tn) (JAC) and GalNAcαThr/Ser (Tn) ; GalNAcα1-3GalNAc 
(DBA). The WGA signal, compared to SWGA, was much higher indicating that WGA was 
binding mostly to sialic acids and not to N-acetylglucosamine. sWGA, as reported by the 
Vector labs datasheet,  binds only  to N-acetylglucosamine and not to sialic acids. This is 
complemented by high signal of SNA which binds Sia α 2-6Gal. The signal for MAL-II was 
very low suggesting that sialic acids on membrane vesicle surfaces are mainly conjugated by 
α 2-6.  
Many of these glycan epitopes have been previously recorded to be present on membrane 
vesicles from H9 T-cell line as evidenced by binding of their corresponding lectins (Con-A, 
PSA, PHA-E, PHA-L, RCA, WGA, SNA) (Krishnamoorthy et al., 2009). It was also shown 
in the study that these epitopes are enriched in membrane vesicles as compared to parent cell 
plasma membrane. Another study using a wide variety of cell lines (SkMel-5, HT29, HCT-
15, H9, SupT1 and Jurkat-Tat-CCR5 cell lines) and human breast milk as source of 
membrane vesicles confirmed most of these epitopes to be common to membrane vesicles 
from different sources (Batista et al., 2011). This suggests that membrane vesicles originate 
from specialised compartments of cells and glycosylation may play an important role in 
sorting glycoproteins to these compartments. Accordingly, it is known that, specific 
glycoforms of prion protein are sorted into exosomes over other forms (Vella et al., 2007). 
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Our study appears to be the first one undertaken on glycosylation of urinary membrane 
vesicles. FLLA could be employed to discover disease-specific differences in membrane 
vesicles glycosylation among different well defined patient samples.  
Taking the study further, nine lectins belonging to seven different classes based on their 
binding specificity were employed on P200,000g and P18,000g extract (prepared using beta-
octyl glucoside{BOG) to enrich constituent glycoproteins and identify them using MS 
analysis. BOG was used to prepare the extract as it dissolves the lipid-rafts (Garner, Smith & 
Hooper, 2008). One hundred and seventy two proteins excluding keratin were identified in 
P200,000 and 97 proteins in P18,000g. Out of these 172 proteins in P200,000g, 64 proteins 
are known glycoproteins (37%). When these 64 proteins were compared with 37 known 
glycoproteins identified in P18,000g only 5 proteins were unique to P18,000g (13%). High 
number of proteins common to both pellets suggest that P18,000g also consists of membrane 
vesicles which due to physico-chemical factors or entrapment in THP fibrils pellet down at 
low speed. It is to be noted that a similar trend was also noted in Chapter 2 in proteomic 
analysis of both these pellets. These 5 proteins unique to P18,000g are non-secretory 
ribonuclease (EDN), clusterin, CD59, mucin 1 and inter-alpha inhibitor H1. EDN was 
previously found to be present in urine and according to Uniprot, it is N-linked glycosylated 
at 5 locations and C-type glycosylated at one site. EDN is an anti-microbial proteins present 
in eosinophil granules and is chemotactic for dendritic cells (Yang et al., 2003). The role of 
extensive glycosylation of this protein in its biological functions is not known.  
Four of these 5 proteins have previously been shown to be secreted with exosomes in urine 
(Pisitkun, Shen & Knepper, 2004). However, Inter-alpha-trypsin inhibitor heavy chain H1 is 
not reported be part of exosomes from any source to the best of our knowledge (Absent in 
Exocarta (Mathivanan et al., 2012)). This protein was also identified in our total proteome 
analysis in Chapter 3. Total 64 known glycoproteins identified in P200,000g were compared 
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with each other and a crude information about glycans carried by these proteins was revealed 
(Table 5.4). When results from the hydrazide method were combined with LAC 
identifications, a total of 108 known glycoproteins were found. This study would serve as a 
platform for future studies on glycosylation of exosomal proteins. A number of sialic acid 
containing glycoproteins and core and α1-2 fucosylated proteins were also identified which 
are presented in results sections. Changes in sialic acid content in the glomerular capillary 
walls of the diabetic nephropathy patients compared to healthy tissues were observed 
previously (Tomino et al., 1988). In this study the binding of WGA decreased with 
neuraminidase treatment suggesting glycan epitopes contained sialic acids. As previously 
discussed, WGA signal in FLLA of P200,000 is mainly because of sialic acid content 
(SWGA signal is much less ruling out N-aceyltglucosamine).  
The changes in glycan content or amount in kindey can be reflected on membrane vesicle 
surface glycosylation which could be detected using FLLA. This is only a hypothesis until 
confirmed with patient samples. However, if this comes true, it can be further expanded to 
plate based hybrid lectin-antibody assays after recognising the glycproteins carrying these 
glycans which might change with disease in kidney and reflected in membrane vesicles. 
Identification of exosomal surface glycome is a first step towards that which we have 
performed using hydrazide chemistry as detailed in results section. Thirty-seven membrane 
glycoproteins including podocalyxcin, GPCR, and solute carrier transporters were identified. 
These proteins reflect the majority of exosomal surface glycome.  
The major category of gene ontology of glycoproteins in cellular component category was 
extracellular proteins followed by plasma membrane and then cytoplasm. Extracellular 
proteins peripherally or transiently attach with plasma membrane and many of them are 
expected to end up in endosomes which might prime them up for secretion with exosomes. 
Twenty seven proteins were identified to be part of exosome/exosome-like vesicles for the 
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first time out of which 5 are known glycoproteins. This suggests that lectin enrichment is 
efficient and can be used to enrich low abundance proteins from urinary membrane vesicles 
for more thorough proteomic characterization. Lectin affinity chromatography, although an 
efficient method of glycoprotein enrichment, sometimes catches non-glycosylated proteins 
which may be enriched as an artefact. For example serum albumin was also identified in our 
list and this could be due to the fact that albumin, being a transporter, is associated with 
multiple proteins. However, glycosylated variants of albumin have been reported (Kragh-
Hansen, Donaldson & Jensen, 2001). Moreover, albumin was also found in all samples from 
hydrazide chemistry method to enrich glycproteins. We have used a stringent method using 
hydrazide chemistry which included washing with 8M urea and 1.5M NaCl three times after 
the oxidised glycoproteins had bound to the hydrazide resin. This should result in all the non-
glycosylated or non-glycated proteins to be washed out. On-column trypsin digestion would 
result in release of peptides of only glycoproteins. Therefore, a possibility of albumin being 
either glycosylated or glycated can not be excluded. However, oxidised proteins could bind to 
hydrazide resin as well (Mirzaei & Regnier, 2007) and these proteins could be non-
glycoyslated. Albumin is known to be prone to oxidation at multiple sites and this could be 
the reason why it may bind to hydrazide resin. Moreover oxidation induced cross-linking of 
proteins has also been reported and this could present another mechanism by which albumin 
and other non-glycosylated proteins could be retained on hydrazide resin despite 8M Urea 
and 1.5M  NaCl washes. 
Deducing from the FLLA results, we noticed that Jacalin bound strongly to P200,000g and 
P18,000g but very little to SN200,000g and not at all to purified THP (Figure 2). Also, in 
lectin blotting Jacalin did not bind much to SN200,000g however some  bands in P200,000 
were apparent (Figure 5.4). This led us to test whether Jacalin chromatography can be used as 
a simple method to enrich urinary membrane vesicles. This would not require any 
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sophisticated instruments like an ultracentrifuge and would also save the labour of setting up 
tedious density gradient procedures. For such a purpose the method appears to work well. To 
achieve the results we first centrifuged whole human urine (50 mL) at 2000g and supernatant 
(SN2000g) was concentrated (using speed vacuum concentrator to 2-3 mL or Vivaspin 
300kDa MWCO) and used for the chromatography step. We are aware that while using the 
Vivaspin, we might lose some membrane vesicles on the filter surface or entrapped in THP 
polymers sticking to the filter. For removing the interference of THP poylmerisation at this 
step, no buffer was added and whole urine was concentrated. This would minimise the THP 
polymerization. And low speed used in the centrifugation for Vivapsin concentration 
(5000rpm) would mean most vesicles would not pellet down at this speed and remain in 
solution. Introduction of Vivaspin at this step was done to minimise 50mL urine to a 
manageable amount as the resin volume was small (1mL). Centrifugation (2000g) before 
Vivaspin concentration would be expected to get rid of any dead or shed cells which may be 
present in urine.  
It was found that, although Jacalin did not show any binding to THP in FLLA, THP was still 
a major protein in the Jacalin elution. It could be due to the reason that THP polymerises in 
the binding buffer and these polymers interact non-specifically with the agarose beads. THP 
polymerization has been previously reported (SERAFINICESSI et al., 1989). To remove 
contamination of THP, SN2000g was filtered using DEF. DEF removed the majority of THP 
from the urine and non-bound of DEF was applied to chromatography with Jacalin-agarose. 
This removed the problem of THP contamination and enrichment of the membrane vesicles 
marker CD63 was observed in elution fraction compared to non-bound fraction where it was 
almost undetectable. Presence of membrane vesicles in the elution of Jacalin was confirmed 
by centrifuging elution fraction of Jacalin at 200,000g and membrane vesicles/exosomal 
marker CD63 was noticed to be pelleting down at this speed. However, DEF filtration is a 
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lengthy procedure and impractical for clinical settings. Moreover, the DEF filtration method 
relies on polymerization of THP and it has been reported that membrane vesicles are 
entrapped in THP polymers (Fernandez-Llama et al., 2010). This would result in potential 
loss of vesicles during filtration on DEF. We looked at other ways of removing THP 
contamination and it was found that getting rid of the salt from binding buffer (changed from 
HEPES buffer saline to phosphate buffer {pH7.4) solves this problem and THP was not 
found in elution anymore. TSG101 in small amounts was also found in the elution. TEM 
analysis revealed that Jacalin enriches a mixture of vesicles including smaller vesicles (same 
size as exosomes) and bigger microvesicles. This vesicle population might be carrying 
specific glycan epitopes on their surface. In the future a use for this specific fraction of 
membrane vesicles can be found. This method can be performed with inexpensive laboratory 
instruments.  
Finally, 108 glycoproteins were identified in this study including the surface glycoproteins of 
exosomes and microvesicles. IPA analysis revealed that multiple proteins are involved in 
kidney size and morphology maintenance as well as some involved in kidney failure and 
other pathologies. Secretion of such clinically important proteins with membrane vesicles is 
of interest. This suggests the potential clinical application of FLLA method as well as 
glycoprotein enrichment protocols although much further work would be needed for such an 
application. Moreover, a simple method for microvesicle enrichment was also developed 
which does not require expensive instrumentation or specialised skills. 
 
 
 
 
 
 
353 
 
5.6 Reference  
Adachi, J., Kumar, C., Zhang, Y., Olsen, J.V. & Mann, M. (2006), "The human urinary proteome 
contains more than 1500 proteins, including a large proportion of membrane proteins", 
GENOME BIOLOGY, vol. 7, no. 9, pp. R80.  
Alter, M.L., Kretschmer, A., Von Websky, K., Tsuprykov', O., Reichetzeder, C., Simon, A., Stasch, J. 
& Hocher, B. (2012), "Early Urinary and Plasma Biomarkers for Experimental Diabetic 
Nephropathy", CLINICAL LABORATORY, vol. 58, no. 7-8, pp. 659-671.  
Barres, C., Blanc, L., Bette-Bobillo, P., Andre, S., Mamoun, R., Gabius, H. & Vidal, M. (2010), 
"Galectin-5 is bound onto the surface of rat reticulocyte exosomes and modulates vesicle uptake 
by macrophages", BLOOD, vol. 115, no. 3, pp. 696-705.  
Batista, B.S., Eng, W.S., Pilobello, K.T., Hendricks-Munoz, K.D. & Mahal, L.K. (2011), 
"Identification of a Conserved Glycan Signature for Microvesicles", JOURNAL OF PROTEOME 
RESEARCH, vol. 10, no. 10, pp. 4624-4633.  
Bhatia, P. & Mukhopadhyay, A. (1999), "Protein glycosylation: Implications for in vivo functions and 
therapeutic applications", ADVANCES IN BIOCHEMICAL 
ENGINEERING/BIOTECHNOLOGY, vol. 64, pp. 155-201.  
Bourne, Y., Astoul, C., Zamboni, V., Peumans, W., Menu-Bouaouiche, L., Van Damme, E., Barre, A. 
& Rouge, P. (2002), "Structural basis for the unusual carbohydrate-binding specificity of jacalin 
towards galactose and mannose", BIOCHEMICAL JOURNAL, vol. 364, no. Part 1, pp. 173-180.  
Cirio, M.C., Hui, Z., Haldin, C.E., Cosentino, C.C., Stuckenholz, C., Chen, X., Hong, S., Dawid, I.B. 
& Hukriede, N.A. (2011), "Lhx1 Is Required for Specification of the Renal Progenitor Cell 
Field", PLOS ONE, vol. 6, no. 4.  
Dai, Z., Fan, J., Liu, Y., Zhou, J., Bai, D., Tan, C., Guo, K., Zhang, Y., Zhao, Y. & Yang, P. (2007), 
"Identification and analysis of alpha 1,6-fucosylated proteins in human normal liver tissues by a 
target glycoproteomic approach", ELECTROPHORESIS, vol. 28, no. 23, SI, pp. 4382-4391.  
Debray, H., Decout, D., Strecker, G., Spik, G. & Montreuil, J. (1981), "Specificity of Twelve Lectins 
Towards Oligosaccharides and Glycopeptides Related to N-Glycosylproteins", EUROPEAN 
JOURNAL OF BIOCHEMISTRY, vol. 117, no. 1, pp. 41-51.  
Escrevente, C., Keller, S., Altevogt, P. & Costa, J. (2011), "Interaction and uptake of exosomes by 
ovarian cancer cells", BMC CANCER, vol. 11, pp. 108.  
Fernandez-Llama, P., Khositseth, S., Gonzales, P.A., Star, R.A., Pisitkun, T. & Knepper, M.A. 
(2010), "Tamm-Horsfall protein and urinary exosome isolation", JOURNAL OF 
HYPERTENSION, vol. 28, no. A, pp. E164.  
Gabius, H.J. & Gabius, S. (1997), Glycosciences: status and perspectives, Chapman \& Hall.  
Garner, A.E., Smith, D.A. & Hooper, N.M. (2008), "Visualization of detergent solubilization of 
membranes: Implications for the isolation of rafts", BIOPHYSICAL JOURNAL, vol. 94, no. 4, 
pp. 1326-1340.  
354 
 
Halim, A., Nilsson, J., Ruetschi, U., Hesse, C. & Larson, G. (2012), "Human Urinary 
Glycoproteomics; Attachment Site Specific Analysis of N- and O-Linked Glycosylations by CID 
and ECD", MOLECULAR \& CELLULAR PROTEOMICS, vol. 11, no. 4, pp. M111.  
Hao, S., Bai, O., Li, F., Yuan, J., Laferte, S. & Xiang, J. (2007), "Mature dendritic cells pulsed with 
exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity", 
IMMUNOLOGY, vol. 120, no. 1, pp. 90-102.  
Hirokawa, T., Boon-Chieng, S. & Mitaku, S. (1998), "SOSUI: classification and secondary structure 
prediction system for membrane proteins", BIOINFORMATICS, vol. 14, no. 4, pp. 378-379.  
Hsu, K. & Mahal, L.K. (2006), "A lectin microarray approach for the rapid analysis of bacterial 
glycans", NATURE PROTOCOLS, vol. 1, no. 2, pp. 543-549.  
Huet, G., Gouyer, V., Delacour, D., Richet, C., Zanetta, J., Delannoy, P. & Degand, P. (2003), 
"Involvement of glycosylation in the intracellular trafficking of glycoproteins in polarized 
epithelial cells", BIOCHIMIE, vol. 85, no. 3-4, pp. 323-330.  
Kragh-Hansen, U., Donaldson, D. & Jensen, P. (2001), "The glycan structure of albumin Redhill, a 
glycosylated variant of human serum albumin", BIOCHIMICA ET BIOPHYSICA ACTA-
PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, vol. 1550, no. 1, pp. 20-26.  
Krishnamoorthy, L., Bess, J.,Julian W., Preston, A.B., Nagashima, K. & Mahal, L.K. (2009), "HIV-1 
and microvesicles from T cells share a common glycome, arguing for a common origin", 
NATURE CHEMICAL BIOLOGY, vol. 5, no. 4, pp. 244-250.  
Larsen, M.R., Jensen, S.S., Jakobsen, L.A. & Heegaard, N.H.H. (2007), "Exploring the sialiome using 
titanium dioxide chromatography and mass spectrometry", MOLECULAR \& CELLULAR 
PROTEOMICS, vol. 6, no. 10, pp. 1778-1787.  
Liener, I.E., Sharon, N. & Goldstein, I.J. (1986), The Lectins: properties, functions, and applications 
in biology and medicine, Academic Press.  
Masyuk, A.I., Huang, B.Q., Ward, C.J., Gradilone, S.A., Banales, J.M., Masyuk, T.V., Radtke, B., 
Splinter, P.L. & LaRusso, N.F. (2010), "Biliary exosomes influence cholangiocyte regulatory 
mechanisms and proliferation through interaction with primary cilia", AMERICAN JOURNAL 
OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, vol. 299, no. 4, pp. 
G990-G999.  
Mathivanan, S., Fahner, C.J., Reid, G.E. & Simpson, R.J. (2012), "ExoCarta 2012: database of 
exosomal proteins, RNA and lipids", NUCLEIC ACIDS RESEARCH, vol. 40, no. D1, pp. 
D1241-D1244.  
McDonald, C.A., Yang, J.Y., Marathe, V., Yen, T. & Macher, B.A. (2009), "Combining Results from 
Lectin Affinity Chromatography and Glycocapture Approaches Substantially Improves the 
Coverage of the Glycoproteome", MOLECULAR \& CELLULAR PROTEOMICS, vol. 8, no. 2, 
pp. 287-301.  
Mirzaei, H. & Regnier, F. (2007), "Identification of yeast oxidized proteins - Chromatographic top-
down approach for identification of carbonylated, fragmented and cross-linked proteins in yeast", 
JOURNAL OF CHROMATOGRAPHY A, vol. 1141, no. 1, pp. 22-31.  
355 
 
Muinelo-Romay, L., Villar-Portela, S., Cuevas, E., Gil-Martin, E. & Fernandez-Briera, A. (2011), 
"Identification of alpha(1,6) fucosylated proteins differentially expressed in human colorectal 
cancer", BMC CANCER, vol. 11, pp. 508.  
Musante, L., Saraswat, M., Duriez, E., Byrne, B., Ravida, A., Domon, B. & Holthofer, H. (2012), 
"Biochemical and Physical Characterisation of Urinary Nanovesicles following CHAPS 
Treatment", PLOS ONE, vol. 7, no. 7, pp. e37279.  
Nieuwland, R. & Sturk, A. (2010), "Why do cells release vesicles?", THROMBOSIS RESEARCH, vol. 
125, Supplement 1, no. 0, pp. S49.  
Nilsson, J., Ruetschi, U., Halim, A., Hesse, C., Carlsohn, E., Brinkmalm, G. & Larson, G. (2009), 
"Enrichment of glycopeptides for glycan structure and attachment site identification", NATURE 
METHODS, vol. 6, no. 11, pp. 809-U26.  
Nishioka, J., Ning, M., Hayashi, T. & Suzuki, K. (1998), "Protein C inhibitor secreted from activated 
platelets efficiently inhibits activated protein C on phosphatidylethanolamine of platelet 
membrane and microvesicles", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 18, pp. 
11281-11287.  
Pilcibello, K.T., Slawek, D.E. & Mahal, L.K. (2007), "A ratiometric lectin microarray approach to 
analysis of the dynamic mammalian glycome", PROCEEDINGS OF THE NATIONAL 
ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 104, no. 28, pp. 
11534-11539.  
Pisitkun, T., Shen, R. & Knepper, M. (2004), "Identification and proteomic profiling of exosomes in 
human urine", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE 
UNITED STATES OF AMERICA, vol. 101, no. 36, pp. 13368-13373.  
Pisitkun, T., Johnstone, R. & Knepper, M.A. (2006), "Discovery of urinary biomarkers", 
MOLECULAR \& CELLULAR PROTEOMICS, vol. 5, no. 10, pp. 1760-1771.  
Reiter, R., Gu, Z., Watabe, T., Thomas, G., Szigeti, K., Davis, E., Wahl, M., Nisitani, S., Yamashiro, 
J., Le Beau, M., Loda, M. & Witte, O. (1998), "Prostate stem cell antigen: A cell surface marker 
overexpressed in prostate cancer", PROCEEDINGS OF THE NATIONAL ACADEMY OF 
SCIENCES OF THE UNITED STATES OF AMERICA, vol. 95, no. 4, pp. 1735-1740.  
Serafinicessi, F., Bellabarba, G., Malagolini, N. & Dallolio, F. (1989), "Rapid isolation of Tamm-
Horsfall glycoprotein (uromodulin) from human-urine", JOURNAL OF IMMUNOLOGICAL 
METHODS, vol. 120, no. 2, pp. 185-189.  
Shipp, M. & Look, A. (1993), "Hematopoietic differentiation antigens that are membrane-associated 
enzymes - cutting is the key", BLOOD, vol. 82, no. 4, pp. 1052-1070.  
Tomino, Y., Inoue, W., Watanabe, S., Yagame, M., Eguchi, K., Nomoto, Y. & Sakai, H. (1988), 
"Detection of glomerular sialic acids in patients with diabetic nephropathy", AMERICAN 
JOURNAL OF NEPHROLOGY, vol. 8, no. 1, pp. 21-26.  
Turner, B., Razick, S., Turinsky, A.L., Vlasblom, J., Crowdy, E.K., Cho, E., Morrison, K., 
Donaldson, I.M. & Wodak, S.J. (2010), "iRefWeb: interactive analysis of consolidated protein 
interaction data and their supporting evidence", DATABASE-THE JOURNAL OF BIOLOGICAL 
DATABASES AND CURATION, vol. 2010, pp. baq023.  
356 
 
Ueno, T., Linder, S., Na, C., Rice, W., Johansson, J. & Weaver, T. (2004), "Processing of pulmonary 
surfactant protein B by napsin and cathepsin H", JOURNAL OF BIOLOGICAL CHEMISTRY, 
vol. 279, no. 16, pp. 16178-16184.  
Vella, L.J., Sharples, R.A., Lawson, V.A., Masters, C.L., Cappai, R. & Hill, A.F. (2007), "Packaging 
of prions into exosomes is associated with a novel pathway of PrP processing", JOURNAL OF 
PATHOLOGY, vol. 211, no. 5, pp. 582-590.  
Wang, L., Li, F., Sun, W., Wu, S., Wang, X., Zhang, L., Zheng, D., Wang, J. & Gao, Y. (2006), 
"Concanavalin A-captured glycoproteins in healthy human urine", MOLECULAR \& 
CELLULAR PROTEOMICS, vol. 5, no. 3, pp. 560-562.  
Wang, Y., Hare, T., Won, B., Stowell, C., Scanlin, T., Glick, M., Hard, K., Vankuik, J. & 
Vliegenthart, J. (1990), "Additional fucosyl residues on membrane-glycoproteins but not a 
secreted glycoprotein from cystic-fibrosis fibroblasts", CLINICA CHIMICA ACTA, vol. 188, no. 
3, pp. 193-210.  
Wang, Z., Hill, S., Luther, J.M., Hachey, D.L. & Schey, K.L. (2011), "Proteomic analysis of urine 
exosomes by multidimensional protein identification technology (MudPIT)", PROTEOMICS, 
vol. 12, no. 2, pp. 329-338.  
Wu, T., Hsieh, S., Li, K., Wu, C., Yu, C., Yang, A. & Tsai, C. (2008), "Altered glycosylation of 
Tamm-Horsfall glycoprotein derived from renal allograft recipients leads to changes in its 
biological function", TRANSPLANT IMMUNOLOGY, vol. 18, no. 3, pp. 237-245.  
Yang, D., Rosenberg, H., Chen, Q., Dyer, K., Kurosaka, K. & Oppenheim, J. (2003), "Eosinophil-
derived neurotoxin (EDN), an antimicrobial protein with chemotactic activities for dendritic 
cells", BLOOD, vol. 102, no. 9, pp. 3396-3403.  
Yaylayan, V. (2003), "Recent advances in the chemistry of Strecker degradation and Amadori 
rearrangement: Implications to aroma and color formation", FOOD SCIENCE AND 
TECHNOLOGY RESEARCH, vol. 9, no. 1, pp. 1-6.  
Zhang, Q., Tang, N., Brock, J.W.C., Mottaz, H.M., Ames, J.M., Baynes, J.W., Smith, R.D. & Metz, 
T.O. (2007), "Enrichment and analysis of nonenzymatically glycated peptides: Boronate affinity 
chromatography coupled with electron-transfer dissociation mass spectrometry", JOURNAL OF 
PROTEOME RESEARCH, vol. 6, no. 6, pp. 2323-2330.  
 
 
 
357 
 
 
 
 
CHAPTER 6 
Purification and identification of 
palmitoylated proteins in human 
urinary membrane vesicles 
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6.1 Introduction 
Post-translational modification (PTM) of proteins can dictate their localization or function or 
both (Walsh, Garneau-Tsodikova & Gatto, 2005). Lipidation of cysteine residues has 
emerged as previously less appreciated but recently found to be a widespread PTM. 
Arguably, the most widespread of the lipidation PTM is palmitoylation of specific cysteine 
residues. This requires C16 fatty-acyl CoA as donors for acyltransferases which transfer the 
C16 to the Cys residue (S-palmitoylation)  (Bijlmakers & Marsh, 2003). The identity of 
enzymes responsible for S-palmitoylation has not been fully defined in contrast to the N-
myristoylation machinery. Non-enzyme dependent palmitoylation has also been found. 
Palmitoylated proteins such as Src family kinases, eNOS and Gα subunits have also been 
observed to be enriched in caveolae (Shenoyscaria et al., 1994; Robbins, Quintrell & Bishop, 
1995). It was recently shown that blocking the protein palmitoylation in a murine model of 
vascular injury results in inhibition of platelet aggregation and decreased incorporation into 
thrombi (Sim, Dilks & Flaumenhaft, 2007). Following this study, 215 proteins were 
identified in another study as candidate palmitoylated proteins in platelets and 51 of them 
were previously known while 103 were new putative palmitoylated proteins (Dowal et al., 
2011). Realising the importance of this PTM, several studies on various cell and tissue types 
have been conducted and hundreds of palmitoylated proteins have been identified (Kang et 
al., 2008; Yang et al., 2010; Dowal et al., 2011; Martin et al., 2012). A picture which has 
emerged for roles of S-palmitoylation is that it can influence and regulate the localisation of 
modified proteins (membrane tethering or lipid raft targetting) and therefore affect their 
function spatially. Moreover palmitoylation can be reversible and dynamic (Kang et al., 
2008) therefore can affect protein’s functions and temporal signal transmission as well.  
It has previously been shown that plasma membrane association can target a highly 
oligomerized cytoplasmic protein to endosome-like domains and into the membrane vesicles 
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like exosomes and microvesicles (Fang et al., 2007). This targeting is independent of class E 
vacuolar protein sorting (VPS) pathways of sorting cargo to multivesicular body (MVB). 
Building on this study it was recently found that plasma membrane anchors like, N-
myristoylation and S-palmitoylation, can target oligomeric proteins to the site of vesicle 
budding and into the exosomes and microvesicles (Shen et al., 2011). The biogenesis of 
MVB and the mechanism of protein sorting to the exosomes/microvesicles are incompletely 
understood. Therefore, we proposed to identify the S-palmitoylated proteins present in 
exosomes isolated from the urine of healthy individuals using traditional ultracentrifugation 
based method. This will help increase our understanding of the protein sorting into these 
exosomes and shed light on the acylome of exosome/microvesicles. For enrichment of S-
palmitoylated proteins we have used the biotin-acyl exchange method which has proven very 
effective in the recent past for identifying palmitoylated proteins (Kang et al., 2008). 
Following purification/enrichment we have identified all the proteins using MudPIT analysis. 
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6.2 Materials and methods 
6.2.1 Exosome/microvesicle isolation from human urine 
Exosomal fraction from urine was purified as described in methods section of Chapter 2. 
Crude P200,000g pellet was used here as  starting  material. 
6.2.2 Biotin-acyl exchange method for enrichment of S-palmitoylated proteins 
All materials, unless specified otherwise were purchased from Sigma Chemical Company, St. 
Louis, MO, USA. For acyl-biotinyl exchange a previously published protocol was followed 
(Roth et al., 2006) with some modifications. Briefly, P200,000g (2mg) extract (prepared by 
incubating with 1% beta-octylglucoside overnight at +4°C) was adjusted to buffer A (Tris 
50mM pH 7.4, 5mM EDTA 4% SDS) and 2mM N-ethyl maleimide (NEM)  was added 
followed by the incubation at +4°C with rotation. The following day, sample was dialysed 
(MWCO 3500 Da) to remove the NEM. Then 1M hydroxylamine (HA) was added with 1mM 
N-[6- (Biotinamido)hexyl]-3'- (2'-pyridyldithio)propionamide biotin (HPDP-biotin) and 
incubated for 1 hour at +25°C (HA+ fraction). For the minus hydroxylamine fraction (HA- 
fraction) same volume of Tris 50mM pH 7.4 was added instead of HA. HA was removed 
from HA+ fraction by dialysis and samples were adjusted to buffer A with 1mM HPDP-
biotin and incubated at +25°C for 1 hour. HPDP-biotin was removed by dialysis (MWCO 
3500 Da). Samples were adjusted to tris pH7.4 and incubated with 100ul streptavididn 
agarose at +25°C for 90 Minutes. Non-bound proteins were removed by washing with tris 
buffer (50mM, pH7.4) 4 times and finally bound proteins were eluted by incubating the resin 
with 1% (v/v) beta-mercaptoethanol at 37C for 20 minutes. Eluate was dialysed (MWCO 
3500 Da) to remove beta-mercaptoethanol and converted to a dry pellet using speed-vacuum 
centrifugation. 
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6.2.3 SDS-PAGE 
SDS-PAGE was carried out as described in methods section of Chapter 2. The gels were 
stained with silver staining for protein detection, as previously described (Shevchenko et al., 
1996). 
6.2.4 Bioinformatic analysis and Gene ontology 
The HA+ protein list was analysed with IPA software (Ingenuity systems, Redwood city, 
CA.) and DAVID Bioinformatics resources 6.7 (Huang, Sherman & Lempicki, 2009a; 
Huang, Sherman & Lempicki, 2009b) (NIH, USA). The graph for biological processes was 
generated with Blast2Go software (Conesa et al., 2005). The CSS PALM 3.0 server 
(http://csspalm.biocuckoo.org/online.php) was used for high stringent prediction of 
palmitoylation of given proteins (Ren et al., 2008). 
6.2.5 LC-MS/MS analysis 
It was carried out as described in the methods section of Chapter 5.  
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6.3 Results 
6.3.1 Purification of S-palmitoylated proteins 
The membrane vesicle pellet (P200,000g) was obtained as described in Chapter 2. This pellet, 
which is enriched in exosomal markers and contains mainly 40-100 nm vesicles (Chapter 2 
Figure 2.2), was used for this study. The acyl-biotin exchange method was used for enriching 
the palmitoylated proteins from membrane vesicle fractions. This method is schematically 
presented in Figure 6.1.  
 
 
Figure 6.1: Schematic representation for purification of palmitoylated proteins using acyl-
biotin exchange chemistry. 
After blocking the free thiol groups of cysteine which may be present in the sample, HA was 
used to cleave the thioester bond of Cys-palmitate. This newly generated free thiol was then 
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biotinylated with HPDP-biotin. Two mg of total protein was divided into two parts and 
processed in parallell. One was treated with HA and the other was just incubated in buffer 
without HA. These two samples HA+ and HA- were then enriched with streptavidin-agarose 
following biotinylation. HPDP-biotin can be cleaved with reducing agents. Therefore, β-
mercaptoethanol was used for eluting the proteins bound to streptavidin-agarose.  This 
method yields a complex mixture of proteins in both the samples as shown in Figure 6.2.  
 
Figure 6.2: SDS-PAGE (T, 10%) of HA+ and HA- fractions enriched by acyl-biotin 
exchange method. 1: HA- 2. HA+ M. Molecular weight marker (in kDa). 
However, the pattern looks similar but there is a visible enrichment of multiple proteins in 
HA+ fraction. Proteins in both the samples were identified by in solution LC-MS/MS.  
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6.3.2 Protein identification by LC-MS/MS 
Excluding keratins, hundred and seventy two (172) proteins were identified in HA+ fraction 
(Supplementary Table 6.1) while 57 proteins were identified in HA- fraction (Supplementary 
Table 6.2). Out of this, 128 proteins were unique to HA+ fraction and 13 were unique to HA- 
fraction while 44 proteins were common (Figure 6.3).  
 
Figure 6.3: Comparison of proteins identified in the fraction HA+ vs HA-. 
The HA- fraction is mainly composed of contaminant proteins getting enriched non-
specifically and/or endogenously biotinylated proteins. These 128 unique proteins in HA+ 
fraction were taken as candidate palmitoylated proteins for further analysis. These 128 
proteins will be referred to as HA+ proteins from here on. Sequences of these proteins were 
retrieved from Batch retrieval-Uniprot service (http://www.uniprot.org/) and submitted to 
CSS Palm 3.0 web server (Ren et al., 2008) (http://csspalm.biocuckoo.org/online.php) which 
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predicts the potential palmitoylated proteins. The threshold was set to high which returned 78 
potentially palmitoylated proteins. These proteins are listed in Supplementary Table 6.A.  
6.3.3 Comparison with previous studies 
There have been a number of studies identifying candidate palmitoylated proteins (High and 
medium confidence) on various tissue and cell-line types. Proteins from yeast, human 
platelets, rat neurons and DU145 cell lines have been identified (Roth et al., 2006; Kang et 
al., 2008; Yang et al., 2010; Dowal et al., 2011; Martin et al., 2012). Table 6.1 presents 12 
proteins from our dataset which have previously been identified as palmitoylated proteins. 
These 12 proteins were part of 78 proteins predicted by CSS Palm3.0 to be palmitoylated. 
These include a number of RAS family members, stomatin and tetraspanin CD9. 
Table 6.1: The known palmitoylated proteins (platelet palm and S-acylation MCP) identified 
in our study. Sub-cellular location, function or type of molecule and biomarker applications 
(IPA, Ingenuity systems), if any, are indicated.  
Serial 
No 
Uniprot 
Accession 
Symbol Entrez 
gene 
name 
Location Functio
n/type 
Biomark
er 
applicati
on 
Reference for 
Biormaker 
Referen
ce 
1 P04746 AMY2A Amylase, 
alpha 2A 
(Pancreat
ic) 
Extra-
cellular 
space 
Enzym
e 
N/A N/A Human 
Platelet 
(Dowal 
et al., 
2011)  
2 Q13510 ASAH1 N-
acylsphin
gosine 
amidohy
drolase 
(acid 
ceramida
se) 1 
Cytoplasm Enzym
e 
Diagnosi
s, Cancer 
http://www.iq
ac.csic.es/ima
ges/stories/IQ
AC-
KT/leaflet%2
0im_002.pdf 
Human 
Platelet 
(Dowal 
et al., 
2011), 
DU145 
cells 
(Yang et 
al., 
2010)  
3 P15291 B4GALT
1 
UDP-
GAL:Bet
aGlcNAc 
beta 1,4 
galactosy
ltransfera
se, 
Cytoplasm Enzym
e 
Diagnosi
s, Cancer 
IPA, 
Ingenuity 
DU145 
cells, 
human 
(Yang et 
al., 
2010) 
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polypepti
de 1 
4 P21926 CD9 CD9 
molecule 
Plasma 
membrane 
Other Efficacy, 
GEFITI
NIB 
IPA, 
Ingenuity 
DU145 
cells, 
human 
(Yang et 
al., 
2010) 
5 P25325 MPST Mercapto
pyruvate 
sulfurtran
sferase 
Cytoplasm Enzym
e 
N/A N/A  (Martin 
et al., 
2012) 
6 P60900 PSMA6 Proteaso
me 
(prosome
, 
macropai
n) 
subunit, 
alpha 
type, 6 
Cytoplasm Peptida
se 
N/A N/A DU145 
cells, 
human 
(Yang et 
al., 
2010) 
7 P61026 RAB10 RAB10, 
member 
RAS 
oncogene 
family 
Cytoplasm Enzym
e 
N/A N/A DU145 
cells, 
human 
(Yang et 
al., 
2010) 
8 Q9NRW1 RAB6B RAB6B, 
member 
RAS 
oncogene 
family 
Cytoplasm Enzym
e 
N/A N/A DU145 
cells, 
human 
(Yang et 
al., 
2010) 
9 P62979 RPS27A Ribosom
al protein 
S27a 
Cytoplasm Enzym
e 
N/A N/A DU145 
cells, 
human 
(Yang et 
al., 
2010) 
10 P62070 RRAS2 Related 
RAS 
viral (r-
ras) 
oncogene 
homolog 
2 
Plasma 
membrane 
Enzym
e 
N/A N/A BW514
7-
derived 
mouse 
T-cell 
hybrido
ma 
(Martin 
et al., 
2012) 
 
11 P27105 STOM Stomatin Plasma 
membrane 
Other N/A N/A Human 
Platelet 
(Dowal 
et al., 
2011), 
DU145 
cells 
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(Yang et 
al., 
2010)  
12 P27348 YWHAQ Tyrosine 
3-
monooxe
genase/tr
yptophan 
5-
monooxe
genase 
activatio
n protein, 
theta 
Cytoplasm Other N/A N/A Human 
Platelet 
(Dowal 
et al., 
2011), 
DU145 
cells 
(Yang et 
al., 
2010)  
 
Most of these proteins’s subcellular location is cytoplasm while stomatin and RRAS2 localise 
to plasma membrane. It is to be noted that most of the known palmitoylated proteins fall into 
the enzyme category which is expected because membrane localization is essential for correct 
functions of many enzymes. ASAH1 activity and B4GALT1 expression has previously been 
used as a biomarker for diagnosis of various types of cancers. CD9 has been used as a 
biomarker for efficacy of Gefitinib which is a selective inhibitor of epidermal growth factor 
receptor’s tyrosine kinase domain. This drug has been developed for non-small cell lung 
cancer. CD9, a tetraspanin, is an exosomal marker proteins and in a previous study it has 
been shown that palmitoylation of CD9 was not necessary for its sorting into exosomes in 
vitro (Abache et al., 2007). It suggests another mechanism is at play for CD9 sorting into 
exosomes. 
Other than these 12 known palmitoylated proteins, 66 proteins from our dataset were also 
predicted to be palmitoylated by CSS PALM 3.0. These proteins were classified by SOSUI 
web server (Hirokawa, Boon-Chieng & Mitaku, 1998) and 28 proteins (42%) were found to 
be membrane proteins. Some of these transmembrane proteins are presented in Table 6.2 
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Table 6.2: Transmembrane proteins found in candidate palmitoylated proteins from our 
dataset. These proteins were predicted to be palmitoylated by CSS PALM 3.0. Uniprot 
accession, gene name and number of transmembrane domains are indicated in the table. 
Uniprot 
accession 
Gene/Protein Name Transmembrane 
domains 
Q15375 Ephrin type-A receptor 7 2 
Q9NZH0 G-protein coupled receptor family C group 5 member B 7 
Q9NQ84 G-protein coupled receptor family C group 5 member C 8 
Q969X1 Protein lifeguard 3 7 
Q13621 Solute carrier family 12 member 1 11 
P22732 Solute carrier family 2, facilitated glucose transporter member 
5 
6 
Q92673 Sortilin-related receptor 2 
O60635 Tetraspanin-1 5 
O75264 Transmembrane protein C19orf77 2 
O00322 Uroplakin-1a 4 
 
Palmitoylation sites are frequently found in cytoplasmic regions flanking transmembrane 
domains or within these domains (Salaun, Greaves & Chamberlain, 2010). Among the 
transmembrane proteins present in our dataset there are two G-protein coupled receptors, 
GPRC5B and GPRC5C. These GPCRs have not been reported to be palmitoylated in the 
literature. However, palmitoylation of GPCR and their cognate G-proteins has emerged as a 
general feature of this family of proteins and multiple GPCRs are already known to be 
palmitoylated (Qanbar & Bouvier 2003; Zheng et al., 2012) and the list is growing by the 
day. GPRC5B and GPRC5C identified in our dataset are potential candidates for 
palmitoylation among other candidate proteins. 
HA+ proteins were also compared to Exocarta database (Mathivanan et al., 2012) and 
previous published studies on urinary exosomes and exosome-like vesicles ( (Pisitkun, Shen 
& Knepper, 2004; Gonzales et al., 2009; Hogan et al., 2009; Wang et al., 2011) Knepper, 
Hogan, Wang). As biotin-acyl exchange is an enrichment method for palmitoylated proteins 
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it might lead to identification of some low-abundance proteins which are part of exosomes 
but not otherwise identified in other studies because of the abundant proteins. All protein 
identifiers were converted to Unigene identifiers to facilitate the comparison.  
 
 
Figure 6.4: Our protein list from Chapter 2 (CP200) and other studies on membrane vesicles 
(Knepper, Hogan and Wang (Pisitkun, Shen & Knepper, 2004; Gonzales et al., 2009; Hogan 
et al., 2009; Wang et al., 2011)) were compared to proteins Unique to HA+ fraction. Unigene 
identifiers were used for all of these studies.  
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Nine proteins were found to be unique to our dataset which were subsequently compared with 
Exocarta (Mathivanan et al., 2012), the biggest database for membrane vesicle proteins and 
mRNA. Three proteins were returned which are unique to our analysis. These proteins 
include plasma membrane proteins like EPH receptor A7 and Copine-9 and are shown in 
Table 6.3. They could potentially be a part of exosomes and exosome-like vesicles. 
Table 6.3: Some of the proteins identified for the first time as being part of exosomes. Gene 
name for the proteins, presence in HA+ or HA- fraction, sub-cellular location, Mascot score 
of their identification and number of protein matches are indicated in the table.  
Uniprot 
accession 
Gene Name Found in 
fraction 
Sub-
cellular 
location 
Mascot 
score 
Protein 
Matches 
Q8IYJ1 Copine-9 HA+ only Plasma 
membrane 
40 1 
Q9UBR2 Cathepsin Z HA+ only Extracellular 
space 
60 1 
Q15375 EPH receptor A7 HA+ only Plasma 
membrane 
86 1 
 
6.3.4 Bioinformatic analysis and gene ontology 
IPA software from Ingenuity systems, DAVID bioinformatics resources (Huang, Sherman & 
Lempicki, 2009a; Huang, Sherman & Lempicki, 2009b) (NIH, USA) and Blast2Go software 
(Conesa et al., 2005) were used for detailed bioinfomatic analysis of the HA+ proteins. An 
annotated list from IPA software produced 111mapped Ids, classified according to their sub-
cellular location and function/type. From this data figures were generated using MS Excel for 
the percentage of proteins localised to various sub-cellular compartments or their functional 
category. Figure 6.5 presents proteins classified according to their sub-cellular localisation. 
371 
 
 
Figure 6.5: Sub-cellular localisation of proteins unique to HA+ fraction. The annotation was 
done with IPA software from Ingenuity systems, USA. 
The biggest category in localisation is cytoplasmic proteins forming 44% of the total 
palmitoyled candidate proteins. This is expected as many cytoplasmic proteins are 
palmitoyled sub-cellularly which changes their location to the membrane where they exert 
their functions (Shenoyscaria et al., 1994). The cytoplasmic proteins are over-represented in 
HA+ fraction compared to total proteome. The next biggest category is extracellular space 
followed by plasma membrane proteins.  Only two nuclear proteins, cofillin-2 and nuclear 
transport factor 2 were identified and 6 proteins were classified as of unknown location. Four 
of these proteins of unknown location are annotated by Uniprot as membrane proteins or 
involved in membrane trafficking (Copine family member IX, Matrix-remodeling-associated 
protein 8, Chromosome 19 open reading frame 77 and Tetraspanin 1) while one is a 
cytoplasmic protein (5'-nucleotidase, cytosolic III-like) and another being signalling protein 
of unknown location (POTE ankyrin domain family, member I).  
Cytoplasm 
Extracellular Space 
Plasma membrane 
Nucleus  
Unknown  
44 
27 
22 
2 
5 
38 
36 
23 
2 
1 
GeneOntology: Sub-cellular location 
CP200 total proteome HA+ Unique 
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Figure 6.6: Protiens unique to HA+ fraction classified according to molecular function. The 
annotation was done with IPA software from Ingenuity systems, USA.  
On classifying the HA+ proteins by molecular function/type (Figure 6.6) the biggest category 
is enzymes (33%). This trend of discovering enzymes as being palmitoylated has been seen in 
previous studies as well. The trafficking of enzyme to membrane domains where their 
activities are needed for normal cell signalling is important and palmitoylation is one of the 
signals for membrane localisation (Shenoyscaria et al., 1994). When compared to total 
proteins, the enzyme category is over-represented in HA+ fraction. Proteases and protease 
inhibitors form another 18% of the list while G-protein coupled receptors (GPRC5B and 
GPRC5C) and kinases, including pyruvate kinase, are also present.  
Enzyme 
Peptidase 
Transporter 
Peptidase inhibitor 
G-protein coupled receptor 
Growth factor 
Kinase  
Transmembrane receptor 
Other  
33 
14 
10 
4 
2 
2 
2 
1 
32 
25 
12 
10 
1 
1 
1 
2 
44 
Gene ontology: Molecular function 
CP200 total proteome HA+ Unique 
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Figure 6.7: Blast2Go software was used to annotate proteins according to the biological 
processes they are involved in. The ‘cut-off’ was kept at 10 sequences and only those 
categories having at least 10 proteins in it were considered. 
Blast2Go software was used for classifying proteins according to the biological processes 
they are involved in (Figure 6.7). The biggest categories involving multiple proteins were 
signalling, cellular response to stimulus and its regulation and metabolic processes. 
Palmitoylation seems to selectively target proteins involved in cell signalling and regulation. 
DAVID bioniformatics resources found some proteins in the HA+ fraction which are 
transporters of proteins and small molecules. These proteins are listed in Table 6.4.  
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Table  6.4:  Proteins annotated by DAVID as being involved in protein and small molecules 
transport. 
ID Gene Name 
P54920 N-ethylmaleimide-sensitive factor attachment protein, alpha 
P61026 RAB10, member RAS oncogene family 
P59190 RAB15, member RAS onocogene family 
Q9H082 RAB33B, member RAS oncogene family 
Q9NRW1 RAB6B, member RAS oncogene family 
P00450 ceruloplasmin (ferroxidase) 
P68871 hemoglobin, beta 
P02790 Hemopexin 
P02649 hypothetical LOC100129500; apolipoprotein E 
P61970 nuclear transport factor 2 
Q8WUM4 programmed cell death 6 interacting protein 
P41222 prostaglandin D2 synthase, hematopoietic; prostaglandin D2 synthase 21kDa (brain) 
Q13621 solute carrier family 12 (sodium/potassium/chloride transporters), member 1 
P22732 solute carrier family 2 (facilitated glucose/fructose transporter), member 5 
Q92673 sortilin-related receptor, L (DLR class) A repeats-containing 
Q9UK41 vacuolar protein sorting 28 homolog (S. cerevisiae) 
Q9UN37 vacuolar protein sorting 4 homolog A (S. cerevisiae) 
 
Among these transport proteins RAB10 and RAB6B are already known to be palimotylated 
(Yang et al., 2010) while RAB15 and RAB33B are very promising candidates. This class 
also includes programmed cell death 6 interacting proteins (Alix) and VPS family proteins 
which are members of endosomal sorting complex required for transport (ESCRT) that is 
involved in sorting proteins into exosomes (Babst et al., 2002a; Babst et al., 2002b; 
Katzmann, Babst & Emr, 2001).  
For further analysis of HA+ proteins, IPA was used in biomarker analysis and 29 proteins 
were returned among the list which has been used as biomarkers of various diseases (Table 
6.5). Different types of cancers and cardiovascular diseases were among the top diseases in 
which these biomarkers are used. 
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Table 6.5: IPA software was used for biomarker analysis of the HA+ proteins. These 
biomarkers are listed according to their applications. 
Symbol Entrez Gene Name Drug (s) GenPept
/UniProt
/Swiss-
Prot 
Accessi
on 
Plas
ma/S
erum 
Ur
ine 
Biomarker 
Application 
(s) 
ACE angiotensin I converting 
enzyme (peptidyl-
dipeptidase A) 1 
pentopril, perindoprilat, 
amlodipine/benazepril, 
lisinopril/hydrochlorothi
azide, benazepril, 
enalapril, perindopril, 
captopril, 
enalapril/felodipine, 
hydrochlorothiazide/mo
exipril, 
benazepril/hydrochlorot
hiazide, 
hydrochlorothiazide/qui
napril, 
fosinopril/hydrochloroth
iazide, 
captopril/hydrochlorothi
azide, 
enalapril/hydrochlorothi
azide, ramipril, 
moexipril, quinapril, 
lisinopril, enalaprilat, 
trandolapril, 
trandolapril/verapamil, 
diltiazem/enalapril, 
fosinopril 
P12821 X x Diagnosis,
Efficacy,Pr
ognosis,Saf
ety 
AGT angiotensinogen (serpin 
peptidase inhibitor, 
clade A, member 8) 
  P01019 X X Efficacy 
ANXA
1 
annexin A1   P04083 X X Diagnosis,
Prognosis,
Unspecifie
d 
Application 
ANXA
5 
annexin A5   P08758 X X Diagnosis 
APOE apolipoprotein E   P02649 X X Diagnosis,
Efficacy,Pr
ognosis,Un
specified 
Application 
B4GAL
T1 
UDP-Gal:betaGlcNAc 
beta 1,4- 
galactosyltransferase, 
  P15291   X Diagnosis 
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polypeptide 1 
CD9 CD9 molecule   P21926   X Efficacy 
CLU Clusterin   P10909 X x Diagnosis,
Efficacy,U
nspecified 
Application 
CP ceruloplasmin 
(ferroxidase) 
  P00450 X X Disease 
Progression
,Efficacy 
CTSD cathepsin D   P07339 X X Diagnosis,
Unspecifie
d 
Application 
DPP4 dipeptidyl-peptidase 4 saxagliptin, talabostat, 
SYR-322, sitagliptin, 
linagliptin, 
metformin/saxagliptin, 
simvastatin/sitagliptin, 
metformin/sitagliptin, 
linagliptin/metformin 
P27487 X X Prognosis 
EZR Ezrin   P15311 X X Prognosis 
FGA fibrinogen alpha chain F2 P02671 X X Diagnosis 
FUCA1 fucosidase, alpha-L- 1, 
tissue 
  P04066   X Diagnosis 
GSN Gelsolin   P06396 X X Disease 
Progression
,Efficacy 
GSTM3 glutathione S-
transferase mu 3 (brain) 
  P21266 X X Diagnosis,
Disease 
Progression
,Prognosis 
GSTP1 glutathione S-
transferase pi 1 
  P09211 X X Diagnosis,
Efficacy,Pr
ognosis,Re
sponse to 
Therapy,Sa
fety,Unspe
cified 
Application 
HSPB1 heat shock 27kDa 
protein 1 
  P04792   X Diagnosis 
KLK3 kallikrein-related 
peptidase 3 
  P07288 X X Diagnosis,
Disease 
Progression
,Efficacy,S
afety,Unsp
ecified 
Application 
LGALS
3BP 
lectin, galactoside-
binding, soluble, 3 
binding protein 
  Q08380 X x Prognosis 
MME membrane metallo-
endopeptidase 
  P08473   X Diagnosis,
Efficacy,U
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nspecified 
Application 
PKM2 pyruvate kinase, muscle   P14618 X X Diagnosis,
Unspecifie
d 
Application 
PLAU plasminogen activator, 
urokinase 
  P00749 X X Disease 
Progression
,Efficacy,P
rognosis,Re
sponse to 
Therapy 
PRDX1 peroxiredoxin 1   Q06830 X X Diagnosis 
PTGDS prostaglandin D2 
synthase 21kDa (brain) 
  P41222 X X Efficacy 
SERPI
NA1 
serpin peptidase 
inhibitor, clade A 
(alpha-1 antiproteinase, 
antitrypsin), member 1 
  P01009 X X Diagnosis,
Disease 
Progression
,Unspecifie
d 
Application 
THBS1 thrombospondin 1   P07996 X X Diagnosis,
Efficacy,Pr
ognosis 
TPI1 triosephosphate 
isomerase 1 
  P60174 X X Diagnosis,
Unspecifie
d 
Application 
YWHA
Z 
tyrosine 3-
monooxygenase/tryptop
han 5-monooxygenase 
activation protein, zeta 
polypeptide 
  P63104   X Diagnosis 
 
Renal toxicity analysis was also carried out and multiple proteins involved in renal failure 
and renal injury etc. were found. These proteins and the diseases they are involved in are 
listed in Table 6.6. 
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Table 6.6: Toxicity function analysis of HA+ proteins by IPA software. Various diseases and 
the proteins involved in these diseases are listed along with p-value for their enrichment. 
Category Functions Annotation p-Value Molecules 
Glomerular Injury Glomerulosclerosis 1.54E-03 AGT,APOE,CLU,GAS6 
Glomerular Injury lipoprotein 
glomerulopathy 
6.71E-03 APOE 
Glomerular Injury renal fibrosis 8.39E-02 AGT 
Glomerular Injury focal segmental 
glomerulosclerosis 
1.02E-01 CLU 
Increased Levels of 
Albumin 
increases flux of albumin 1.34E-02 THBS1 
Increased Levels of 
Albumin 
increases excretion of 
albumin 
3.31E-02 AGT 
Increased Levels of 
Creatinine 
increases clearance of 
creatinine 
9.00E-02 AGT 
Increased Levels of 
Creatinine 
increases quantity of 
creatinine 
1.66E-01 AGT 
Increased Levels of 
Potassium 
increases quantity of K+ 6.51E-02 SLC12A1 
Increased Levels of 
Potassium 
increases excretion of K+ 9.61E-02 AGT 
Kidney Failure renal failure 6.98E-05 ACE,AGT,AMY2A,GSTP1,PTG
DS,SLC12A1,THBS1 
Kidney Failure acute renal failure 2.25E-03 ACE,GSTP1,SLC12A1 
Kidney Failure failure of kidney 3.23E-02 AGT,SLC12A1 
Kidney Failure end stage renal disease 9.86E-02 ACE,AGT 
Kidney Failure tubulo-interstitial fibrosis 2.36E-01 AGT 
Nephrosis minimal change nephrotic 
syndrome 
5.88E-02 CLU 
Renal Atrophy atrophy of kidney 3.58E-04 ACE,AGT,EFEMP1 
Renal Damage damage of 
tubulointerstitium 
3.32E-03 ACE,APOE 
Renal Damage damage of kidney 3.40E-03 ACE,AGT,HPX,THBS1 
Renal Damage injury of kidney 6.88E-02 AGT,THBS1 
Renal Damage injury of renal glomerulus 9.00E-02 AGT 
Renal Damage reperfusion injury of 
kidney 
1.02E-01 THBS1 
Renal Damage damage of renal tubule 1.44E-01 THBS1 
Renal Degeneration degeneration of kidney 7.14E-02 CLU 
Renal Dilation vasodilation of kidney 1.34E-02 AGT 
Renal Dysfunction dysfunction of kidney 1.08E-01 AGT 
Renal Necrosis/Cell 
Death 
cell death of kidney cells 1.70E-03 AGT,APOE,CLU,GSTP1,HSPB
1,PTGDS,VTN,YWHAQ 
Renal Necrosis/Cell 
Death 
cell death of kidney cell 
lines 
1.18E-02 AGT,GSTP1,HSPB1,PTGDS,V
TN,YWHAQ 
Renal Necrosis/Cell 
Death 
necrosis of renal 
glomerulus 
2.00E-02 PLAU 
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Renal Nephritis membranous 
glomerulonephritis 
9.00E-02 CLU 
Renal Nephritis focal glomerulonephritis 9.61E-02 ACE 
Renal Nephritis Nephritis 1.04E-01 ACE,AGT,APCS,CLU 
Renal Nephritis Glomerulonephritis 1.64E-01 ACE,APCS,CLU 
Renal Tubule Injury proximal tubular toxicity 3.75E-05 CP,FGA,FGB (includes 
EG:110135),GSTP1,HPX,HSPB
1 
Renal Tubule Injury damage of 
tubulointerstitium 
3.32E-03 ACE,APOE 
Renal Tubule Injury damage of renal tubule 1.44E-01 THBS1 
 
These proteins listed in Table 6.6 are involved in signalling processes in various kidney 
pathologies. These would make good drug targets and biomarker candidates for these 
diseases. Another interesting analysis carried out by IPA was finding the upstream regulators 
of HA+ proteins. This will likely shed light on what pathways these proteins are involved in. 
These upstream regulators are GPCRs, growth factors and cytokines among others. Selected 
parts of this analysis are presented in table 6.7. 
Table 6.7: Upstream regulators of the HA+ proteins. Multiple proteins are regulated by these 
regulators listed in column 1.  
Upstream 
Regulator 
Molecule 
Type 
p-value 
of 
overlap 
Target molecules in dataset 
P2RY2 G-protein 
coupled 
receptor 
1.17E-03 SLC12A1,VTN 
CXCR4 G-protein 
coupled 
receptor 
1.57E-02 CD9,DPP4 
AGTR1 G-protein 
coupled 
receptor 
1.66E-02 AGT,CP 
CCR5 G-protein 
coupled 
receptor 
1.75E-02 CD9,SERPINA1 
GPR39 G-protein 
coupled 
receptor 
2.30E-02 CLU 
ADORA2A G-protein 
coupled 
2.68E-02 COL6A1,NAPA (includes EG:108124),VPS4A 
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receptor 
NFkB 
(complex) 
Complex 8.54E-06 AGT,APOE,B4GALT1,CLU,FTH1 (includes 
EG:14319),FUCA1,GAS6,HSPB1,IGHG3,IGKC 
IL6 cytokine 3.63E-06 AGT,ANPEP,ANXA1,APCS,APOE,CLU,CP,FGA,F
GB (includes EG:110135),KLK3 
IFNG 
(includes 
EG:15978) 
Cytokine 3.81E-06 AGRN,AGT,AZGP1,CP,CTSC,CTSD,CTSZ,DPP4,F
TH1 (includes EG:14319),GAS6 
IL1B Cytokine 1.24E-05 ANXA1,APCS,APOE,CP,CTSZ,DPP4,FGB (includes 
EG:110135),GAS6,GSTA1,GUSB 
TNF Cytokine 3.12E-05 ACE,AGT,ANPEP,APCS,APOE,B4GALT1,CLU,CP,
CTSC,CTSZ 
GH1 Cytokine 4.85E-05 AGT,APOE,CLU,FTH1 (includes 
EG:14319),GSTP1,HBB,PRDX1,YWHAZ 
OSM Cytokine 6.26E-04 ACE,ANXA1,ASAH1,COL6A1,FGA,FGB (includes 
EG:110135),PLAU,QSOX1,SERPINA1,UPK1A 
IL13 Cytokine 6.77E-04 CTSC,EZR,GAS6,GSN,PLAU,QSOX1,SERPINA1,T
HBS1 
EDN1 Cytokine 2.34E-03 ANXA1,ANXA5,EZR,PLAU,THBS1 
CSF2 Cytokine 2.94E-03 ABP1 (includes 
EG:26),ACE,CTSC,HBB,MME,QSOX1 
IL5 Cytokine 3.51E-03 ABP1 (includes 
EG:26),CTSC,PKM2,QSOX1,RRAS2,TPI1 
PRL Cytokine 5.12E-03 ANXA5,CLU,CTSA,CTSD,MME 
IL1A Cytokine 2.39E-02 DPP4,FTH1 (includes EG:14319),PLAU,SERPINA1 
IL4 (includes 
EG:16189) 
Cytokine 3.51E-02 APOE,CTSC,DPP4,IGHG3,KLK3,LGALS3BP,PLAU
,PSMA6 
IL8 Cytokine 3.53E-02 ANXA1,KLK3 
EGF (includes 
EG:13645) 
growth factor 3.04E-06 ANPEP,B4GALT1,CLU,CTSD,DPP4,EZR,GSTP1,ID
H1,KLK3,PLAU 
FGF19 growth factor 5.20E-06 AMY2A,APOE,MME,PTGDS,SERPINA1,SLC2A5 
AGT growth factor 5.06E-04 ACE,AGT,COL6A1,CP,EFEMP1,HSPB1,IDH1,PLA
U,SOD3 
TGFB1 
(includes 
EG:21803) 
growth factor 5.50E-03 ACE,ANPEP,APOE,CLU,COL6A1,CTSC,CTSD,FT
H1 (includes EG:14319),GSN,GUSB 
FGF2 growth factor 6.78E-03 ACE,ANPEP,FTH1 (includes 
EG:14319),PLAU,THBS1,YWHAZ 
VEGFA growth factor 7.01E-03 ACE,ANPEP,CSTB,PLAU,THBS1 
KITLG growth factor 9.18E-03 FTH1 (includes EG:14319),GAS6,HBB,MME,PKM2 
IGF1 growth factor 9.84E-03 ANPEP,CLU,CTSD,HBB,PLAU,THBS1 
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6.4 Discussion 
Palmitoylation is a PTM which is reversible and dynamically regulated (Kang et al., 2008; 
Martin et al., 2012) although mechanisms involved in the turnover of palmitoylated proteins 
are not clearly understood. While protein acyltransferases and protein acylthioesterases are 
known to regulated enzymatic recycling of palmitoylation in many proteins (Resh, 2006; 
Smotrys & Linder, 2004) controlling membrane association in a reversible manner, many 
palmitoylated proteins are not regulated by them (Resh, 2006; Linder & Deschenes, 2007). 
Palmitoylation of proteins was not understood better for many years mainly because of the 
lack of method available to detect the palmitoylation and identification of modified proteins. 
The traditional method for detecting palmitoylation was 
3
H palmitate labelling of cells 
(Drisdel et al., 2006). Following the labelling the proteins can be purified and analysed by 
SDS-PAGE. However other than the disadvantage of radioactive material handling, it has two 
distinct disadvantages. First, the method usually requires very long labelling and exposure 
times and second, it is limited to the analysis of live cells. Another method is the metabolic 
labelling of cells with 17-Octadecayonic acid (17-ODYA) (Martin et al., 2012) but this too is 
limited for analysing living cells.  
Recently a new method has been described which exchanges the acyl group with biotin in 
three simple steps (Roth et al., 2006). This method is called acyl-biotin exchange (ABE). 
Biotinylated proteins can then be purified using streptavidin-agarose and identified by LC-
MS/MS. This is the only method which can be applied to any type of samples to detect and 
identify palmitoylated proteins. We have used the ABE method here and purified candidate 
palmitoylated proteins from urinary exosomes and identified them by LC-MS/MS. The 
method is described in Figure 6.1. The two fractions HA+ and HA- allowed identification of 
172 and 57 proteins, respectively. Multiple proteins are shared among the two fractions. 
Theoretically there should be no overlap between the two fractions but endogenously 
382 
 
biotinylated proteins, incomplete blocking of free thiols by NEM, non-specific biotinylation 
and non-specific binding of proteins to streptavidin-agarose matrix lead to a significant 
number of overlaps between the two groups. For example the maleimide group, although 
specific to thiols at low concentration is known to react with non-thiol goups at high 
concentrations (Tyagarajan, Pretzer & Wiktorowicz, 2003).  
Therefore we have only considered proteins which are unique to HA+ fraction as candidate 
palmitoylated proteins and proteins found in HA- fractions are not considered. Of the 128 
proteins unique to HA+ fraction we have identified 12 proteins which were previously 
identified as being biotinylated in other studies (Dowal et al., 2011; Yang et al., 2010; Martin 
et al., 2012). These proteins include RAS family members RAB10, RAB6B and RRAS2, 
tetraspanin CD9 and proteasome subunit PSMA6. RAS family members RABs are involved 
in membrane trafficking and proteins containing ciliary targeting signals are transported to 
preicentriolar recycling endosomes with the aid of RAB10 (Nachury, Seeley & Jin, 2010). 
The endosomal system trafficking including exosome release is controlled by RAB proteins 
(Hendrix & Hume, 2011). Palmitoylation of RAB proteins therefore seems logical and it 
would be expected to control their membrane association in a reversible manner. R-RAS2, on 
the other hand can transform cells if its activity is aletred (Graham et al., 1994) and its 
overexpression may contribute to development of human breast cancers (Clark et al., 1996). 
This protein may contribute to the effect of exosomes uptake by recipient cells. Tetraspanin 
CD9 is a part of tetraspanin web domains on plasma membrane and takes part in cell 
adhesion, cell motility and tumor metastasis (Ikeyama et al., 1993; Masellissmith & Shaw, 
1994). Acylation of this protein will help in its association with specialised plasma membrane 
domains.  
Another protein identified in the current study and known to be palmitoylated is Stomatin 
(Snyers, Umlauf & Prohaska, 1999) which is known to be enriched in lipid-rafts (Mairhofer 
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et al., 2002). Raft-like domains are known to be enriched in exosomes and palmitoylation of 
this protein will help its association with rafts and subsequent incorporation into exosomes. 
Proteasome subunit alpha type-6 was also detected in our analysis and it is previously known 
to be a candidate palmitoylated protein (Yang et al., 2010). All 7 alpha and 7 beta chains of 
20S proteasomes have been previously detected in mesenchymal exosomes and it was also 
shown that a functional 20S proteasome co-purifies with exosomes in blood (Lai et al., 
2012). This has implications for recipient cells of these exosomes as proteasome acquisition 
will help degrade misfolded and oxidised proteins. It is to be noted that the ABE method will 
also result in enrichment of proteins which uses thioester linkages for attachment of other 
groups like lipoic acid. Currently no method exists to differentiate between the two but not 
many lipoic acid-modified proteins are known. Moreover, many of the known palmitoylated 
proteins detected by ABE have been validated in many studies by metabolic labelling which 
is specific for palmitoylation (Martin et al., 2012) confirming that ABE mostly detects 
palmitoylated proteins. 
ABE enrichment also helped identify some of the low-abundance proteins which were 
previously not known to be part of exosomes. These 18 proteins were not found in Exocarta 
which is the biggest database of exosomal proteins and RNA species. But when compared to 
our list from chapter 2 and other membrane vesicles studies, three  proteins were found to be 
unique  to our dataset (Table 6.3). One of these proteins is Ephrin type-A receptor 7 which is 
a receptor tyrosine kinase which binds GPI-anchored ephrin-A family ligands and modulates 
cell-cell adhesion and repulsion. It is typically a brain protein but it is also expressed in 
kidney cells (Genecards.org). These are new candidate exosomal proteins and expand the 
coverage of exosomal proteins.  
Annotation of HA+ proteins by DAVID returned a category of proteins which are involved in 
transport of proteins and small molecules (Table 6.3). It is previously known that palmitoyl-
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CoA which is a lipid palmitate donor supports budding and fusion of vesicles thereby 
inducing golgi transport assay. This effect is thought to be due to resulting palmitoylation of a 
protein upon supply of palmitoyl-CoA (Glick & Rothman, 1987; Pfanner et al., 1990). 
Therefore these transporters are good candidate for palmitoylation with many of them being 
intracellular transporters. 
IPA revealed 29 biomarkers present in HA+ fractions as well as multiple proteins involved in 
pathogenesis of various kidney pathologies (Table 6.4 & 6.5). These findings demonstrate the 
power of urinary exosome analysis for understanding pathologies and finding sensitive 
biomarkers of various diseases. Another analysis performed by IPA was the finding of 
upstream regulators for multiple proteins form the HA+ fractions (Table 6.6). Two of these 
regulators are interleukin-6 (IL-6) and tumor necrosis factor-α (TNF- α) which regulate 
multiple proteins found in our analysis in the HA+ fractions. It is previously known that IL-6 
and TNF- α may contribute to Th cell imbalance, cardiovascular disease and wasting in 
patients with end stage kidney disease (ESRD) in uremic millieu (Stenvinkel et al., 2005). Il-
6 is elevated in most of the ESRD patients and reduced renal function affects TNF- α 
clearance in rats (Bemelmans, Gouma & Buurman, 1993). Anti-cytokine therapies have been 
proposed for ESRD patients (Ridker et al., 1999; Huang et al., 2003; Zhao & Zhang, 2003; 
Stenvinkel et al., 2005) and the downstream targets of these cytokines would be excellent 
candidates for monitoring biomarkers of such therapies. 
In conclusion, we have identified 128 proteins which are unique to HA+ fractions. Seventy 
nine proteins from these 128 were predicted as high-confidence palmitoylated proteins by 
CSS-PALM 3.0 online server. Twelve previously known palmitoylated proteins were 
detected which confirmed their PTM status in urinary exosomes. Sixty six candidate 
palmitoylated proteins were established by their presence in only HA+ fraction. This study 
serves as a platform for the future studies on human urinary exosome and exosome-like 
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vesicles to verify the presence of palmitoylated proteins and further validate these results. 
IPA analysis and DAVID annotation detected the presence of several biomarker candidates as 
well as molecular targets for diseases.    
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Supplementary Table 6.1: Proteins identified in HA+ fraction. Uniprot accession, protein 
description, score, molecular weight (in Dalton), number of protein matches and prediction of 
palmitoylation or known status are indictaed in the table. 
Accession Description score Mol wt. Prot 
matches 
Known palmitoylated or 
predicted (CSS 
PALM3.0) 
P27348 14-3-3 protein theta OS=Homo sapiens 
GN=YWHAQ PE=1 SV=1 
52 28032 1 Known & Predicted 
P63104 14-3-3 protein zeta/delta OS=Homo sapiens 
GN=YWHAZ PE=1 SV=1 
87 27899 2 None 
Q9BUT1 3-hydroxybutyrate dehydrogenase type 2 
OS=Homo sapiens GN=BDH2 PE=1 SV=2 
58 27049 1 Predicted 
P25325 3-mercaptopyruvate sulfurtransferase 
OS=Homo sapiens GN=MPST PE=1 SV=3 
41 33443 1 Known & Predicted 
Q13510 Acid ceramidase OS=Homo sapiens 
GN=ASAH1 PE=1 SV=5 
73 45087 2 Known & Predicted 
O00468 Agrin OS=Homo sapiens GN=AGRN PE=1 
SV=4 
104 222861 2 Predicted 
P01009 Alpha-1-antitrypsin OS=Homo sapiens 
GN=SERPINA1 PE=1 SV=3 
101 46878 2 Predicted 
P02765 Alpha-2-HS-glycoprotein OS=Homo sapiens 
GN=AHSG PE=1 SV=1 
51 40098 1 Predicted 
P54802 Alpha-N-acetylglucosaminidase OS=Homo 
sapiens GN=NAGLU PE=1 SV=2 
213 82670 5 Common with HA- 
P54920 Alpha-soluble NSF attachment protein 
OS=Homo sapiens GN=NAPA PE=1 SV=3 
56 33667 1 None 
P19801 Amiloride-sensitive amine oxidase [copper-
containing] OS=Homo sapiens GN=ABP1 
PE=1 SV=4 
45 85723 1 None 
P15144 Aminopeptidase N OS=Homo sapiens 
GN=ANPEP PE=1 SV=4 
335 109870 10 None 
P12821 Angiotensin-converting enzyme OS=Homo 
sapiens GN=ACE PE=1 SV=1 
45 150418 1 None 
P01019 Angiotensinogen OS=Homo sapiens 
GN=AGT PE=1 SV=1 
54 53406 1 None 
P04083 Annexin A1 OS=Homo sapiens GN=ANXA1 
PE=1 SV=2 
143 38918 2 Predicted 
P08758 Annexin A5 OS=Homo sapiens GN=ANXA5 
PE=1 SV=2 
109 35971 3 Predicted 
P05090 Apolipoprotein D OS=Homo sapiens 
GN=APOD PE=1 SV=1 
134 21547 3 Common with HA- 
P02649 Apolipoprotein E OS=Homo sapiens 
GN=APOE PE=1 SV=1 
225 36246 6 Predicted 
P15291 Beta-1,4-galactosyltransferase 1 OS=Homo 
sapiens GN=B4GALT1 PE=1 SV=5 
42 44291 1 Known & Predicted 
P16278 Beta-galactosidase OS=Homo sapiens 
GN=GLB1 PE=1 SV=2 
128 76483 4 None 
P08236 Beta-glucuronidase OS=Homo sapiens 
GN=GUSB PE=1 SV=2 
53 75027 1 Predicted 
Q93088 Betaine--homocysteine S-methyltransferase 
1 OS=Homo sapiens GN=BHMT PE=1 SV=2 
44 45426 1 Predicted 
Q9Y6W3 Calpain-7 OS=Homo sapiens GN=CAPN7 
PE=1 SV=1 
41 93335 1 Predicted 
P31944 Caspase-14 OS=Homo sapiens GN=CASP14 
PE=1 SV=2 
80 27947 2 Common with HA- 
P07339 Cathepsin D OS=Homo sapiens GN=CTSD 
PE=1 SV=1 
46 45037 1 Predicted 
Q9UBR2 Cathepsin Z OS=Homo sapiens GN=CTSZ 
PE=1 SV=1 
60 34530 1 None 
P21926 CD9 antigen OS=Homo sapiens GN=CD9 
PE=1 SV=4 
47 25969 1 Known & Predicted 
P00450 Ceruloplasmin OS=Homo sapiens GN=CP 
PE=1 SV=1 
68 122983 2 None 
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P10909 Clusterin OS=Homo sapiens GN=CLU PE=1 
SV=1 
88 53031 2 None 
Q9Y281 Cofilin-2 OS=Homo sapiens GN=CFL2 PE=1 
SV=1 
63 18839 1 None 
P12109 Collagen alpha-1(VI) chain OS=Homo 
sapiens GN=COL6A1 PE=1 SV=3 
71 109602 2 Predicted 
P39059 Collagen alpha-1(XV) chain OS=Homo 
sapiens GN=COL15A1 PE=1 SV=2 
79 142202 2 Common with HA- 
P01024 Complement C3 OS=Homo sapiens GN=C3 
PE=1 SV=2 
113 188569 3 Common with HA- 
Q8IYJ1 Copine-9 OS=Homo sapiens GN=CPNE9 
PE=1 SV=3 
40 62281 1 None 
O60494 Cubilin OS=Homo sapiens GN=CUBN PE=1 
SV=5 
610 407262 17 Common with HA- 
P04080 Cystatin-B OS=Homo sapiens GN=CSTB 
PE=1 SV=2 
72 11190 2 Predicted 
Q969T7 Cytosolic 5~-nucleotidase III-like protein 
OS=Homo sapiens GN=NT5C3L PE=1 SV=3 
41 33792 1 Predicted 
P81605 Dermcidin OS=Homo sapiens GN=DCD 
PE=1 SV=2 
71 11391 1 Common with HA- 
Q08554 Desmocollin-1 OS=Homo sapiens GN=DSC1 
PE=1 SV=2 
116 101406 3 Common with HA- 
Q02413 Desmoglein-1 OS=Homo sapiens GN=DSG1 
PE=1 SV=2 
272 114702 7 Common with HA- 
P15924 Desmoplakin OS=Homo sapiens GN=DSP 
PE=1 SV=3 
210 334021 5 Common with HA- 
P16444 Dipeptidase 1 OS=Homo sapiens GN=DPEP1 
PE=1 SV=3 
141 46101 4 Predicted 
P53634 Dipeptidyl peptidase 1 OS=Homo sapiens 
GN=CTSC PE=1 SV=2 
48 52619 1 None 
P27487 Dipeptidyl peptidase 4 OS=Homo sapiens 
GN=DPP4 PE=1 SV=2 
94 88907 4 Predicted 
Q03001 Dystonin OS=Homo sapiens GN=DST PE=1 
SV=4 
42 865259 1 Predicted 
Q12805 EGF-containing fibulin-like extracellular 
matrix protein 1 OS=Homo sapiens 
GN=EFEMP1 PE=1 SV=2 
242 56885 4 Predicted 
Q9H223 EH domain-containing protein 4 OS=Homo 
sapiens GN=EHD4 PE=1 SV=1 
46 61365 1 None 
Q15375 Ephrin type-A receptor 7 OS=Homo sapiens 
GN=EPHA7 PE=1 SV=3 
86 113735 1 Predicted 
P27105 Erythrocyte band 7 integral membrane 
protein OS=Homo sapiens GN=STOM PE=1 
SV=3 
119 31882 2 Known & Predicted 
P08294 Extracellular superoxide dismutase [Cu-Zn] 
OS=Homo sapiens GN=SOD3 PE=1 SV=2 
53 26291 1 Predicted 
P15311 Ezrin OS=Homo sapiens GN=EZR PE=1 
SV=4 
79 69484 2 None 
Q01469 Fatty acid-binding protein, epidermal 
OS=Homo sapiens GN=FABP5 PE=1 SV=3 
45 15497 1 Common with HA- 
P02794 Ferritin heavy chain OS=Homo sapiens 
GN=FTH1 PE=1 SV=2 
48 21383 1 None 
P02671 Fibrinogen alpha chain OS=Homo sapiens 
GN=FGA PE=1 SV=2 
58 95656 1 Predicted 
P02675 Fibrinogen beta chain OS=Homo sapiens 
GN=FGB PE=1 SV=2 
47 56577 1 Predicted 
Q5D862 Filaggrin-2 OS=Homo sapiens GN=FLG2 
PE=1 SV=1 
67 249296 1 Common with HA- 
P05062 Fructose-bisphosphate aldolase B OS=Homo 
sapiens GN=ALDOB PE=1 SV=2 
81 39961 2 Predicted 
Q08380 Galectin-3-binding protein OS=Homo 
sapiens GN=LGALS3BP PE=1 SV=1 
96 66202 3 None 
Q92820 Gamma-glutamyl hydrolase OS=Homo 
sapiens GN=GGH PE=1 SV=2 
77 36340 2 Predicted 
P06396 Gelsolin OS=Homo sapiens GN=GSN PE=1 
SV=1 
79 86043 2 Common with HA- 
P08263 Glutathione S-transferase A1 OS=Homo 
sapiens GN=GSTA1 PE=1 SV=3 
83 25672 2 None 
P21266 Glutathione S-transferase Mu 3 OS=Homo 
sapiens GN=GSTM3 PE=1 SV=3 
104 26998 3 Predicted 
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P09211 Glutathione S-transferase P OS=Homo 
sapiens GN=GSTP1 PE=1 SV=2 
79 23569 1 Predicted 
Q9NZH0 G-protein coupled receptor family C group 5 
member B OS=Homo sapiens GN=GPRC5B 
PE=2 SV=2 
53 45279 1 Predicted 
Q9NQ84 G-protein coupled receptor family C group 5 
member C OS=Homo sapiens GN=GPRC5C 
PE=1 SV=2 
96 48732 2 Predicted 
Q14393 Growth arrest-specific protein 6 OS=Homo 
sapiens GN=GAS6 PE=1 SV=2 
114 81678 2 Predicted 
P62873 Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-1 OS=Homo 
sapiens GN=GNB1 PE=1 SV=3 
55 38151 1 Predicted 
P00738 Haptoglobin OS=Homo sapiens GN=HP 
PE=1 SV=1 
246 45861 7 Common with HA- 
P08107 Heat shock 70 kDa protein 1A/1B OS=Homo 
sapiens GN=HSPA1A PE=1 SV=5 
67 70294 2 Predicted 
P04792 Heat shock protein beta-1 OS=Homo 
sapiens GN=HSPB1 PE=1 SV=2 
42 22826 1 None 
P68871 Hemoglobin subunit beta OS=Homo sapiens 
GN=HBB PE=1 SV=2 
53 16102 1 None 
P02790 Hemopexin OS=Homo sapiens GN=HPX 
PE=1 SV=2 
45 52385 1 Predicted 
P04196 Histidine-rich glycoprotein OS=Homo 
sapiens GN=HRG PE=1 SV=1 
41 60510 1 Predicted 
Q86YZ3 Hornerin OS=Homo sapiens GN=HRNR 
PE=1 SV=2 
75 283140 2 Common with HA- 
P01876 Ig alpha-1 chain C region OS=Homo sapiens 
GN=IGHA1 PE=1 SV=2 
141 38486 3 Common with HA- 
P01859 Ig gamma-2 chain C region OS=Homo 
sapiens GN=IGHG2 PE=1 SV=2 
98 36505 3 Common with HA- 
P01860 Ig gamma-3 chain C region OS=Homo 
sapiens GN=IGHG3 PE=1 SV=2 
184 42287 5 None 
P01825 Ig heavy chain V-II region NEWM OS=Homo 
sapiens PE=1 SV=1 
43 12953 1 None 
P01767 Ig heavy chain V-III region BUT OS=Homo 
sapiens PE=1 SV=1 
96 12485 3 None 
P01768 Ig heavy chain V-III region CAM OS=Homo 
sapiens PE=1 SV=1 
95 13773 2 None 
P01781 Ig heavy chain V-III region GAL OS=Homo 
sapiens PE=1 SV=1 
84 12836 2 None 
P01765 Ig heavy chain V-III region TIL OS=Homo 
sapiens PE=1 SV=1 
85 12462 2 None 
P01779 Ig heavy chain V-III region TUR OS=Homo 
sapiens PE=1 SV=1 
90 12537 2 None 
P01764 Ig heavy chain V-III region VH26 OS=Homo 
sapiens PE=1 SV=1 
87 12745 2 None 
P01834 Ig kappa chain C region OS=Homo sapiens 
GN=IGKC PE=1 SV=1 
73 11773 1 None 
P01593 Ig kappa chain V-I region AG OS=Homo 
sapiens PE=1 SV=1 
96 12099 1 None 
P01598 Ig kappa chain V-I region EU OS=Homo 
sapiens PE=1 SV=1 
169 11895 3 Predicted 
P01613 Ig kappa chain V-I region Ni OS=Homo 
sapiens PE=1 SV=1 
48 12352 1 Predicted 
P01611 Ig kappa chain V-I region Wes OS=Homo 
sapiens PE=1 SV=1 
65 11715 1 Predicted 
P01614 Ig kappa chain V-II region Cum OS=Homo 
sapiens PE=1 SV=1 
81 12782 1 Common with HA- 
P01620 Ig kappa chain V-III region SIE OS=Homo 
sapiens PE=1 SV=1 
89 11882 1 Predicted 
P01625 Ig kappa chain V-IV region Len OS=Homo 
sapiens PE=1 SV=2 
47 12746 1 Predicted 
P80748 Ig lambda chain V-III region LOI OS=Homo 
sapiens PE=1 SV=1 
96 12042 1 None 
P01717 Ig lambda chain V-IV region Hil OS=Homo 
sapiens PE=1 SV=1 
94 11624 2 None 
P0CG05 Ig lambda-2 chain C regions OS=Homo 
sapiens GN=IGLC2 PE=1 SV=1 
41 11458 1 None 
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P01871 Ig mu chain C region OS=Homo sapiens 
GN=IGHM PE=1 SV=3 
115 49960 3 Common with HA- 
Q9Y6R7 IgGFc-binding protein OS=Homo sapiens 
GN=FCGBP PE=1 SV=3 
315 596443 9 Predicted 
P01591 Immunoglobulin J chain OS=Homo sapiens 
GN=IGJ PE=1 SV=4 
142 18543 4 Common with HA- 
Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 
OS=Homo sapiens GN=ITIH4 PE=1 SV=4 
229 103521 7 Common with HA- 
O75874 Isocitrate dehydrogenase [NADP] 
cytoplasmic OS=Homo sapiens GN=IDH1 
PE=1 SV=2 
63 46915 1 None 
P53990 IST1 homolog OS=Homo sapiens GN=IST1 
PE=1 SV=1 
79 39897 2 None 
P14923 Junction plakoglobin OS=Homo sapiens 
GN=JUP PE=1 SV=3 
97 82434 3 Common with HA- 
P13645 Keratin, type I cytoskeletal 10 OS=Homo 
sapiens GN=KRT10 PE=1 SV=6 
746 59020 17 Common with HA- 
P13646 Keratin, type I cytoskeletal 13 OS=Homo 
sapiens GN=KRT13 PE=1 SV=4 
344 49900 10 Common with HA- 
P02533 Keratin, type I cytoskeletal 14 OS=Homo 
sapiens GN=KRT14 PE=1 SV=4 
533 51872 14 Common with HA- 
P19012 Keratin, type I cytoskeletal 15 OS=Homo 
sapiens GN=KRT15 PE=1 SV=3 
202 49409 6 Common with HA- 
P08779 Keratin, type I cytoskeletal 16 OS=Homo 
sapiens GN=KRT16 PE=1 SV=4 
491 51578 14 Common with HA- 
Q04695 Keratin, type I cytoskeletal 17 OS=Homo 
sapiens GN=KRT17 PE=1 SV=2 
215 48361 7 Common with HA- 
P08727 Keratin, type I cytoskeletal 19 OS=Homo 
sapiens GN=KRT19 PE=1 SV=4 
97 44079 3 Common with HA- 
P35527 Keratin, type I cytoskeletal 9 OS=Homo 
sapiens GN=KRT9 PE=1 SV=3 
348 62255 9 Common with HA- 
P04264 Keratin, type II cytoskeletal 1 OS=Homo 
sapiens GN=KRT1 PE=1 SV=6 
938 66170 25 Common with HA- 
P35908 Keratin, type II cytoskeletal 2 epidermal 
OS=Homo sapiens GN=KRT2 PE=1 SV=2 
727 65678 20 Common with HA- 
P19013 Keratin, type II cytoskeletal 4 OS=Homo 
sapiens GN=KRT4 PE=1 SV=4 
116 57649 3 Common with HA- 
P13647 Keratin, type II cytoskeletal 5 OS=Homo 
sapiens GN=KRT5 PE=1 SV=3 
361 62568 12 Common with HA- 
P02538 Keratin, type II cytoskeletal 6A OS=Homo 
sapiens GN=KRT6A PE=1 SV=3 
482 60293 15 Common with HA- 
P04259 Keratin, type II cytoskeletal 6B OS=Homo 
sapiens GN=KRT6B PE=1 SV=5 
397 60315 14 Common with HA- 
P48668 Keratin, type II cytoskeletal 6C OS=Homo 
sapiens GN=KRT6C PE=1 SV=3 
478 60273 15 Common with HA- 
Q8N1N4 Keratin, type II cytoskeletal 78 OS=Homo 
sapiens GN=KRT78 PE=2 SV=2 
65 57629 2 Common with HA- 
P05787 Keratin, type II cytoskeletal 8 OS=Homo 
sapiens GN=KRT8 PE=1 SV=7 
99 53671 3 Common with HA- 
P01042 Kininogen-1 OS=Homo sapiens GN=KNG1 
PE=1 SV=2 
157 72996 5 Common with HA- 
P07195 L-lactate dehydrogenase B chain OS=Homo 
sapiens GN=LDHB PE=1 SV=2 
126 36900 4 None 
P98164 Low-density lipoprotein receptor-related 
protein 2 OS=Homo sapiens GN=LRP2 PE=1 
SV=3 
756 540376 21 Common with HA- 
P10619 Lysosomal protective protein OS=Homo 
sapiens GN=CTSA PE=1 SV=2 
77 54944 1 Predicted 
O43451 Maltase-glucoamylase, intestinal OS=Homo 
sapiens GN=MGAM PE=1 SV=5 
195 211031 6 Common with HA- 
O00187 Mannan-binding lectin serine protease 2 
OS=Homo sapiens GN=MASP2 PE=1 SV=4 
129 77193 3 None 
P33908 Mannosyl-oligosaccharide 1,2-alpha-
mannosidase IA OS=Homo sapiens 
GN=MAN1A1 PE=1 SV=3 
69 73150 2 None 
Q9BRK3 Matrix-remodeling-associated protein 8 
OS=Homo sapiens GN=MXRA8 PE=1 SV=1 
75 49500 2 None 
Q6W4X9 Mucin-6 OS=Homo sapiens GN=MUC6 PE=1 
SV=3 
47 263159 1 Predicted 
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Q9H8L6 Multimerin-2 OS=Homo sapiens GN=MMRN2 
PE=1 SV=2 
70 105028 1 Predicted 
O96009 Napsin-A OS=Homo sapiens GN=NAPSA 
PE=1 SV=1 
74 45700 2 Common with HA- 
P08473 Neprilysin OS=Homo sapiens GN=MME 
PE=1 SV=2 
198 86144 5 Predicted 
P59665 Neutrophil defensin 1 OS=Homo sapiens 
GN=DEFA1 PE=1 SV=1 
92 10536 2 Common with HA- 
P61970 Nuclear transport factor 2 OS=Homo sapiens 
GN=NUTF2 PE=1 SV=1 
94 14640 2 Predicted 
Q6UX06 Olfactomedin-4 OS=Homo sapiens 
GN=OLFM4 PE=1 SV=1 
261 57529 5 Common with HA- 
P04746 Pancreatic alpha-amylase OS=Homo sapiens 
GN=AMY2A PE=1 SV=2 
178 58354 4 Known & Predicted 
Q06830 Peroxiredoxin-1 OS=Homo sapiens 
GN=PRDX1 PE=1 SV=1 
51 22324 1 None 
P30041 Peroxiredoxin-6 OS=Homo sapiens 
GN=PRDX6 PE=1 SV=3 
69 25133 2 None 
P30086 Phosphatidylethanolamine-binding protein 1 
OS=Homo sapiens GN=PEBP1 PE=1 SV=3 
126 21158 2 None 
P05154 Plasma serine protease inhibitor OS=Homo 
sapiens GN=SERPINA5 PE=1 SV=3 
201 45760 6 Common with HA- 
P01833 Polymeric immunoglobulin receptor 
OS=Homo sapiens GN=PIGR PE=1 SV=4 
235 84429 5 Common with HA- 
P0CG38 POTE ankyrin domain family member I 
OS=Homo sapiens GN=POTEI PE=3 SV=1 
50 122858 1 Predicted 
P01133 Pro-epidermal growth factor OS=Homo 
sapiens GN=EGF PE=1 SV=2 
398 137613 11 Common with HA- 
Q8WUM4 Programmed cell death 6-interacting protein 
OS=Homo sapiens GN=PDCD6IP PE=1 
SV=1 
199 96590 6 None 
P12273 Prolactin-inducible protein OS=Homo 
sapiens GN=PIP PE=1 SV=1 
57 16847 1 Common with HA- 
P41222 Prostaglandin-H2 D-isomerase OS=Homo 
sapiens GN=PTGDS PE=1 SV=1 
49 21243 1 Predicted 
P07288 Prostate-specific antigen OS=Homo sapiens 
GN=KLK3 PE=1 SV=2 
48 29293 1 None 
P15309 Prostatic acid phosphatase OS=Homo 
sapiens GN=ACPP PE=1 SV=3 
41 44880 1 Common with HA- 
P60900 Proteasome subunit alpha type-6 OS=Homo 
sapiens GN=PSMA6 PE=1 SV=1 
47 27838 1 Known & Predicted 
P02760 Protein AMBP OS=Homo sapiens GN=AMBP 
PE=1 SV=1 
165 39886 3 Common with HA- 
Q969X1 Protein lifeguard 3 OS=Homo sapiens 
GN=TMBIM1 PE=1 SV=2 
67 34927 1 Predicted 
Q8WVV4 Protein POF1B OS=Homo sapiens 
GN=POF1B PE=1 SV=3 
49 68878 1 Predicted 
P31151 Protein S100-A7 OS=Homo sapiens 
GN=S100A7 PE=1 SV=4 
54 11578 1 Common with HA- 
P05109 Protein S100-A8 OS=Homo sapiens 
GN=S100A8 PE=1 SV=1 
143 10885 4 Common with HA- 
P06702 Protein S100-A9 OS=Homo sapiens 
GN=S100A9 PE=1 SV=1 
124 13291 2 Common with HA- 
P49221 Protein-glutamine gamma-
glutamyltransferase 4 OS=Homo sapiens 
GN=TGM4 PE=1 SV=2 
134 77951 3 Predicted 
A6NMY6 Putative annexin A2-like protein OS=Homo 
sapiens GN=ANXA2P2 PE=5 SV=2 
128 38806 3 None 
Q5VTE0 Putative elongation factor 1-alpha-like 3 
OS=Homo sapiens GN=EEF1A1P5 PE=5 
SV=1 
66 50495 2 Predicted 
P14618 Pyruvate kinase isozymes M1/M2 OS=Homo 
sapiens GN=PKM2 PE=1 SV=4 
92 58470 2 Predicted 
P61026 Ras-related protein Rab-10 OS=Homo 
sapiens GN=RAB10 PE=1 SV=1 
71 22755 2 Known & Predicted 
P59190 Ras-related protein Rab-15 OS=Homo 
sapiens GN=RAB15 PE=1 SV=1 
51 24660 1 None 
Q9H082 Ras-related protein Rab-33B OS=Homo 
sapiens GN=RAB33B PE=1 SV=1 
51 26043 1 Predicted 
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Q9NRW1 Ras-related protein Rab-6B OS=Homo 
sapiens GN=RAB6B PE=1 SV=1 
51 23561 1 Known & Predicted 
P62070 Ras-related protein R-Ras2 OS=Homo 
sapiens GN=RRAS2 PE=1 SV=1 
56 23613 1 Known & Predicted 
P04279 Semenogelin-1 OS=Homo sapiens 
GN=SEMG1 PE=1 SV=2 
138 52157 3 Common with HA- 
P02787 Serotransferrin OS=Homo sapiens GN=TF 
PE=1 SV=3 
486 79294 16 Common with HA- 
P29508 Serpin B3 OS=Homo sapiens GN=SERPINB3 
PE=1 SV=2 
83 44594 2 Common with HA- 
P02768 Serum albumin OS=Homo sapiens GN=ALB 
PE=1 SV=2 
446 71317 13 Common with HA- 
P02743 Serum amyloid P-component OS=Homo 
sapiens GN=APCS PE=1 SV=2 
56 25485 1 None 
Q13621 Solute carrier family 12 member 1 
OS=Homo sapiens GN=SLC12A1 PE=1 SV=2 
53 122627 1 Predicted 
P22732 Solute carrier family 2, facilitated glucose 
transporter member 5 OS=Homo sapiens 
GN=SLC2A5 PE=1 SV=1 
83 55394 2 Predicted 
Q92673 Sortilin-related receptor OS=Homo sapiens 
GN=SORL1 PE=1 SV=2 
59 253798 1 Predicted 
O00391 Sulfhydryl oxidase 1 OS=Homo sapiens 
GN=QSOX1 PE=1 SV=3 
41 83324 1 Predicted 
O60635 Tetraspanin-1 OS=Homo sapiens 
GN=TSPAN1 PE=1 SV=2 
47 26910 1 Predicted 
P10599 Thioredoxin OS=Homo sapiens GN=TXN 
PE=1 SV=3 
79 12015 1 Common with HA- 
P07996 Thrombospondin-1 OS=Homo sapiens 
GN=THBS1 PE=1 SV=2 
184 133291 5 Predicted 
Q9UKU6 Thyrotropin-releasing hormone-degrading 
ectoenzyme OS=Homo sapiens GN=TRHDE 
PE=2 SV=1 
76 117439 2 Predicted 
P04066 Tissue alpha-L-fucosidase OS=Homo sapiens 
GN=FUCA1 PE=1 SV=4 
76 53940 1 None 
O75264 Transmembrane protein C19orf77 OS=Homo 
sapiens GN=C19orf77 PE=2 SV=2 
59 15012 1 Predicted 
P60174 Triosephosphate isomerase OS=Homo 
sapiens GN=TPI1 PE=1 SV=3 
50 31057 1 Predicted 
O14773 Tripeptidyl-peptidase 1 OS=Homo sapiens 
GN=TPP1 PE=1 SV=2 
108 61723 2 Predicted 
P62979 Ubiquitin-40S ribosomal protein S27a 
OS=Homo sapiens GN=RPS27A PE=1 SV=2 
70 18296 1 Known & Predicted 
Q8IX04 Ubiquitin-conjugating enzyme E2 variant 3 
OS=Homo sapiens GN=UEVLD PE=1 SV=2 
50 52516 1 Predicted 
P00749 Urokinase-type plasminogen activator 
OS=Homo sapiens GN=PLAU PE=1 SV=2 
141 49901 4 Predicted 
P07911 Uromodulin OS=Homo sapiens GN=UMOD 
PE=1 SV=1 
330 72451 8 Common with HA- 
O00322 Uroplakin-1a OS=Homo sapiens GN=UPK1A 
PE=2 SV=1 
44 29429 1 Predicted 
Q9UK41 Vacuolar protein sorting-associated protein 
28 homolog OS=Homo sapiens GN=VPS28 
PE=1 SV=1 
52 25694 1 None 
Q9UN37 Vacuolar protein sorting-associated protein 
4A OS=Homo sapiens GN=VPS4A PE=1 
SV=1 
63 49152 1 None 
Q12907 Vesicular integral-membrane protein VIP36 
OS=Homo sapiens GN=LMAN2 PE=1 SV=1 
190 40545 5 Common with HA- 
Q7Z5L0 Vitelline membrane outer layer protein 1 
homolog OS=Homo sapiens GN=VMO1 
PE=1 SV=1 
178 22034 3 Common with HA- 
P04004 Vitronectin OS=Homo sapiens GN=VTN 
PE=1 SV=1 
66 55069 1 Predicted 
P25311 Zinc-alpha-2-glycoprotein OS=Homo sapiens 
GN=AZGP1 PE=1 SV=2 
54 34465 1 None 
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Supplementary Table 6.2: Proteins identified in HA- fraction. Uniprot accession, protein 
description, score, molecular weight (in Dalton), number of protein matches and prediction of 
palmitoylation or known status are indictaed in the table. 
Accession  Description Score Mol wt. prot_matches 
P54802 Alpha-N-acetylglucosaminidase OS=Homo sapiens GN=NAGLU PE=1 
SV=2 
138 82670 2 
P05090 Apolipoprotein D OS=Homo sapiens GN=APOD PE=1 SV=1 119 21547 3 
Q9NZT1 Calmodulin-like protein 5 OS=Homo sapiens GN=CALML5 PE=1 
SV=2 
45 15883 1 
P31944 Caspase-14 OS=Homo sapiens GN=CASP14 PE=1 SV=2 67 27947 1 
Q8IWA5 Choline transporter-like protein 2 OS=Homo sapiens GN=SLC44A2 
PE=1 SV=3 
40 81610 1 
P39059 Collagen alpha-1(XV) chain OS=Homo sapiens GN=COL15A1 PE=1 
SV=2 
63 142202 1 
P01024 Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 45 188569 1 
O60494 Cubilin OS=Homo sapiens GN=CUBN PE=1 SV=5 200 407262 3 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 68 11391 1 
Q6E0U4 Dermokine OS=Homo sapiens GN=DMKN PE=1 SV=3 60 47282 1 
Q08554 Desmocollin-1 OS=Homo sapiens GN=DSC1 PE=1 SV=2 74 101406 2 
Q02413 Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2 120 114702 3 
P15924 Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 122 334021 3 
Q01469 Fatty acid-binding protein, epidermal OS=Homo sapiens GN=FABP5 
PE=1 SV=3 
50 15497 1 
Q5D862 Filaggrin-2 OS=Homo sapiens GN=FLG2 PE=1 SV=1 78 249296 1 
O75223 Gamma-glutamylcyclotransferase OS=Homo sapiens GN=GGCT 
PE=1 SV=1 
53 21222 1 
P04406 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens 
GN=GAPDH PE=1 SV=3 
68 36201 1 
P00738 Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 104 45861 2 
Q86YZ3 Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 162 283140 4 
P01876 Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2 132 38486 3 
P01877 Ig alpha-2 chain C region OS=Homo sapiens GN=IGHA2 PE=1 SV=3 46 37301 1 
P01857 Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1 PE=1 
SV=1 
146 36596 2 
P01859 Ig gamma-2 chain C region OS=Homo sapiens GN=IGHG2 PE=1 
SV=2 
76 36505 1 
P01614 Ig kappa chain V-II region Cum OS=Homo sapiens PE=1 SV=1 69 12782 1 
P0CF74 Ig lambda-6 chain C region OS=Homo sapiens GN=IGLC6 PE=4 
SV=1 
57 11441 1 
P01871 Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 59 49960 1 
P01591 Immunoglobulin J chain OS=Homo sapiens GN=IGJ PE=1 SV=4 102 18543 2 
Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens 
GN=ITIH4 PE=1 SV=4 
104 103521 2 
P14923 Junction plakoglobin OS=Homo sapiens GN=JUP PE=1 SV=3 118 82434 3 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 
SV=6 
731 59020 16 
P13646 Keratin, type I cytoskeletal 13 OS=Homo sapiens GN=KRT13 PE=1 
SV=4 
188 49900 5 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 
SV=4 
557 51872 12 
P19012 Keratin, type I cytoskeletal 15 OS=Homo sapiens GN=KRT15 PE=1 
SV=3 
166 49409 5 
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P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 
SV=4 
514 51578 12 
Q04695 Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 
SV=2 
345 48361 9 
P08727 Keratin, type I cytoskeletal 19 OS=Homo sapiens GN=KRT19 PE=1 
SV=4 
139 44079 4 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 
SV=3 
732 62255 16 
P04264 Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 
SV=6 
1202 66170 27 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens 
GN=KRT2 PE=1 SV=2 
1020 65678 25 
P12035 Keratin, type II cytoskeletal 3 OS=Homo sapiens GN=KRT3 PE=1 
SV=3 
144 64549 3 
P19013 Keratin, type II cytoskeletal 4 OS=Homo sapiens GN=KRT4 PE=1 
SV=4 
143 57649 4 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 
SV=3 
615 62568 16 
P02538 Keratin, type II cytoskeletal 6A OS=Homo sapiens GN=KRT6A PE=1 
SV=3 
546 60293 17 
P04259 Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 
SV=5 
472 60315 15 
Q14CN4 Keratin, type II cytoskeletal 72 OS=Homo sapiens GN=KRT72 PE=1 
SV=2 
78 56470 2 
Q7RTS7 Keratin, type II cytoskeletal 74 OS=Homo sapiens GN=KRT74 PE=1 
SV=2 
111 58229 3 
Q8N1N4 Keratin, type II cytoskeletal 78 OS=Homo sapiens GN=KRT78 PE=2 
SV=2 
128 57629 4 
P05787 Keratin, type II cytoskeletal 8 OS=Homo sapiens GN=KRT8 PE=1 
SV=7 
45 53671 1 
P01042 Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2 49 72996 1 
P98164 Low-density lipoprotein receptor-related protein 2 OS=Homo sapiens 
GN=LRP2 PE=1 SV=3 
163 540376 4 
O43451 Maltase-glucoamylase, intestinal OS=Homo sapiens GN=MGAM 
PE=1 SV=5 
51 211031 1 
O00187 Mannan-binding lectin serine protease 2 OS=Homo sapiens 
GN=MASP2 PE=1 SV=4 
102 77193 1 
O96009 Napsin-A OS=Homo sapiens GN=NAPSA PE=1 SV=1 53 45700 1 
P59665 Neutrophil defensin 1 OS=Homo sapiens GN=DEFA1 PE=1 SV=1 97 10536 2 
Q6UX06 Olfactomedin-4 OS=Homo sapiens GN=OLFM4 PE=1 SV=1 100 57529 2 
P05154 Plasma serine protease inhibitor OS=Homo sapiens GN=SERPINA5 
PE=1 SV=3 
148 45760 2 
P01833 Polymeric immunoglobulin receptor OS=Homo sapiens GN=PIGR 
PE=1 SV=4 
140 84429 2 
P01133 Pro-epidermal growth factor OS=Homo sapiens GN=EGF PE=1 SV=2 286 137613 8 
P12273 Prolactin-inducible protein OS=Homo sapiens GN=PIP PE=1 SV=1 80 16847 1 
P15309 Prostatic acid phosphatase OS=Homo sapiens GN=ACPP PE=1 SV=3 100 44880 2 
P02760 Protein AMBP OS=Homo sapiens GN=AMBP PE=1 SV=1 128 39886 3 
P31151 Protein S100-A7 OS=Homo sapiens GN=S100A7 PE=1 SV=4 52 11578 1 
P05109 Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 95 10885 2 
P06702 Protein S100-A9 OS=Homo sapiens GN=S100A9 PE=1 SV=1 134 13291 3 
A6NMY6 Putative annexin A2-like protein OS=Homo sapiens GN=ANXA2P2 
PE=5 SV=2 
94 38806 2 
A8MT79 Putative zinc-alpha-2-glycoprotein-like 1 OS=Homo sapiens PE=5 
SV=2 
46 23080 1 
P04279 Semenogelin-1 OS=Homo sapiens GN=SEMG1 PE=1 SV=2 47 52157 1 
P02787 Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 145 79294 3 
Q96P63 Serpin B12 OS=Homo sapiens GN=SERPINB12 PE=1 SV=1 49 46646 1 
P29508 Serpin B3 OS=Homo sapiens GN=SERPINB3 PE=1 SV=2 58 44594 1 
P02768 Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 277 71317 7 
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Q9H2G4 Testis-specific Y-encoded-like protein 2 OS=Homo sapiens 
GN=TSPYL2 PE=1 SV=1 
46 79615 1 
P10599 Thioredoxin OS=Homo sapiens GN=TXN PE=1 SV=3 78 12015 1 
P07911 Uromodulin OS=Homo sapiens GN=UMOD PE=1 SV=1 467 72451 10 
Q12907 Vesicular integral-membrane protein VIP36 OS=Homo sapiens 
GN=LMAN2 PE=1 SV=1 
128 40545 2 
Q7Z5L0 Vitelline membrane outer layer protein 1 homolog OS=Homo sapiens 
GN=VMO1 PE=1 SV=1 
73 22034 1 
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CONCLUSIONS AND FUTURE WORK 
 
This thesis presented an alternative method for removing contamination of high-abundance 
proteins while isolating urinary membrane vesicles (40-100nm). Although they have been 
called exosomes in the literature, multiple studies have emphasised that the differential 
centrifugation method enriches vesicles of various types and not only exosomes. The 
alternative method we have developed for removing contamination with high-abundance 
proteins while isolating urinary membrane vesicles involved a mild detergent (CHAPS) 
treatment. This method is also better at preserving the biological activity of protein 
constituents of urinary membrane vesicles, as demonstrated in case of DPP-IV and 
nephrilysin. This method would be superior to the methods published by previous workers 
(employing DTT) if an activity-based assay or biomarkers is to be developed. Building on 
this method proteomic analysis of the isolated urinary membrane vesicles was carried out. 
The methodology used was developed with minimum number of steps possible and 437 
proteins in the high-speed pellet and 155 proteins in the low speed pellet were identified. 
Twenty % of the proteins identified in the high-speed pellet were previously not described as 
being part of exosomes which validates our method. This method is relatively easy to 
perform and less time and labor-consuming. Therefore, this method can be applied to large 
number of samples for qualitative and quantitative proteomic analysis of these vesicles. This 
can also be applied on clinical samples for quantitative studies for biomarker discovery.  
Most of the studies in urine have been focussed on smaller vesicles (Exosomes and 
‘exosome-like’ vesicles) and bigger vesicles like microvesicles and microparticles have been 
largely ignored. Microvesicles also have the potential to provide a different set of biomarkers 
for various diseases because they are mainly released upon cell stimulation. In a diseased 
state, abnormal cell stimulation can occur and microvesicles can provide a non-invasive way 
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of detecting and monitoring these changes. However, to the best of our knowledge, there are 
no methods available to specifically isolate microvesicles from urine. This is also supported 
by the fact that in the differential centrifugation method exosomes are present in low speed 
pellet. We have developed a lipid affinity-based method to isolate bigger membrane vesicles 
(mainly 200-750nm). No smaller vesicles were found in the isolated fraction using this 
method. It is for the first time that such a method has been developed. The fraction isolated 
using this method was also largely free of high-abundant proteins like albumin and Tamm-
Horsfall protein. This method is very easy to perform and requires no sophisticated 
instrument or specialised training. It can be applied to a large number of samples with ease. It 
would open up an area of investigation to further characterise microvesicles from urine. 
Building on this method, similar methods to isolate microvesicles from other body fluid can 
also be developed in the future.  
For further characterization of the membrane vesicles (high-speed pellet), glycoproteome of 
these vesicles was established using various glycobiological tools and techniques. One 
hundred and eight glycoproteins were identified unambiguously. The surface glycan profile 
of these vesicles was characterised and surface membrane glycoproteins were also identified. 
This study is a first attempt on characterising and identifying glycoprotein constituents of 
urinary membrane vesicles. This would greatly aid future studies on identifying glyco-
biomarkers of renal and cardiovascular diseases. A plate-based FLLA assay was developed 
which can be expanded in the future to screen patient urine samples. If differences in surface 
glycosylation are found among healthy and disease samples a diagnostic test can be 
developed, building on this study, in the future.  
Other PTMs, like ubiquitination and palmitoylation, were also profiled and a number of 
candidate modified proteins were identified. Ubiquitination and palmitoylation play a role in 
sorting proteins to membrane vesicles. Future studies can build upon this study to identify the 
401 
 
mechanism of sorting of proteins into membrane vesicles as well as validate the PTM status 
of these proteins. Both these modifications are dynamic and tightly controlled and differences 
in profile of these PTMs can likely be found among healthy and disease state which could 
identify new biomarkers or shed light upon molecular mechanism of disease progression. 
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Appendix-A 
Identification of ubiquitin-
conjugated proteins in urinary 
exosomes and exosome-like 
vesicles 
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A.1 Introduction 
‘Ubiquitin-like’ proteins (Ubl) comprises of a family of compounds which are structurally 
and functionally similar to a significant extent (Welchman, Gordon & Mayer, 2005; 
Kerscher, Felberbaum & Hochstrasser, 2006). The C-terminus of this class of proteins can be 
ligated to lysine side chain amino group of the substrate proteins by the action of three 
enzymes namely activating enzyme (E1), conjugating enzyme (E2) and a ligase (E3) (Pickart, 
2001; Weissman, 2001). The substrates can be singly or multiply monoubiquitinated 
implying the addition of a single ubiquitin moiety to one or several lysine at a time. 
Alternatively, they can be polyubiquitinated implying the addition of a chain of ubiquitin 
proteins to a single lysine residue in the substrate (Wilkinson, 1995). Unlike other Ubls, 
ubiquitination might utilise hundreds of E1, E2 and E3 enzymes and sometimes an E4 
ubiquitin elongation factor may be needed (Koegl et al., 1999; Hoppe, 2005; Welchman, 
Gordon & Mayer, 2005; Chiu, Sun & Chen, 2007; Jin et al., 2007). Lys48 linked ubiquitin 
chains target the substrate proteins for degradation by proteasome system while Lys63 linked 
chains is implied in DNA damage repair, cellcular signalling, intracellular trafficking and 
ribosomal biogenesis. All these functions have been reviewed extensively in previous reports 
(Hochstrasser, 2004; Pickart & Eddins, 2004; Chen, 2005; Welchman, Gordon & Mayer, 
2005; Kerscher, Felberbaum & Hochstrasser, 2006; Mukhopadhyay & Riezman, 2007).  
Another important function of monoubiquitination has been reported to be in the sorting of 
proteins at the multivesicular bodies (MVB) into the luminal vesicles which may later be 
released as exosomes (Katzmann, Odorizzi & Emr, 2002; Raiborg, Rusten & Stenmark, 
2003; Babst, 2005). Mono-ubiquitinated membrane proteins are engaged with endosomal 
sorting machinery with the help of ubiquitin-interaction motifs (UIMs) found e.g. in the 
hepatocyte-growth-factor-regulated tyrosine-kinase substrate (Hrs or Vps27 in yeast) and in 
the signal transduction adapter molecule (STAM) (Clague, 2002). Hrs recruits endosomal 
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sorting complex required for transport-I (ESCRT-I) to the endosomes by interacting with 
ESCRT-I subunit tumour suppressor gene-101 (TSG101) (Pornillos et al., 2003). This is 
followed by assembly of ESCRT-II and III complexes on the endosomes and subsequent 
concentration of cargo of ubiquitinated receptors (Katzmann, Babst & Emr, 2001; Babst et 
al., 2002b). After the sorting, recruitment of Doa4 by ESCRT-III results in deubiquitination 
of sorted membrane proteins before they can be incorporated into MVB vesicles (Amerik et 
al., 2000). Deubiquitination of cargo and sorting complex subunits before they can be 
incorporated into MVB vesicles implies that ubiquitinated proteins should not be present in 
exosomes. However, it has been reported that dendritic cell and human B-cell derived 
exosomes contain ubiquitinated proteins (Buschow et al., 2005). It was also found in the 
same study that majority of these proteins were not integral membrane proteins. These 
cytoplasmic proteins were polyubiquinated although it could not be ruled out if 
monoubiquitinated proteins were present as well. In this paper it was suggested that 
polyubiquitinated proteins were involved in regulation of MVB protein sorting. However, the 
identity of these proteins as well as the relevance of their presence in exosomes remains 
unclear.  
To identify the target proteins to be modified by ‘ubiquitin-like’ modifiers, the main approach 
has been the expression of tagged version of these modifiers in cell lines and subsequent 
enrichment of these modifier-conjugated proteins by affinity chromatography (Vertegaal et 
al., 2006). This is followed by their identification or quantification by mass spectrometric 
(MS) analysis. However, this approach can not be applied to human body fluids or tissues. 
Therefore, we have performed multiple immuno-affinity chromatography on extracts of 
exosomes isolated from human urine. This enrichment of ubiquitin conjugated proteins was 
followed by identification of these proteins by MS. 
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A.2 Material and methods 
A.2.1 Isolation of exosomes from urine 
Membrane vesicle fraction of urine (P200, 000g) was isolated form urine of healthy human 
volunteers as described in Chapter 2. 
A.2.2 Immunoaffinity chromatography (IAC) 
Extract of exosomes was prepared by incubating 1mg of exosomal pellet (P200,000g) with 
1% (w/v) beta-octyl glucoside (BOG) overnight at 4°C. The extract was diluted 1.5 times to 
reach .66% (w/v) BOG and 10mM phosphate (Buffer A, pH 7.2). Two different antibodies 
were used for IAC. One was clone FK-1 (Enzo life sciences, Famingdale, NY) which 
reocgnises only poly-ubiquitinated proteins while the other was anti-ubiquitin antibody 
(Dako, Carpentaria, CA). A negative control was taken by performing IAC using an unrelated 
rabbit IgG antibody. Antibodies were coupled to Dynabeads (M270, amine, Dynal, 
Inviteogen, Carlsbad, CA) as described for anti-albumin antibodies in methods section 2.2.11 
in Chapter 2. Buffer A was used for binding of antibody-beads and proteins in extract. After 
overnight incubation at 4°C (on rotation) the beads were washed five times with phosphate 
buffered saline (PBS) and bound proteins were eluted by incubating beads with 100mM 
glycine (pH 2.3) for 2 hours at room temperature. The eluate was dialysed and the proteins 
were reduced, alkylated and trypsin digested (as described in Chapter 2) followed by their 
identification by LC-MS/MS. 
A.2.3 SDS-PAGE and western blotting 
SDS-PAGE and subsequent transfer of proteins to PVDF membrane was done as described in 
methods section of Chapter 2. Anti-ubiquitin antibody from Dako was rabbit IgG and it was 
used in dilutions of 1:1,000 and incubated with blots overnight at +4°C on rotation. The 
secondary antibody anti-rabbit IgG-IRDye 800 (Li-Cor biosciences) was used in dilutions of 
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1:5,000 for one hour at room temperature (RT). Anti-polyubiquitin antibody (Fk-1, Enzo life 
sciences) was an IgM. Therefore, it was biotinylated using Biotin N-hydroxysuccinimide 
ester (NHS-Biotin, Sigma, St Louis, MO). Briefly, freshly prepared NHS-biotin in 
dimethylsulfoxide (DMSO) was added to 100µg of antibody at final NHS-biotin 
concentration of 10mM. The solution was incubated at RT for 2 hours. Hundred mM Tris 
buffer (Final concentration) was added to the antibody solution to quench remaining NHS-
biotin for 30 minutes. The resulting solution was directly incubated with blots at dilution of 
1:500 overnight at +4°C on rotation. The next day, blot was developed with streaptavidin-
IRDye 800 for 1 hour at RT and images were acquired with Odyssey imaging system (Li-Cor 
biosciences, Lincoln, NE). 
A.2.4 LC-MS/MS identification of bound proteins  
LC-MS/MS analysis was carried out as described in Chapter 5. 
A.2.5 Bioinformatic analysis and gene ontology 
Proteins identified in immuno-precipitations of both the antibodies were analysed by IPA 
(Ingenuity systems, Redwood City, CA), DAVID bioinformatics resources 6.7 (Huang, 
Sherman & Lempicki, 2009a; Huang, Sherman & Lempicki, 2009b) (NIH, USA) and 
Blast2Go software (Conesa et al., 2005). They were classified into various categories based 
on biological processes they are involved in, their sub-cellular localisation and molecular 
functions.  
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A.3 Results 
A.3.1 Immuno-affinity chomatography 
In a previous report it was shown that exosomes contain mostly poly-ubiquitinated, soluble 
proteins and very few membrane proteins (Buschow et al., 2005). Moreover, in our analysis 
of membrane vesicle proteome in Chapter 3, we have found polyubiquitin. Membrane vesicle 
fraction (P200,000g) as well as P18,000g and SN200,000 were probed with both the 
antibodies for  presence of ubiquitinated proteins (Figure A.1). 
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Figure A.1: This figure present western blotting of various fractions of human urine obtained 
by differential centrifugation method, as described in Chapter 2. Ub is the anti-ubiquitin 
antibody from Dako and FK-1 antibody is from Enzo Life sciences, which recognises only 
poly-ubiquitinated proteins. Molecular weight markers (in kDa) are shown in panel A and B 
at left and right to the picture, respectively. Lane 1: P18,000g, Lane2: P200,000g, Lane3: 
SN200,000g. 
As can be seen in the Figure A.1 panel A, the ubiquitin antibody from Dako recognises 
multiple proteins (8-10 clearly visible as well as other faint bands) in various fractions. 
P200,000g presents a band at proximately 10kDa which could be free ubiquitin (Mol wt. 
approximately 8kDa). Then there are multiple proteins from 12-18kDa which should be 
ubiquitinated proteins. There are other high molecular weight bands present at very low 
intensity. In FK-1 blot of P200,000g (Lane2, Panel B) there are multiple bands from 37 to 
180kDa. There is a smear of high intensity from approximately 120 to 180kDa. In 
SN200,000g, there is a big smear from 150 to 180kDa and multiple proteins below this 
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molecular  weight up to 40kDa. There are multiple ubiquitinated proteins present in 
P200,000g as seen in Figure A.1. Therefore, we have employed immuno-affinity 
chromatography (on P200,000g) using two different antibodies. One of which is FK-1 which 
recognises only poly-ubiquitinated proteins. The second antibody (Anti-ubiquitin from Dako) 
was raised against cow erythrocyte ubiquitin and cross-reacts strongly with human ubiquitin. 
The resulting antibody has been previously shown to detect presence of ubiquitinated 
filamentous inclusions in human chronic, neurodegenerative disorders like Alzheimer’s 
disease (Lowe et al., 2001). This antibody most likely recognises both mono- and poly-
ubiquitinated proteins as well as free ubiquitin (the band at ~50kDa is common to both 
antibodies).  
A.3.2 Identification of enriched proteins by LC-MS/MS 
Excluding keratins, 47 proteins were identified from FK-1 IAC (Supplementary Tables A.1 & 
A.2) and 47 from Ub IAC (Supplementary Tables A.3 & A.4). Seventy one unique proteins 
were identified in total while 23 proteins were shared among the elutions of these two 
antibodies (Figure A.2).  
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Figure A.2: Comparison between the proteins identified in Fk-1 and Ub immunoprecipitates. 
 
An unrelated antibody (Rabbit IgG) immobilised to the dynabeads and performed the IAC 
with exosomal extract using the same protocol as the one used for anti-ubiquitin antibodies. 
As a control, all the proteins identified in this manner serve as our negative control (56 
proteins, Supplementary Table A.5). In total 16 proteins from negative control were common 
with proteins identified in FK-1 and Ub IAC. The remaining 55 proteins are candidate 
proteins as being ubiquitinated proteins. 
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A.3.3 Comparison with previous studies 
There have been multiple studies identifying the substrate for ubiquitin conjugation although 
our approach to identify ubiquitin-conjugated proteins in exosomes is the first one. We 
compare 71 non-redundant proteins identified in our study to all previous studies which have 
identified ubiquitin substrates. Out of 71 proteins, 39 proteins have been identified as being 
ubiquitinated in previous studies with many of them identified in multiple studies. These 
proteins are presented in Table A.1. Out of these 39 proteins, 14 proteins were also found in 
the negative control. After removing these 14 proteins from consideration, 25 potentially 
ubiquitinated proteins in urinary exosomes can be found in Table A.1. 
Table A.1: Proteins previously known to be ubiquitinated in various studies. Uniprot 
accession, entrez gene name, sub-cellular localisation, type of proteins, presence of protein in 
Fk-1 and Ub dako  antibody elutions and reference of the previous studies are given in the 
Table. Rows highlighted in light blue colour are the proteins which were also identified in 
negative control. Sub-cellular localisation and type of proteins is presented as annotated by 
IPA (Ingenuity systems). 
Uniprot 
accession 
Symbol Entrez Gene Name Location Type 
 (s) 
Present in 
IP 
References 
A6NDJ8 RAB43L RAB43 like protein   Ub Dako  (Lopitz-
Otsoa et al., 
2012) 
O43633 CHMP2A charged 
multivesicular body 
protein 2A 
Cytoplasm Other Ub Dako  (Wagner et 
al., 2011),  
(Danielsen et 
al., 2011) 
P01834 IGKC immunoglobulin 
kappa constant 
Extracellular 
Space 
Other Both  (Danielsen 
et al., 2011) 
P01857 IGHG1 immunoglobulin 
heavy constant 
gamma 1 (G1m 
marker) 
Extracellular 
Space 
Other Fk-1 hUbiqiotome 
P01877 IGHA2 immunoglobulin 
heavy constant alpha 
2 (A2m marker) 
Extracellular 
Space 
Other Fk-1  (Wagner et 
al., 2011),  
(Danielsen et 
al., 2011) 
P02788 LTF lactotransferrin Extracellular Peptid both  (Lopitz-
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Space ase Otsoa et al., 
2012) 
P04279 SEMG1 semenogelin I Extracellular 
Space 
Other Ub Dako  (Vanderwerf 
et al., 2009),  
(Altun et al., 
2011) 
P06576 ATP5B ATP synthase, H+ 
transporting, 
mitochondrial F1 
complex, beta 
polypeptide 
Cytoplasm Transp
orter 
Ub Dako  (Wagner et 
al., 2011),  
(Danielsen et 
al., 2011) 
P08236 GUSB glucuronidase, beta Cytoplasm Enzym
e 
Fk-1  (Wagner et 
al., 2011) 
P14923 JUP junction plakoglobin Plasma 
Membrane 
Other Fk-1 UbiProt,  
(Lopitz-
Otsoa et al., 
2012) 
P35573 AGL amylo-alpha-1, 6-
glucosidase, 4-alpha-
glucanotransferase 
Cytoplasm Enzym
e 
Fk-1 hUbiqiotome 
P53990 IST1 increased sodium 
tolerance 1 homolog 
(yeast) 
Cytoplasm other Ub Dako  (Kim et al., 
2011),  
(Wagner et 
al., 2011),  
(Danielsen et 
al., 2011) 
P59190 RAB15 RAB15, member 
RAS oncogene 
family 
Cytoplasm Enzym
e 
Ub Dako  (Lopitz-
Otsoa et al., 
2012) 
P60709 ACTB actin, beta Cytoplasm Other Fk-1  (Lopitz-
Otsoa et al., 
2012),  
(Danielsen et 
al., 2011) 
P61626 LYZ Lysozyme Extracellular 
Space 
Enzym
e 
Both  (Altun et al., 
2011),  
(Danielsen et 
al., 2011) 
Q13510 ASAH1 N-acylsphingosine 
amidohydrolase (acid 
ceramidase) 1 
Cytoplasm Enzym
e 
Fk-1  (Wagner et 
al., 2011) 
Q15678 PTPN14 protein tyrosine 
phosphatase, non-
receptor type 14 
Cytoplasm Phosp
hatase 
Ub Dako  (Altun et al., 
2011) 
Q7LBR1 CHMP1B charged 
multivesicular body 
protein 1B 
Plasma 
Membrane 
Enzym
e 
Ub Dako  (Wagner et 
al., 2011),  
(Danielsen et 
al., 2011) 
Q92820 GGH gamma-glutamyl 
hydrolase 
(conjugase, 
folylpolygammagluta
myl hydrolase) 
Cytoplasm Peptid
ase 
Fk-1  (Wagner et 
al., 2011),  
(Danielsen et 
al., 2011) 
Q9BY43 CHMP4A charged Cytoplasm Other Ub Dako  (Danielsen 
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multivesicular body 
protein 4A 
et al., 2011) 
Q9H082 RAB33B RAB33B, member 
RAS oncogene 
family 
Cytoplasm Enzym
e 
Ub Dako  (Lopitz-
Otsoa et al., 
2012),   
(Danielsen et 
al., 2011) 
Q9H444 CHMP4B charged 
multivesicular body 
protein 4B 
Cytoplasm Other Both  (Wagner et 
al., 2011),  
(Danielsen et 
al., 2011) 
Q9NRW
1 
RAB6B RAB6B, member 
RAS oncogene 
family 
Cytoplasm Enzym
e 
Ub Dako  (Lopitz-
Otsoa et al., 
2012),  
(Danielsen et 
al., 2011) 
Q9NZZ3 CHMP5 charged 
multivesicular body 
protein 5 
Cytoplasm Other Both  (Wagner et 
al., 2011),  
(Danielsen et 
al., 2011) 
P10909 CLU Clusterin Cytoplasm Chaper
on 
Fk-1  (Rizzi et al., 
2009) 
 
These known ubiquitinated proteins contain multiple families and types of proteins. There are 
charged multivesicular body proteins (CHMP 1B, 2A, 4A, 4B and 5), RAS oncogene family 
members (RAB 6B, 15, 33B and RAB43 like), enzymes like acid ceramidase and gamma-
glutamyl hydrolase and a tyrosine phosphatase PTPN14. CHMP proteins are part of 
endosomal sorting complex required for transport-III (ESCRT-III). A map of their interaction 
was drawn with ConsensusPathDB-human (Kamburov et al., 2011) which is presented in 
Figure A.3. 
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Figure A.3: Components of ESCRT-III complex. Boxes with red outline are the ones found 
in our study. 
These proteins interact physically with each other to form ESCRT-III complex which is 
required for budding and scission of ILVs into the MVB endosomes (Wollert et al., 2009). 
Their presence is expected as they are known to be secreted with exosomes although their 
status in exosomes as potentially ubiquitinated proteins is a new finding. 
Proteins identified in our analysis were compared to previous studies published on proteomic 
analysis of urinary exosomes and exosome-like vesicles (Pisitkun, Shen & Knepper, 2004; 
Gonzales et al., 2009; Wang et al., 2011) (Knepper, Wang) as well as our dataset from 
Chpater 3. 
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Figure A.4: Comparison of identified proteins with proteomic studies of urinary exosome 
and ‘exosome-like’ vesicle studies (Pisitkun, Shen & Knepper, 2004; Gonzales et al., 2009; 
Wang et al., 2011) (Knepper and Wang) and dataset from Chapter 3.  
Seven proteins were found to be unique to our study. These proteins are identified for the first 
time as being part of urinary membrane vesicles. Two of these proteins are previously known 
to be associated with exosomes from other sources (Exocarta (Mathivanan et al., 2012)). 
These proteins are indicated in the table A.2. 
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Table A.2: Proteins identified in urinary membrane vesicle pellet (P200,000g) for the first 
time. 
Uniprot 
accesssion 
Gene/protein Name Known 
ubiquitinated 
or candidate 
Found in 
Exocarta 
(Mathivanan 
et al., 2012) 
Mascot 
score  
Protein 
matches 
A6NDJ8 Putative Rab-43-like protein Known  No 54 1 
A6NMY6 Putative annexin A2-like 
protein 
Candidate Yes 71 2 
P01596 Ig kappa chain V-I region 
CAR 
Candidate No 69 1 
P01597 Ig kappa chain V-I region 
DEE 
Candidate No 45 1 
P01614 Ig kappa chain V-II region 
Cum 
Candidate No 68 1 
P01700 Ig lambda chain V-I region 
HA 
Candidate No 46 1 
Q9NRW1 Ras-related protein Rab-6B Known Yes 54 1 
  
Out of these 7 proteins presented in table A.2, two proteins putative Rab-43-like protein and 
RAS related protein Rab-6B are previously known to be ubquitinated (Table A.1). While 5 
others are candidate ubiquitinated protein identified only in IAC. Other than 38 known 
ubiquitinated proteins, we also identified 30 candidate proteins which could be ubiquitinated. 
In this list of 30 proteins, we have excluded proteins which were also identified in our 
negative control. These 30 proteins are indicated in supplementary tables at the end of the 
text.  
A.3.4 Bioinformatic analysis and Gene ontology 
After removing the proteins also found in negative control, 55 proteins containing unique 
known and candidate ubiquitinated proteins were submitted to analysis by IPA (Ingnuity 
systems), DAVID bioinformatics resources (Huang, Sherman & Lempicki, 2009a; Huang, 
Sherman & Lempicki, 2009b) (NIH, USA) and Blast2Go software (Conesa et al., 2005). 
These proteins were classified according to the cellular component to which they belong, 
their molecular functions and biological processes in which they are involved. Figure A.5 
presents the sub-cellular localisation of these proteins and the biggest category is extra-
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cellular space (44%) followed by cytoplasm (39%) and then plasma membrane (15%). 
Extracellular space proteins are over-represented in ubiquitin known and candidate 
identifications while plasma membrane proteins are under-represented. 
 
Figure A.5: Sub-cellular localisation of the proteins as annotated by IPA software (Ingenuity 
systems, USA). 
Proteins present in extracellular space would be expected to endocytosed and reach endosome 
compartment where they could be target of ubiquitination. Cytoplasmic and plasma 
membrane associated proteins are already known targets of ubiquitination. However, plasma 
membrane proteins are under-represented compared to whole proteome of urinary membrane 
vesicles. It suggests that only a fraction of membrane proteins sorted to membrane vesicles 
are subjected to ubiquitination. 
Cytoplasm 
Extracellular Space 
Nucleus 
Plasma Membrane 
Unknown 
38 
36 
2 
23 
1 
39 
44 
14 
2 
Gene ontology: Sub-cellular distribution 
Ubiquitin total CP200 total Proteome 
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Figure A.6: Molecular functions of the proteins as annotated by IPA software (Ingenuity 
systems, USA). 
When these proteins were classified according to molecular functions (Figure A.6), the 
biggest annotated category (38% were not annotated) was enzymes (17%) followed by 
proteases and protease inhibitors (13% and 8%, respectively) and then transporter proteins 
(10%). Proteins involved in vesicular transport (like RABs) and cargos sorting into ILVs (like 
CHMP proteins) are already known targets of ubiquitination. Compared to the total proteome 
(Chapter 3), peptidase and transporter were similarly represented while enzymes were under-
represented in ubiquitinated protein identification. It suggests that among the enzymes sorted 
to membrane vesicles, only a subset is subject to ubiquitination. However, we have to also 
keep in mind that Chapter 3 is not the most exhaustive of datasets of membrane vesicles and 
many more proteins make up parts of these vesicles.  
Cytokine 
Enzyme 
G-protein coupled receptor 
Growth factor 
Ion channel 
Kinase 
Transmembrane receptor 
Peptidase 
Transcription/translation regulator 
Phosphatase 
Transporter 
Other  
Endopeptidase inhibitor 
Antigen binding 
1 
25 
1 
1 
1 
1 
2 
12 
1 
1 
10 
44 
17 
2 
2 
12 
2 
10 
37 
8 
8 
Gene Ontology: Molecular function 
Ubiquitin total CP200 Total proteome 
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Figure A.7: Presents the annotation of the proteins according to the biological processes in 
which they are involved. This figure was generated by Blast2Go software and threshold for 
inclusion of a category put at minimum 15 sequences per category.  
Biological processes, in which these proteins are involved, are shown in Figure A.7. Vesicle-
mediated transport, cellular component organisation and macromolecule localisation are 
some of the major categories. Categories also enriched include those for metabolic process, 
regulation of cellular processes and immune and defense responses.  
Proteins identified in our analysis (subtracting the negative control proteins) were subjected 
to biomarker filter analysis by IPA using cardiovascular and renal diseases, human species, 
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detection in blood/plasma and urine as various parameters. Biomarkers found in this analysis 
are presented in table A.3.  
Table A.3: Biomarkers found in the proteins present in our identifications upon IPA 
biomarker filter analysis. Symbols, gene name, sub-cellular  localisation, family of proteins, 
Uniprot Id, presence in plasma/urine, and type of bioarmker applications along with the one 
representative disease is indicated in the table. Cardiovascular disease and endocrine 
disorders were top disease in which these proteins have been sued as biomarkers. 
Symbol Entrez Gene 
Name 
Location Family GenPept
/UniProt
/Swiss-
Prot 
Accessi
on 
Pla
sm
a/S
eru
m 
Uri
ne 
Biomarker 
Application 
(s) 
Diseas
es 
APOE Apolipoprote
in E 
Extracellular 
Space 
Transpo
rter 
P02649 X X Diagnosis, 
Efficacy, 
Prognosis, 
Unspecified 
Application 
Cardio
vascula
r 
disease 
CLU Clusterin Extracellular 
Space 
Other P10909 X X Diagnosis, 
Efficacy, 
Unspecified 
Application 
Cardio
vascula
r 
disease 
EGF 
(include
s 
EG:136
45) 
Epidermal 
growth factor 
Extracellular 
Space 
growth 
factor 
P01133 X X Diagnosis, 
Efficacy, 
Prognosis, 
Response to 
Therapy, 
Unspecified 
Application 
Endocr
ine 
system 
dosord
ers 
F2 Coagulation 
factor II 
(thrombin) 
Extracellular 
Space 
Peptidas
e 
P00734 X X Diagnosis Cardio
vascula
r 
disease 
JUP Junction 
plakoglobin 
Plasma 
Membrane 
Other P14923 X X Diagnosis Cardio
vascula
r 
disease 
KNG1 Kininogen 1 Extracellular 
Space 
Other P01042 x X Efficacy Cardio
vascula
r 
disease 
LRP2 Low density 
lipoprotein 
receptor-
Plasma 
Membrane 
Transpo
rter 
P98164 X X Diagnosis Endocr
ine 
system 
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related 
protein 2 
dosord
ers 
PLG Plasminogen Extracellular 
Space 
Peptidas
e 
P00747 X X Diagnosis Cardio
vascula
r 
disease 
RETN Resistin Extracellular 
Space 
Other Q9HD8
9 
X X Diagnosis, 
Disease 
Progression, 
Efficacy 
Cardio
vascula
r 
disease 
SERPI
NA5 
Serpin 
peptidase 
inhibitor, 
clade A 
(alpha-1 
antiproteinas
e, 
antitrypsin), 
member 5 
Extracellular 
Space 
Other P05154 X X Diagnosis Cardio
vascula
r 
disease 
SLPI Secretory 
leukocyte 
peptidase 
inhibitor 
Cytoplasm Other P03973 X X Diagnosis, 
Prognosis 
Cardio
vascula
r 
disease 
 
Upon further analysis of the protein list with IPA some proteins involved in glomerular injury 
were also identified which are presented in table A.4. 
Table A.4: Presents the molecules involved in glomerular injury. Type of injury, name of 
molecules found and p-value of their enrichment is indicated in the table.  
Category Functions Annotation p-Value Molecules # 
Molecules 
Glomerular 
Injury 
Glomerulosclerosis 6.07E-
05 
APOE,C3,CLU,IGHG1 4 
Glomerular 
Injury 
lipoprotein glomerulopathy 2.90E-
03 
APOE 1 
Glomerular 
Injury 
focal segmental 
glomerulosclerosis 
4.54E-
02 
CLU 1 
 
These proteins not only are good targets to verify their ubiquitination status in urinary 
exosomes but also to investigate if their status changes in animal model systems for 
glomerular injury. Upon annotation with DAVID, in our 30 new candidate proteins for 
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ubiquitination we found 3 proteins which are annotated as being part of cytoplasmic vesicles 
(Table A.5).  
Table A.5: Proteins among the candidate ubiquitinated proteins annotated by DAVID as 
being part of cytoplasmic vesicles.  
Serial 
Number 
ID Gene Name 
1 789717 Epidermal growth factor (beta-
urogastrone) 
2 774646 Low density lipoprotein-related protein 2 
3 774379 Polymeric immunoglobulin receptor 
   
These proteins are strong candidates for ubiquitination as they end up in endosome 
compartments. Megalin, for example, is a multi-ligand receptor which acts with cubulin and 
is inetrnalised upon ligand binding. We searched for megalin ligands among our 
identifications and Figure A.8 shows the megalin interaction network that we found within 
our identifications.  
 
Figure A.8: Interacting proteins of Megalin that were found in our analysis. This figure was 
manually generated. Data from BioGRID
3.1
 was used to search for Megalin interacting 
partners. 
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Clusterin, apolipoprotein-E, immunoglobulins (Ig) light chains and albumin are the megalin 
ligands identified in our study. While albumin and clusterin have been identified as 
ubiquitinated in a previous study (Lopitz-Otsoa et al., 2012; Rizzi et al., 2009), Ig light 
chains and apolipoprotein-E are novel candidates found in our study. However albumin was 
also found in negative control therefore left out of consideration. Immune and inflammation 
signalling proteins are also targets of ubiquitination (Chen, 2005) therefore we looked for 
such proteins in our list. We found a category of proteins in our list which were annotated as 
being involved in inflammatory response (Table A.6). 
Table A.6: Proteins found in our identifications which are annotated by DAVID as being 
involved in inflammatory response. 
ID Gene Name 
P02743 amyloid P component, serum 
P10909 Clusterin 
P00734 coagulation factor II (thrombin) 
P01042 kininogen 1 
P61626 lysozyme (renal amyloidosis) 
O00187 mannan-binding lectin serine peptidase 2 
P01024 similar to Complement C3 precursor; complement component 3; hypothetical protein 
LOC100133511 
 
Analysis of proteins identified in our study, by IPA, identified two pathways enriched among 
the proteins identified. First one is a pathway which involves ubiquitin targets and ubiquitin 
specific protease 54 (USP54) binding partners. The pathway is shown in Figure A.9.  
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Figure A.9:  A pathway found in our data by IPA. The picture was generated using Path 
Designer tool in the IPA. Proteins shown in red or blue are the ones which are present in our 
identifications.  
This pathway was annotated by IPA as being involved in infectious diseases, cellular 
assembly and organization as well as DNA recombination, replication and repair. USP54, 
although inactive as a deubiquitinating protease (Quesada et al., 2004), contains microtubule 
interacting and transport (MIT) domain which interacts with CHMP proteins (Rigden et al., 
2009). This domain is found in proteins involved in intracellular transport and this pathway 
fits well in context of exosomal secretion machinery.  
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Another pathway which was enriched in our identification (by IPA analysis) is related to 
nuclear factor kappa B (NFkB) activation. This pathway is shown in figure A.10. 
 
Figure A.10:  A pathway found in our data by IPA. The picture was generated using Path 
Designer tool in the IPA. The proteins in pink or grey circles are the ones present in our 
identifications. Pink circles are the proteins which directly influence the nuclear localisation 
of NFkB.  
The proteins shown in Figure A.10 are mostly either extracellular or part of plasma 
membrane and increase or decrease the nuclear localisation of NFkB. Previously  it is known 
that NFkB activation in B-cells regulate HLA secretion with exosomes (Arita et al., 2008). 
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Another study has also shown that exosome treatment of cells activate the NFkB pathway and 
lead to inflammation (Anand et al., 2010). 
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A.4 Discussion 
IAC was carried out on urinary exosomal extract and proteins were identified by LC-MS/MS. 
A number of proteins get enriched in the immunoprecipitations not only because of their 
specific affinity but also due to non-specific interaction with matrix stationary phase, protein-
protein interactions and protein aggregation. To avoid the consideration of such proteins as 
ubiquitinated in our study an unrelated rabbit IgG was immobilised to the Dynabeads and 
IAC was carried out with same protocol as the anti-ubiquitin (Ub) antibody and all the 
proteins found in this way were considered as a negative control. We identified 71 proteins in 
total using two different antibodies, clone FK-1 which recognises only poly-ubiquitinated 
proteins and anti-ubiquitin (Dako) which is not so well characterised but may recognise both 
mono- and poly-ubiquitinated proteins. Thirty-nine previously known ubiquitinated proteins 
were identified but 14 of these proteins were present in negative control as well so they were 
not considered as potential Ub substrate. We prepared a membrane vesicle extract by 
incubating the exosomal pellet (P200,000g) with 1% (w/v) beta-octyl glucoside (BOG) 
overnight at 4°C. There are two reasons for that; one being that exosomes are enriched in 
‘lipid raft-like’ domains and BOG can solubilise these rafts (Garner, Smith & Hooper, 2008) 
and second is that BOG has previously been shown to increase the specificity of immuno-
precipitation (IP) (Zhang & Neubert, 2006). It was shown in the study that BOG, when 
present above its critical micelle concentration (.7%) in the IP buffer, increases both the 
sensitivity and selectivity of immuno-capture. This objective was achieved as 55% of the 
total proteins identified in our analysis are previously known to be ubiquitinated. 
Among the proteins identified one interesting category was CHMP family proteins. We 
identified 5 of the 10 CHMP proteins known to constitute the ESCRT-III complex. This 
complex is required for ILV formation and scission (Wollert et al., 2009). ESCRT-III 
interacts with the endosomal membrane (Whitley et al., 2003) and recruits cargo to be 
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included in MVB pathway (Babst et al., 2002a). ESCRT-III recruits Doa4 which 
deubiquitinates the cargo before it is included in MVB ILVs (Babst et al., 2002a). However, 
this sequence of events is incomplete as according to this scenarios exosomes, which are 
derived from MVB later in the pathway, should be free of ubiquitinated proteins. But 
ubiquitinated proteins are present in exosomes as shown previously (Buschow et al., 2005) 
and by our study. This means that ubiquitination plays as yet unknown role in MVB cargo 
sorting. The presence of ESCRT-III complex proteins in ubiquitinated form in exosomes also 
raises question about recycling of this complex as well as maintaining the free ubiquitin pool 
of the cells. Further studies will be required to answer these aspects of MVB sorting. It has 
been suggested that Ub dependent sorting of cell surface receptors into MVB might regulate 
their stability as well as turnover of misfolded proteins (Babst et al., 2002a). Clusterin which 
was identified in our study is known to bind to unfolded proteins and chaperon-client 
complex is internalised and targeted for lysosomal degradation (Kounnas et al., 1995). It is 
possible that subsequent to the ubiquitination of inetrnalised proteins a decision is taken to 
either degrade it in lysosome or secrete ILVs as exosome by fusing MVB with plasma 
membrane. 
Endocytosis of receptor ligand complexes leads them into endosomes and ubiquitination of 
endocytic cargo is a constitutive process (Katzmann, Odorizzi & Emr, 2002). In our 
candidate ubiquitinated proteins list at least 3 proteins EGF, megalin and polymeric 
immunoglobulin receptor were found which end up in endosomes upon endocytosis. These 
receptors need to be either recycled or degraded in the cell and Ub plays an important role in 
these two decisions. Decision of degradation further leads to another choice in which either 
MVB fuse with lysosomes or with plasma membrane releasing these proteins as part of 
exosomes. Therefore these 3 proteins are very strong candidate for ubiquitination and further 
studies will be needed to confirm this. Moreover, surface expression and ectodomain 
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shedding of EGF family member pro-amphiregulin is already known to be tightly controlled 
by ubiquitination (Fukuda et al., 2012). There is no reason to believe that this can not be the 
case for EGF. Megalin is involved in internalisation of Ig light chains by proximal tubule (Li 
et al., 2008) and can also lead to light chain induced nephrotoxicity in pathological conditions 
(Basnayake et al., 2010). Ig light chains and megalin, both were also found in our study. IgA, 
IgM and their receptor, polymeric immunoglobulin receptor, all were identified. However, it 
remains to be established whether these interacting proteins were present as complexes and 
were enriched indirectly with only one or few of them being ubiquitinated or all of them are 
secreted as part of exosomes in ubiquitinated form. 
NFkB is implicated in inductions and resolution of inflammations upon stimulation by a 
variety of molecules and ligands (Belen Sanz et al., 2010). Both the classical and alternative 
pathways have been shown to be activated in kidney diseases and injury (Belen Sanz et al., 
2010). Moreover, NFkB activation is known to be upregulated in experimental renal disease 
(Guijarro & Egido, 2001). We have found a number of proteins in our identifications which 
affect the nuclear localisation of NFkB including Ig light chains as discussed previously. 
Exosomal localisation of NFkB effectors in ubiquitinated form raises questions whether 
exosomes serve as a dumping ground for this class of proteins? And whether their secretion 
with exosomes serves as a homeostatic mechanism which controls cellular levels of NFkB 
effectors? Further studies will be needed to establish the connection of exosomal proteins 
with NFkB pathway.   
Another family of proteins known to be ubiquitinated and present in our analysis is RAB, 
RAS oncogene family members. RAB6B and RAB33B are involved in retrograde transport 
of cargo from early endosomes to trans-Golgi network (TGN)  (Starr et al., 2010) while 
RAB15 is involved in recycling of internalised receptors from recycling endosomes (Strick & 
Elferink, 2005). Receptors which are recycled might include polymeric immunoglobulin 
430 
 
receptor and megalin, as previously discussed. A picture emerges in which distinct steps in 
vesicle mediated transport from golgi to endosomes and vice versa, endosome to lysosome 
and endosome to plasma membrane is tightly regulated by ubiquitination of not only effector 
transport proteins but also of the cargo itself. While the  exact reasons why only some of the 
ubiquitinated proteins and transporters end up in exosomes and not other components of the 
system remains to be answered in detail, this study provides the target molecules which can 
be studied further.  
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Supplementary Table A.1: Proteins identified in Fk-1 IAC sample 1. Uniprot accession, 
protein description, score, molecular weight (in Dalton) and number of protein matches are 
indicated in the table. 
Accession Description Score Mol Wt. prot_matches 
Q13510 Acid ceramidase OS=Homo sapiens GN=ASAH1 PE=1 SV=5 60 45095 1 
P05090 Apolipoprotein D OS=Homo sapiens GN=APOD PE=1 SV=1 78 21552 3 
P02649 Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 SV=1 50 36248 1 
P08236 Beta-glucuronidase OS=Homo sapiens GN=GUSB PE=1 SV=2 41 75033 1 
P31944 Caspase-14 OS=Homo sapiens GN=CASP14 PE=1 SV=2 82 27952 2 
Q9NZZ3 Charged multivesicular body protein 5 OS=Homo sapiens GN=CHMP5 
PE=1 SV=1 
42 24613 1 
P10909 Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 45 53041 1 
P01024 Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 57 188596 1 
P01040 Cystatin-A OS=Homo sapiens GN=CSTA PE=1 SV=1 41 11000 1 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 108 11393 4 
Q02413 Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2 138 114720 5 
P15924 Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 258 334063 9 
Q92820 Gamma-glutamyl hydrolase OS=Homo sapiens GN=GGH PE=1 SV=2 46 36347 1 
P35573 Glycogen debranching enzyme OS=Homo sapiens GN=AGL PE=1 
SV=3 
46 176856 1 
Q86YZ3 Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 133 283156 3 
P01877 Ig alpha-2 chain C region OS=Homo sapiens GN=IGHA2 PE=1 SV=3 128 37315 4 
P01857 Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1 PE=1 SV=1 132 36605 4 
P01766 Ig heavy chain V-III region BRO OS=Homo sapiens PE=1 SV=1 41 13334 1 
P01762 Ig heavy chain V-III region TRO OS=Homo sapiens PE=1 SV=1 41 13580 1 
P01764 Ig heavy chain V-III region VH26 OS=Homo sapiens PE=1 SV=1 40 12748 1 
P01834 Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 SV=1 139 11776 3 
P01596 Ig kappa chain V-I region CAR OS=Homo sapiens PE=1 SV=1 69 11812 1 
P01597 Ig kappa chain V-I region DEE OS=Homo sapiens PE=1 SV=1 148 11770 2 
P01614 Ig kappa chain V-II region Cum OS=Homo sapiens PE=1 SV=1 68 12784 1 
P01616 Ig kappa chain V-II region MIL OS=Homo sapiens PE=1 SV=1 70 12164 1 
P01620 Ig kappa chain V-III region SIE OS=Homo sapiens PE=1 SV=1 71 11884 2 
P01700 Ig lambda chain V-I region HA OS=Homo sapiens PE=1 SV=1 46 12005 1 
P0CG05 Ig lambda-2 chain C regions OS=Homo sapiens GN=IGLC2 PE=1 
SV=1 
51 11461 1 
P01871 Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 41 49972 1 
P01591 Immunoglobulin J chain OS=Homo sapiens GN=IGJ PE=1 SV=4 62 18551 1 
P14923 Junction plakoglobin OS=Homo sapiens GN=JUP PE=1 SV=3 84 82447 2 
Q14525 Keratin, type I cuticular Ha3-II OS=Homo sapiens GN=KRT33B PE=2 
SV=3 
87 47345 3 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 
SV=6 
1187 59024 31 
P13646 Keratin, type I cytoskeletal 13 OS=Homo sapiens GN=KRT13 PE=1 
SV=4 
191 49905 7 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 
SV=4 
619 51877 19 
P19012 Keratin, type I cytoskeletal 15 OS=Homo sapiens GN=KRT15 PE=1 212 49413 8 
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SV=3 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 
SV=4 
569 51584 18 
Q04695 Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 
SV=2 
289 48366 9 
P08727 Keratin, type I cytoskeletal 19 OS=Homo sapiens GN=KRT19 PE=1 
SV=4 
161 44079 6 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 1611 62259 42 
Q9NSB4 Keratin, type II cuticular Hb2 OS=Homo sapiens GN=KRT82 PE=1 
SV=3 
49 58008 1 
P04264 Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 
SV=6 
2188 66173 61 
Q7Z794 Keratin, type II cytoskeletal 1b OS=Homo sapiens GN=KRT77 PE=1 
SV=3 
481 62154 12 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 
PE=1 SV=2 
788 65683 22 
P12035 Keratin, type II cytoskeletal 3 OS=Homo sapiens GN=KRT3 PE=1 
SV=3 
113 64552 3 
P19013 Keratin, type II cytoskeletal 4 OS=Homo sapiens GN=KRT4 PE=1 
SV=4 
207 57656 6 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 
SV=3 
425 62572 14 
P02538 Keratin, type II cytoskeletal 6A OS=Homo sapiens GN=KRT6A PE=1 
SV=3 
454 60298 15 
P04259 Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 
SV=5 
516 60320 16 
Q3SY84 Keratin, type II cytoskeletal 71 OS=Homo sapiens GN=KRT71 PE=1 
SV=3 
113 57778 3 
Q14CN4 Keratin, type II cytoskeletal 72 OS=Homo sapiens GN=KRT72 PE=1 
SV=2 
97 56481 3 
P05787 Keratin, type II cytoskeletal 8 OS=Homo sapiens GN=KRT8 PE=1 
SV=7 
107 53671 3 
Q6KB66 Keratin, type II cytoskeletal 80 OS=Homo sapiens GN=KRT80 PE=1 
SV=2 
93 51016 2 
P02788 Lactotransferrin OS=Homo sapiens GN=LTF PE=1 SV=6 125 80046 3 
P98164 Low-density lipoprotein receptor-related protein 2 OS=Homo sapiens 
GN=LRP2 PE=1 SV=3 
67 540699 1 
P61626 Lysozyme C OS=Homo sapiens GN=LYZ PE=1 SV=1 42 16990 1 
Q13835 Plakophilin-1 OS=Homo sapiens GN=PKP1 PE=1 SV=2 58 84142 1 
P01833 Polymeric immunoglobulin receptor OS=Homo sapiens GN=PIGR PE=1 
SV=4 
78 84450 1 
P01133 Pro-epidermal growth factor OS=Homo sapiens GN=EGF PE=1 SV=2 46 137677 1 
P05109 Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 42 10886 1 
P06702 Protein S100-A9 OS=Homo sapiens GN=S100A9 PE=1 SV=1 77 13292 2 
A6NMY6 Putative annexin A2-like protein OS=Homo sapiens GN=ANXA2P2 
PE=5 SV=2 
71 38809 2 
P02768 Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 106 71352 3 
P02743 Serum amyloid P-component OS=Homo sapiens GN=APCS PE=1 SV=2 86 25487 2 
Q9P2P6 StAR-related lipid transfer protein 9 OS=Homo sapiens GN=STARD9 
PE=1 SV=3 
48 521940 1 
 
 
 
438 
 
Supplementary Table A.2: Proteins identified in Fk-1 IAC sample 2. Uniprot accession, 
protein description, score, molecular weight (in Dalton) and number of protein matches are 
indicated in the table. 
Accession Description Score  Mol Wt. prot_matches 
P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 40 42052 1 
Q9H444 Charged multivesicular body protein 4b OS=Homo sapiens 
GN=CHMP4B PE=1 SV=1 
83 24935 3 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 77 11391 2 
P01876 Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2 85 38486 3 
P01834 Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 SV=1 134 11773 4 
P01591 Immunoglobulin J chain OS=Homo sapiens GN=IGJ PE=1 SV=4 129 18543 6 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 
SV=6 
1469 59020 70 
P13646 Keratin, type I cytoskeletal 13 OS=Homo sapiens GN=KRT13 PE=1 
SV=4 
204 49900 8 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 
SV=4 
1038 51872 45 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 
SV=4 
660 51578 36 
Q04695 Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 
SV=2 
259 48361 10 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 
SV=3 
1057 62255 35 
P04264 Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 
SV=6 
1528 66170 75 
Q7Z794 Keratin, type II cytoskeletal 1b OS=Homo sapiens GN=KRT77 PE=1 
SV=3 
528 62149 27 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens 
GN=KRT2 PE=1 SV=2 
751 65678 36 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 
SV=3 
97 62568 4 
P02538 Keratin, type II cytoskeletal 6A OS=Homo sapiens GN=KRT6A PE=1 
SV=3 
368 60293 19 
P04259 Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 
SV=5 
298 60315 12 
P48668 Keratin, type II cytoskeletal 6C OS=Homo sapiens GN=KRT6C PE=1 
SV=3 
302 60273 8 
Q3SY84 Keratin, type II cytoskeletal 71 OS=Homo sapiens GN=KRT71 PE=1 
SV=3 
107 57769 11 
P59665 Neutrophil defensin 1 OS=Homo sapiens GN=DEFA1 PE=1 SV=1 52 10536 1 
P01133 Pro-epidermal growth factor OS=Homo sapiens GN=EGF PE=1 SV=2 42 137613 1 
P07911 Uromodulin OS=Homo sapiens GN=UMOD PE=1 SV=1 758 72451 25 
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Supplementary Table A.3: Proteins identified in Ub IAC sample 1. Uniprot accession, 
protein description, score, molecular weight (in Dalton) and number of protein matches are 
indicated in the table. 
Accession Description Score  Mol Wt. prot_matches 
P03973 Antileukoproteinase OS=Homo sapiens GN=SLPI PE=1 SV=2 59 15228 2 
P05090 Apolipoprotein D OS=Homo sapiens GN=APOD PE=1 SV=1 96 21547 2 
P06576 ATP synthase subunit beta, mitochondrial OS=Homo sapiens GN=ATP5B PE=1 
SV=3 
80 56525 1 
P31944 Caspase-14 OS=Homo sapiens GN=CASP14 PE=1 SV=2 77 27947 1 
P01040 Cystatin-A OS=Homo sapiens GN=CSTA PE=1 SV=1 52 11000 1 
Q02413 Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2 62 114702 1 
P15924 Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 90 334021 3 
Q01469 Fatty acid-binding protein, epidermal OS=Homo sapiens GN=FABP5 PE=1 SV=3 43 15497 1 
Q5D862 Filaggrin-2 OS=Homo sapiens GN=FLG2 PE=1 SV=1 56 249296 1 
Q86YZ3 Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 42 283140 1 
P01876 Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2 117 38486 4 
P01834 Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 SV=1 88 11773 1 
P01593 Ig kappa chain V-I region AG OS=Homo sapiens PE=1 SV=1 45 12099 1 
P01597 Ig kappa chain V-I region DEE OS=Homo sapiens PE=1 SV=1 45 11768 1 
P01620 Ig kappa chain V-III region SIE OS=Homo sapiens PE=1 SV=1 66 11882 1 
Q15323 Keratin, type I cuticular Ha1 OS=Homo sapiens GN=KRT31 PE=2 SV=3 139 48633 6 
Q14525 Keratin, type I cuticular Ha3-II OS=Homo sapiens GN=KRT33B PE=2 SV=3 157 47325 6 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 809 59020 27 
P13646 Keratin, type I cytoskeletal 13 OS=Homo sapiens GN=KRT13 PE=1 SV=4 213 49900 7 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 526 51872 19 
P19012 Keratin, type I cytoskeletal 15 OS=Homo sapiens GN=KRT15 PE=1 SV=3 205 49409 8 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 393 51578 14 
Q04695 Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 SV=2 312 48361 12 
P08727 Keratin, type I cytoskeletal 19 OS=Homo sapiens GN=KRT19 PE=1 SV=4 194 44079 10 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 1295 62255 36 
P04264 Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 1758 66170 46 
Q7Z794 Keratin, type II cytoskeletal 1b OS=Homo sapiens GN=KRT77 PE=1 SV=3 370 62149 10 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 
SV=2 
639 65678 21 
P19013 Keratin, type II cytoskeletal 4 OS=Homo sapiens GN=KRT4 PE=1 SV=4 102 57649 2 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 327 62568 10 
P02538 Keratin, type II cytoskeletal 6A OS=Homo sapiens GN=KRT6A PE=1 SV=3 255 60293 9 
P04259 Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 SV=5 312 60315 11 
P48668 Keratin, type II cytoskeletal 6C OS=Homo sapiens GN=KRT6C PE=1 SV=3 242 60273 9 
P08729 Keratin, type II cytoskeletal 7 OS=Homo sapiens GN=KRT7 PE=1 SV=5 89 51411 2 
Q3SY84 Keratin, type II cytoskeletal 71 OS=Homo sapiens GN=KRT71 PE=1 SV=3 99 57769 2 
A6NCN2 Keratin-81-like protein OS=Homo sapiens PE=2 SV=3 52 54972 1 
P01042 Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2 59 72996 1 
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P61626 Lysozyme C OS=Homo sapiens GN=LYZ PE=1 SV=1 41 16982 1 
O00187 Mannan-binding lectin serine protease 2 OS=Homo sapiens GN=MASP2 PE=1 
SV=4 
63 77193 1 
P05154 Plasma serine protease inhibitor OS=Homo sapiens GN=SERPINA5 PE=1 SV=3 94 45760 2 
P00747 Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2 44 93247 1 
P01133 Pro-epidermal growth factor OS=Homo sapiens GN=EGF PE=1 SV=2 100 137613 2 
P05109 Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 60 10885 1 
P06702 Protein S100-A9 OS=Homo sapiens GN=S100A9 PE=1 SV=1 88 13291 1 
P00734 Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2 48 71475 1 
A6NDJ8 Putative Rab-43-like protein ENSP00000330714 OS=Homo sapiens PE=5 SV=3 54 20425 1 
P59190 Ras-related protein Rab-15 OS=Homo sapiens GN=RAB15 PE=1 SV=1 54 24660 1 
Q9H082 Ras-related protein Rab-33B OS=Homo sapiens GN=RAB33B PE=1 SV=1 54 26043 1 
Q9NRW1 Ras-related protein Rab-6B OS=Homo sapiens GN=RAB6B PE=1 SV=1 54 23561 1 
Q9HD89 Resistin OS=Homo sapiens GN=RETN PE=2 SV=1 105 12096 3 
Q96P63 Serpin B12 OS=Homo sapiens GN=SERPINB12 PE=1 SV=1 48 46646 1 
P29508 Serpin B3 OS=Homo sapiens GN=SERPINB3 PE=1 SV=2 47 44594 1 
P02768 Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 45 71317 1 
P07911 Uromodulin OS=Homo sapiens GN=UMOD PE=1 SV=1 335 72451 10 
 
Supplementary Table A.4: Proteins identified in Ub IAC sample 2. Uniprot accession, 
protein description, score, molecular weight (in Dalton) and number of protein matches are 
indicated in the table. 
Accession Description Score  Mol Wt. prot_matches 
P05090 Apolipoprotein D OS=Homo sapiens GN=APOD PE=1 SV=1 42 21547 1 
Q7LBR1 Charged multivesicular body protein 1b OS=Homo sapiens 
GN=CHMP1B PE=1 SV=1 
50 22152 2 
O43633 Charged multivesicular body protein 2a OS=Homo sapiens 
GN=CHMP2A PE=1 SV=1 
41 25088 1 
Q9BY43 Charged multivesicular body protein 4a OS=Homo sapiens 
GN=CHMP4A PE=1 SV=3 
56 25083 1 
Q9H444 Charged multivesicular body protein 4b OS=Homo sapiens 
GN=CHMP4B PE=1 SV=1 
93 24935 3 
Q9NZZ3 Charged multivesicular body protein 5 OS=Homo sapiens GN=CHMP5 
PE=1 SV=1 
116 24612 4 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 149 11391 6 
P01876 Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2 121 38486 6 
P01834 Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 SV=1 233 11773 5 
P01614 Ig kappa chain V-II region Cum OS=Homo sapiens PE=1 SV=1 48 12782 1 
P01591 Immunoglobulin J chain OS=Homo sapiens GN=IGJ PE=1 SV=4 166 18543 9 
P53990 IST1 homolog OS=Homo sapiens GN=IST1 PE=1 SV=1 131 39897 8 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 
SV=6 
1349 59020 59 
P13646 Keratin, type I cytoskeletal 13 OS=Homo sapiens GN=KRT13 PE=1 
SV=4 
176 49900 8 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 
SV=4 
627 51872 30 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 
SV=4 
590 51578 31 
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Q04695 Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 
SV=2 
80 48361 4 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 1509 62255 50 
P04264 Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 
SV=6 
1569 66170 68 
Q7Z794 Keratin, type II cytoskeletal 1b OS=Homo sapiens GN=KRT77 PE=1 
SV=3 
593 62149 26 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 
PE=1 SV=2 
836 65678 35 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 
SV=3 
129 62568 6 
P02538 Keratin, type II cytoskeletal 6A OS=Homo sapiens GN=KRT6A PE=1 
SV=3 
155 60293 12 
P04259 Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 
SV=5 
341 60315 14 
P48668 Keratin, type II cytoskeletal 6C OS=Homo sapiens GN=KRT6C PE=1 
SV=3 
137 60273 5 
Q7RTS7 Keratin, type II cytoskeletal 74 OS=Homo sapiens GN=KRT74 PE=1 
SV=2 
66 58229 7 
P02788 Lactotransferrin OS=Homo sapiens GN=LTF PE=1 SV=6 92 80014 3 
P59665 Neutrophil defensin 1 OS=Homo sapiens GN=DEFA1 PE=1 SV=1 78 10536 3 
P05154 Plasma serine protease inhibitor OS=Homo sapiens GN=SERPINA5 
PE=1 SV=3 
53 45760 1 
Q9HD89 Resistin OS=Homo sapiens GN=RETN PE=2 SV=1 47 12096 1 
P04279 Semenogelin-1 OS=Homo sapiens GN=SEMG1 PE=1 SV=2 74 52157 2 
Q15678 Tyrosine-protein phosphatase non-receptor type 14 OS=Homo sapiens 
GN=PTPN14 PE=1 SV=2 
40 136031 1 
P07911 Uromodulin OS=Homo sapiens GN=UMOD PE=1 SV=1 992 72451 40 
 
Supplementary Table A.5: Proteins identified in rabbit IgG IAC (negative control). Uniprot 
accession, protein description, score, molecular weight (in Dalton) and number of protein 
matches are indicated in the table. 
Accession Description Score  Mol Wt. prot_matches 
P04745 Alpha-amylase 1 OS=Homo sapiens GN=AMY1A PE=1 SV=2 78 58415 1 
P05090 Apolipoprotein D OS=Homo sapiens GN=APOD PE=1 SV=1 84 21547 3 
P31944 Caspase-14 OS=Homo sapiens GN=CASP14 PE=1 SV=2 117 27947 3 
P01040 Cystatin-A OS=Homo sapiens GN=CSTA PE=1 SV=1 132 11000 3 
P01036 Cystatin-S OS=Homo sapiens GN=CST4 PE=1 SV=3 44 16489 1 
P01037 Cystatin-SN OS=Homo sapiens GN=CST1 PE=1 SV=3 44 16605 1 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 146 11391 4 
Q08554 Desmocollin-1 OS=Homo sapiens GN=DSC1 PE=1 SV=2 68 101406 1 
Q02413 Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2 146 114702 4 
P15924 Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 128 334021 3 
P14625 Endoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=1 61 92696 1 
Q01469 Fatty acid-binding protein, epidermal OS=Homo sapiens GN=FABP5 
PE=1 SV=3 
40 15497 1 
Q5D862 Filaggrin-2 OS=Homo sapiens GN=FLG2 PE=1 SV=1 84 249296 1 
Q86YZ3 Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 150 283140 4 
P01876 Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2 41 38486 1 
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Q15323 Keratin, type I cuticular Ha1 OS=Homo sapiens GN=KRT31 PE=2 
SV=3 
307 48633 9 
Q14525 Keratin, type I cuticular Ha3-II OS=Homo sapiens GN=KRT33B 
PE=2 SV=3 
214 47325 7 
O76011 Keratin, type I cuticular Ha4 OS=Homo sapiens GN=KRT34 PE=2 
SV=2 
187 50818 6 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 
SV=6 
826 59020 17 
P13646 Keratin, type I cytoskeletal 13 OS=Homo sapiens GN=KRT13 PE=1 
SV=4 
323 49900 10 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 
SV=4 
585 51872 14 
P19012 Keratin, type I cytoskeletal 15 OS=Homo sapiens GN=KRT15 PE=1 
SV=3 
268 49409 8 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 
SV=4 
544 51578 14 
Q04695 Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 
SV=2 
375 48361 9 
P08727 Keratin, type I cytoskeletal 19 OS=Homo sapiens GN=KRT19 PE=1 
SV=4 
149 44079 4 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 
SV=3 
713 62255 17 
P78386 Keratin, type II cuticular Hb5 OS=Homo sapiens GN=KRT85 PE=1 
SV=1 
237 57306 9 
O43790 Keratin, type II cuticular Hb6 OS=Homo sapiens GN=KRT86 PE=1 
SV=1 
375 55120 14 
P04264 Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 
SV=6 
1151 66170 30 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens 
GN=KRT2 PE=1 SV=2 
1033 65678 27 
Q01546 Keratin, type II cytoskeletal 2 oral OS=Homo sapiens GN=KRT76 
PE=1 SV=2 
163 66370 6 
P12035 Keratin, type II cytoskeletal 3 OS=Homo sapiens GN=KRT3 PE=1 
SV=3 
185 64549 5 
P19013 Keratin, type II cytoskeletal 4 OS=Homo sapiens GN=KRT4 PE=1 
SV=4 
136 57649 5 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 
SV=3 
612 62568 18 
P02538 Keratin, type II cytoskeletal 6A OS=Homo sapiens GN=KRT6A PE=1 
SV=3 
715 60293 20 
P04259 Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 
SV=5 
647 60315 19 
P48668 Keratin, type II cytoskeletal 6C OS=Homo sapiens GN=KRT6C PE=1 
SV=3 
643 60273 18 
Q14CN4 Keratin, type II cytoskeletal 72 OS=Homo sapiens GN=KRT72 PE=1 
SV=2 
127 56470 4 
Q86Y46 Keratin, type II cytoskeletal 73 OS=Homo sapiens GN=KRT73 PE=1 
SV=1 
131 59457 5 
O95678 Keratin, type II cytoskeletal 75 OS=Homo sapiens GN=KRT75 PE=1 
SV=2 
236 59809 8 
A6NCN2 Keratin-81-like protein OS=Homo sapiens PE=2 SV=3 321 54972 12 
Q52LG2 Keratin-associated protein 13-2 OS=Homo sapiens GN=KRTAP13-2 
PE=1 SV=1 
47 19912 1 
P07195 L-lactate dehydrogenase B chain OS=Homo sapiens GN=LDHB PE=1 
SV=2 
66 36900 1 
P59665 Neutrophil defensin 1 OS=Homo sapiens GN=DEFA1 PE=1 SV=1 46 10536 1 
P12273 Prolactin-inducible protein OS=Homo sapiens GN=PIP PE=1 SV=1 43 16847 1 
P31151 Protein S100-A7 OS=Homo sapiens GN=S100A7 PE=1 SV=4 45 11578 1 
P05109 Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 115 10885 3 
P06702 Protein S100-A9 OS=Homo sapiens GN=S100A9 PE=1 SV=1 108 13291 2 
P14618 Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PKM2 
PE=1 SV=4 
113 58470 1 
Q96P63 Serpin B12 OS=Homo sapiens GN=SERPINB12 PE=1 SV=1 46 46646 1 
P29508 Serpin B3 OS=Homo sapiens GN=SERPINB3 PE=1 SV=2 42 44594 1 
P02768 Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 71 71317 2 
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Q9H2G4 Testis-specific Y-encoded-like protein 2 OS=Homo sapiens 
GN=TSPYL2 PE=1 SV=1 
43 79615 1 
P10599 Thioredoxin OS=Homo sapiens GN=TXN PE=1 SV=3 66 12015 1 
Q9BQE3 Tubulin alpha-1C chain OS=Homo sapiens GN=TUBA1C PE=1 SV=1 51 50548 1 
P62979 Ubiquitin-40S ribosomal protein S27a OS=Homo sapiens 
GN=RPS27A PE=1 SV=2 
71 18296 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
